data_2dgr_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dgr _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.889 0.376 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.5 t -141.73 161.25 38.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 90.4 m -131.28 124.18 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.165 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.5 pt -114.29 153.14 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.125 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 52.6 mm-40 -109.87 106.26 15.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 74.7 t -77.59 135.61 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.42 ' C ' HG11 ' A' ' 114' ' ' VAL . 8.9 ttp-105 -104.8 120.89 42.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.862 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.42 HG11 ' C ' ' A' ' 113' ' ' ARG . 4.6 m -136.46 150.72 71.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.609 0.718 . . . . 0.0 111.124 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.469 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.7 130.63 19.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.682 2.255 . . . . 0.0 112.363 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -45.04 -22.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.939 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.413 ' HB2' ' NH1' ' A' ' 117' ' ' ARG . 14.7 ttm105 -72.08 -44.23 63.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.918 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.469 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 74.9 t -76.03 -31.68 22.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 122' ' ' VAL . 42.6 t -39.3 -74.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -38.74 -34.33 0.26 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.547 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -71.67 -44.21 64.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 110.876 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.407 ' N ' ' O ' ' A' ' 119' ' ' VAL . 86.9 t -66.04 -62.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.119 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 84.7 t -46.8 -48.27 7.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.85 172.71 49.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.97 91.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 12.2 mmtp 53.13 38.59 27.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 78.32 72.89 1.13 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.535 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.39 -27.25 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.102 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 65.7 m -98.68 -44.77 6.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 9.3 tp -60.64 -25.19 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.9 tttp -66.51 -32.0 73.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -67.26 -43.58 81.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 77.3 mt -57.89 -56.88 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.159 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 29.4 mt-30 -45.24 -31.97 1.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -82.07 -55.69 4.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 mmm180 -56.28 -24.42 42.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -109.75 -13.03 14.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 54.3 52.79 11.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.462 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 26.8 p -129.99 170.04 14.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.155 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -102.28 94.91 5.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 82.3 mt -93.9 125.83 46.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.76 130.12 68.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.6 p -84.11 145.29 45.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.611 0.719 . . . . 0.0 111.094 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -179.78 3.17 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -80.56 -172.11 44.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -92.55 -31.62 15.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.828 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 9.6 t0 -112.1 35.97 3.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -131.3 169.93 15.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -67.82 144.28 97.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.615 0.721 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.25 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.705 2.27 . . . . 0.0 112.319 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.2 t -148.26 113.83 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -84.06 141.46 31.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.93 121.53 45.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.6 122.47 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 43.0 m -112.9 122.93 49.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.563 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 169.54 -173.09 43.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 16.1 mmt -52.39 159.24 1.66 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.602 0.715 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -0.86 7.54 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.658 2.239 . . . . 0.0 112.302 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -115.7 -26.03 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.462 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.3 m-20 -85.11 -54.63 4.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.563 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 24.9 m -53.68 -32.54 21.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -79.14 -23.5 43.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -76.27 -37.51 57.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -70.76 -38.5 73.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 57.5 ttt180 -54.43 -44.21 72.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.93 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -55.58 -49.28 73.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -59.93 -45.98 90.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 94.9 mt -53.18 -58.96 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.126 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -62.4 -32.69 73.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -51.45 -42.31 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -56.28 -33.5 65.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 81.6 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.993 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.922 0.392 . . . . 0.0 110.924 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.7 t -137.56 164.68 28.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 99.2 m -138.14 115.29 10.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.075 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.44 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 42.4 pt -107.89 151.88 9.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.44 ' NE2' ' C ' ' A' ' 110' ' ' ILE . 1.1 mp0 -110.98 106.72 15.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.444 HG12 ' CG1' ' A' ' 114' ' ' VAL . 86.9 t -73.7 141.39 16.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 42.5 ttp85 -108.67 110.13 21.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.444 ' CG1' HG12 ' A' ' 112' ' ' VAL . 2.5 m -132.59 148.85 71.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.675 0.75 . . . . 0.0 111.112 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.463 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.74 145.84 58.49 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.439 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 19.3 t80 -53.93 -41.54 67.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.41 ' NH1' HG23 ' A' ' 118' ' ' VAL . 3.9 ptm180 -54.85 -29.46 55.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.871 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.463 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 15.8 t -85.6 -34.82 8.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.439 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 77.8 t -37.32 -66.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.52 -33.28 4.41 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.1 mt -70.61 -57.02 5.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.844 0.354 . . . . 0.0 110.889 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 62.9 t -56.37 -55.98 16.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.12 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.4 t -47.14 -55.57 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.36 167.85 43.91 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_exo -47.96 93.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.648 2.232 . . . . 0.0 112.356 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.3 tmtt? 60.89 46.43 8.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 59.59 61.59 7.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.493 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.47 -41.56 5.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.843 0.354 . . . . 0.0 111.122 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.2 m -78.91 -46.42 18.5 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 10.7 tp -51.57 -34.39 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.088 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.7 tttt -66.55 -40.58 89.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 25.9 ttp180 -62.3 -22.24 65.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.96 -41.43 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -67.95 -30.64 69.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' A' ' 136' ' ' ARG . 10.1 pt20 -80.7 -48.63 12.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.938 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.502 ' N ' ' CG ' ' A' ' 135' ' ' GLN . 60.0 mtt180 -59.03 -35.25 72.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 49.9 p -100.11 -13.28 19.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.136 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 19.8 m80 58.93 54.22 5.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 34.2 p -132.19 -176.79 4.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.091 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -116.74 97.4 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.953 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 74.4 mt -94.61 133.12 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -115.11 134.94 56.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.6 p -88.1 146.98 39.5 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.591 0.71 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -178.27 2.28 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -87.38 169.55 39.7 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 8.6 ptt85 -70.63 -40.54 73.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.837 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -105.54 42.24 1.26 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.846 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 26.5 mmtp -136.08 168.22 19.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.37 144.06 98.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.659 0.742 . . . . 0.0 110.901 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 82.78 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.693 2.262 . . . . 0.0 112.359 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 76.2 t -133.29 129.62 56.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.149 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -96.53 139.95 31.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -112.78 110.01 19.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.116 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.3 t -101.33 133.22 45.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.15 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 19.9 m -119.46 135.42 54.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.425 ' N ' HG12 ' A' ' 161' ' ' VAL . . . 153.64 -177.1 31.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.529 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 12.1 mmt -49.27 158.36 0.75 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.549 0.69 . . . . 0.0 110.918 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 0.49 5.55 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -117.76 -29.79 5.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.453 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.1 m-20 -79.18 -47.93 15.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.425 HG12 ' N ' ' A' ' 156' ' ' GLY . 15.7 m -66.15 -26.64 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -66.99 -40.39 87.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 7.5 ttt85 -66.88 -56.51 9.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -46.7 -46.27 20.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.055 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.3 ttt180 -49.7 -39.96 38.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -60.67 -52.1 66.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -58.56 -33.55 70.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 67.7 mt -63.24 -66.43 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.4 -32.54 74.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.72 -54.98 2.0 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.115 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -39.89 -40.56 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 71.1 mt . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.939 0.399 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.406 ' HG1' ' N ' ' A' ' 109' ' ' THR . 10.0 t -128.66 158.61 38.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.406 ' N ' ' HG1' ' A' ' 108' ' ' THR . 23.5 m -130.12 113.69 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.177 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.524 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 43.3 pt -103.48 154.85 5.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.524 ' NE2' ' C ' ' A' ' 110' ' ' ILE . 1.6 mp0 -112.54 107.98 16.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 88.7 t -77.79 141.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.414 ' C ' HG13 ' A' ' 114' ' ' VAL . 1.8 tmt_? -110.2 117.39 33.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.842 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.414 HG13 ' C ' ' A' ' 113' ' ' ARG . 12.2 m -137.6 151.11 70.25 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.629 0.728 . . . . 0.0 111.112 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.463 ' O ' ' N ' ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.78 126.7 13.6 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.659 2.24 . . . . 0.0 112.351 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -36.4 -35.53 0.08 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.942 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.8 tpp85 -59.74 -46.88 87.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.463 ' N ' ' O ' ' A' ' 115' ' ' PRO . 48.8 t -72.41 -31.14 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.1 t -45.59 -59.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -52.73 -41.54 57.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.479 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -61.89 -48.89 78.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.83 0.348 . . . . 0.0 110.882 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 84.1 t -64.04 -52.65 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.8 t -49.15 -56.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.166 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 88.49 172.73 46.89 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.93 100.66 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.722 2.281 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? 50.89 43.25 28.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.901 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.35 80.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.526 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.69 -31.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 40.5 m -89.91 -39.47 13.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.425 HD11 ' CG2' ' A' ' 141' ' ' ILE . 5.0 tp -65.07 -29.34 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.179 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -67.76 -42.21 82.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.937 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 70.3 mtp180 -56.16 -43.79 78.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.841 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 57.2 mt -57.44 -44.84 85.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -51.71 -38.18 54.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.935 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -79.2 -51.11 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -55.68 -30.72 61.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.9 p -106.63 -10.88 16.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 56.13 51.51 11.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.41 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.2 p -137.34 143.08 41.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -78.33 95.54 5.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.425 ' CG2' HD11 ' A' ' 130' ' ' ILE . 78.8 mt -88.34 110.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 98.4 t -95.85 120.84 45.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.094 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 82.4 p -77.79 147.3 74.07 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.569 0.699 . . . . 0.0 111.134 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 171.95 13.5 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.685 2.256 . . . . 0.0 112.386 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.67 177.87 54.05 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 7.5 ptp85 -77.69 -33.59 53.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.788 0.327 . . . . 0.0 110.864 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -110.5 41.58 1.74 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.825 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.7 mmmt -137.84 159.33 42.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -57.21 145.25 67.22 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.657 0.742 . . . . 0.0 110.87 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 96.78 0.61 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.67 2.247 . . . . 0.0 112.319 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.8 t -145.52 132.65 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.0 m-85 -102.36 117.13 34.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.99 109.4 20.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 56.8 t -100.14 122.61 52.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.113 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 49.9 m -108.19 131.71 54.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.146 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.407 ' C ' HG12 ' A' ' 161' ' ' VAL . . . 157.18 177.63 30.48 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.498 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 10.5 mmt -42.51 159.41 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.553 0.692 . . . . 0.0 110.867 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 0.83 5.06 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.702 2.268 . . . . 0.0 112.37 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -118.42 -37.33 3.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.41 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.4 m-20 -69.3 -45.67 69.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.407 HG12 ' C ' ' A' ' 156' ' ' GLY . 15.2 m -67.83 -37.12 77.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.82 -42.44 84.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -64.16 -48.37 76.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.97 -47.93 43.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -51.05 -43.76 60.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.842 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -53.28 -44.74 68.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -68.15 -56.3 9.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 73.2 mt -47.7 -45.68 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.135 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -70.29 -45.04 67.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.44 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.32 -57.24 2.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.113 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.44 ' C ' ' O ' ' A' ' 170' ' ' ALA . 47.5 m80 -35.38 -34.62 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.431 ' N ' ' O ' ' A' ' 170' ' ' ALA . 58.5 mt . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.129 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.857 0.361 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.4 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 6.4 t -139.92 163.53 32.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.14 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -129.28 125.69 37.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.161 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.5 pt -112.18 164.51 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 50.3 mm-40 -121.71 97.93 5.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.467 HG12 ' N ' ' A' ' 113' ' ' ARG . 95.3 t -68.78 142.74 15.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.125 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.467 ' N ' HG12 ' A' ' 112' ' ' VAL . 25.3 ttt85 -112.55 121.56 45.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.2 m -141.98 151.07 58.27 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.616 0.722 . . . . 0.0 111.147 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.474 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.3 Cg_endo -69.8 125.54 12.24 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.671 2.247 . . . . 0.0 112.344 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.437 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.7 t80 -35.26 -33.21 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.876 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 115' ' ' PRO . 87.3 mtt-85 -61.68 -49.94 74.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.867 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.462 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 55.3 t -68.72 -35.03 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 56.1 t -39.06 -62.76 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -54.43 -38.92 63.83 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.467 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.7 mt -63.34 -43.54 97.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.4 t -68.48 -61.95 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 88.8 t -40.78 -49.04 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.119 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 78.45 172.86 41.37 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -47.95 97.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.653 2.235 . . . . 0.0 112.409 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 47.83 50.47 15.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.913 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.79 74.33 0.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -121.78 -45.15 2.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 67.2 m -82.21 -44.73 15.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.401 HG21 ' N ' ' A' ' 131' ' ' LYS . 6.4 tp -57.43 -38.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.401 ' N ' HG21 ' A' ' 130' ' ' ILE . 38.5 mttp -53.58 -39.87 65.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.405 ' HD2' ' N ' ' A' ' 132' ' ' ARG . 1.0 OUTLIER -57.75 -36.07 71.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 46.8 mt -69.94 -46.9 71.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -55.15 -39.83 69.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -78.28 -45.5 22.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -58.07 -37.59 74.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.84 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 81.8 p -101.23 -11.45 19.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 59.89 48.31 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.414 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 62.7 p -127.36 162.95 25.09 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -96.79 94.78 7.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.936 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 79.2 mt -90.43 122.3 41.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.106 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 68.9 t -113.81 129.46 69.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.119 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.6 p -77.47 147.75 75.92 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.576 0.703 . . . . 0.0 111.183 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 177.81 5.22 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.43 165.22 51.49 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -68.2 -45.95 71.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 0.0 110.879 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -101.7 42.75 1.11 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -136.07 173.43 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -67.2 143.94 97.92 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 89.12 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.368 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 77.9 t -134.7 134.49 54.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.089 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -104.05 122.72 45.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -92.82 123.95 36.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.122 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 46.5 t -118.71 119.09 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 156' ' ' GLY . 89.3 m -107.35 138.1 44.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.144 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.448 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.88 -169.96 31.28 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.436 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 12.0 mmt -52.53 159.47 1.66 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.561 0.696 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.4 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.4 Cg_endo -69.81 0.56 5.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.656 2.237 . . . . 0.0 112.35 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.38 -47.17 2.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.414 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 28.8 m-20 -65.42 -44.9 85.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.448 ' CG1' ' CA ' ' A' ' 156' ' ' GLY . 18.7 m -63.79 -37.87 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.154 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -73.53 -31.65 63.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 46.4 mtp180 -69.57 -36.9 76.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -64.32 -37.41 87.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.08 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -53.68 -58.66 6.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.812 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . 0.467 ' HG3' ' N ' ' A' ' 167' ' ' GLU . 1.0 OUTLIER -48.74 -35.44 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.926 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . 0.467 ' N ' ' HG3' ' A' ' 166' ' ' GLU . 5.4 mm-40 -69.47 -46.76 65.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 93.9 mt -63.32 -49.36 83.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.165 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -60.61 -41.7 95.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.5 -53.07 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -40.17 -41.06 1.22 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 68.7 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.109 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.437 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 6.9 t -125.38 162.5 24.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.135 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.5 m -135.49 122.29 21.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.098 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.7 pt -111.81 156.12 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.17 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 47.7 mm-40 -111.74 98.83 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 88.9 t -66.04 141.42 18.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.137 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.4 ttp180 -112.33 113.24 25.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.42 ' CG2' HG21 ' A' ' 119' ' ' VAL . 3.8 m -132.8 151.07 77.41 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.432 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 126.72 13.64 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.352 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.411 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -36.44 -33.4 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 115' ' ' PRO . 84.8 mtt180 -62.22 -52.54 63.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.831 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.432 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 54.6 t -67.6 -34.15 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.098 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.42 HG21 ' CG2' ' A' ' 114' ' ' VAL . 48.1 t -40.17 -66.62 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.098 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.86 -36.5 26.7 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.475 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.5 mt -66.34 -41.84 89.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.883 0.373 . . . . 0.0 110.955 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.4 t -71.81 -54.6 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.107 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 92.5 t -50.95 -49.14 28.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.18 172.67 46.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.477 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -47.96 105.47 0.09 OUTLIER 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.712 2.274 . . . . 0.0 112.313 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 9.0 tppt? 45.5 44.5 9.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 64.11 76.07 0.32 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.484 ' O ' ' CZ ' ' A' ' 132' ' ' ARG . . . -124.21 -26.82 3.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 111.119 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 96.2 m -93.77 -35.91 12.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.145 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.1 tp -72.76 -29.94 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.155 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.448 ' HG3' ' N ' ' A' ' 132' ' ' ARG . 8.3 ptmt -58.94 -36.95 75.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.484 ' CZ ' ' O ' ' A' ' 128' ' ' ALA . 0.7 OUTLIER -67.04 -52.69 39.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.858 179.996 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.6 mt -46.4 -50.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.408 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 60.9 mt-30 -46.2 -35.39 5.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -81.31 -51.43 8.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -52.07 -35.3 47.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.875 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.4 p -104.1 -11.18 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.152 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 67.5 m80 55.99 54.66 7.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.872 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.465 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 82.5 p -137.38 147.37 45.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.169 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -80.5 97.38 7.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.408 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 85.5 mt -90.84 118.52 36.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -106.48 123.46 61.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.175 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.4 p -81.84 148.95 62.5 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.585 0.707 . . . . 0.0 111.124 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 172.57 12.39 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.06 157.93 34.19 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 6.0 ptp180 -55.09 -42.3 72.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.9 p-10 -102.02 43.81 1.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -135.7 168.11 19.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -69.56 149.45 96.99 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.688 0.756 . . . . 0.0 110.832 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 91.38 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 96.9 t -145.67 130.42 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.168 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -99.46 136.45 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.911 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -107.55 106.47 16.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.08 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.5 t -100.44 117.77 46.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 85.1 m -106.55 136.18 46.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.16 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.79 175.88 24.76 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.45 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 13.4 mmt -41.68 159.56 0.18 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.52 0.676 . . . . 0.0 110.912 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.437 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 54.0 Cg_endo -69.76 0.81 5.11 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.663 2.242 . . . . 0.0 112.374 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.11 -35.1 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.905 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.465 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.3 m-20 -72.03 -46.95 55.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -64.09 -37.59 80.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -55.44 -45.09 76.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.845 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -57.27 -54.57 45.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.74 -51.96 8.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 68.8 ttp85 -45.28 -45.17 11.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.855 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -61.49 -42.47 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -61.92 -57.32 12.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 78.3 mt -52.46 -49.56 42.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -63.54 -43.76 96.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.866 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.58 -57.5 2.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' A' ' 170' ' ' ALA . 37.9 m80 -37.13 -38.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 51.1 mt . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.103 -179.992 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.889 0.376 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.438 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 1.6 t -135.34 174.58 10.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.18 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.419 ' N ' ' OG1' ' A' ' 108' ' ' THR . 56.7 m -148.16 127.26 12.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.15 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.2 pt -118.35 155.12 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.494 ' CD ' ' N ' ' A' ' 111' ' ' GLN . 1.0 OUTLIER -108.53 97.14 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.474 HG12 ' N ' ' A' ' 113' ' ' ARG . 82.7 t -68.14 137.89 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.183 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.474 ' N ' HG12 ' A' ' 112' ' ' VAL . 24.9 ttt180 -103.44 116.5 32.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.891 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.55 147.4 61.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.602 0.715 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.471 ' O ' ' N ' ' A' ' 117' ' ' ARG . 54.4 Cg_endo -69.7 126.94 13.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.663 2.242 . . . . 0.0 112.344 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.412 ' C ' ' O ' ' A' ' 115' ' ' PRO . 32.4 t80 -36.59 -31.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' PRO . 15.2 ttm180 -64.66 -51.6 61.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.463 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 42.3 t -64.89 -31.65 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.118 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.8 t -41.63 -70.68 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.11 -28.48 1.33 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.6 mt -75.11 -48.95 21.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 0.0 110.936 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 40.1 t -59.83 -60.13 2.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.104 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.1 t -46.06 -63.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.107 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 89.04 172.46 46.16 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_exo -48.04 99.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.7 2.267 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 30.5 tttm 49.75 49.69 19.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.06 73.66 0.46 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.18 -38.76 2.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 111.12 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 80.1 m -83.64 -44.98 13.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.164 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 10.0 tp -57.84 -26.92 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.3 tttt -63.79 -45.78 88.13 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -36.19 56.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.928 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 48.6 mt -66.57 -58.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.131 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 -52.1 -36.05 49.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.877 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 56.3 mm-40 -78.74 -34.68 45.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -67.26 -38.5 85.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.835 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 53.1 p -107.18 -0.4 22.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.138 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 37.1 m170 52.71 52.59 13.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 16.5 p -123.08 179.98 4.48 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.115 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -117.11 98.18 6.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 79.5 mt -90.62 127.1 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.117 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 75.3 t -112.07 121.05 63.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.0 p -74.78 145.96 82.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.585 0.707 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 179.98 3.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.632 2.221 . . . . 0.0 112.297 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.42 165.04 51.37 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.5 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -70.04 -45.04 68.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 0.0 110.868 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 49.6 m-20 -103.22 41.74 1.23 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -133.01 174.45 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -68.28 144.3 96.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.598 0.713 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 100.97 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 91.4 t -149.88 130.55 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -100.68 132.61 45.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.45 111.59 24.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.124 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 41.5 t -99.91 117.96 45.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.108 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 96.2 m -109.53 131.97 54.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.41 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 158.44 -177.81 34.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 20.4 mmt -49.59 158.31 0.84 Allowed Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.557 0.694 . . . . 0.0 110.901 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.438 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.75 -1.96 9.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -115.6 -23.36 8.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -84.82 -54.76 4.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.41 HG13 ' C ' ' A' ' 156' ' ' GLY . 5.5 m -58.26 -27.0 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.149 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -70.38 -39.13 74.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.875 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.45 -50.42 45.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -52.5 -42.99 64.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 18.5 ttm180 -47.14 -53.17 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.898 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -50.85 -43.88 59.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.72 -51.37 69.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 50.2 mt -55.26 -44.09 73.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.163 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -68.18 -44.46 75.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -42.68 -51.28 5.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.086 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -42.01 -38.66 1.69 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 57.1 mt . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.154 -179.98 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.426 ' NE2' HG23 ' A' ' 155' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.88 0.372 . . . . 0.0 110.935 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.421 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 9.6 t -134.72 164.47 27.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 89.8 m -131.25 122.46 26.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.179 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.4 pt -114.5 148.9 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.0 mm-40 -109.33 101.35 10.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 88.2 t -70.2 143.27 14.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.138 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.407 ' C ' HG12 ' A' ' 114' ' ' VAL . 6.9 ttm180 -114.04 120.93 42.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.851 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.407 HG12 ' C ' ' A' ' 113' ' ' ARG . 11.1 m -139.68 150.92 64.84 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.653 0.739 . . . . 0.0 111.117 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 118' ' ' VAL . 54.1 Cg_endo -69.74 125.49 12.22 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.655 2.236 . . . . 0.0 112.344 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.8 t80 -34.52 -35.53 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 115' ' ' PRO . 75.5 mtt-85 -59.56 -49.37 78.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' A' ' 115' ' ' PRO . 55.7 t -69.61 -35.28 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.107 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.9 t -39.51 -63.37 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.171 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.89 -42.23 37.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.0 mt -60.46 -43.46 96.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.816 0.341 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.407 ' HA ' ' CE1' ' A' ' 171' ' ' HIS . 58.3 t -69.98 -60.37 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.12 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.5 t -37.08 -51.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.42 166.79 42.44 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_exo -48.01 92.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.36 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 53.3 mmtt 58.51 41.63 22.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.918 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.54 66.29 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -111.76 -40.36 4.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.884 0.373 . . . . 0.0 111.115 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.3 m -84.82 -43.94 13.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.413 HD11 ' CG2' ' A' ' 141' ' ' ILE . 7.0 tp -58.52 -28.18 35.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -71.32 -43.42 67.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 35.0 ttm-85 -60.16 -39.95 88.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 58.0 mt -59.21 -50.1 81.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -48.77 -36.8 17.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.922 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -80.21 -51.08 9.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.913 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -54.2 -33.64 58.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.9 p -104.2 -14.83 15.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.141 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 9.8 m80 60.26 52.76 4.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 77.7 p -138.81 145.22 39.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -78.42 100.21 6.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.413 ' CG2' HD11 ' A' ' 130' ' ' ILE . 93.9 mt -96.23 122.08 47.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.083 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.4 t -112.96 132.28 62.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.6 p -85.17 152.53 58.59 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.626 0.727 . . . . 0.0 111.114 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.48 3.68 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.665 2.244 . . . . 0.0 112.364 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.88 169.76 53.41 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -70.1 -47.47 61.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.837 0.351 . . . . 0.0 110.872 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -103.79 40.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 18.3 mmmt -131.66 172.17 12.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -68.77 144.23 95.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.632 0.729 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 99.25 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.695 2.263 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 85.4 t -148.99 118.71 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.95 149.86 24.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.19 109.5 14.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.043 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 68.4 t -102.4 133.69 45.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.16 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.426 HG23 ' NE2' ' A' ' 107' ' ' GLN . 25.9 m -118.81 135.45 54.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.472 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 150.85 -179.33 27.65 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.433 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 14.5 mmt -43.49 159.44 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.534 0.683 . . . . 0.0 110.884 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.421 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.8 -0.17 6.56 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -119.29 -39.23 2.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -68.63 -40.42 80.33 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.472 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 20.2 m -72.42 -34.86 49.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -59.96 -39.93 87.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 43.6 ttt180 -61.27 -55.68 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.24 -43.08 3.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.092 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 72.1 ttt-85 -56.31 -40.65 74.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -54.57 -45.46 73.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -66.61 -57.16 7.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.917 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.7 mt -49.0 -45.82 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.165 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -71.13 -44.22 66.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.51 -57.97 1.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.129 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.413 ' C ' ' O ' ' A' ' 170' ' ' ALA . 13.2 m170 -36.19 -40.18 0.21 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.857 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 50.2 mt . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.971 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.401 ' CA ' ' HE3' ' A' ' 157' ' ' MET . 8.8 pt20 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -130.63 168.34 17.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.2 m -136.96 118.67 15.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.0 pt -107.3 150.62 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.112 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -109.61 94.16 4.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 79.4 t -67.16 139.74 20.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -109.25 111.89 23.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.2 m -128.39 150.89 75.56 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.589 0.709 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.5 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.77 123.56 10.22 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.668 2.245 . . . . 0.0 112.373 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 22.8 t80 -34.84 -32.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.5 ' N ' ' O ' ' A' ' 115' ' ' PRO . 50.5 mtt85 -62.68 -49.13 76.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.477 ' N ' ' O ' ' A' ' 115' ' ' PRO . 56.0 t -70.35 -31.31 46.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.5 t -43.07 -64.46 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.1 -41.17 22.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.486 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 18.0 mt -63.19 -47.94 80.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.879 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 61.5 t -62.66 -61.71 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.131 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.6 t -43.16 -50.39 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 80.74 173.01 46.49 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.464 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' LYS . 64.6 Cg_exo -47.92 114.64 1.17 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.674 2.249 . . . . 0.0 112.372 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' PRO . 0.0 OUTLIER 34.13 43.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.886 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.38 84.45 0.12 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -133.52 -34.37 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 58.9 m -89.72 -43.7 10.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.089 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.21 -27.79 38.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.094 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttmt -68.29 -37.46 80.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.8 ttm180 -64.33 -46.82 81.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.854 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 36.6 mt -55.69 -42.8 71.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.407 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 79.0 mt-30 -57.23 -24.35 54.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.98 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 51.9 mm-40 -89.83 -47.03 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.401 ' NH1' ' OE2' ' A' ' 167' ' ' GLU . 6.3 ptm180 -64.16 -31.54 72.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.485 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 73.9 p -100.23 -12.83 19.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.158 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 27.2 m80 57.21 54.4 6.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.458 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 72.5 p -141.76 140.62 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -78.47 97.28 5.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.407 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 96.2 mt -88.78 108.71 19.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.138 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -91.95 133.65 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.116 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.0 p -91.81 146.13 32.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.558 0.694 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 177.17 5.82 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.733 2.289 . . . . 0.0 112.297 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.87 -178.02 50.11 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.514 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 50.3 ptt85 -83.08 -38.47 22.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.834 0.35 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -110.0 41.81 1.64 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -135.61 164.86 26.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -62.25 142.58 95.84 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.923 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 103.57 1.19 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.655 2.237 . . . . 0.0 112.348 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.3 t -148.28 115.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -86.96 128.44 35.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.915 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.36 104.28 14.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.464 HG12 ' CG1' ' A' ' 161' ' ' VAL . 60.3 t -95.9 122.2 47.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.437 HG22 ' N ' ' A' ' 156' ' ' GLY . 87.6 m -108.65 137.15 47.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.437 ' N ' HG22 ' A' ' 155' ' ' THR . . . 151.95 -179.76 28.26 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' MET . . . . . 0.401 ' HE3' ' CA ' ' A' ' 107' ' ' GLN . 15.6 mmt -47.12 159.34 0.4 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 110.897 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 0.28 5.86 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.718 2.278 . . . . 0.0 112.351 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -118.4 -32.1 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.846 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.458 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.0 m-20 -73.58 -48.49 32.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.464 ' CG1' HG12 ' A' ' 154' ' ' VAL . 32.9 m -65.62 -40.13 87.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -51.17 -41.88 60.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 15.3 ttm180 -65.24 -47.58 76.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.819 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.94 54.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.09 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.49 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 22.7 ttt85 -55.3 -45.26 76.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.854 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -60.98 -38.18 85.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . 0.485 ' OE1' ' CG2' ' A' ' 137' ' ' THR . 12.8 mt-10 -66.94 -50.52 62.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.886 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 66.6 mt -60.75 -43.41 95.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.49 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 60.3 mt-10 -66.15 -47.46 73.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.411 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -45.35 -55.36 6.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.411 ' C ' ' O ' ' A' ' 170' ' ' ALA . 30.0 m170 -37.23 -41.01 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 56.4 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.414 ' CD ' ' C ' ' A' ' 107' ' ' GLN . 4.8 pp0? . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.92 0.391 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.443 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 5.7 t -133.1 165.35 24.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.134 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.1 m -133.54 122.47 23.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -116.11 147.73 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -105.97 106.77 17.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 113' ' ' ARG . 97.6 t -71.83 141.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.107 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.469 ' N ' HG12 ' A' ' 112' ' ' VAL . 47.0 ttp180 -111.7 115.91 29.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.882 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.407 HG12 ' C ' ' A' ' 113' ' ' ARG . 4.1 m -136.57 150.27 69.82 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.564 0.697 . . . . 0.0 111.158 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.466 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.71 130.22 19.01 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.344 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -40.6 -33.76 0.3 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.433 ' HB3' ' NH1' ' A' ' 117' ' ' ARG . 5.6 mmm180 -61.76 -48.24 81.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.466 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 54.5 t -71.7 -32.67 46.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.9 t -40.73 -65.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.81 -40.42 26.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.89 -40.65 98.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 0.0 110.926 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.421 ' CG1' HD11 ' A' ' 130' ' ' ILE . 59.1 t -69.01 -63.5 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 95.5 t -38.43 -50.85 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.15 169.19 42.95 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -47.98 105.74 0.09 OUTLIER 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.697 2.265 . . . . 0.0 112.32 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt 45.22 39.29 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.921 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.76 86.51 0.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.479 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -134.87 -39.07 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.808 0.337 . . . . 0.0 111.047 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.0 m -86.65 -43.8 12.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.175 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.421 HD11 ' CG1' ' A' ' 122' ' ' VAL . 4.9 tp -60.95 -41.27 88.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.56 -38.39 69.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.835 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -58.62 -45.91 88.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.2 mt -55.26 -43.41 70.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.132 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.442 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 68.1 mt-30 -56.51 -37.18 70.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 135' ' ' GLN . 7.4 mm-40 -78.67 -54.24 6.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.922 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 23.0 mmm-85 -51.17 -34.83 33.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 70.0 p -102.52 -12.76 17.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 36.0 m80 57.22 52.94 8.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 63.8 p -136.11 159.19 42.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -89.34 98.88 12.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.442 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 71.1 mt -97.31 112.93 30.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.185 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.459 HG13 ' N ' ' A' ' 143' ' ' THR . 70.7 t -102.6 135.57 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.459 ' N ' HG13 ' A' ' 142' ' ' VAL . 59.8 p -85.03 149.62 53.48 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.564 0.697 . . . . 0.0 111.146 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 177.58 5.44 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.2 161.84 49.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptp85 -66.48 -44.06 83.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -103.57 39.67 1.56 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.864 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -133.92 166.57 22.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -61.49 145.76 90.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.669 0.747 . . . . 0.0 110.904 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.7 98.16 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.653 2.235 . . . . 0.0 112.39 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 87.0 t -149.53 125.33 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.59 150.1 20.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.14 113.19 21.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.9 t -104.93 123.12 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.46 HG21 ' N ' ' A' ' 156' ' ' GLY . 89.4 m -112.23 139.24 47.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.115 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.46 ' N ' HG21 ' A' ' 155' ' ' THR . . . 147.49 -173.79 27.48 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 16.2 mmt -48.56 159.32 0.54 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.502 0.668 . . . . 0.0 110.892 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.443 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.9 Cg_endo -69.76 -1.06 7.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.657 2.238 . . . . 0.0 112.337 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -115.67 -49.79 2.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -59.47 -41.64 90.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 m -72.3 -34.33 48.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -58.34 -42.32 86.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -65.99 -36.78 84.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.892 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -60.02 -31.52 70.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 48.3 ttt180 -71.64 -52.4 18.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.85 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -62.54 -30.57 71.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -70.98 -54.34 11.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 72.1 mt -58.61 -46.69 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -65.0 -37.52 87.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.61 -53.79 6.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -41.8 -32.99 0.45 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 83.5 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.111 180.0 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.888 0.375 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.8 t -133.42 170.44 15.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.19 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.4 m -141.98 129.01 20.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.453 ' O ' ' NE2' ' A' ' 111' ' ' GLN . 20.4 pt -122.04 158.91 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . 0.454 ' CD ' ' N ' ' A' ' 111' ' ' GLN . 1.2 mp0 -113.81 106.37 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.96 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 93.9 t -75.61 142.28 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -110.37 120.31 42.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -142.49 150.71 55.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.615 0.721 . . . . 0.0 111.154 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.467 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.77 125.26 11.93 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.323 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.462 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 27.1 t80 -35.85 -34.65 0.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.959 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.428 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.0 ttp180 -59.74 -49.91 75.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.467 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 56.1 t -69.56 -34.27 60.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.462 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 98.9 t -40.15 -66.97 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.147 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.64 -41.14 18.47 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.513 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.2 mt -62.22 -43.32 99.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -68.03 -62.12 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.075 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.5 t -40.04 -54.03 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.177 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 87.64 167.57 43.67 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_exo -47.93 94.8 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.717 2.278 . . . . 0.0 112.338 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 29.6 mtpt 55.07 42.17 31.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.905 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.32 79.01 0.31 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.478 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -128.47 -38.78 1.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.867 0.365 . . . . 0.0 111.104 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.2 m -87.08 -40.26 14.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.087 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.0 tp -64.7 -33.33 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.141 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 18.2 tttp -59.49 -42.34 91.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -54.96 -47.79 74.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.812 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 54.3 mt -54.8 -48.81 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.426 ' CG ' HD11 ' A' ' 141' ' ' ILE . 61.1 mt-30 -48.25 -38.59 18.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 86.7 mm-40 -81.12 -52.56 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -51.37 -32.64 26.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.4 p -106.53 -13.56 15.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.141 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 41.2 m80 60.0 53.43 4.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.463 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 55.2 p -135.49 139.79 44.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.121 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -77.75 90.47 4.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.979 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.442 HG23 ' N ' ' A' ' 142' ' ' VAL . 78.9 mt -83.29 142.14 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.163 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.442 ' N ' HG23 ' A' ' 141' ' ' ILE . 86.6 t -131.01 121.23 49.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.119 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 78.6 p -73.0 150.01 90.05 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.562 0.696 . . . . 0.0 111.152 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 176.91 6.17 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.252 . . . . 0.0 112.363 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -77.08 150.46 37.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -57.17 -36.42 70.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -110.34 40.35 1.98 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 49.2 mmtt -134.72 165.77 24.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.42 144.54 62.35 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 94.01 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.658 2.239 . . . . 0.0 112.396 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.423 HG11 ' N ' ' A' ' 152' ' ' PHE . 89.3 t -145.72 135.55 18.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.089 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . 0.423 ' N ' HG11 ' A' ' 151' ' ' VAL . 47.1 m-85 -102.51 128.43 49.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -100.21 109.86 22.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 67.3 t -100.77 130.17 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.138 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 21.7 m -117.91 135.1 54.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.135 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.407 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 153.87 179.72 29.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.504 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 18.9 mmt -46.57 159.28 0.36 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.53 0.681 . . . . 0.0 110.905 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 0.85 5.06 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.673 2.249 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -118.47 -29.13 5.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.914 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.463 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 8.4 m-20 -78.22 -46.47 20.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.838 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.458 HG21 ' N ' ' A' ' 162' ' ' ASP . 16.0 m -68.32 -23.56 28.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . 0.458 ' N ' HG21 ' A' ' 161' ' ' VAL . 45.9 t0 -66.72 -39.12 87.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 24.2 ttm-85 -70.15 -46.87 63.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.37 -34.62 58.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.118 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.6 ttm180 -64.48 -50.87 65.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -62.9 -24.68 67.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -77.08 -56.5 4.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.957 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 76.2 mt -52.73 -53.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -56.28 -43.37 78.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -41.78 -58.3 2.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.444 ' C ' ' O ' ' A' ' 170' ' ' ALA . 9.8 m80 -34.45 -36.07 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 170' ' ' ALA . 64.9 mt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.869 0.366 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -125.61 159.48 32.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.2 m -128.51 116.42 19.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -104.77 155.32 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -114.42 101.0 8.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 91.3 t -69.64 141.97 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 23.6 ttp180 -111.67 112.05 23.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.4 m -134.11 151.4 76.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.614 0.721 . . . . 0.0 111.108 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.542 ' CB ' ' NH1' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.74 138.37 37.72 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.682 2.255 . . . . 0.0 112.322 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.0 t80 -46.96 -37.91 9.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.542 ' NH1' ' CB ' ' A' ' 115' ' ' PRO . 8.6 ptp85 -59.01 -38.62 79.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.468 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 19.8 t -78.0 -36.42 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.171 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 97.1 t -41.37 -63.7 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.07 -39.21 18.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.3 mt -65.15 -43.9 90.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 0.0 110.921 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 73.4 t -71.57 -60.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.7 t -42.28 -45.54 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 73.92 173.34 27.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.482 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.4 Cg_exo -48.03 114.74 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.7 pttm 36.1 39.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.895 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.44 73.77 0.78 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.61 -38.49 3.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 m -85.5 -44.25 12.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.1 tp -60.82 -31.16 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -68.03 -40.18 82.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -60.85 -44.23 97.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.833 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 73.0 mt -54.58 -54.58 21.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.126 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 138' ' ' HIS . 76.1 mt-30 -42.81 -30.9 0.43 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -78.27 -53.72 7.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.4 -32.17 56.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 74.1 p -102.22 -17.5 15.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.178 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 134' ' ' GLN . 16.9 m170 59.27 54.94 4.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.821 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.452 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.3 p -135.28 174.51 10.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -106.21 89.94 3.21 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.8 mt -82.89 137.14 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 91.7 t -124.63 132.14 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.166 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.7 p -90.26 147.86 37.82 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.582 0.706 . . . . 0.0 111.166 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -179.11 2.67 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.315 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.44 176.92 51.5 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.52 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . 0.421 ' C ' ' HD3' ' A' ' 146' ' ' ARG . 0.2 OUTLIER -80.23 -35.29 36.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -106.87 39.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 38.7 mmtt -138.01 175.43 9.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -71.98 143.41 86.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.592 0.71 . . . . 0.0 110.935 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 89.66 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.644 2.229 . . . . 0.0 112.394 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 75.4 t -138.17 119.64 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.71 148.88 25.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.86 105.62 10.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.08 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.0 t -100.89 127.03 54.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.128 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -112.79 138.68 49.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.415 ' C ' HG11 ' A' ' 161' ' ' VAL . . . 150.4 176.04 23.03 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 14.0 mmt -41.03 159.4 0.16 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.582 0.706 . . . . 0.0 110.87 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 0.58 5.4 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.706 2.271 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -118.35 -35.46 3.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.452 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.1 m-20 -69.25 -46.31 67.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.904 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.415 HG11 ' C ' ' A' ' 156' ' ' GLY . 33.7 m -68.88 -38.61 78.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.134 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -52.37 -42.04 63.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 42.0 ttt85 -63.82 -52.56 59.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -45.58 -49.28 14.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.079 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 44.4 ttt180 -51.6 -40.5 59.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -57.61 -47.98 80.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -65.04 -56.69 11.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.937 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 65.4 mt -47.84 -50.69 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.132 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -65.89 -47.03 76.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.433 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.83 -55.75 1.46 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 170' ' ' ALA . 95.2 m-70 -36.02 -43.11 0.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.833 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 73.6 mt . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.092 179.996 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.853 0.358 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.407 ' HG1' ' N ' ' A' ' 109' ' ' THR . 8.8 t -147.71 156.97 43.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.162 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.407 ' N ' ' HG1' ' A' ' 108' ' ' THR . 97.8 m -127.9 122.49 32.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -111.27 154.84 12.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -109.9 101.76 10.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.413 HG11 ' N ' ' A' ' 113' ' ' ARG . 54.0 t -69.67 132.98 32.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.413 ' N ' HG11 ' A' ' 112' ' ' VAL . 14.9 ttp180 -100.39 118.95 37.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.14 150.45 58.85 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.624 0.726 . . . . 0.0 111.085 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 133.18 24.98 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -42.42 -26.89 0.13 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 60.2 ttp85 -69.35 -54.06 16.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 35.8 t -63.65 -27.29 42.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.1 t -46.5 -71.09 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -43.68 -34.67 2.79 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 8.7 mt -67.39 -44.19 79.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 83.9 t -69.42 -65.58 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.9 t -37.63 -61.5 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.78 166.15 38.64 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.514 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_exo -47.97 93.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt 56.98 54.03 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.939 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 54.93 70.95 0.8 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.71 -41.14 2.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 111.084 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 73.7 m -78.59 -44.5 23.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.155 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.5 tp -54.4 -29.59 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.7 tptp -54.57 -44.64 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -61.27 -22.12 64.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 70.5 mt -83.1 -31.56 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.136 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.404 ' CG ' ' HB ' ' A' ' 141' ' ' ILE . 44.8 mt-30 -83.34 -24.45 32.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . 0.463 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.82 -41.01 19.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.463 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 14.9 mmm180 -64.62 -35.68 81.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -100.56 -18.12 16.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.16 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.4 m80 62.28 46.18 6.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.822 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.441 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.6 p -120.67 164.55 16.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 t80 -95.66 88.25 4.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.404 ' HB ' ' CG ' ' A' ' 134' ' ' GLN . 79.9 mt -88.69 132.81 32.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.103 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.4 t -117.96 132.09 68.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.167 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 64.4 p -85.55 148.07 48.25 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.596 0.713 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 176.49 6.73 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.647 2.231 . . . . 0.0 112.356 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.56 179.22 53.24 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.48 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -79.16 -43.25 24.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.884 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.7 p-10 -104.79 43.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 52.9 mmtt -134.08 169.04 17.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -66.57 143.99 98.43 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.669 0.747 . . . . 0.0 110.91 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 95.7 0.56 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 2.267 . . . . 0.0 112.313 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.2 t -147.7 119.59 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.172 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -88.27 140.27 29.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.02 110.17 20.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.081 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -103.98 122.51 56.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 93.6 m -111.03 130.59 55.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.153 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.491 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 158.31 178.16 32.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.475 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 12.5 mmt -45.37 158.94 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -0.69 7.2 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.737 2.291 . . . . 0.0 112.32 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.78 -25.38 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.908 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.441 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 5.5 m-20 -83.07 -48.52 10.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 34.1 m -64.78 -36.96 78.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -58.36 -45.28 88.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.855 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -61.46 -43.91 98.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.873 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.92 -44.01 70.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 18.6 ttm180 -59.42 -42.85 92.8 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.872 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -53.37 -42.88 67.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.935 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -71.3 -51.61 23.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.877 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 61.6 mt -49.34 -53.99 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -67.38 -41.45 85.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.59 -61.44 0.71 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 170' ' ' ALA . 32.7 m170 -34.46 -41.29 0.12 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.842 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 93.4 mt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.981 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.903 0.382 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.4 t -129.47 159.66 35.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -131.24 120.64 23.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.187 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 25.0 pt -111.15 152.89 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 38.2 mm-40 -108.02 100.66 9.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.896 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.472 HG11 ' N ' ' A' ' 113' ' ' ARG . 88.4 t -73.09 141.97 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.147 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.472 ' N ' HG11 ' A' ' 112' ' ' VAL . 37.5 ttt-85 -104.98 120.88 42.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.93 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.496 HG21 ' CD1' ' A' ' 152' ' ' PHE . 4.8 m -140.49 151.07 62.84 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.688 0.756 . . . . 0.0 111.074 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.467 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.2 Cg_endo -69.79 138.4 37.64 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.685 2.256 . . . . 0.0 112.314 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -47.52 -26.21 1.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.927 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 ttm180 -69.6 -46.99 65.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.835 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.467 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 41.2 t -68.39 -29.37 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.108 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.4 t -42.27 -65.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.66 -34.08 9.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.4 -46.11 61.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.85 0.357 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 91.9 t -64.89 -57.92 9.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 90.2 t -55.28 -49.24 74.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.94 172.69 48.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.44 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.95 99.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.652 2.235 . . . . 0.0 112.382 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? 54.01 42.71 31.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.46 68.38 1.67 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.52 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.28 -35.18 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.893 0.378 . . . . 0.0 111.109 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 33.1 m -75.94 -39.41 56.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.4 tp -67.21 -23.08 29.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -62.58 -38.5 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -66.44 -37.8 85.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.844 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 66.7 mt -70.48 -49.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.116 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -52.32 -37.49 55.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -81.82 -52.41 7.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 -52.89 -33.87 52.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.7 p -103.54 -15.15 15.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.165 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 17.8 m170 60.95 53.79 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 81.5 p -138.01 138.27 38.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.135 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 51.9 t80 -76.74 91.92 3.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt -83.64 134.41 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.125 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.1 t -120.28 129.32 75.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.137 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 41.6 p -83.8 153.12 63.94 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.54 0.686 . . . . 0.0 111.191 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 177.06 5.97 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.684 2.256 . . . . 0.0 112.366 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -75.06 155.67 48.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.45 -28.49 70.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.86 0.362 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -119.91 38.01 4.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -135.91 162.13 33.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -53.99 143.86 40.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.638 0.732 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.73 97.68 0.65 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.695 2.263 . . . . 0.0 112.331 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.3 t -145.32 117.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . 0.496 ' CD1' HG21 ' A' ' 114' ' ' VAL . 35.4 m-85 -86.73 146.31 26.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.86 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -121.74 99.13 6.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 46.6 t -87.63 131.1 36.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -117.09 131.07 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.177 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.427 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 156.43 175.13 27.04 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.456 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 21.6 mmt -39.2 159.49 0.1 Allowed Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.576 0.703 . . . . 0.0 110.902 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.723 2.282 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -119.7 -38.38 2.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 37.2 m-20 -66.77 -46.42 75.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.427 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 20.5 m -67.72 -38.1 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -52.89 -43.1 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 11.9 ttt180 -61.89 -57.92 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.06 -48.54 4.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 16.9 ttp85 -48.34 -40.24 24.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -55.48 -64.82 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 58.1 mm-40 -54.22 -46.35 72.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 47.7 mt -44.63 -65.91 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.082 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.417 ' O ' ' CG1' ' A' ' 172' ' ' ILE . 0.7 OUTLIER -69.36 -29.52 67.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.861 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -48.74 -48.99 40.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -46.89 -26.32 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.417 ' CG1' ' O ' ' A' ' 169' ' ' GLU . 69.6 mt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--O 1.233 0.189 0 CA-C-O 120.889 0.376 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.9 t -124.5 168.4 13.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.123 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 25.6 m -137.34 124.63 21.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 23.0 pt -122.46 155.24 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.091 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -105.2 111.66 24.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 70.4 t -76.77 135.04 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.424 ' C ' HG12 ' A' ' 114' ' ' VAL . 7.3 tmm_? -106.65 117.65 34.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.424 HG12 ' C ' ' A' ' 113' ' ' ARG . 8.7 m -137.96 151.05 69.42 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.669 0.747 . . . . 0.0 111.121 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 134.37 27.98 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -47.09 -21.98 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 91.7 mtt-85 -72.59 -44.02 62.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 39.6 t -74.31 -34.41 36.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.15 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.8 t -38.23 -69.92 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.155 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.31 -36.21 4.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.472 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -68.01 -44.16 77.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.882 0.373 . . . . 0.0 110.958 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.53 -63.28 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.3 t -40.88 -50.43 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.142 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 79.97 169.08 38.51 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.05 101.23 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.353 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.4 tptm 50.26 44.39 26.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.71 72.9 0.7 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.63 -39.81 2.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 111.12 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -84.49 -43.57 14.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.4 tp -58.53 -37.88 67.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 27.4 tttm -57.09 -43.2 81.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 74.3 mtt-85 -57.27 -44.35 83.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.425 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 58.7 mt -57.93 -46.43 87.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.164 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.6 mt-30 -60.8 -20.32 61.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 -90.28 -45.6 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -66.97 -32.7 74.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.45 ' CG2' ' OE2' ' A' ' 167' ' ' GLU . 66.7 p -101.48 -15.63 17.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 11.6 m170 56.79 49.91 13.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 57.9 p -131.8 146.8 52.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.173 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 26.1 t80 -78.85 96.64 5.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 91.4 mt -90.97 115.63 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.73 124.99 61.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.12 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.0 p -76.65 152.62 83.2 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.604 0.716 . . . . 0.0 111.177 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 175.79 7.67 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.692 2.261 . . . . 0.0 112.337 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.51 158.98 46.0 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.467 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . 0.416 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 12.6 ptp180 -62.27 -44.01 97.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.867 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.416 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 30.8 t0 -103.95 42.35 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.901 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 8.0 mmmm -138.34 163.93 30.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.96 148.73 83.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 101.44 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.709 2.273 . . . . 0.0 112.344 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.2 t -153.82 119.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.094 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -89.79 156.93 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.87 104.76 9.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.138 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 34.1 t -95.81 124.0 48.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.418 ' C ' HG11 ' A' ' 161' ' ' VAL . 66.7 m -115.53 134.06 55.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.145 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 154.09 -172.37 32.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.5 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 18.0 mmt -50.45 159.4 0.87 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.581 0.705 . . . . 0.0 110.868 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.678 2.252 . . . . 0.0 112.362 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -120.03 -33.38 3.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 57.3 m-20 -73.62 -48.73 30.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 17.3 m -63.67 -36.1 75.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -61.15 -38.91 88.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -63.17 -40.74 98.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -61.78 -33.39 74.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 47.0 ttp85 -67.16 -50.48 61.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.42 -26.04 66.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . 0.45 ' OE2' ' CG2' ' A' ' 137' ' ' THR . 67.5 mt-10 -77.83 -52.91 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 72.6 mt -58.81 -40.15 79.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -71.87 -38.59 70.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.916 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.2 -54.85 5.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 43.8 m170 -41.65 -32.07 0.34 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 76.9 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.993 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.425 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 10.2 t -127.55 161.3 29.12 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.082 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.7 m -132.31 122.4 25.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.26 156.11 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 49.3 mm-40 -109.88 100.55 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.943 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.445 HG11 ' N ' ' A' ' 113' ' ' ARG . 94.4 t -67.85 141.01 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.445 ' N ' HG11 ' A' ' 112' ' ' VAL . 34.6 ttp180 -109.3 124.77 51.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.86 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -146.52 149.57 37.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.56 0.695 . . . . 0.0 111.142 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 139.03 39.31 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.326 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 t80 -49.17 -20.91 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 ttm-85 -74.35 -46.24 41.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 16.7 t -68.6 -37.28 77.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.151 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 87.3 t -39.75 -64.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.098 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.72 -36.6 13.26 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 12.8 mt -70.04 -43.08 71.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.775 0.321 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 48.8 t -67.31 -63.1 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 96.4 t -38.97 -49.77 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.87 172.61 33.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -47.95 102.81 0.05 OUTLIER 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 91.0 mttt 46.16 44.41 12.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.58 70.67 1.08 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.11 -37.06 3.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 111.088 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 35.4 m -87.96 -44.39 11.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.158 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.6 tp -60.79 -28.06 42.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.153 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.9 ttpp -64.67 -46.97 80.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.938 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.2 mtt180 -51.74 -50.55 60.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 56.8 mt -50.14 -54.95 6.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.135 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -45.89 -37.07 5.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.901 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -79.79 -59.15 2.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -43.51 -37.64 2.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.861 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.6 p -101.03 -22.81 14.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.086 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.7 m80 69.85 52.62 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 81.0 p -133.46 155.19 49.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.142 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 35.4 t80 -90.07 95.47 10.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.964 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 90.3 mt -86.77 138.49 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.5 t -129.28 124.08 59.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.187 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.3 p -80.18 152.68 74.0 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.562 0.696 . . . . 0.0 111.121 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -175.59 1.2 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.6 169.48 45.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.31 -22.87 59.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 20.3 p-10 -123.0 40.77 3.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -138.94 174.19 10.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -68.02 143.94 96.62 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.611 0.72 . . . . 0.0 110.915 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 91.15 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.646 2.231 . . . . 0.0 112.32 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.7 t -138.74 120.04 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.139 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -89.1 147.94 23.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -117.92 113.56 21.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.115 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.407 HG11 ' CB ' ' A' ' 161' ' ' VAL . 53.8 t -106.68 124.4 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 60.2 m -111.54 137.38 49.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.61 -177.27 29.61 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.441 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 22.7 mmt -47.28 159.1 0.43 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.545 0.688 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.425 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 54.0 Cg_endo -69.72 -1.29 8.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -115.71 -37.01 4.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.839 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 -71.13 -50.62 31.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.903 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 32.0 m -59.4 -29.51 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.091 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.02 -42.06 94.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -65.83 -32.21 73.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -66.82 -36.3 82.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.084 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.42 ' CG ' ' OE1' ' A' ' 169' ' ' GLU . 41.5 ttt180 -65.31 -59.57 3.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 1.7 pp20? -51.92 -31.46 28.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -67.56 -55.39 13.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.4 mt -58.27 -53.66 43.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.42 ' OE1' ' CG ' ' A' ' 165' ' ' ARG . 29.0 mt-10 -58.77 -41.52 86.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -41.38 -59.23 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 50.1 m170 -37.75 -37.91 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 84.1 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.998 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.898 0.38 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.1 t -133.97 163.96 28.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.11 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 56.8 m -131.87 126.16 33.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.152 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.4 pt -111.84 155.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.133 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -112.59 101.01 9.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 90.5 t -72.75 141.28 16.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.139 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.412 ' C ' HG13 ' A' ' 114' ' ' VAL . 15.8 ttm180 -111.6 115.37 29.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.412 HG13 ' C ' ' A' ' 113' ' ' ARG . 3.5 m -133.37 150.69 75.85 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.658 0.742 . . . . 0.0 111.103 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.481 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.5 Cg_endo -69.84 123.84 10.47 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.636 2.224 . . . . 0.0 112.31 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -35.2 -32.82 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 115' ' ' PRO . 10.9 mmm180 -63.12 -51.96 64.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.463 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 40.1 t -65.36 -32.19 57.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.159 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 122' ' ' VAL . 75.8 t -42.66 -72.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 119' ' ' VAL . . . -37.64 -36.79 0.31 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.5 mt -69.99 -39.59 75.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.898 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.483 ' N ' ' O ' ' A' ' 119' ' ' VAL . 38.4 t -68.92 -63.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.3 t -43.97 -55.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.079 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.84 172.83 49.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -48.03 107.09 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.638 2.225 . . . . 0.0 112.369 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 43.9 39.16 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.73 75.47 0.52 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -120.34 -41.51 2.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.086 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 83.4 m -81.49 -44.77 16.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.151 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.413 HG22 ' N ' ' A' ' 131' ' ' LYS . 9.7 tp -54.67 -40.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.149 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.413 ' N ' HG22 ' A' ' 130' ' ' ILE . 10.4 ttpp -51.72 -44.55 63.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.416 ' HA ' ' CG ' ' A' ' 135' ' ' GLN . 21.8 mtp180 -63.63 -20.58 65.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 71.4 mt -79.81 -37.44 18.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.407 ' HG2' ' CD1' ' A' ' 141' ' ' ILE . 69.1 mt-30 -78.12 -26.96 48.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . 0.466 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.85 -41.38 19.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.466 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 13.9 mmt180 -62.4 -39.26 92.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 38.8 p -101.3 -6.53 24.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.155 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 74.1 m80 55.2 52.8 11.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.451 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 13.1 p -129.02 150.15 50.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.18 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -90.66 92.6 8.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.407 ' CD1' ' HG2' ' A' ' 134' ' ' GLN . 69.7 mt -84.67 124.08 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 79.7 t -100.41 109.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.443 HG21 ' CE2' ' A' ' 152' ' ' PHE . 69.6 p -79.04 148.84 72.45 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.707 . . . . 0.0 111.125 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.86 23.17 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.27 -164.33 27.75 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.482 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -71.67 -54.2 11.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.783 0.325 . . . . 0.0 110.849 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -103.88 41.29 1.31 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.66 140.05 50.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.943 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.52 143.31 2.95 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 82.14 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.653 2.236 . . . . 0.0 112.347 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.3 t -139.63 119.93 14.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.128 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 143' ' ' THR . 23.9 m-85 -90.58 147.43 23.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.856 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -119.53 98.57 6.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.07 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 58.0 t -86.12 119.27 34.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.187 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.1 m -107.71 132.34 53.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.115 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.431 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 155.64 -173.0 33.76 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 22.9 mmt -50.58 158.7 1.02 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.589 0.709 . . . . 0.0 110.874 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -2.49 10.24 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.695 2.263 . . . . 0.0 112.353 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -113.25 -32.67 6.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.451 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 21.4 m-20 -77.16 -53.57 7.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 17.8 m -54.29 -34.55 27.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.151 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . 0.436 ' C ' ' OE2' ' A' ' 166' ' ' GLU . 23.2 t0 -59.38 -67.86 0.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.858 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 21.3 ttm-85 -43.76 -51.27 7.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.75 -36.5 3.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.6 ttp180 -72.57 -34.61 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.921 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 166' ' ' GLU . 0.1 OUTLIER -57.77 -39.68 78.01 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.888 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -71.56 -53.72 12.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 70.3 mt -49.96 -48.98 22.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -65.26 -43.38 91.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.438 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -44.39 -57.66 3.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.08 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.438 ' C ' ' O ' ' A' ' 170' ' ' ALA . 11.4 m80 -35.45 -37.91 0.09 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 66.7 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 -179.982 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.473 ' CD ' ' C ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.861 0.362 . . . . 0.0 110.943 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.8 t -134.31 157.33 46.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 91.5 m -128.4 118.29 22.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.9 pt -106.91 154.34 7.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.4 mm-40 -112.27 105.74 14.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.447 HG22 ' CD ' ' A' ' 165' ' ' ARG . 93.4 t -82.12 144.77 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.16 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.44 ' O ' ' CG1' ' A' ' 114' ' ' VAL . 7.9 mpt_? -109.54 147.37 33.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.44 ' CG1' ' O ' ' A' ' 113' ' ' ARG . 7.6 m -158.45 151.11 18.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.627 0.727 . . . . 0.0 111.151 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.47 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.7 Cg_endo -69.72 127.03 14.03 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.713 2.275 . . . . 0.0 112.361 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -41.42 -24.42 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.918 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 115' ' ' PRO . 46.9 mtt85 -71.28 -43.81 66.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.47 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 41.2 t -74.56 -34.96 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.093 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.1 t -39.71 -63.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.36 -39.2 9.66 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.495 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -67.56 -46.62 72.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.881 0.372 . . . . 0.0 110.937 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 59.0 t -63.79 -63.88 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 87.1 t -40.4 -49.59 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 72.7 172.87 22.04 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.477 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.7 Cg_exo -47.99 118.21 2.98 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.718 2.279 . . . . 0.0 112.352 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.434 ' C ' ' O ' ' A' ' 125' ' ' PRO . 8.0 ptpp? 35.25 43.63 0.13 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 62.46 65.66 3.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.447 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.33 -39.27 6.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.838 0.351 . . . . 0.0 111.048 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.1 m -83.91 -50.34 8.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.158 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.3 tp -49.94 -40.8 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 25.0 tttp -60.92 -43.88 97.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 49.4 mtt180 -54.33 -41.14 68.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 54.8 mt -59.28 -49.93 81.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -47.77 -34.67 8.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -80.59 -54.44 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 53.7 mtt-85 -51.96 -33.42 37.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.865 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 37.4 p -103.59 -16.62 15.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 72.8 m80 61.23 51.15 4.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.45 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 38.0 p -136.52 141.51 43.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.129 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -77.15 97.42 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 79.8 mt -89.93 141.48 14.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.5 t -125.91 129.09 72.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.072 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 35.3 p -86.12 149.14 49.4 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.583 0.706 . . . . 0.0 111.135 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 177.83 5.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.663 2.242 . . . . 0.0 112.364 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.35 170.91 52.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . 0.422 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 18.8 ptt180 -71.34 -42.24 68.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.33 . . . . 0.0 110.861 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.422 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 2.5 p30 -104.61 42.09 1.25 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.82 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -139.18 159.3 42.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.894 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -58.03 142.59 79.63 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.623 0.725 . . . . 0.0 110.895 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 101.77 0.96 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.319 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -147.83 115.16 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.099 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -82.89 143.5 30.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.97 106.71 12.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 47.4 t -95.51 123.15 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 72.8 m -110.58 129.93 55.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.45 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 157.78 178.8 32.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.478 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 14.0 mmt -44.56 159.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.561 0.696 . . . . 0.0 110.877 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 0.75 5.19 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.643 2.229 . . . . 0.0 112.32 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -117.99 -37.53 3.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.878 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.45 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.4 m-20 -71.14 -45.71 62.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.45 ' CG1' ' CA ' ' A' ' 156' ' ' GLY . 13.8 m -66.8 -38.16 80.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -55.9 -39.63 71.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -62.78 -47.21 84.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -49.32 -42.83 42.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.068 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.447 ' CD ' HG22 ' A' ' 112' ' ' VAL . 11.7 tpt180 -48.9 -46.63 43.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 49.0 mm-40 -63.74 -37.46 87.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -63.3 -59.65 4.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 58.8 mt -53.03 -50.44 44.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.138 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -59.97 -43.25 95.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.415 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -47.0 -56.03 7.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.099 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.415 ' C ' ' O ' ' A' ' 170' ' ' ALA . 27.3 m170 -37.17 -41.34 0.38 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 57.3 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 -179.971 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.887 0.375 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.431 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 7.5 t -133.78 164.2 27.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 93.1 m -132.69 124.55 28.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.135 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.9 pt -110.47 152.02 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 4.6 mm-40 -108.17 96.77 6.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.418 HG11 ' N ' ' A' ' 113' ' ' ARG . 76.9 t -68.02 137.05 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.418 ' N ' HG11 ' A' ' 112' ' ' VAL . 32.7 ttt180 -108.58 115.71 30.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.916 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.413 HG13 ' C ' ' A' ' 113' ' ' ARG . 11.4 m -137.29 151.11 70.92 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.589 0.709 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.455 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 54.3 Cg_endo -69.72 127.77 15.1 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.355 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -39.56 -27.34 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 115' ' ' PRO . 22.0 ttm180 -67.12 -44.94 78.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.899 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.455 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 55.2 t -74.51 -29.15 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 74.1 t -45.12 -63.07 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.104 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.91 -38.26 30.52 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.49 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.5 mt -66.78 -45.5 78.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.903 0.382 . . . . 0.0 110.971 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.9 t -66.28 -58.23 7.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.13 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.3 t -44.16 -54.85 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . 0.411 ' O ' ' N ' ' A' ' 126' ' ' LYS . . . 85.12 172.77 49.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.494 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.0 88.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.411 ' N ' ' O ' ' A' ' 124' ' ' GLY . 34.4 tttp 58.01 48.64 12.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.891 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.69 60.03 7.01 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.502 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.93 -40.21 6.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.845 0.355 . . . . 0.0 111.069 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 94.2 m -85.77 -50.79 6.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 8.4 tp -52.53 -28.98 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.12 -49.14 71.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -51.04 -40.14 57.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.882 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.4 mt -63.46 -47.16 92.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.401 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 70.4 mt-30 -48.1 -36.85 14.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 67.3 mm-40 -82.24 -50.12 9.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.7 mtt85 -52.78 -33.91 50.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.882 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.3 p -105.68 -12.08 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.144 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 15.5 m170 58.26 54.12 5.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 70.5 p -139.46 139.11 36.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -75.25 97.94 3.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.401 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 78.9 mt -87.71 122.99 40.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.147 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.02 128.27 62.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 34.1 p -87.38 144.32 35.62 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.583 0.706 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -177.28 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.705 2.27 . . . . 0.0 112.304 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -90.7 -175.16 44.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 6.1 ptp85 -84.9 -41.16 16.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -100.77 40.08 1.31 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -138.42 169.44 17.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.91 144.18 95.47 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.713 0.768 . . . . 0.0 110.89 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 87.5 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.727 2.285 . . . . 0.0 112.316 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.4 t -137.86 121.17 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -91.12 143.98 26.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -114.87 104.57 12.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.425 HG13 ' CB ' ' A' ' 161' ' ' VAL . 46.7 t -95.05 124.41 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 27.0 m -110.83 132.8 53.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.402 ' C ' HG12 ' A' ' 161' ' ' VAL . . . 155.13 177.56 28.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 22.8 mmt -43.03 159.55 0.21 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.56 0.695 . . . . 0.0 110.865 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . 0.431 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.79 0.69 5.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.736 2.291 . . . . 0.0 112.339 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -118.71 -35.66 3.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.907 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.447 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 71.0 m-20 -69.33 -45.75 68.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.882 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.425 ' CB ' HG13 ' A' ' 154' ' ' VAL . 35.2 m -67.01 -39.38 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.143 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -54.5 -42.3 70.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.865 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -53.89 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.92 -52.25 25.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.412 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 50.0 ttt85 -42.51 -39.38 2.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.866 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -68.49 -45.53 72.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -58.57 -54.55 45.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 84.4 mt -55.12 -51.12 57.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.412 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 66.0 mt-10 -59.13 -46.0 89.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.901 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.445 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.13 -57.55 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.06 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 170' ' ' ALA . 14.7 m170 -34.9 -42.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 74.9 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.127 179.987 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.0 t -123.53 159.67 28.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.174 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 84.2 m -130.26 120.69 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.097 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.3 pt -108.38 154.97 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.109 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.9 mm-40 -113.82 96.14 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.47 HG11 ' CG2' ' A' ' 168' ' ' ILE . 96.0 t -66.68 140.73 18.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.127 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.417 ' N ' HG12 ' A' ' 112' ' ' VAL . 6.9 tpp180 -106.14 110.96 23.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.32 151.27 77.25 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 0.0 111.11 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.454 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 149.79 67.37 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.703 2.269 . . . . 0.0 112.334 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -55.24 -39.34 69.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.923 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.437 ' HG3' ' N ' ' A' ' 118' ' ' VAL . 4.6 ptp180 -57.78 -41.85 82.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.454 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 16.5 t -71.53 -37.29 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.5 t -43.06 -69.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.138 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -41.21 -34.46 0.94 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.7 mt -71.22 -56.92 5.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.83 -57.58 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.145 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 74.5 t -49.77 -54.74 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.11 169.84 42.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -47.93 97.37 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.718 2.278 . . . . 0.0 112.347 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.0 mttt 54.52 47.65 22.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.888 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.84 68.18 1.79 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -112.2 -38.38 4.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 0.0 111.1 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 72.6 m -86.46 -42.71 13.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.152 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.2 tp -62.87 -36.48 75.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.2 ttpt -55.89 -46.18 78.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -53.83 -41.86 67.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 65.8 mt -61.38 -59.21 4.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -41.54 -36.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.899 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -80.83 -53.37 6.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -51.19 -34.53 32.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.1 p -105.93 -8.47 17.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 13.5 m170 53.58 54.55 9.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.866 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.422 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.1 p -135.39 147.75 49.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -82.66 96.85 8.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 75.1 mt -89.94 116.16 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.145 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.0 t -102.76 113.99 41.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.156 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.9 p -72.57 153.42 91.69 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.521 0.677 . . . . 0.0 111.154 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 177.66 5.31 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.678 2.252 . . . . 0.0 112.375 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -85.01 170.69 45.66 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.502 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . 0.459 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 4.2 ptm85 -69.53 -48.49 60.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 110.922 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . 0.459 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.7 p30 -99.92 43.42 1.06 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -138.54 168.79 19.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -66.82 144.25 98.47 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.632 0.729 . . . . 0.0 110.926 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 100.16 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.311 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.5 t -147.06 127.92 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -96.62 125.89 41.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.96 99.58 9.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.074 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.3 t -88.77 133.69 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.2 m -120.04 128.79 53.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.74 178.25 31.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 9.0 mmt -41.04 159.2 0.17 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.559 0.695 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.7 8.91 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.678 2.252 . . . . 0.0 112.333 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . 0.448 ' C ' ' OE1' ' A' ' 159' ' ' GLU . 0.5 OUTLIER -116.97 -38.06 3.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.965 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . 0.422 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.9 m-20 -67.35 -45.55 76.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.423 HG13 ' C ' ' A' ' 156' ' ' GLY . 30.0 m -68.51 -40.04 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -53.19 -40.26 64.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 33.1 ttt-85 -64.68 -59.17 4.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.33 -45.82 6.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 21.1 ttm180 -47.71 -45.15 28.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -53.96 -61.19 2.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -53.6 -39.12 64.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . 0.47 ' CG2' HG11 ' A' ' 112' ' ' VAL . 61.2 mt -55.84 -70.55 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.402 ' O ' ' C ' ' A' ' 170' ' ' ALA . 2.3 pt-20 -59.69 -33.21 71.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.899 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 169' ' ' GLU . . . -37.25 -57.1 0.91 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.083 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 170' ' ' ALA . 17.6 m80 -37.63 -41.84 0.51 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.837 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 74.2 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.849 0.356 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.3 t -135.43 161.97 33.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.113 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.7 m -136.2 124.97 23.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.098 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.7 pt -114.28 154.3 15.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.3 mm-40 -109.58 106.55 16.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 113' ' ' ARG . 94.4 t -73.85 137.99 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.457 ' N ' HG13 ' A' ' 112' ' ' VAL . 16.0 ttm180 -109.54 115.68 30.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.87 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.417 HG12 ' C ' ' A' ' 113' ' ' ARG . 4.5 m -135.51 150.8 73.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.653 0.739 . . . . 0.0 111.109 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.4 Cg_endo -69.77 129.14 17.07 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.345 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -39.47 -28.59 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.894 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.6 mmt180 -65.86 -51.43 58.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.848 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.412 ' O ' ' C ' ' A' ' 119' ' ' VAL . 28.9 t -66.59 -36.7 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.16 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 118' ' ' VAL . 77.4 t -37.32 -69.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.114 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.93 -39.49 8.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.2 mt -64.67 -41.14 96.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 123' ' ' VAL . 22.0 t -68.89 -64.99 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.098 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 122' ' ' VAL . 89.4 t -37.35 -46.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.41 173.13 32.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.417 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.1 Cg_exo -47.99 112.55 0.6 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.658 2.239 . . . . 0.0 112.341 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.2 ptmt 36.64 41.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.905 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.55 83.29 0.2 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.471 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.38 -41.34 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.864 0.364 . . . . 0.0 111.083 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 39.5 m -84.16 -44.18 14.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.121 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.8 tp -60.02 -40.47 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -58.28 -41.93 85.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.898 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -56.45 -42.68 78.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.88 -48.23 88.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . 0.433 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 78.9 mt-30 -48.56 -36.72 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.929 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 4.3 mm100 -82.48 -54.84 4.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.93 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -49.95 -32.53 15.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -105.6 -13.6 15.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.105 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 28.0 m80 58.84 54.41 5.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 68.5 p -139.88 143.3 36.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -77.49 100.55 6.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.922 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.433 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 75.9 mt -92.79 119.1 39.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.3 t -109.6 127.52 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.104 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.6 p -85.26 151.61 56.91 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.562 0.696 . . . . 0.0 111.197 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 177.67 5.33 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.689 2.26 . . . . 0.0 112.354 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.7 168.15 49.18 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.44 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.19 -43.91 93.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.814 0.34 . . . . 0.0 110.836 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -103.18 43.6 1.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -132.45 171.61 13.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.21 148.85 91.54 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 110.871 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 87.64 0.56 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.349 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.4 t -143.78 121.13 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.087 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -90.31 153.64 20.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.832 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.7 106.96 11.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.094 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.409 HG12 ' CB ' ' A' ' 161' ' ' VAL . 50.7 t -97.74 125.28 50.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 75.1 m -112.3 137.38 50.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.49 -173.13 31.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.495 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' MET . . . . . 0.415 ' HB3' ' CD ' ' A' ' 159' ' ' GLU . 8.2 mmt -53.89 159.86 2.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 0.0 110.877 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -0.55 7.02 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.672 2.248 . . . . 0.0 112.391 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' GLU . . . . . 0.415 ' CD ' ' HB3' ' A' ' 157' ' ' MET . 23.5 pm0 -118.01 -26.25 6.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -82.63 -43.51 16.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.409 ' CB ' HG12 ' A' ' 154' ' ' VAL . 35.7 m -69.5 -35.14 65.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -56.76 -47.81 79.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.9 ttt-85 -57.31 -55.24 37.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.21 -45.38 5.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -52.43 -45.5 66.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -64.39 -42.53 96.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -58.39 -53.84 53.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 91.0 mt -55.59 -54.79 21.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -56.63 -46.23 81.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' ALA . . . . . 0.441 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.36 -60.29 0.8 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.132 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 170' ' ' ALA . 40.7 m170 -34.95 -38.77 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.872 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 74.7 mt . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.093 -179.961 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 13.3 t -117.49 -56.88 2.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.865 0.364 . . . . 0.0 110.845 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.0 m -138.32 151.82 47.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.87 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.53 53.69 0.23 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 10.9 t -154.73 135.74 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.888 0.375 . . . . 0.0 110.901 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.1 t -92.87 105.54 17.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 145.67 116.26 1.01 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -111.33 -75.31 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -57.51 -178.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.889 0.376 . . . . 0.0 110.944 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.5 t -141.73 161.25 38.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 90.4 m -131.28 124.18 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.165 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.5 pt -114.29 153.14 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.125 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 52.6 mm-40 -109.87 106.26 15.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 74.7 t -77.59 135.61 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.42 ' C ' HG11 ' A' ' 114' ' ' VAL . 8.9 ttp-105 -104.8 120.89 42.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.862 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.42 HG11 ' C ' ' A' ' 113' ' ' ARG . 4.6 m -136.46 150.72 71.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.609 0.718 . . . . 0.0 111.124 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.469 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.7 130.63 19.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.682 2.255 . . . . 0.0 112.363 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -45.04 -22.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.939 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.413 ' HB2' ' NH1' ' A' ' 117' ' ' ARG . 14.7 ttm105 -72.08 -44.23 63.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.918 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.469 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 74.9 t -76.03 -31.68 22.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 122' ' ' VAL . 42.6 t -39.3 -74.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -38.74 -34.33 0.26 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.547 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -71.67 -44.21 64.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 110.876 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.407 ' N ' ' O ' ' A' ' 119' ' ' VAL . 86.9 t -66.04 -62.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.119 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 84.7 t -46.8 -48.27 7.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.85 172.71 49.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.97 91.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 12.2 mmtp 53.13 38.59 27.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 78.32 72.89 1.13 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.535 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.39 -27.25 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.102 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 65.7 m -98.68 -44.77 6.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 9.3 tp -60.64 -25.19 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.9 tttp -66.51 -32.0 73.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -67.26 -43.58 81.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 77.3 mt -57.89 -56.88 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.159 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 29.4 mt-30 -45.24 -31.97 1.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -82.07 -55.69 4.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 mmm180 -56.28 -24.42 42.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -109.75 -13.03 14.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 54.3 52.79 11.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.462 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 26.8 p -129.99 170.04 14.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.155 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -102.28 94.91 5.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 82.3 mt -93.9 125.83 46.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.76 130.12 68.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.6 p -84.11 145.29 45.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.611 0.719 . . . . 0.0 111.094 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -179.78 3.17 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -80.56 -172.11 44.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -92.55 -31.62 15.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.828 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 9.6 t0 -112.1 35.97 3.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -131.3 169.93 15.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -67.82 144.28 97.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.615 0.721 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.25 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.705 2.27 . . . . 0.0 112.319 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.2 t -148.26 113.83 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -84.06 141.46 31.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.93 121.53 45.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.6 122.47 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 43.0 m -112.9 122.93 49.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.563 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 169.54 -173.09 43.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 16.1 mmt -52.39 159.24 1.66 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.602 0.715 . . . . 0.0 110.857 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -0.86 7.54 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.658 2.239 . . . . 0.0 112.302 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -115.7 -26.03 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.462 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.3 m-20 -85.11 -54.63 4.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.563 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 24.9 m -53.68 -32.54 21.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -79.14 -23.5 43.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -76.27 -37.51 57.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -70.76 -38.5 73.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 57.5 ttt180 -54.43 -44.21 72.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.93 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -55.58 -49.28 73.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -59.93 -45.98 90.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 94.9 mt -53.18 -58.96 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.126 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -62.4 -32.69 73.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -51.45 -42.31 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -56.28 -33.5 65.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 81.6 mt -47.97 -38.16 7.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 26.1 m -88.76 -39.39 13.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.405 HD13 ' C ' ' A' ' 174' ' ' LEU . 0.9 OUTLIER -55.35 130.63 43.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.896 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.47 ' CZ ' ' HB3' ' A' ' 175' ' ' ARG . 4.3 ptp180 -77.36 118.0 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.2 t -132.42 85.22 2.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 135.87 172.27 12.6 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.501 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 161.64 45.13 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.705 2.27 . . . . 0.0 112.355 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 65.8 p -108.69 -43.45 4.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.1 t -51.36 117.38 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.854 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.452 -179.94 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 22.8 t 65.76 41.7 3.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.791 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.3 t -86.61 -43.58 12.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.867 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 75.36 167.02 20.6 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.522 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 84.1 p -102.18 45.04 0.98 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.876 0.37 . . . . 0.0 110.877 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 67.0 p -82.03 167.91 18.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.88 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -71.54 -42.06 56.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.508 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 148.73 -89.75 0.14 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.459 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 -62.62 177.44 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.922 0.392 . . . . 0.0 110.924 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.7 t -137.56 164.68 28.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 99.2 m -138.14 115.29 10.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.075 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.44 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 42.4 pt -107.89 151.88 9.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.44 ' NE2' ' C ' ' A' ' 110' ' ' ILE . 1.1 mp0 -110.98 106.72 15.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.444 HG12 ' CG1' ' A' ' 114' ' ' VAL . 86.9 t -73.7 141.39 16.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 42.5 ttp85 -108.67 110.13 21.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.444 ' CG1' HG12 ' A' ' 112' ' ' VAL . 2.5 m -132.59 148.85 71.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.675 0.75 . . . . 0.0 111.112 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.463 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.74 145.84 58.49 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.439 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 19.3 t80 -53.93 -41.54 67.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.41 ' NH1' HG23 ' A' ' 118' ' ' VAL . 3.9 ptm180 -54.85 -29.46 55.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.871 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.463 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 15.8 t -85.6 -34.82 8.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.439 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 77.8 t -37.32 -66.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.52 -33.28 4.41 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.1 mt -70.61 -57.02 5.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.844 0.354 . . . . 0.0 110.889 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 62.9 t -56.37 -55.98 16.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.12 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.4 t -47.14 -55.57 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.36 167.85 43.91 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_exo -47.96 93.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.648 2.232 . . . . 0.0 112.356 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.3 tmtt? 60.89 46.43 8.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 59.59 61.59 7.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.493 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.47 -41.56 5.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.843 0.354 . . . . 0.0 111.122 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.2 m -78.91 -46.42 18.5 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 10.7 tp -51.57 -34.39 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.088 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.7 tttt -66.55 -40.58 89.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 25.9 ttp180 -62.3 -22.24 65.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.96 -41.43 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -67.95 -30.64 69.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' A' ' 136' ' ' ARG . 10.1 pt20 -80.7 -48.63 12.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.938 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.502 ' N ' ' CG ' ' A' ' 135' ' ' GLN . 60.0 mtt180 -59.03 -35.25 72.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 49.9 p -100.11 -13.28 19.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.136 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 19.8 m80 58.93 54.22 5.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 34.2 p -132.19 -176.79 4.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.091 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -116.74 97.4 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.953 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 74.4 mt -94.61 133.12 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -115.11 134.94 56.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.6 p -88.1 146.98 39.5 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.591 0.71 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -178.27 2.28 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -87.38 169.55 39.7 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 8.6 ptt85 -70.63 -40.54 73.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.837 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -105.54 42.24 1.26 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.846 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 26.5 mmtp -136.08 168.22 19.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.37 144.06 98.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.659 0.742 . . . . 0.0 110.901 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 82.78 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.693 2.262 . . . . 0.0 112.359 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 76.2 t -133.29 129.62 56.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.149 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -96.53 139.95 31.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -112.78 110.01 19.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.116 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.3 t -101.33 133.22 45.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.15 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 19.9 m -119.46 135.42 54.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.425 ' N ' HG12 ' A' ' 161' ' ' VAL . . . 153.64 -177.1 31.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.529 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 12.1 mmt -49.27 158.36 0.75 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.549 0.69 . . . . 0.0 110.918 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 0.49 5.55 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -117.76 -29.79 5.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.453 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.1 m-20 -79.18 -47.93 15.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.425 HG12 ' N ' ' A' ' 156' ' ' GLY . 15.7 m -66.15 -26.64 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -66.99 -40.39 87.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 7.5 ttt85 -66.88 -56.51 9.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -46.7 -46.27 20.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.055 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.3 ttt180 -49.7 -39.96 38.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -60.67 -52.1 66.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -58.56 -33.55 70.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 67.7 mt -63.24 -66.43 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.4 -32.54 74.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.72 -54.98 2.0 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.115 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -39.89 -40.56 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 71.1 mt -43.59 -50.63 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 62.4 p -61.53 -50.98 70.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 3.7 mp -52.07 175.33 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -164.88 120.87 1.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 4.6 t -123.15 166.97 14.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.857 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -51.99 146.06 14.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.508 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 154.66 67.7 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.664 2.243 . . . . 0.0 112.396 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 4.9 m -167.24 137.2 2.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.871 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.3 m -144.07 120.35 10.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.461 -179.916 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.9 m -90.39 97.5 11.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.907 0.385 . . . . 0.0 110.837 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.3 m -116.0 155.06 28.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.44 116.38 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.463 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 17.9 p -126.76 -36.0 2.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.833 0.349 . . . . 0.0 110.812 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' GLY . 17.7 t -78.27 155.2 30.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.816 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 104' ' ' SER . . . -34.6 -47.62 0.63 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 178.27 -58.15 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -97.59 160.84 14.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.939 0.399 . . . . 0.0 110.869 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.406 ' HG1' ' N ' ' A' ' 109' ' ' THR . 10.0 t -128.66 158.61 38.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.406 ' N ' ' HG1' ' A' ' 108' ' ' THR . 23.5 m -130.12 113.69 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.177 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.524 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 43.3 pt -103.48 154.85 5.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.524 ' NE2' ' C ' ' A' ' 110' ' ' ILE . 1.6 mp0 -112.54 107.98 16.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 88.7 t -77.79 141.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.414 ' C ' HG13 ' A' ' 114' ' ' VAL . 1.8 tmt_? -110.2 117.39 33.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.842 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.414 HG13 ' C ' ' A' ' 113' ' ' ARG . 12.2 m -137.6 151.11 70.25 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.629 0.728 . . . . 0.0 111.112 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.463 ' O ' ' N ' ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.78 126.7 13.6 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.659 2.24 . . . . 0.0 112.351 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -36.4 -35.53 0.08 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.942 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.8 tpp85 -59.74 -46.88 87.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.463 ' N ' ' O ' ' A' ' 115' ' ' PRO . 48.8 t -72.41 -31.14 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.1 t -45.59 -59.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -52.73 -41.54 57.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.479 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -61.89 -48.89 78.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.83 0.348 . . . . 0.0 110.882 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 84.1 t -64.04 -52.65 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.8 t -49.15 -56.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.166 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 88.49 172.73 46.89 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.93 100.66 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.722 2.281 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? 50.89 43.25 28.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.901 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.35 80.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.526 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.69 -31.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 40.5 m -89.91 -39.47 13.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.425 HD11 ' CG2' ' A' ' 141' ' ' ILE . 5.0 tp -65.07 -29.34 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.179 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -67.76 -42.21 82.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.937 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 70.3 mtp180 -56.16 -43.79 78.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.841 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 57.2 mt -57.44 -44.84 85.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 73.8 mt-30 -51.71 -38.18 54.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.935 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -79.2 -51.11 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -55.68 -30.72 61.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.9 p -106.63 -10.88 16.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 56.13 51.51 11.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.41 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.2 p -137.34 143.08 41.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -78.33 95.54 5.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.425 ' CG2' HD11 ' A' ' 130' ' ' ILE . 78.8 mt -88.34 110.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 98.4 t -95.85 120.84 45.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.094 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 82.4 p -77.79 147.3 74.07 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.569 0.699 . . . . 0.0 111.134 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 171.95 13.5 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.685 2.256 . . . . 0.0 112.386 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.67 177.87 54.05 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 7.5 ptp85 -77.69 -33.59 53.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.788 0.327 . . . . 0.0 110.864 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -110.5 41.58 1.74 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.825 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.7 mmmt -137.84 159.33 42.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -57.21 145.25 67.22 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.657 0.742 . . . . 0.0 110.87 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 96.78 0.61 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.67 2.247 . . . . 0.0 112.319 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.8 t -145.52 132.65 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.0 m-85 -102.36 117.13 34.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.99 109.4 20.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 56.8 t -100.14 122.61 52.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.113 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 49.9 m -108.19 131.71 54.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.146 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.407 ' C ' HG12 ' A' ' 161' ' ' VAL . . . 157.18 177.63 30.48 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.498 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 10.5 mmt -42.51 159.41 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.553 0.692 . . . . 0.0 110.867 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 0.83 5.06 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.702 2.268 . . . . 0.0 112.37 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -118.42 -37.33 3.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.41 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.4 m-20 -69.3 -45.67 69.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.407 HG12 ' C ' ' A' ' 156' ' ' GLY . 15.2 m -67.83 -37.12 77.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.82 -42.44 84.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -64.16 -48.37 76.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.97 -47.93 43.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -51.05 -43.76 60.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.842 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -53.28 -44.74 68.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -68.15 -56.3 9.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 73.2 mt -47.7 -45.68 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.135 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -70.29 -45.04 67.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.44 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.32 -57.24 2.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.113 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.44 ' C ' ' O ' ' A' ' 170' ' ' ALA . 47.5 m80 -35.38 -34.62 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.431 ' N ' ' O ' ' A' ' 170' ' ' ALA . 58.5 mt -54.84 -49.06 72.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 170' ' ' ALA . 14.5 t -94.83 44.18 1.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.12 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 64.2 tp -110.17 148.27 32.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 176' ' ' SER . 6.2 ptm180 -108.0 54.42 0.66 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 175' ' ' ARG . 6.2 t 34.41 42.66 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -77.65 178.21 52.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.499 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 123.34 10.0 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 43.8 t -69.62 131.48 44.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 5.6 t -44.4 155.46 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.467 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.7 p -71.79 81.04 0.87 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.873 0.368 . . . . 0.0 110.82 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.422 ' HG ' ' N ' ' A' ' 102' ' ' GLY . 42.9 t -148.84 155.8 41.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.889 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.422 ' N ' ' HG ' ' A' ' 101' ' ' SER . . . -175.8 60.14 0.11 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.479 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 58.6 m -45.35 100.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.941 0.401 . . . . 0.0 110.876 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 21.0 m -39.13 -47.95 1.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.871 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -114.62 91.15 0.56 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.464 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -136.14 31.83 2.57 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.549 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 -116.74 176.99 4.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.857 0.361 . . . . 0.0 110.918 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.4 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 6.4 t -139.92 163.53 32.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.14 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -129.28 125.69 37.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.161 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.5 pt -112.18 164.51 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 50.3 mm-40 -121.71 97.93 5.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.467 HG12 ' N ' ' A' ' 113' ' ' ARG . 95.3 t -68.78 142.74 15.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.125 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.467 ' N ' HG12 ' A' ' 112' ' ' VAL . 25.3 ttt85 -112.55 121.56 45.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.2 m -141.98 151.07 58.27 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.616 0.722 . . . . 0.0 111.147 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.474 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.3 Cg_endo -69.8 125.54 12.24 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.671 2.247 . . . . 0.0 112.344 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.437 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.7 t80 -35.26 -33.21 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.876 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 115' ' ' PRO . 87.3 mtt-85 -61.68 -49.94 74.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.867 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.462 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 55.3 t -68.72 -35.03 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 56.1 t -39.06 -62.76 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -54.43 -38.92 63.83 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.467 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.7 mt -63.34 -43.54 97.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.4 t -68.48 -61.95 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 88.8 t -40.78 -49.04 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.119 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 78.45 172.86 41.37 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -47.95 97.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.653 2.235 . . . . 0.0 112.409 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 47.83 50.47 15.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.913 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.79 74.33 0.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -121.78 -45.15 2.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 67.2 m -82.21 -44.73 15.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.401 HG21 ' N ' ' A' ' 131' ' ' LYS . 6.4 tp -57.43 -38.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.401 ' N ' HG21 ' A' ' 130' ' ' ILE . 38.5 mttp -53.58 -39.87 65.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.405 ' HD2' ' N ' ' A' ' 132' ' ' ARG . 1.0 OUTLIER -57.75 -36.07 71.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 46.8 mt -69.94 -46.9 71.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -55.15 -39.83 69.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -78.28 -45.5 22.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -58.07 -37.59 74.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.84 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 81.8 p -101.23 -11.45 19.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 59.89 48.31 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.414 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 62.7 p -127.36 162.95 25.09 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -96.79 94.78 7.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.936 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 79.2 mt -90.43 122.3 41.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.106 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 68.9 t -113.81 129.46 69.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.119 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.6 p -77.47 147.75 75.92 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.576 0.703 . . . . 0.0 111.183 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 177.81 5.22 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.43 165.22 51.49 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -68.2 -45.95 71.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 0.0 110.879 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -101.7 42.75 1.11 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -136.07 173.43 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -67.2 143.94 97.92 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 89.12 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.368 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 77.9 t -134.7 134.49 54.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.089 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -104.05 122.72 45.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -92.82 123.95 36.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.122 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 46.5 t -118.71 119.09 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 156' ' ' GLY . 89.3 m -107.35 138.1 44.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.144 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.448 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.88 -169.96 31.28 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.436 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 12.0 mmt -52.53 159.47 1.66 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.561 0.696 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.4 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.4 Cg_endo -69.81 0.56 5.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.656 2.237 . . . . 0.0 112.35 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.38 -47.17 2.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.414 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 28.8 m-20 -65.42 -44.9 85.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.448 ' CG1' ' CA ' ' A' ' 156' ' ' GLY . 18.7 m -63.79 -37.87 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.154 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -73.53 -31.65 63.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 46.4 mtp180 -69.57 -36.9 76.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -64.32 -37.41 87.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.08 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -53.68 -58.66 6.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.812 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . 0.467 ' HG3' ' N ' ' A' ' 167' ' ' GLU . 1.0 OUTLIER -48.74 -35.44 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.926 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.467 ' N ' ' HG3' ' A' ' 166' ' ' GLU . 5.4 mm-40 -69.47 -46.76 65.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 93.9 mt -63.32 -49.36 83.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.165 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -60.61 -41.7 95.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.5 -53.07 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -40.17 -41.06 1.22 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 68.7 mt -44.2 -50.42 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.109 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 78.3 p -93.95 42.1 1.09 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 7.0 tt -95.03 -54.13 3.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.914 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 10.4 ptm180 -113.82 164.29 13.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.852 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 48.3 t -71.72 -62.52 1.39 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -174.57 -157.39 15.92 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.517 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 179' ' ' SER . 54.0 Cg_endo -69.76 2.7 3.29 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.353 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 178' ' ' PRO . 34.6 t -34.58 119.34 0.44 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.846 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.4 p -69.55 -21.8 63.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 179.977 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.532 -0.227 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 68.5 m -134.01 113.23 11.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.854 -179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 30.8 p -56.17 -25.72 47.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -120.41 167.41 13.75 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.496 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 26.7 m -59.63 133.33 55.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.89 0.376 . . . . 0.0 110.888 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.6 t -68.35 176.94 2.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.889 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -86.59 -179.15 49.3 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.453 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -94.06 -97.66 1.58 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -110.83 168.81 9.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.437 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 6.9 t -125.38 162.5 24.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.135 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.5 m -135.49 122.29 21.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.098 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.7 pt -111.81 156.12 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.17 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 47.7 mm-40 -111.74 98.83 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 88.9 t -66.04 141.42 18.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.137 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.4 ttp180 -112.33 113.24 25.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.42 ' CG2' HG21 ' A' ' 119' ' ' VAL . 3.8 m -132.8 151.07 77.41 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.432 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 126.72 13.64 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.352 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.411 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -36.44 -33.4 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 115' ' ' PRO . 84.8 mtt180 -62.22 -52.54 63.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.831 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.432 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 54.6 t -67.6 -34.15 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.098 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.42 HG21 ' CG2' ' A' ' 114' ' ' VAL . 48.1 t -40.17 -66.62 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.098 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.86 -36.5 26.7 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.475 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.5 mt -66.34 -41.84 89.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.883 0.373 . . . . 0.0 110.955 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.4 t -71.81 -54.6 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.107 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 92.5 t -50.95 -49.14 28.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.18 172.67 46.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.477 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -47.96 105.47 0.09 OUTLIER 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.712 2.274 . . . . 0.0 112.313 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 9.0 tppt? 45.5 44.5 9.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 64.11 76.07 0.32 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.484 ' O ' ' CZ ' ' A' ' 132' ' ' ARG . . . -124.21 -26.82 3.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 111.119 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 96.2 m -93.77 -35.91 12.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.145 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.1 tp -72.76 -29.94 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.155 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.448 ' HG3' ' N ' ' A' ' 132' ' ' ARG . 8.3 ptmt -58.94 -36.95 75.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.484 ' CZ ' ' O ' ' A' ' 128' ' ' ALA . 0.7 OUTLIER -67.04 -52.69 39.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.858 179.996 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.6 mt -46.4 -50.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.408 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 60.9 mt-30 -46.2 -35.39 5.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -81.31 -51.43 8.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -52.07 -35.3 47.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.875 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.4 p -104.1 -11.18 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.152 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 67.5 m80 55.99 54.66 7.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.872 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.465 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 82.5 p -137.38 147.37 45.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.169 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -80.5 97.38 7.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.408 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 85.5 mt -90.84 118.52 36.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.3 t -106.48 123.46 61.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.175 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.4 p -81.84 148.95 62.5 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.585 0.707 . . . . 0.0 111.124 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 172.57 12.39 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.06 157.93 34.19 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 6.0 ptp180 -55.09 -42.3 72.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.9 p-10 -102.02 43.81 1.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -135.7 168.11 19.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -69.56 149.45 96.99 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.688 0.756 . . . . 0.0 110.832 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 91.38 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 96.9 t -145.67 130.42 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.168 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -99.46 136.45 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.911 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -107.55 106.47 16.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.08 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.5 t -100.44 117.77 46.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 85.1 m -106.55 136.18 46.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.16 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.79 175.88 24.76 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.45 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 13.4 mmt -41.68 159.56 0.18 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.52 0.676 . . . . 0.0 110.912 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.437 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 54.0 Cg_endo -69.76 0.81 5.11 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.663 2.242 . . . . 0.0 112.374 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.11 -35.1 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.905 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.465 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.3 m-20 -72.03 -46.95 55.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -64.09 -37.59 80.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -55.44 -45.09 76.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.845 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -57.27 -54.57 45.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.74 -51.96 8.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 68.8 ttp85 -45.28 -45.17 11.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.855 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -61.49 -42.47 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -61.92 -57.32 12.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 78.3 mt -52.46 -49.56 42.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -63.54 -43.76 96.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.866 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.58 -57.5 2.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' A' ' 170' ' ' ALA . 37.9 m80 -37.13 -38.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 51.1 mt -49.31 -53.33 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.103 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 174' ' ' LEU . 91.8 m -81.92 -43.13 18.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.185 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.421 ' C ' ' O ' ' A' ' 173' ' ' THR . 8.6 tt -35.92 -48.61 0.58 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 13.3 ttt85 -151.82 108.1 3.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 24.3 m -65.95 176.65 1.57 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -65.84 -97.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.502 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 111.28 2.77 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 64.2 m -54.48 -60.34 3.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 2.6 m -117.94 121.56 41.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.478 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 87.0 p -165.87 125.94 1.74 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 110.83 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.3 t -164.98 136.86 4.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.861 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -122.36 62.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.493 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 50.8 m -39.14 -58.12 1.2 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.963 0.411 . . . . 0.0 110.866 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.8 t -74.16 133.64 42.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.843 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -112.59 -128.84 5.07 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.53 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.72 109.24 0.84 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.508 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -69.81 172.51 7.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.889 0.376 . . . . 0.0 110.91 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.438 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 1.6 t -135.34 174.58 10.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.18 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.419 ' N ' ' OG1' ' A' ' 108' ' ' THR . 56.7 m -148.16 127.26 12.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.15 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 21.2 pt -118.35 155.12 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.494 ' CD ' ' N ' ' A' ' 111' ' ' GLN . 1.0 OUTLIER -108.53 97.14 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.474 HG12 ' N ' ' A' ' 113' ' ' ARG . 82.7 t -68.14 137.89 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.183 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.474 ' N ' HG12 ' A' ' 112' ' ' VAL . 24.9 ttt180 -103.44 116.5 32.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.891 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.55 147.4 61.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.602 0.715 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.471 ' O ' ' N ' ' A' ' 117' ' ' ARG . 54.4 Cg_endo -69.7 126.94 13.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.663 2.242 . . . . 0.0 112.344 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.412 ' C ' ' O ' ' A' ' 115' ' ' PRO . 32.4 t80 -36.59 -31.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' PRO . 15.2 ttm180 -64.66 -51.6 61.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.463 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 42.3 t -64.89 -31.65 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.118 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.8 t -41.63 -70.68 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.11 -28.48 1.33 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.6 mt -75.11 -48.95 21.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 0.0 110.936 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 40.1 t -59.83 -60.13 2.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.104 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.1 t -46.06 -63.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.107 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 89.04 172.46 46.16 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_exo -48.04 99.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.7 2.267 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 30.5 tttm 49.75 49.69 19.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.06 73.66 0.46 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.18 -38.76 2.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 111.12 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 80.1 m -83.64 -44.98 13.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.164 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 10.0 tp -57.84 -26.92 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.3 tttt -63.79 -45.78 88.13 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -36.19 56.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.928 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 48.6 mt -66.57 -58.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.131 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 -52.1 -36.05 49.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.877 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 56.3 mm-40 -78.74 -34.68 45.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -67.26 -38.5 85.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.835 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 53.1 p -107.18 -0.4 22.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.138 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 37.1 m170 52.71 52.59 13.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 16.5 p -123.08 179.98 4.48 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.115 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -117.11 98.18 6.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 79.5 mt -90.62 127.1 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.117 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 75.3 t -112.07 121.05 63.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.0 p -74.78 145.96 82.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.585 0.707 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 179.98 3.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.632 2.221 . . . . 0.0 112.297 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.42 165.04 51.37 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.5 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -70.04 -45.04 68.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 0.0 110.868 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 49.6 m-20 -103.22 41.74 1.23 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -133.01 174.45 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -68.28 144.3 96.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.598 0.713 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 100.97 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 91.4 t -149.88 130.55 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -100.68 132.61 45.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.45 111.59 24.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.124 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 41.5 t -99.91 117.96 45.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.108 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 96.2 m -109.53 131.97 54.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.41 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 158.44 -177.81 34.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 20.4 mmt -49.59 158.31 0.84 Allowed Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.557 0.694 . . . . 0.0 110.901 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.438 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.75 -1.96 9.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -115.6 -23.36 8.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -84.82 -54.76 4.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.41 HG13 ' C ' ' A' ' 156' ' ' GLY . 5.5 m -58.26 -27.0 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.149 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -70.38 -39.13 74.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.875 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.45 -50.42 45.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -52.5 -42.99 64.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 18.5 ttm180 -47.14 -53.17 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.898 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -50.85 -43.88 59.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.72 -51.37 69.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 50.2 mt -55.26 -44.09 73.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.163 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -68.18 -44.46 75.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.407 ' C ' HD13 ' A' ' 174' ' ' LEU . . . -42.68 -51.28 5.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.086 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -42.01 -38.66 1.69 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 57.1 mt -52.5 -61.61 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.154 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.9 t -87.34 37.05 0.76 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.407 HD13 ' C ' ' A' ' 170' ' ' ALA . 11.4 mt -131.75 150.99 51.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -67.19 141.51 57.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.8 p -142.35 124.06 15.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.86 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -133.86 86.11 0.27 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.5 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 123.2 9.86 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.716 2.277 . . . . 0.0 112.329 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.9 t -64.13 152.02 41.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 66.7 m -58.56 133.33 55.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.507 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 63.2 p -79.52 158.76 27.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.87 0.367 . . . . 0.0 110.847 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.6 m -80.18 103.37 10.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.846 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -97.21 -97.61 1.93 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 54.9 m -118.58 131.57 56.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.874 0.368 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 87.8 p -84.26 -47.99 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.828 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -99.84 175.6 27.74 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.463 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -134.11 -54.17 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.483 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.426 ' NE2' HG23 ' A' ' 155' ' ' THR . 0.0 OUTLIER -70.61 175.36 4.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.88 0.372 . . . . 0.0 110.935 -179.879 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.421 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 9.6 t -134.72 164.47 27.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 89.8 m -131.25 122.46 26.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.179 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.4 pt -114.5 148.9 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.0 mm-40 -109.33 101.35 10.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 88.2 t -70.2 143.27 14.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.138 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.407 ' C ' HG12 ' A' ' 114' ' ' VAL . 6.9 ttm180 -114.04 120.93 42.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.851 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.407 HG12 ' C ' ' A' ' 113' ' ' ARG . 11.1 m -139.68 150.92 64.84 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.653 0.739 . . . . 0.0 111.117 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.468 ' O ' ' N ' ' A' ' 118' ' ' VAL . 54.1 Cg_endo -69.74 125.49 12.22 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.655 2.236 . . . . 0.0 112.344 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.8 t80 -34.52 -35.53 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 115' ' ' PRO . 75.5 mtt-85 -59.56 -49.37 78.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' A' ' 115' ' ' PRO . 55.7 t -69.61 -35.28 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.107 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.9 t -39.51 -63.37 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.171 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.89 -42.23 37.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.0 mt -60.46 -43.46 96.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.816 0.341 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.407 ' HA ' ' CE1' ' A' ' 171' ' ' HIS . 58.3 t -69.98 -60.37 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.12 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.5 t -37.08 -51.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.42 166.79 42.44 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_exo -48.01 92.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.36 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 53.3 mmtt 58.51 41.63 22.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.918 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.54 66.29 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -111.76 -40.36 4.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.884 0.373 . . . . 0.0 111.115 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.3 m -84.82 -43.94 13.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.413 HD11 ' CG2' ' A' ' 141' ' ' ILE . 7.0 tp -58.52 -28.18 35.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -71.32 -43.42 67.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 35.0 ttm-85 -60.16 -39.95 88.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 58.0 mt -59.21 -50.1 81.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.128 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -48.77 -36.8 17.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.922 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -80.21 -51.08 9.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.913 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -54.2 -33.64 58.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.9 p -104.2 -14.83 15.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.141 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 9.8 m80 60.26 52.76 4.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 77.7 p -138.81 145.22 39.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -78.42 100.21 6.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.413 ' CG2' HD11 ' A' ' 130' ' ' ILE . 93.9 mt -96.23 122.08 47.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.083 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.4 t -112.96 132.28 62.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.6 p -85.17 152.53 58.59 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.626 0.727 . . . . 0.0 111.114 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.48 3.68 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.665 2.244 . . . . 0.0 112.364 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.88 169.76 53.41 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -70.1 -47.47 61.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.837 0.351 . . . . 0.0 110.872 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -103.79 40.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 18.3 mmmt -131.66 172.17 12.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -68.77 144.23 95.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.632 0.729 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 99.25 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.695 2.263 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 85.4 t -148.99 118.71 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.95 149.86 24.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.19 109.5 14.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.043 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 68.4 t -102.4 133.69 45.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.16 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.426 HG23 ' NE2' ' A' ' 107' ' ' GLN . 25.9 m -118.81 135.45 54.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.472 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 150.85 -179.33 27.65 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.433 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 14.5 mmt -43.49 159.44 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.534 0.683 . . . . 0.0 110.884 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.421 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.8 -0.17 6.56 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -119.29 -39.23 2.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -68.63 -40.42 80.33 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.472 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 20.2 m -72.42 -34.86 49.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -59.96 -39.93 87.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 43.6 ttt180 -61.27 -55.68 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.24 -43.08 3.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.092 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 72.1 ttt-85 -56.31 -40.65 74.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -54.57 -45.46 73.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -66.61 -57.16 7.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.917 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.7 mt -49.0 -45.82 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.165 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -71.13 -44.22 66.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.51 -57.97 1.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.129 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.413 ' C ' ' O ' ' A' ' 170' ' ' ALA . 13.2 m170 -36.19 -40.18 0.21 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.857 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 50.2 mt -49.28 -58.79 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 27.6 m -66.82 -48.3 69.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.151 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 5.2 mp -66.76 172.81 3.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.93 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HD3' ' C ' ' A' ' 175' ' ' ARG . 0.2 OUTLIER -153.7 135.93 14.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.873 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.6 t 64.79 42.24 4.64 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.852 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 82.52 -170.13 50.0 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 154.13 68.2 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.712 2.274 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 67.3 m -59.22 123.89 18.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.874 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -132.2 128.2 37.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.894 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.474 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.509 -0.237 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 29.4 m -96.7 103.0 14.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.839 0.352 . . . . 0.0 110.842 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.0 p -150.52 126.33 10.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.11 112.9 2.01 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.479 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.2 t -59.34 146.45 39.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 55.0 p -153.49 110.24 3.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.851 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -173.4 -179.05 43.81 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.508 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.91 103.59 1.87 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.442 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.401 ' CA ' ' HE3' ' A' ' 157' ' ' MET . 8.8 pt20 -80.73 172.77 13.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -130.63 168.34 17.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.2 m -136.96 118.67 15.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.0 pt -107.3 150.62 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.112 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -109.61 94.16 4.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 79.4 t -67.16 139.74 20.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -109.25 111.89 23.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.2 m -128.39 150.89 75.56 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.589 0.709 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.5 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.77 123.56 10.22 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.668 2.245 . . . . 0.0 112.373 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 22.8 t80 -34.84 -32.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.5 ' N ' ' O ' ' A' ' 115' ' ' PRO . 50.5 mtt85 -62.68 -49.13 76.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.477 ' N ' ' O ' ' A' ' 115' ' ' PRO . 56.0 t -70.35 -31.31 46.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.5 t -43.07 -64.46 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.1 -41.17 22.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.486 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 18.0 mt -63.19 -47.94 80.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.879 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 61.5 t -62.66 -61.71 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.131 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.6 t -43.16 -50.39 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 80.74 173.01 46.49 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.464 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' LYS . 64.6 Cg_exo -47.92 114.64 1.17 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.674 2.249 . . . . 0.0 112.372 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' PRO . 0.0 OUTLIER 34.13 43.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.886 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.38 84.45 0.12 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -133.52 -34.37 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 58.9 m -89.72 -43.7 10.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.089 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.6 tp -68.21 -27.79 38.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.094 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttmt -68.29 -37.46 80.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.8 ttm180 -64.33 -46.82 81.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.854 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 36.6 mt -55.69 -42.8 71.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.13 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.407 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 79.0 mt-30 -57.23 -24.35 54.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.98 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 51.9 mm-40 -89.83 -47.03 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.401 ' NH1' ' OE2' ' A' ' 167' ' ' GLU . 6.3 ptm180 -64.16 -31.54 72.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.485 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 73.9 p -100.23 -12.83 19.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.158 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 27.2 m80 57.21 54.4 6.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.458 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 72.5 p -141.76 140.62 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -78.47 97.28 5.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.407 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 96.2 mt -88.78 108.71 19.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.138 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -91.95 133.65 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.116 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.0 p -91.81 146.13 32.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.558 0.694 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 177.17 5.82 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.733 2.289 . . . . 0.0 112.297 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.87 -178.02 50.11 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.514 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 50.3 ptt85 -83.08 -38.47 22.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.834 0.35 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -110.0 41.81 1.64 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -135.61 164.86 26.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -62.25 142.58 95.84 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.923 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 103.57 1.19 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.655 2.237 . . . . 0.0 112.348 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.3 t -148.28 115.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -86.96 128.44 35.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.915 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.36 104.28 14.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.464 HG12 ' CG1' ' A' ' 161' ' ' VAL . 60.3 t -95.9 122.2 47.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.437 HG22 ' N ' ' A' ' 156' ' ' GLY . 87.6 m -108.65 137.15 47.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.437 ' N ' HG22 ' A' ' 155' ' ' THR . . . 151.95 -179.76 28.26 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' MET . . . . . 0.401 ' HE3' ' CA ' ' A' ' 107' ' ' GLN . 15.6 mmt -47.12 159.34 0.4 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 110.897 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 0.28 5.86 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.718 2.278 . . . . 0.0 112.351 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -118.4 -32.1 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.846 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.458 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.0 m-20 -73.58 -48.49 32.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.464 ' CG1' HG12 ' A' ' 154' ' ' VAL . 32.9 m -65.62 -40.13 87.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -51.17 -41.88 60.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 15.3 ttm180 -65.24 -47.58 76.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.819 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.94 54.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.09 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.49 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 22.7 ttt85 -55.3 -45.26 76.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.854 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -60.98 -38.18 85.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.485 ' OE1' ' CG2' ' A' ' 137' ' ' THR . 12.8 mt-10 -66.94 -50.52 62.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.886 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 66.6 mt -60.75 -43.41 95.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.49 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 60.3 mt-10 -66.15 -47.46 73.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.411 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -45.35 -55.36 6.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.411 ' C ' ' O ' ' A' ' 170' ' ' ALA . 30.0 m170 -37.23 -41.01 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 56.4 mt -43.72 -52.39 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 98.3 m -99.22 92.18 5.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.169 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 23.5 tp -172.06 134.33 0.74 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.971 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 38.2 ptt85 -97.82 79.2 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 26.1 t -159.47 130.44 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 152.03 146.2 4.3 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.51 5.53 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.689 2.26 . . . . 0.0 112.371 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' SER . . . . . 0.407 ' O ' ' C ' ' A' ' 180' ' ' SER . 18.5 m -45.25 118.34 1.67 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 179' ' ' SER . 79.7 p -37.77 110.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.482 179.979 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 64.1 m -130.16 151.6 50.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.872 0.368 . . . . 0.0 110.86 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 35.9 m -128.42 151.98 48.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -132.97 135.15 7.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 94.4 p -156.52 127.56 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.853 0.358 . . . . 0.0 110.841 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 92.7 p -106.56 112.92 26.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.838 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 114.78 175.19 18.57 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.525 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.453 ' O ' ' CE ' ' A' ' 157' ' ' MET . . . 117.07 41.64 0.69 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.443 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.414 ' CD ' ' C ' ' A' ' 107' ' ' GLN . 4.8 pp0? -120.15 173.07 7.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.92 0.391 . . . . 0.0 110.904 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.443 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 5.7 t -133.1 165.35 24.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.134 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.1 m -133.54 122.47 23.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -116.11 147.73 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -105.97 106.77 17.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 113' ' ' ARG . 97.6 t -71.83 141.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.107 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.469 ' N ' HG12 ' A' ' 112' ' ' VAL . 47.0 ttp180 -111.7 115.91 29.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.882 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.407 HG12 ' C ' ' A' ' 113' ' ' ARG . 4.1 m -136.57 150.27 69.82 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.564 0.697 . . . . 0.0 111.158 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.466 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.71 130.22 19.01 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.344 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -40.6 -33.76 0.3 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.433 ' HB3' ' NH1' ' A' ' 117' ' ' ARG . 5.6 mmm180 -61.76 -48.24 81.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.466 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 54.5 t -71.7 -32.67 46.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.9 t -40.73 -65.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.81 -40.42 26.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.89 -40.65 98.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 0.0 110.926 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.421 ' CG1' HD11 ' A' ' 130' ' ' ILE . 59.1 t -69.01 -63.5 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 95.5 t -38.43 -50.85 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.15 169.19 42.95 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -47.98 105.74 0.09 OUTLIER 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.697 2.265 . . . . 0.0 112.32 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt 45.22 39.29 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.921 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.76 86.51 0.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.479 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -134.87 -39.07 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.808 0.337 . . . . 0.0 111.047 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.0 m -86.65 -43.8 12.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.175 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.421 HD11 ' CG1' ' A' ' 122' ' ' VAL . 4.9 tp -60.95 -41.27 88.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.56 -38.39 69.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.835 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -58.62 -45.91 88.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.2 mt -55.26 -43.41 70.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.132 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.442 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 68.1 mt-30 -56.51 -37.18 70.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 135' ' ' GLN . 7.4 mm-40 -78.67 -54.24 6.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.922 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 23.0 mmm-85 -51.17 -34.83 33.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 70.0 p -102.52 -12.76 17.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 36.0 m80 57.22 52.94 8.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 63.8 p -136.11 159.19 42.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -89.34 98.88 12.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.442 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 71.1 mt -97.31 112.93 30.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.185 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.459 HG13 ' N ' ' A' ' 143' ' ' THR . 70.7 t -102.6 135.57 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.459 ' N ' HG13 ' A' ' 142' ' ' VAL . 59.8 p -85.03 149.62 53.48 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.564 0.697 . . . . 0.0 111.146 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 177.58 5.44 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.2 161.84 49.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptp85 -66.48 -44.06 83.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -103.57 39.67 1.56 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.864 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -133.92 166.57 22.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -61.49 145.76 90.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.669 0.747 . . . . 0.0 110.904 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.7 98.16 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.653 2.235 . . . . 0.0 112.39 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 87.0 t -149.53 125.33 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.59 150.1 20.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.14 113.19 21.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.9 t -104.93 123.12 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.46 HG21 ' N ' ' A' ' 156' ' ' GLY . 89.4 m -112.23 139.24 47.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.115 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.46 ' N ' HG21 ' A' ' 155' ' ' THR . . . 147.49 -173.79 27.48 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' MET . . . . . 0.453 ' CE ' ' O ' ' A' ' 106' ' ' GLY . 16.2 mmt -48.56 159.32 0.54 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.502 0.668 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.443 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.9 Cg_endo -69.76 -1.06 7.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.657 2.238 . . . . 0.0 112.337 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -115.67 -49.79 2.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -59.47 -41.64 90.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.2 m -72.3 -34.33 48.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -58.34 -42.32 86.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -65.99 -36.78 84.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.892 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -60.02 -31.52 70.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 48.3 ttt180 -71.64 -52.4 18.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.85 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -62.54 -30.57 71.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -70.98 -54.34 11.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 72.1 mt -58.61 -46.69 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -65.0 -37.52 87.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.61 -53.79 6.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -41.8 -32.99 0.45 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 83.5 mt -50.81 -51.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.111 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 6.1 t -77.61 -21.86 51.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.19 144.45 55.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 9.4 mtp-105 -138.24 114.24 10.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 6.4 t -101.54 -60.29 1.55 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -161.72 151.9 22.18 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 161.03 47.5 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.647 2.231 . . . . 0.0 112.353 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.7 t -132.48 -61.4 0.86 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 54.1 m -56.67 129.87 42.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.5 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 36.4 t -103.8 158.71 16.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.938 0.399 . . . . 0.0 110.809 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.6 p -111.7 174.24 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.847 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -139.61 -103.94 0.58 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.524 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.7 t -104.9 100.26 9.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.856 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 76.8 p -89.36 -44.89 9.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.813 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 144.63 178.02 19.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.469 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -84.96 -113.2 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.508 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? -77.54 175.59 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.888 0.375 . . . . 0.0 110.934 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.8 t -133.42 170.44 15.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.19 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.4 m -141.98 129.01 20.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.453 ' O ' ' NE2' ' A' ' 111' ' ' GLN . 20.4 pt -122.04 158.91 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.454 ' CD ' ' N ' ' A' ' 111' ' ' GLN . 1.2 mp0 -113.81 106.37 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.96 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 93.9 t -75.61 142.28 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -110.37 120.31 42.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -142.49 150.71 55.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.615 0.721 . . . . 0.0 111.154 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.467 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.77 125.26 11.93 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.323 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.462 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 27.1 t80 -35.85 -34.65 0.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.959 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.428 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.0 ttp180 -59.74 -49.91 75.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.467 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 56.1 t -69.56 -34.27 60.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.462 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 98.9 t -40.15 -66.97 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.147 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.64 -41.14 18.47 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.513 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.2 mt -62.22 -43.32 99.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -68.03 -62.12 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.075 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.5 t -40.04 -54.03 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.177 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 87.64 167.57 43.67 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_exo -47.93 94.8 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.717 2.278 . . . . 0.0 112.338 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 29.6 mtpt 55.07 42.17 31.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.905 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.32 79.01 0.31 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.478 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -128.47 -38.78 1.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.867 0.365 . . . . 0.0 111.104 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.2 m -87.08 -40.26 14.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.087 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.0 tp -64.7 -33.33 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.141 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 18.2 tttp -59.49 -42.34 91.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -54.96 -47.79 74.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.812 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 54.3 mt -54.8 -48.81 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.426 ' CG ' HD11 ' A' ' 141' ' ' ILE . 61.1 mt-30 -48.25 -38.59 18.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 86.7 mm-40 -81.12 -52.56 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -51.37 -32.64 26.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.4 p -106.53 -13.56 15.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.141 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 41.2 m80 60.0 53.43 4.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.463 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 55.2 p -135.49 139.79 44.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.121 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -77.75 90.47 4.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.979 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.442 HG23 ' N ' ' A' ' 142' ' ' VAL . 78.9 mt -83.29 142.14 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.163 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.442 ' N ' HG23 ' A' ' 141' ' ' ILE . 86.6 t -131.01 121.23 49.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.119 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 78.6 p -73.0 150.01 90.05 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.562 0.696 . . . . 0.0 111.152 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 176.91 6.17 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.252 . . . . 0.0 112.363 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -77.08 150.46 37.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -57.17 -36.42 70.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -110.34 40.35 1.98 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 49.2 mmtt -134.72 165.77 24.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.42 144.54 62.35 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 94.01 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.658 2.239 . . . . 0.0 112.396 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.423 HG11 ' N ' ' A' ' 152' ' ' PHE . 89.3 t -145.72 135.55 18.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.089 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.423 ' N ' HG11 ' A' ' 151' ' ' VAL . 47.1 m-85 -102.51 128.43 49.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -100.21 109.86 22.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 67.3 t -100.77 130.17 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.138 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 21.7 m -117.91 135.1 54.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.135 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.407 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 153.87 179.72 29.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.504 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 18.9 mmt -46.57 159.28 0.36 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.53 0.681 . . . . 0.0 110.905 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 0.85 5.06 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.673 2.249 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -118.47 -29.13 5.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.914 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.463 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 8.4 m-20 -78.22 -46.47 20.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.838 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.458 HG21 ' N ' ' A' ' 162' ' ' ASP . 16.0 m -68.32 -23.56 28.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . 0.458 ' N ' HG21 ' A' ' 161' ' ' VAL . 45.9 t0 -66.72 -39.12 87.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 24.2 ttm-85 -70.15 -46.87 63.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.37 -34.62 58.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.118 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 13.6 ttm180 -64.48 -50.87 65.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -62.9 -24.68 67.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -77.08 -56.5 4.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.957 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 76.2 mt -52.73 -53.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -56.28 -43.37 78.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -41.78 -58.3 2.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.444 ' C ' ' O ' ' A' ' 170' ' ' ALA . 9.8 m80 -34.45 -36.07 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 170' ' ' ALA . 64.9 mt -54.1 -61.21 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.147 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.9 t -67.85 -25.11 65.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.123 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 9.7 tp -60.34 147.58 40.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -92.14 156.86 17.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 24.7 p -108.95 -44.99 3.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -79.31 142.71 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -2.26 9.87 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.66 2.24 . . . . 0.0 112.36 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 44.3 m -156.94 163.24 39.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.0 m -153.6 138.99 17.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.479 -179.944 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.4 p -146.35 137.61 24.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.911 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.1 m -100.53 86.51 3.16 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.847 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 60.99 -136.97 48.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.534 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.9 p -111.95 126.91 55.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.832 0.349 . . . . 0.0 110.821 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 57.7 m -119.7 149.62 41.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.841 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -81.24 77.52 2.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.46 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -160.94 80.03 0.15 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -87.25 161.95 17.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.869 0.366 . . . . 0.0 110.913 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -125.61 159.48 32.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.2 m -128.51 116.42 19.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -104.77 155.32 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -114.42 101.0 8.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 91.3 t -69.64 141.97 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 23.6 ttp180 -111.67 112.05 23.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.4 m -134.11 151.4 76.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.614 0.721 . . . . 0.0 111.108 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.542 ' CB ' ' NH1' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.74 138.37 37.72 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.682 2.255 . . . . 0.0 112.322 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.0 t80 -46.96 -37.91 9.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.542 ' NH1' ' CB ' ' A' ' 115' ' ' PRO . 8.6 ptp85 -59.01 -38.62 79.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.468 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 19.8 t -78.0 -36.42 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.171 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 97.1 t -41.37 -63.7 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.07 -39.21 18.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.3 mt -65.15 -43.9 90.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 0.0 110.921 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 73.4 t -71.57 -60.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.7 t -42.28 -45.54 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 73.92 173.34 27.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.482 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.4 Cg_exo -48.03 114.74 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.7 pttm 36.1 39.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.895 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.44 73.77 0.78 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.61 -38.49 3.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 m -85.5 -44.25 12.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.1 tp -60.82 -31.16 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -68.03 -40.18 82.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -60.85 -44.23 97.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.833 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 73.0 mt -54.58 -54.58 21.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.126 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 138' ' ' HIS . 76.1 mt-30 -42.81 -30.9 0.43 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -78.27 -53.72 7.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.4 -32.17 56.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 74.1 p -102.22 -17.5 15.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.178 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 134' ' ' GLN . 16.9 m170 59.27 54.94 4.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.821 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.452 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.3 p -135.28 174.51 10.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -106.21 89.94 3.21 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.8 mt -82.89 137.14 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 91.7 t -124.63 132.14 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.166 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.7 p -90.26 147.86 37.82 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.582 0.706 . . . . 0.0 111.166 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -179.11 2.67 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.315 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.44 176.92 51.5 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.52 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . 0.421 ' C ' ' HD3' ' A' ' 146' ' ' ARG . 0.2 OUTLIER -80.23 -35.29 36.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -106.87 39.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 38.7 mmtt -138.01 175.43 9.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -71.98 143.41 86.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.592 0.71 . . . . 0.0 110.935 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 89.66 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.644 2.229 . . . . 0.0 112.394 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 75.4 t -138.17 119.64 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.71 148.88 25.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.86 105.62 10.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.08 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 96.0 t -100.89 127.03 54.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.128 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -112.79 138.68 49.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.415 ' C ' HG11 ' A' ' 161' ' ' VAL . . . 150.4 176.04 23.03 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 14.0 mmt -41.03 159.4 0.16 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.582 0.706 . . . . 0.0 110.87 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 0.58 5.4 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.706 2.271 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -118.35 -35.46 3.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.452 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.1 m-20 -69.25 -46.31 67.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.904 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.415 HG11 ' C ' ' A' ' 156' ' ' GLY . 33.7 m -68.88 -38.61 78.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.134 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -52.37 -42.04 63.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 42.0 ttt85 -63.82 -52.56 59.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -45.58 -49.28 14.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.079 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 44.4 ttt180 -51.6 -40.5 59.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -57.61 -47.98 80.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -65.04 -56.69 11.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.937 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 65.4 mt -47.84 -50.69 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.132 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -65.89 -47.03 76.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.433 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.83 -55.75 1.46 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 170' ' ' ALA . 95.2 m-70 -36.02 -43.11 0.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.833 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 73.6 mt -44.49 -58.24 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.092 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 174' ' ' LEU . 95.5 m -58.82 -52.12 67.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 173' ' ' THR . 9.3 tp -35.78 135.35 0.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.939 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -66.29 151.44 47.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 40.1 m -78.63 147.49 33.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -103.17 -80.98 1.49 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -32.62 18.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 2.244 . . . . 0.0 112.373 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 3.7 t 66.99 51.42 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 9.8 m 56.13 43.77 26.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.826 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.491 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 29.9 p 40.85 42.29 1.42 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.859 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.9 m -56.39 172.76 0.21 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.851 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 164.01 46.31 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 53.4 m -83.2 140.46 32.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.892 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 57.2 p -137.63 128.76 27.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.861 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.83 124.06 5.37 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.495 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.94 -108.89 0.57 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.497 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 -71.54 -176.92 1.69 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.853 0.358 . . . . 0.0 110.914 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.407 ' HG1' ' N ' ' A' ' 109' ' ' THR . 8.8 t -147.71 156.97 43.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.162 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.407 ' N ' ' HG1' ' A' ' 108' ' ' THR . 97.8 m -127.9 122.49 32.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -111.27 154.84 12.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -109.9 101.76 10.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.413 HG11 ' N ' ' A' ' 113' ' ' ARG . 54.0 t -69.67 132.98 32.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.413 ' N ' HG11 ' A' ' 112' ' ' VAL . 14.9 ttp180 -100.39 118.95 37.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.14 150.45 58.85 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.624 0.726 . . . . 0.0 111.085 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 133.18 24.98 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -42.42 -26.89 0.13 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 60.2 ttp85 -69.35 -54.06 16.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 35.8 t -63.65 -27.29 42.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.1 t -46.5 -71.09 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -43.68 -34.67 2.79 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 8.7 mt -67.39 -44.19 79.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 83.9 t -69.42 -65.58 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.9 t -37.63 -61.5 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.78 166.15 38.64 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.514 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_exo -47.97 93.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt 56.98 54.03 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.939 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 54.93 70.95 0.8 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.71 -41.14 2.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 111.084 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 73.7 m -78.59 -44.5 23.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.155 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.5 tp -54.4 -29.59 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.7 tptp -54.57 -44.64 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -61.27 -22.12 64.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 70.5 mt -83.1 -31.56 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.136 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.404 ' CG ' ' HB ' ' A' ' 141' ' ' ILE . 44.8 mt-30 -83.34 -24.45 32.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . 0.463 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.82 -41.01 19.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.935 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.463 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 14.9 mmm180 -64.62 -35.68 81.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -100.56 -18.12 16.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.16 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.4 m80 62.28 46.18 6.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.822 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.441 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.6 p -120.67 164.55 16.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 t80 -95.66 88.25 4.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.404 ' HB ' ' CG ' ' A' ' 134' ' ' GLN . 79.9 mt -88.69 132.81 32.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.103 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.4 t -117.96 132.09 68.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.167 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 64.4 p -85.55 148.07 48.25 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.596 0.713 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 176.49 6.73 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.647 2.231 . . . . 0.0 112.356 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.56 179.22 53.24 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.48 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -79.16 -43.25 24.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.884 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.7 p-10 -104.79 43.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 52.9 mmtt -134.08 169.04 17.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -66.57 143.99 98.43 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.669 0.747 . . . . 0.0 110.91 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 95.7 0.56 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 2.267 . . . . 0.0 112.313 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.2 t -147.7 119.59 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.172 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -88.27 140.27 29.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.02 110.17 20.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.081 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -103.98 122.51 56.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 93.6 m -111.03 130.59 55.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.153 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.491 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 158.31 178.16 32.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.475 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 12.5 mmt -45.37 158.94 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -0.69 7.2 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.737 2.291 . . . . 0.0 112.32 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.78 -25.38 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.908 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.441 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 5.5 m-20 -83.07 -48.52 10.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 34.1 m -64.78 -36.96 78.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -58.36 -45.28 88.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.855 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -61.46 -43.91 98.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.873 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.92 -44.01 70.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 18.6 ttm180 -59.42 -42.85 92.8 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.872 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -53.37 -42.88 67.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.935 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -71.3 -51.61 23.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.877 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 61.6 mt -49.34 -53.99 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -67.38 -41.45 85.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.59 -61.44 0.71 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 170' ' ' ALA . 32.7 m170 -34.46 -41.29 0.12 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.842 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 93.4 mt -47.78 -55.34 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 49.6 p -99.93 88.26 3.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.3 tp -150.43 157.25 42.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 18.9 ttt180 -160.15 142.47 13.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 39.5 m -61.33 126.23 26.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 133.32 -95.03 0.28 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.495 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 101.55 0.93 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.692 2.261 . . . . 0.0 112.315 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 t -165.81 174.34 9.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 87.1 p -84.55 -43.78 14.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.452 179.963 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.3 t -156.54 112.84 3.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.864 0.364 . . . . 0.0 110.851 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.9 m -102.46 170.03 8.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 103' ' ' SER . . . 156.89 -79.46 0.18 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.526 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 102' ' ' GLY . 8.3 t -36.54 110.15 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.858 0.361 . . . . 0.0 110.867 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.9 t -74.89 168.65 19.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.855 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -153.96 -48.08 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.504 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.71 111.65 1.66 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -55.92 169.83 0.34 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.4 t -129.47 159.66 35.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -131.24 120.64 23.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.187 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 25.0 pt -111.15 152.89 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 38.2 mm-40 -108.02 100.66 9.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.896 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.472 HG11 ' N ' ' A' ' 113' ' ' ARG . 88.4 t -73.09 141.97 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.147 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.472 ' N ' HG11 ' A' ' 112' ' ' VAL . 37.5 ttt-85 -104.98 120.88 42.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.93 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.496 HG21 ' CD1' ' A' ' 152' ' ' PHE . 4.8 m -140.49 151.07 62.84 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.688 0.756 . . . . 0.0 111.074 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.467 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.2 Cg_endo -69.79 138.4 37.64 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.685 2.256 . . . . 0.0 112.314 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -47.52 -26.21 1.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.927 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 ttm180 -69.6 -46.99 65.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.835 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.467 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 41.2 t -68.39 -29.37 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.108 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.4 t -42.27 -65.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.66 -34.08 9.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.4 -46.11 61.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.85 0.357 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 91.9 t -64.89 -57.92 9.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 90.2 t -55.28 -49.24 74.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.94 172.69 48.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.44 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.95 99.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.652 2.235 . . . . 0.0 112.382 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? 54.01 42.71 31.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.46 68.38 1.67 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.52 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.28 -35.18 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.893 0.378 . . . . 0.0 111.109 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 33.1 m -75.94 -39.41 56.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.4 tp -67.21 -23.08 29.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -62.58 -38.5 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -66.44 -37.8 85.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.844 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 66.7 mt -70.48 -49.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.116 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -52.32 -37.49 55.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -81.82 -52.41 7.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 -52.89 -33.87 52.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.7 p -103.54 -15.15 15.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.165 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 17.8 m170 60.95 53.79 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 81.5 p -138.01 138.27 38.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.135 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 51.9 t80 -76.74 91.92 3.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt -83.64 134.41 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.125 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.1 t -120.28 129.32 75.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.137 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 41.6 p -83.8 153.12 63.94 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.54 0.686 . . . . 0.0 111.191 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 177.06 5.97 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.684 2.256 . . . . 0.0 112.366 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -75.06 155.67 48.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.45 -28.49 70.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.86 0.362 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -119.91 38.01 4.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -135.91 162.13 33.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -53.99 143.86 40.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.638 0.732 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.73 97.68 0.65 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.695 2.263 . . . . 0.0 112.331 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.3 t -145.32 117.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.496 ' CD1' HG21 ' A' ' 114' ' ' VAL . 35.4 m-85 -86.73 146.31 26.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.86 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -121.74 99.13 6.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 46.6 t -87.63 131.1 36.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -117.09 131.07 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.177 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.427 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 156.43 175.13 27.04 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.456 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 21.6 mmt -39.2 159.49 0.1 Allowed Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.576 0.703 . . . . 0.0 110.902 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.723 2.282 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -119.7 -38.38 2.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 37.2 m-20 -66.77 -46.42 75.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.427 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 20.5 m -67.72 -38.1 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -52.89 -43.1 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 11.9 ttt180 -61.89 -57.92 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.06 -48.54 4.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 16.9 ttp85 -48.34 -40.24 24.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -55.48 -64.82 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 58.1 mm-40 -54.22 -46.35 72.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 47.7 mt -44.63 -65.91 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.082 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.417 ' O ' ' CG1' ' A' ' 172' ' ' ILE . 0.7 OUTLIER -69.36 -29.52 67.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.861 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -48.74 -48.99 40.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -46.89 -26.32 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.417 ' CG1' ' O ' ' A' ' 169' ' ' GLU . 69.6 mt -51.71 -39.08 23.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.8 t -99.62 45.44 0.99 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.425 HD21 ' N ' ' A' ' 174' ' ' LEU . 4.3 mm? -131.35 162.79 29.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -106.46 111.09 23.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 2.1 m -141.24 168.14 20.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.828 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 154.85 66.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -48.08 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.629 2.219 . . . . 0.0 112.309 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 22.9 t -153.94 152.23 30.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.843 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.4 t -133.86 82.58 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.885 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.0 t -100.53 -53.91 2.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.896 0.379 . . . . 0.0 110.826 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.1 m -123.34 98.4 5.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.897 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 52.42 -158.93 3.21 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 8.8 t -120.48 94.93 4.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.867 0.365 . . . . 0.0 110.875 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 36.7 m -151.42 172.67 15.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.88 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -112.85 -59.89 0.42 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.473 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.416 ' C ' ' HE2' ' A' ' 157' ' ' MET . . . -149.97 -83.01 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.489 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -91.23 159.31 16.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.885 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.9 t -124.5 168.4 13.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.123 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 25.6 m -137.34 124.63 21.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 23.0 pt -122.46 155.24 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.091 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -105.2 111.66 24.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 70.4 t -76.77 135.04 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.424 ' C ' HG12 ' A' ' 114' ' ' VAL . 7.3 tmm_? -106.65 117.65 34.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.424 HG12 ' C ' ' A' ' 113' ' ' ARG . 8.7 m -137.96 151.05 69.42 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.669 0.747 . . . . 0.0 111.121 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 134.37 27.98 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -47.09 -21.98 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 91.7 mtt-85 -72.59 -44.02 62.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 39.6 t -74.31 -34.41 36.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.15 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.8 t -38.23 -69.92 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.155 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.31 -36.21 4.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.472 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -68.01 -44.16 77.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.882 0.373 . . . . 0.0 110.958 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.53 -63.28 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.3 t -40.88 -50.43 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.142 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 79.97 169.08 38.51 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.05 101.23 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.353 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.4 tptm 50.26 44.39 26.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.71 72.9 0.7 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.63 -39.81 2.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 111.12 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -84.49 -43.57 14.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.4 tp -58.53 -37.88 67.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 27.4 tttm -57.09 -43.2 81.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 74.3 mtt-85 -57.27 -44.35 83.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.425 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 58.7 mt -57.93 -46.43 87.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.164 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 53.6 mt-30 -60.8 -20.32 61.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 -90.28 -45.6 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -66.97 -32.7 74.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.45 ' CG2' ' OE2' ' A' ' 167' ' ' GLU . 66.7 p -101.48 -15.63 17.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 11.6 m170 56.79 49.91 13.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 57.9 p -131.8 146.8 52.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.173 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 26.1 t80 -78.85 96.64 5.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 91.4 mt -90.97 115.63 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.73 124.99 61.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.12 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.0 p -76.65 152.62 83.2 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.604 0.716 . . . . 0.0 111.177 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 175.79 7.67 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.692 2.261 . . . . 0.0 112.337 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.51 158.98 46.0 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.467 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . 0.416 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 12.6 ptp180 -62.27 -44.01 97.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.867 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.416 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 30.8 t0 -103.95 42.35 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.901 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 8.0 mmmm -138.34 163.93 30.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.96 148.73 83.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 101.44 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.709 2.273 . . . . 0.0 112.344 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.2 t -153.82 119.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.094 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -89.79 156.93 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.87 104.76 9.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.138 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 34.1 t -95.81 124.0 48.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.418 ' C ' HG11 ' A' ' 161' ' ' VAL . 66.7 m -115.53 134.06 55.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.145 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 154.09 -172.37 32.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.5 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' MET . . . . . 0.416 ' HE2' ' C ' ' A' ' 106' ' ' GLY . 18.0 mmt -50.45 159.4 0.87 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.581 0.705 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.678 2.252 . . . . 0.0 112.362 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -120.03 -33.38 3.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 57.3 m-20 -73.62 -48.73 30.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 17.3 m -63.67 -36.1 75.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -61.15 -38.91 88.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -63.17 -40.74 98.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -61.78 -33.39 74.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 47.0 ttp85 -67.16 -50.48 61.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.42 -26.04 66.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.45 ' OE2' ' CG2' ' A' ' 137' ' ' THR . 67.5 mt-10 -77.83 -52.91 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 72.6 mt -58.81 -40.15 79.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -71.87 -38.59 70.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.916 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.2 -54.85 5.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 43.8 m170 -41.65 -32.07 0.34 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 76.9 mt -55.79 -44.81 78.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.443 ' O ' ' C ' ' A' ' 174' ' ' LEU . 88.4 m -63.85 -50.35 69.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 173' ' ' THR . 33.2 mt -34.41 -55.74 0.52 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 48.53 45.27 21.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 2.6 m -38.82 -48.49 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.836 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 147.7 -96.1 0.17 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.483 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 161.83 44.41 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.67 2.247 . . . . 0.0 112.349 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 31.8 p -126.4 104.03 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.902 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 2.8 m -66.21 113.52 4.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.881 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.479 179.977 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 47.7 m 46.78 42.18 11.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 110.864 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 t -101.5 123.1 45.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.889 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 51.69 -160.55 2.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.541 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 35.3 t -126.59 103.18 7.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.371 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.5 m -148.64 121.98 9.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.816 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 63.86 161.59 0.42 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -168.33 -106.49 0.19 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.51 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -95.05 167.48 11.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.425 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 10.2 t -127.55 161.3 29.12 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.082 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.7 m -132.31 122.4 25.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.26 156.11 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 49.3 mm-40 -109.88 100.55 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.943 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.445 HG11 ' N ' ' A' ' 113' ' ' ARG . 94.4 t -67.85 141.01 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.445 ' N ' HG11 ' A' ' 112' ' ' VAL . 34.6 ttp180 -109.3 124.77 51.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.86 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -146.52 149.57 37.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.56 0.695 . . . . 0.0 111.142 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 139.03 39.31 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.326 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 t80 -49.17 -20.91 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 ttm-85 -74.35 -46.24 41.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 16.7 t -68.6 -37.28 77.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.151 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 87.3 t -39.75 -64.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.098 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.72 -36.6 13.26 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 12.8 mt -70.04 -43.08 71.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.775 0.321 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 48.8 t -67.31 -63.1 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 96.4 t -38.97 -49.77 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.87 172.61 33.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -47.95 102.81 0.05 OUTLIER 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 91.0 mttt 46.16 44.41 12.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.58 70.67 1.08 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.11 -37.06 3.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 111.088 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 35.4 m -87.96 -44.39 11.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.158 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 6.6 tp -60.79 -28.06 42.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.153 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.9 ttpp -64.67 -46.97 80.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.938 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.2 mtt180 -51.74 -50.55 60.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 56.8 mt -50.14 -54.95 6.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.135 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -45.89 -37.07 5.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.901 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -79.79 -59.15 2.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -43.51 -37.64 2.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.861 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.6 p -101.03 -22.81 14.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.086 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.7 m80 69.85 52.62 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 81.0 p -133.46 155.19 49.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.142 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 35.4 t80 -90.07 95.47 10.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.964 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 90.3 mt -86.77 138.49 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.094 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.5 t -129.28 124.08 59.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.187 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.3 p -80.18 152.68 74.0 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.562 0.696 . . . . 0.0 111.121 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -175.59 1.2 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.6 169.48 45.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.31 -22.87 59.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 20.3 p-10 -123.0 40.77 3.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -138.94 174.19 10.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -68.02 143.94 96.62 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.611 0.72 . . . . 0.0 110.915 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 91.15 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.646 2.231 . . . . 0.0 112.32 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.7 t -138.74 120.04 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.139 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -89.1 147.94 23.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -117.92 113.56 21.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.115 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.407 HG11 ' CB ' ' A' ' 161' ' ' VAL . 53.8 t -106.68 124.4 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 60.2 m -111.54 137.38 49.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.61 -177.27 29.61 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.441 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 22.7 mmt -47.28 159.1 0.43 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.545 0.688 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.425 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 54.0 Cg_endo -69.72 -1.29 8.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -115.71 -37.01 4.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.839 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 -71.13 -50.62 31.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.903 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 32.0 m -59.4 -29.51 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.091 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.02 -42.06 94.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -65.83 -32.21 73.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -66.82 -36.3 82.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.084 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.42 ' CG ' ' OE1' ' A' ' 169' ' ' GLU . 41.5 ttt180 -65.31 -59.57 3.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 1.7 pp20? -51.92 -31.46 28.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -67.56 -55.39 13.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.4 mt -58.27 -53.66 43.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.42 ' OE1' ' CG ' ' A' ' 165' ' ' ARG . 29.0 mt-10 -58.77 -41.52 86.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -41.38 -59.23 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 50.1 m170 -37.75 -37.91 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 84.1 mt -45.95 -65.29 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.0 t -65.59 -32.21 73.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.201 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 5.2 tt -52.29 113.42 1.03 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.908 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 69.38 44.74 0.9 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.869 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 93.7 p -98.96 145.76 26.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.848 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 112.5 -176.31 17.66 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 91.95 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.713 2.275 . . . . 0.0 112.32 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 71.7 m -93.53 134.83 35.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 1.5 t 70.66 41.95 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.872 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.486 -179.963 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 92.5 p -90.63 -49.01 6.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.856 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.3 t 65.31 42.06 4.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -109.55 140.47 15.75 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.434 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.9 t -104.42 -47.93 3.97 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.899 0.381 . . . . 0.0 110.898 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.0 t -60.63 170.52 1.41 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -139.15 -92.62 0.25 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.453 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.15 98.32 0.88 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.536 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -98.94 169.38 9.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.901 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.1 t -133.97 163.96 28.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.11 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 56.8 m -131.87 126.16 33.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.152 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.4 pt -111.84 155.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.133 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -112.59 101.01 9.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 90.5 t -72.75 141.28 16.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.139 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.412 ' C ' HG13 ' A' ' 114' ' ' VAL . 15.8 ttm180 -111.6 115.37 29.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.412 HG13 ' C ' ' A' ' 113' ' ' ARG . 3.5 m -133.37 150.69 75.85 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.658 0.742 . . . . 0.0 111.103 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.481 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.5 Cg_endo -69.84 123.84 10.47 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.636 2.224 . . . . 0.0 112.31 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -35.2 -32.82 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 115' ' ' PRO . 10.9 mmm180 -63.12 -51.96 64.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.463 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 40.1 t -65.36 -32.19 57.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.159 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 122' ' ' VAL . 75.8 t -42.66 -72.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 119' ' ' VAL . . . -37.64 -36.79 0.31 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.5 mt -69.99 -39.59 75.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.898 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.483 ' N ' ' O ' ' A' ' 119' ' ' VAL . 38.4 t -68.92 -63.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.3 t -43.97 -55.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.079 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.84 172.83 49.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -48.03 107.09 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.638 2.225 . . . . 0.0 112.369 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 43.9 39.16 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.73 75.47 0.52 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -120.34 -41.51 2.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.086 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 83.4 m -81.49 -44.77 16.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.151 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.413 HG22 ' N ' ' A' ' 131' ' ' LYS . 9.7 tp -54.67 -40.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.149 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.413 ' N ' HG22 ' A' ' 130' ' ' ILE . 10.4 ttpp -51.72 -44.55 63.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.416 ' HA ' ' CG ' ' A' ' 135' ' ' GLN . 21.8 mtp180 -63.63 -20.58 65.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 71.4 mt -79.81 -37.44 18.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.407 ' HG2' ' CD1' ' A' ' 141' ' ' ILE . 69.1 mt-30 -78.12 -26.96 48.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . 0.466 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.85 -41.38 19.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.466 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 13.9 mmt180 -62.4 -39.26 92.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 38.8 p -101.3 -6.53 24.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.155 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 74.1 m80 55.2 52.8 11.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.451 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 13.1 p -129.02 150.15 50.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.18 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -90.66 92.6 8.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.407 ' CD1' ' HG2' ' A' ' 134' ' ' GLN . 69.7 mt -84.67 124.08 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 79.7 t -100.41 109.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.443 HG21 ' CE2' ' A' ' 152' ' ' PHE . 69.6 p -79.04 148.84 72.45 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.707 . . . . 0.0 111.125 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.86 23.17 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.27 -164.33 27.75 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.482 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -71.67 -54.2 11.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.783 0.325 . . . . 0.0 110.849 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -103.88 41.29 1.31 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.66 140.05 50.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.943 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.52 143.31 2.95 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 82.14 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.653 2.236 . . . . 0.0 112.347 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.3 t -139.63 119.93 14.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.128 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 143' ' ' THR . 23.9 m-85 -90.58 147.43 23.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.856 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -119.53 98.57 6.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.07 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 58.0 t -86.12 119.27 34.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.187 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.1 m -107.71 132.34 53.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.115 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.431 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 155.64 -173.0 33.76 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 22.9 mmt -50.58 158.7 1.02 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.589 0.709 . . . . 0.0 110.874 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -2.49 10.24 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.695 2.263 . . . . 0.0 112.353 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -113.25 -32.67 6.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.451 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 21.4 m-20 -77.16 -53.57 7.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' A' ' 156' ' ' GLY . 17.8 m -54.29 -34.55 27.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.151 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . 0.436 ' C ' ' OE2' ' A' ' 166' ' ' GLU . 23.2 t0 -59.38 -67.86 0.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.858 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 21.3 ttm-85 -43.76 -51.27 7.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.75 -36.5 3.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.6 ttp180 -72.57 -34.61 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.921 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 166' ' ' GLU . 0.1 OUTLIER -57.77 -39.68 78.01 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.888 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -71.56 -53.72 12.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 70.3 mt -49.96 -48.98 22.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -65.26 -43.38 91.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.438 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -44.39 -57.66 3.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.08 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.438 ' C ' ' O ' ' A' ' 170' ' ' ALA . 11.4 m80 -35.45 -37.91 0.09 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 66.7 mt -51.99 -55.47 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 30.2 m -68.12 -47.35 68.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 4.7 tp -48.65 113.55 0.79 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.24 116.13 28.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 36.8 m -80.07 -52.79 7.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 79.73 175.09 47.48 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.47 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.82 0.28 5.92 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.682 2.255 . . . . 0.0 112.338 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 3.8 m -47.58 150.71 0.94 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 4.5 m -84.62 124.2 31.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.851 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.475 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.5 m -102.84 120.35 40.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.889 0.376 . . . . 0.0 110.865 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 t -113.05 99.99 8.27 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 178.41 144.47 5.62 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 68.7 m -109.05 143.62 38.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.886 0.374 . . . . 0.0 110.855 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.3 p -49.53 -55.44 13.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.32 42.27 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.45 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -114.34 -46.69 0.62 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.47 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.473 ' CD ' ' C ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -92.69 178.59 5.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.861 0.362 . . . . 0.0 110.943 -179.872 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.8 t -134.31 157.33 46.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 91.5 m -128.4 118.29 22.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.9 pt -106.91 154.34 7.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.4 mm-40 -112.27 105.74 14.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.447 HG22 ' CD ' ' A' ' 165' ' ' ARG . 93.4 t -82.12 144.77 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.16 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.44 ' O ' ' CG1' ' A' ' 114' ' ' VAL . 7.9 mpt_? -109.54 147.37 33.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.44 ' CG1' ' O ' ' A' ' 113' ' ' ARG . 7.6 m -158.45 151.11 18.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.627 0.727 . . . . 0.0 111.151 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.47 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.7 Cg_endo -69.72 127.03 14.03 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.713 2.275 . . . . 0.0 112.361 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -41.42 -24.42 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.918 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 115' ' ' PRO . 46.9 mtt85 -71.28 -43.81 66.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.47 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 41.2 t -74.56 -34.96 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.093 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.1 t -39.71 -63.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.36 -39.2 9.66 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.495 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -67.56 -46.62 72.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.881 0.372 . . . . 0.0 110.937 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 59.0 t -63.79 -63.88 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 87.1 t -40.4 -49.59 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 72.7 172.87 22.04 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.477 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.7 Cg_exo -47.99 118.21 2.98 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.718 2.279 . . . . 0.0 112.352 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.434 ' C ' ' O ' ' A' ' 125' ' ' PRO . 8.0 ptpp? 35.25 43.63 0.13 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 62.46 65.66 3.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.447 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.33 -39.27 6.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.838 0.351 . . . . 0.0 111.048 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.1 m -83.91 -50.34 8.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.158 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 7.3 tp -49.94 -40.8 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 25.0 tttp -60.92 -43.88 97.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 49.4 mtt180 -54.33 -41.14 68.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 54.8 mt -59.28 -49.93 81.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -47.77 -34.67 8.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -80.59 -54.44 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 53.7 mtt-85 -51.96 -33.42 37.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.865 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 37.4 p -103.59 -16.62 15.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.149 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 72.8 m80 61.23 51.15 4.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.45 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 38.0 p -136.52 141.51 43.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.129 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -77.15 97.42 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 79.8 mt -89.93 141.48 14.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.137 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.5 t -125.91 129.09 72.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.072 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 35.3 p -86.12 149.14 49.4 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.583 0.706 . . . . 0.0 111.135 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 177.83 5.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.663 2.242 . . . . 0.0 112.364 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.35 170.91 52.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . 0.422 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 18.8 ptt180 -71.34 -42.24 68.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.33 . . . . 0.0 110.861 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.422 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 2.5 p30 -104.61 42.09 1.25 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.82 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -139.18 159.3 42.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.894 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -58.03 142.59 79.63 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.623 0.725 . . . . 0.0 110.895 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 101.77 0.96 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.319 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -147.83 115.16 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.099 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -82.89 143.5 30.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.97 106.71 12.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 47.4 t -95.51 123.15 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 72.8 m -110.58 129.93 55.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.45 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 157.78 178.8 32.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.478 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 14.0 mmt -44.56 159.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.561 0.696 . . . . 0.0 110.877 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 0.75 5.19 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.643 2.229 . . . . 0.0 112.32 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -117.99 -37.53 3.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.878 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.45 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.4 m-20 -71.14 -45.71 62.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.45 ' CG1' ' CA ' ' A' ' 156' ' ' GLY . 13.8 m -66.8 -38.16 80.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -55.9 -39.63 71.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -62.78 -47.21 84.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -49.32 -42.83 42.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.068 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.447 ' CD ' HG22 ' A' ' 112' ' ' VAL . 11.7 tpt180 -48.9 -46.63 43.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 49.0 mm-40 -63.74 -37.46 87.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -63.3 -59.65 4.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 58.8 mt -53.03 -50.44 44.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.138 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -59.97 -43.25 95.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.415 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -47.0 -56.03 7.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.099 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.415 ' C ' ' O ' ' A' ' 170' ' ' ALA . 27.3 m170 -37.17 -41.34 0.38 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 57.3 mt -46.57 -57.82 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 13.9 t -89.66 42.46 1.09 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.172 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 55.8 tp -78.0 90.89 4.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.904 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? 59.24 46.76 12.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.902 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 71.8 m -67.9 160.1 29.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.913 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.77 -95.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -2.9 10.91 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.714 2.276 . . . . 0.0 112.358 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 16.5 t -93.22 114.94 27.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 93.9 p -75.87 -45.86 33.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.388 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.3 t -121.82 165.29 16.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.871 0.367 . . . . 0.0 110.871 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.9 m -48.51 152.84 0.86 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.85 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -135.13 -99.63 0.61 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.482 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.8 t -173.7 145.39 1.17 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.842 0.353 . . . . 0.0 110.869 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 92.0 p -82.49 96.4 8.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.839 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -122.18 166.24 14.85 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.437 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.13 104.59 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -83.01 174.9 10.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.887 0.375 . . . . 0.0 110.911 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.431 ' CG2' ' HA ' ' A' ' 158' ' ' PRO . 7.5 t -133.78 164.2 27.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 93.1 m -132.69 124.55 28.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.135 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.9 pt -110.47 152.02 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 4.6 mm-40 -108.17 96.77 6.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.418 HG11 ' N ' ' A' ' 113' ' ' ARG . 76.9 t -68.02 137.05 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.418 ' N ' HG11 ' A' ' 112' ' ' VAL . 32.7 ttt180 -108.58 115.71 30.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.916 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.413 HG13 ' C ' ' A' ' 113' ' ' ARG . 11.4 m -137.29 151.11 70.92 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.589 0.709 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.455 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 54.3 Cg_endo -69.72 127.77 15.1 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.355 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -39.56 -27.34 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 115' ' ' PRO . 22.0 ttm180 -67.12 -44.94 78.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.899 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.455 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 55.2 t -74.51 -29.15 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 74.1 t -45.12 -63.07 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.104 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.91 -38.26 30.52 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.49 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.5 mt -66.78 -45.5 78.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.903 0.382 . . . . 0.0 110.971 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.9 t -66.28 -58.23 7.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.13 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.3 t -44.16 -54.85 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . 0.411 ' O ' ' N ' ' A' ' 126' ' ' LYS . . . 85.12 172.77 49.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.494 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.0 88.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.411 ' N ' ' O ' ' A' ' 124' ' ' GLY . 34.4 tttp 58.01 48.64 12.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.891 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.69 60.03 7.01 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.502 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.93 -40.21 6.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.845 0.355 . . . . 0.0 111.069 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 94.2 m -85.77 -50.79 6.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 8.4 tp -52.53 -28.98 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.12 -49.14 71.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -51.04 -40.14 57.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.882 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.4 mt -63.46 -47.16 92.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.401 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 70.4 mt-30 -48.1 -36.85 14.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 67.3 mm-40 -82.24 -50.12 9.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.7 mtt85 -52.78 -33.91 50.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.882 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.3 p -105.68 -12.08 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.144 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 15.5 m170 58.26 54.12 5.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.447 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 70.5 p -139.46 139.11 36.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -75.25 97.94 3.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.401 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 78.9 mt -87.71 122.99 40.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.147 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.02 128.27 62.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 34.1 p -87.38 144.32 35.62 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.583 0.706 . . . . 0.0 111.128 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -177.28 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.705 2.27 . . . . 0.0 112.304 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -90.7 -175.16 44.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 6.1 ptp85 -84.9 -41.16 16.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -100.77 40.08 1.31 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -138.42 169.44 17.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.91 144.18 95.47 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.713 0.768 . . . . 0.0 110.89 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 87.5 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.727 2.285 . . . . 0.0 112.316 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.4 t -137.86 121.17 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 69.9 m-85 -91.12 143.98 26.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -114.87 104.57 12.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.425 HG13 ' CB ' ' A' ' 161' ' ' VAL . 46.7 t -95.05 124.41 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 27.0 m -110.83 132.8 53.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.402 ' C ' HG12 ' A' ' 161' ' ' VAL . . . 155.13 177.56 28.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 22.8 mmt -43.03 159.55 0.21 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.56 0.695 . . . . 0.0 110.865 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.431 ' HA ' ' CG2' ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.79 0.69 5.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.736 2.291 . . . . 0.0 112.339 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -118.71 -35.66 3.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.907 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.447 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 71.0 m-20 -69.33 -45.75 68.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.882 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.425 ' CB ' HG13 ' A' ' 154' ' ' VAL . 35.2 m -67.01 -39.38 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.143 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -54.5 -42.3 70.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.865 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -53.89 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.92 -52.25 25.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.412 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 50.0 ttt85 -42.51 -39.38 2.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.866 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -68.49 -45.53 72.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -58.57 -54.55 45.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 84.4 mt -55.12 -51.12 57.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.412 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 66.0 mt-10 -59.13 -46.0 89.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.901 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.445 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.13 -57.55 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.06 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 170' ' ' ALA . 14.7 m170 -34.9 -42.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 74.9 mt -47.85 -53.46 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.127 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 38.5 m -73.03 -44.68 60.52 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -43.38 130.4 4.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 23.3 ptt180 -86.93 129.54 34.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.468 ' O ' ' C ' ' A' ' 177' ' ' GLY . 3.3 m -122.64 -46.06 2.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . 0.468 ' C ' ' O ' ' A' ' 176' ' ' SER . . . -32.73 96.21 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.486 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . 0.431 ' N ' ' O ' ' A' ' 176' ' ' SER . 53.7 Cg_endo -69.71 168.75 20.6 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.667 2.244 . . . . 0.0 112.392 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 180' ' ' SER . 30.6 t -93.74 153.92 18.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.857 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 179' ' ' SER . 83.0 p 37.46 42.21 0.32 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.863 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.458 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 t -152.5 174.06 14.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.883 0.373 . . . . 0.0 110.844 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.4 p -165.97 174.59 9.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.832 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -108.65 90.99 0.64 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.465 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.7 t -50.25 145.55 6.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.362 . . . . 0.0 110.86 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.3 t -83.64 41.79 0.81 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.866 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 149.37 154.72 6.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.49 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -101.96 -102.21 2.61 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.509 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -52.63 157.78 1.47 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.867 0.365 . . . . 0.0 110.961 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.0 t -123.53 159.67 28.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.174 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 84.2 m -130.26 120.69 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.097 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.3 pt -108.38 154.97 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.109 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.9 mm-40 -113.82 96.14 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.47 HG11 ' CG2' ' A' ' 168' ' ' ILE . 96.0 t -66.68 140.73 18.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.127 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.417 ' N ' HG12 ' A' ' 112' ' ' VAL . 6.9 tpp180 -106.14 110.96 23.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.32 151.27 77.25 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 0.0 111.11 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.454 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 149.79 67.37 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.703 2.269 . . . . 0.0 112.334 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -55.24 -39.34 69.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.923 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.437 ' HG3' ' N ' ' A' ' 118' ' ' VAL . 4.6 ptp180 -57.78 -41.85 82.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.454 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 16.5 t -71.53 -37.29 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.5 t -43.06 -69.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.138 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -41.21 -34.46 0.94 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.7 mt -71.22 -56.92 5.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.83 -57.58 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.145 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 74.5 t -49.77 -54.74 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.11 169.84 42.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -47.93 97.37 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.718 2.278 . . . . 0.0 112.347 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.0 mttt 54.52 47.65 22.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.888 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.84 68.18 1.79 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -112.2 -38.38 4.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 0.0 111.1 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 72.6 m -86.46 -42.71 13.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.152 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.2 tp -62.87 -36.48 75.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.2 ttpt -55.89 -46.18 78.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -53.83 -41.86 67.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 65.8 mt -61.38 -59.21 4.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.4 mt-30 -41.54 -36.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.899 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -80.83 -53.37 6.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -51.19 -34.53 32.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.1 p -105.93 -8.47 17.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 13.5 m170 53.58 54.55 9.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.866 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.422 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.1 p -135.39 147.75 49.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -82.66 96.85 8.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 75.1 mt -89.94 116.16 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.145 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.0 t -102.76 113.99 41.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.156 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.9 p -72.57 153.42 91.69 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.521 0.677 . . . . 0.0 111.154 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 177.66 5.31 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.678 2.252 . . . . 0.0 112.375 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -85.01 170.69 45.66 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.502 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . 0.459 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 4.2 ptm85 -69.53 -48.49 60.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 110.922 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . 0.459 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.7 p30 -99.92 43.42 1.06 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -138.54 168.79 19.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -66.82 144.25 98.47 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.632 0.729 . . . . 0.0 110.926 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 100.16 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.311 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 90.5 t -147.06 127.92 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -96.62 125.89 41.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.96 99.58 9.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.074 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.3 t -88.77 133.69 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.2 m -120.04 128.79 53.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.423 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.74 178.25 31.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 9.0 mmt -41.04 159.2 0.17 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.559 0.695 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.7 8.91 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.678 2.252 . . . . 0.0 112.333 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.448 ' C ' ' OE1' ' A' ' 159' ' ' GLU . 0.5 OUTLIER -116.97 -38.06 3.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.965 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . 0.422 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.9 m-20 -67.35 -45.55 76.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.423 HG13 ' C ' ' A' ' 156' ' ' GLY . 30.0 m -68.51 -40.04 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 29.8 t0 -53.19 -40.26 64.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 33.1 ttt-85 -64.68 -59.17 4.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.33 -45.82 6.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 21.1 ttm180 -47.71 -45.15 28.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -53.96 -61.19 2.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -53.6 -39.12 64.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . 0.47 ' CG2' HG11 ' A' ' 112' ' ' VAL . 61.2 mt -55.84 -70.55 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.402 ' O ' ' C ' ' A' ' 170' ' ' ALA . 2.3 pt-20 -59.69 -33.21 71.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.899 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 169' ' ' GLU . . . -37.25 -57.1 0.91 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.083 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 170' ' ' ALA . 17.6 m80 -37.63 -41.84 0.51 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.837 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 74.2 mt -41.5 -54.32 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 174' ' ' LEU . 66.9 p -61.67 -46.0 91.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.166 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 173' ' ' THR . 20.7 tp -34.56 151.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 39.4 mtt-85 -144.46 136.76 26.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 40.1 p -102.02 43.43 1.07 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.826 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 147.98 94.74 0.14 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . 0.4 ' O ' ' C ' ' A' ' 179' ' ' SER . 53.9 Cg_endo -69.8 -14.1 35.49 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.632 2.221 . . . . 0.0 112.385 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' SER . . . . . 0.4 ' C ' ' O ' ' A' ' 178' ' ' PRO . 17.4 m -38.29 141.98 0.2 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.82 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 34.6 p -121.03 135.82 55.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.83 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.502 -179.993 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.434 -0.267 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 83.8 p -81.29 168.37 18.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.898 0.38 . . . . 0.0 110.827 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 33.4 t -119.52 115.46 24.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -177.27 -79.19 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 66.5 p -127.56 42.85 3.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.874 0.369 . . . . 0.0 110.897 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 29.2 p -75.77 111.28 10.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.867 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -117.78 -160.76 11.77 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.462 ' O ' ' CE ' ' A' ' 157' ' ' MET . . . 153.32 118.9 0.73 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -175.42 177.54 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.849 0.356 . . . . 0.0 110.938 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.3 t -135.43 161.97 33.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.113 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.7 m -136.2 124.97 23.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.098 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.7 pt -114.28 154.3 15.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.3 mm-40 -109.58 106.55 16.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.457 HG13 ' N ' ' A' ' 113' ' ' ARG . 94.4 t -73.85 137.99 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.457 ' N ' HG13 ' A' ' 112' ' ' VAL . 16.0 ttm180 -109.54 115.68 30.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.87 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.417 HG12 ' C ' ' A' ' 113' ' ' ARG . 4.5 m -135.51 150.8 73.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.653 0.739 . . . . 0.0 111.109 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.4 Cg_endo -69.77 129.14 17.07 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.345 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -39.47 -28.59 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.894 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.6 mmt180 -65.86 -51.43 58.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.848 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.412 ' O ' ' C ' ' A' ' 119' ' ' VAL . 28.9 t -66.59 -36.7 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.16 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 118' ' ' VAL . 77.4 t -37.32 -69.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.114 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.93 -39.49 8.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.2 mt -64.67 -41.14 96.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 123' ' ' VAL . 22.0 t -68.89 -64.99 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.098 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 122' ' ' VAL . 89.4 t -37.35 -46.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.41 173.13 32.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.417 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.1 Cg_exo -47.99 112.55 0.6 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.658 2.239 . . . . 0.0 112.341 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.2 ptmt 36.64 41.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.905 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.55 83.29 0.2 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.471 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.38 -41.34 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.864 0.364 . . . . 0.0 111.083 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 39.5 m -84.16 -44.18 14.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.121 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.8 tp -60.02 -40.47 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 37.0 tttp -58.28 -41.93 85.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.898 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -56.45 -42.68 78.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.88 -48.23 88.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . 0.433 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 78.9 mt-30 -48.56 -36.72 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.929 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 4.3 mm100 -82.48 -54.84 4.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.93 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -49.95 -32.53 15.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -105.6 -13.6 15.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.105 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 28.0 m80 58.84 54.41 5.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 68.5 p -139.88 143.3 36.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -77.49 100.55 6.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.922 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.433 ' CG1' ' HG2' ' A' ' 134' ' ' GLN . 75.9 mt -92.79 119.1 39.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.3 t -109.6 127.52 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.104 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.6 p -85.26 151.61 56.91 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.562 0.696 . . . . 0.0 111.197 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 177.67 5.33 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.689 2.26 . . . . 0.0 112.354 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.7 168.15 49.18 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.44 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.19 -43.91 93.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.814 0.34 . . . . 0.0 110.836 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -103.18 43.6 1.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -132.45 171.61 13.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.21 148.85 91.54 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 110.871 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 87.64 0.56 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.349 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.4 t -143.78 121.13 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.087 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -90.31 153.64 20.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.832 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.7 106.96 11.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.094 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.409 HG12 ' CB ' ' A' ' 161' ' ' VAL . 50.7 t -97.74 125.28 50.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 75.1 m -112.3 137.38 50.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.49 -173.13 31.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.495 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' MET . . . . . 0.462 ' CE ' ' O ' ' A' ' 106' ' ' GLY . 8.2 mmt -53.89 159.86 2.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 0.0 110.877 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -0.55 7.02 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.672 2.248 . . . . 0.0 112.391 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.415 ' CD ' ' HB3' ' A' ' 157' ' ' MET . 23.5 pm0 -118.01 -26.25 6.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -82.63 -43.51 16.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.409 ' CB ' HG12 ' A' ' 154' ' ' VAL . 35.7 m -69.5 -35.14 65.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -56.76 -47.81 79.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.9 ttt-85 -57.31 -55.24 37.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.21 -45.38 5.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -52.43 -45.5 66.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -64.39 -42.53 96.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -58.39 -53.84 53.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 91.0 mt -55.59 -54.79 21.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -56.63 -46.23 81.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' ALA . . . . . 0.441 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.36 -60.29 0.8 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.132 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 170' ' ' ALA . 40.7 m170 -34.95 -38.77 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.872 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 74.7 mt -50.71 -59.4 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.093 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.32 46.32 0.93 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.2 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 9.5 tt -145.21 124.16 12.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -106.69 142.79 35.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.823 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 22.7 m -99.51 167.52 10.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.847 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 115.28 -178.54 17.82 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 163.2 39.18 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 73.1 m -120.36 -44.48 2.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.9 t -56.29 -58.22 8.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.962 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.889 0.376 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.5 t -141.73 161.25 38.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 90.4 m -131.28 124.18 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.165 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.5 pt -114.29 153.14 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.125 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 52.6 mm-40 -109.87 106.26 15.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.553 HG22 ' HG3' ' A' ' 165' ' ' ARG . 74.7 t -77.59 135.61 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.114 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 8.9 ttp-105 -104.8 120.89 42.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.862 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.6 m -136.46 150.72 71.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.609 0.718 . . . . 0.0 111.124 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.534 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.7 130.63 19.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.682 2.255 . . . . 0.0 112.363 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -45.04 -22.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.939 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.425 ' HB2' ' NH1' ' A' ' 117' ' ' ARG . 14.7 ttm105 -72.08 -44.23 63.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.918 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.637 HG12 HG23 ' A' ' 122' ' ' VAL . 74.9 t -76.03 -31.68 22.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 122' ' ' VAL . 42.6 t -39.3 -74.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -38.74 -34.33 0.26 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.547 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.421 HD12 ' HA ' ' A' ' 118' ' ' VAL . 13.2 mt -71.67 -44.21 64.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.637 HG23 HG12 ' A' ' 118' ' ' VAL . 86.9 t -66.04 -62.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.119 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.412 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 84.7 t -46.8 -48.27 7.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.85 172.71 49.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.97 91.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 12.2 mmtp 53.13 38.59 27.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 78.32 72.89 1.13 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.535 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.39 -27.25 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.102 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 65.7 m -98.68 -44.77 6.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.606 HD11 HG21 ' A' ' 141' ' ' ILE . 9.3 tp -60.64 -25.19 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.9 tttp -66.51 -32.0 73.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -67.26 -43.58 81.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.582 HD12 HD12 ' A' ' 130' ' ' ILE . 77.3 mt -57.89 -56.88 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.159 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.592 ' HG3' HD12 ' A' ' 141' ' ' ILE . 29.4 mt-30 -45.24 -31.97 1.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -82.07 -55.69 4.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 mmm180 -56.28 -24.42 42.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.422 HG21 ' HA ' ' A' ' 164' ' ' ALA . 80.6 p -109.75 -13.03 14.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 54.3 52.79 11.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.479 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 26.8 p -129.99 170.04 14.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.155 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -102.28 94.91 5.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.606 HG21 HD11 ' A' ' 130' ' ' ILE . 82.3 mt -93.9 125.83 46.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.76 130.12 68.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.6 p -84.11 145.29 45.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.611 0.719 . . . . 0.0 111.094 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -179.78 3.17 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -80.56 -172.11 44.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -92.55 -31.62 15.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.828 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 9.6 t0 -112.1 35.97 3.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -131.3 169.93 15.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -67.82 144.28 97.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.615 0.721 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.25 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.705 2.27 . . . . 0.0 112.319 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.2 t -148.26 113.83 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.412 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 55.9 m-85 -84.06 141.46 31.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.93 121.53 45.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.6 122.47 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 43.0 m -112.9 122.93 49.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.563 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 169.54 -173.09 43.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.623 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.1 mmt -52.39 159.24 1.66 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.602 0.715 . . . . 0.0 110.857 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -0.86 7.54 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.658 2.239 . . . . 0.0 112.302 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -115.7 -26.03 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.479 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.3 m-20 -85.11 -54.63 4.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 157' ' ' MET . 24.9 m -53.68 -32.54 21.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -79.14 -23.5 43.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -76.27 -37.51 57.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ALA . . . . . 0.422 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -70.76 -38.5 73.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.092 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.553 ' HG3' HG22 ' A' ' 112' ' ' VAL . 57.5 ttt180 -54.43 -44.21 72.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.93 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -55.58 -49.28 73.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 17.8 mm-40 -59.93 -45.98 90.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.929 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 94.9 mt -53.18 -58.96 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.126 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -62.4 -32.69 73.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -51.45 -42.31 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -56.28 -33.5 65.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.566 HG12 HG21 ' A' ' 118' ' ' VAL . 81.6 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.418 ' OE1' HG22 ' A' ' 155' ' ' THR . 25.2 pt20 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.922 0.392 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.7 t -137.56 164.68 28.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.512 ' OG1' HG23 ' A' ' 155' ' ' THR . 99.2 m -138.14 115.29 10.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.075 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 42.4 pt -107.89 151.88 9.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.434 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 2.1 mp0 -110.98 106.72 15.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 151' ' ' VAL . 86.9 t -73.7 141.39 16.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 42.5 ttp85 -108.67 110.13 21.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.469 HG13 HG12 ' A' ' 112' ' ' VAL . 2.5 m -132.59 148.85 71.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.675 0.75 . . . . 0.0 111.112 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.481 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.74 145.84 58.49 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.532 ' HA ' HG23 ' A' ' 119' ' ' VAL . 19.3 t80 -53.93 -41.54 67.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -54.85 -29.46 55.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.481 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 15.8 t -85.6 -34.82 8.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HA ' ' A' ' 116' ' ' TYR . 77.8 t -37.32 -66.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.52 -33.28 4.41 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.1 mt -70.61 -57.02 5.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.844 0.354 . . . . 0.0 110.889 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.43 HG23 HG12 ' A' ' 118' ' ' VAL . 62.9 t -56.37 -55.98 16.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.12 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.4 t -47.14 -55.57 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.36 167.85 43.91 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_exo -47.96 93.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.648 2.232 . . . . 0.0 112.356 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.3 tmtt? 60.89 46.43 8.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 59.59 61.59 7.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.493 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.47 -41.56 5.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.843 0.354 . . . . 0.0 111.122 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.2 m -78.91 -46.42 18.5 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.618 HD11 HG21 ' A' ' 141' ' ' ILE . 10.7 tp -51.57 -34.39 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.088 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.7 tttt -66.55 -40.58 89.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 25.9 ttp180 -62.3 -22.24 65.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.96 -41.43 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.488 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.4 mt-30 -67.95 -30.64 69.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' A' ' 136' ' ' ARG . 10.1 pt20 -80.7 -48.63 12.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.938 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.502 ' N ' ' CG ' ' A' ' 135' ' ' GLN . 60.0 mtt180 -59.03 -35.25 72.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 49.9 p -100.11 -13.28 19.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.136 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 19.8 m80 58.93 54.22 5.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.47 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 34.2 p -132.19 -176.79 4.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.091 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -116.74 97.4 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.953 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.707 HG12 HG22 ' A' ' 154' ' ' VAL . 74.4 mt -94.61 133.12 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -115.11 134.94 56.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.6 p -88.1 146.98 39.5 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.591 0.71 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -178.27 2.28 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -87.38 169.55 39.7 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 8.6 ptt85 -70.63 -40.54 73.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.837 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -105.54 42.24 1.26 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.846 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 26.5 mmtp -136.08 168.22 19.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.37 144.06 98.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.659 0.742 . . . . 0.0 110.901 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 82.78 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.693 2.262 . . . . 0.0 112.359 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 112' ' ' VAL . 76.2 t -133.29 129.62 56.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -96.53 139.95 31.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -112.78 110.01 19.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.116 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.707 HG22 HG12 ' A' ' 141' ' ' ILE . 96.3 t -101.33 133.22 45.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.512 HG23 ' OG1' ' A' ' 109' ' ' THR . 19.9 m -119.46 135.42 54.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.422 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 153.64 -177.1 31.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.529 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.542 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.1 mmt -49.27 158.36 0.75 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.549 0.69 . . . . 0.0 110.918 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 0.49 5.55 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -117.76 -29.79 5.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.47 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.1 m-20 -79.18 -47.93 15.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.542 HG22 ' O ' ' A' ' 157' ' ' MET . 15.7 m -66.15 -26.64 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -66.99 -40.39 87.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 7.5 ttt85 -66.88 -56.51 9.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -46.7 -46.27 20.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.055 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.3 ttt180 -49.7 -39.96 38.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 36.6 mt-10 -60.67 -52.1 66.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -58.56 -33.55 70.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 67.7 mt -63.24 -66.43 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.4 -32.54 74.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -39.72 -54.98 2.0 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.115 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -39.89 -40.56 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.444 HG12 HG21 ' A' ' 118' ' ' VAL . 71.1 mt . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.939 0.399 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.0 t -128.66 158.61 38.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.5 m -130.12 113.69 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.3 pt -103.48 154.85 5.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.106 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.462 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 2.3 mp0 -112.54 107.98 16.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.818 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.7 t -77.79 141.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -110.2 117.39 33.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.842 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 168' ' ' ILE . 12.2 m -137.6 151.11 70.25 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.629 0.728 . . . . 0.0 111.112 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.503 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.78 126.7 13.6 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.659 2.24 . . . . 0.0 112.351 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -36.4 -35.53 0.08 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.942 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.8 tpp85 -59.74 -46.88 87.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.503 HG23 ' HG2' ' A' ' 115' ' ' PRO . 48.8 t -72.41 -31.14 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.57 ' O ' HG23 ' A' ' 123' ' ' VAL . 53.1 t -45.59 -59.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -52.73 -41.54 57.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.479 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -61.89 -48.89 78.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.83 0.348 . . . . 0.0 110.882 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 84.1 t -64.04 -52.65 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 119' ' ' VAL . 93.8 t -49.15 -56.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.166 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 88.49 172.73 46.89 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.93 100.66 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.722 2.281 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? 50.89 43.25 28.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.901 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.35 80.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.526 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.69 -31.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 40.5 m -89.91 -39.47 13.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.965 HD11 HG21 ' A' ' 141' ' ' ILE . 5.0 tp -65.07 -29.34 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.179 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.521 ' HD2' HG23 ' A' ' 130' ' ' ILE . 2.0 mptm? -67.76 -42.21 82.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.937 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 70.3 mtp180 -56.16 -43.79 78.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.841 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 57.2 mt -57.44 -44.84 85.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.447 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.8 mt-30 -51.71 -38.18 54.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.935 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -79.2 -51.11 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -55.68 -30.72 61.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.9 p -106.63 -10.88 16.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 56.13 51.51 11.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.2 p -137.34 143.08 41.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -78.33 95.54 5.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.965 HG21 HD11 ' A' ' 130' ' ' ILE . 78.8 mt -88.34 110.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 98.4 t -95.85 120.84 45.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.094 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 82.4 p -77.79 147.3 74.07 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.569 0.699 . . . . 0.0 111.134 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 171.95 13.5 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.685 2.256 . . . . 0.0 112.386 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.67 177.87 54.05 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 7.5 ptp85 -77.69 -33.59 53.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.788 0.327 . . . . 0.0 110.864 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -110.5 41.58 1.74 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.825 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.7 mmmt -137.84 159.33 42.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -57.21 145.25 67.22 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.657 0.742 . . . . 0.0 110.87 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.409 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.5 Cg_endo -69.8 96.78 0.61 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.67 2.247 . . . . 0.0 112.319 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 112' ' ' VAL . 94.8 t -145.52 132.65 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.0 m-85 -102.36 117.13 34.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.99 109.4 20.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.429 HG22 HG12 ' A' ' 141' ' ' ILE . 56.8 t -100.14 122.61 52.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 49.9 m -108.19 131.71 54.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.146 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.415 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.18 177.63 30.48 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.498 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.501 ' O ' HG22 ' A' ' 161' ' ' VAL . 10.5 mmt -42.51 159.41 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.553 0.692 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 0.83 5.06 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.702 2.268 . . . . 0.0 112.37 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -118.42 -37.33 3.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.425 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.4 m-20 -69.3 -45.67 69.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -67.83 -37.12 77.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.82 -42.44 84.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -64.16 -48.37 76.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.97 -47.93 43.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.531 ' HG3' HG22 ' A' ' 112' ' ' VAL . 33.2 ttt180 -51.05 -43.76 60.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -53.28 -44.74 68.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -68.15 -56.3 9.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.461 HG22 HG11 ' A' ' 114' ' ' VAL . 73.2 mt -47.7 -45.68 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -70.29 -45.04 67.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.44 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.32 -57.24 2.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.113 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.44 ' C ' ' O ' ' A' ' 170' ' ' ALA . 47.5 m80 -35.38 -34.62 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.478 HG12 HG21 ' A' ' 118' ' ' VAL . 58.5 mt . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.129 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.857 0.361 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.4 t -139.92 163.53 32.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.14 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -129.28 125.69 37.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.161 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.5 pt -112.18 164.51 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 50.3 mm-40 -121.71 97.93 5.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG13 ' A' ' 151' ' ' VAL . 95.3 t -68.78 142.74 15.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.125 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.3 ttt85 -112.55 121.56 45.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.2 m -141.98 151.07 58.27 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.616 0.722 . . . . 0.0 111.147 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.3 Cg_endo -69.8 125.54 12.24 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.671 2.247 . . . . 0.0 112.344 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.437 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.7 t80 -35.26 -33.21 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.876 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 115' ' ' PRO . 87.3 mtt-85 -61.68 -49.94 74.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.867 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.3 t -68.72 -35.03 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 56.1 t -39.06 -62.76 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -54.43 -38.92 63.83 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.467 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.7 mt -63.34 -43.54 97.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.558 HG23 HG12 ' A' ' 118' ' ' VAL . 89.4 t -68.48 -61.95 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 88.8 t -40.78 -49.04 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.119 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 78.45 172.86 41.37 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -47.95 97.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.653 2.235 . . . . 0.0 112.409 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 47.83 50.47 15.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.913 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.79 74.33 0.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -121.78 -45.15 2.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 67.2 m -82.21 -44.73 15.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.619 HD11 HG21 ' A' ' 141' ' ' ILE . 6.4 tp -57.43 -38.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.5 mttp -53.58 -39.87 65.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.416 ' HD2' ' N ' ' A' ' 132' ' ' ARG . 1.0 OUTLIER -57.75 -36.07 71.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.58 HD12 HD12 ' A' ' 130' ' ' ILE . 46.8 mt -69.94 -46.9 71.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.61 ' HG3' HD12 ' A' ' 141' ' ' ILE . 42.4 mt-30 -55.15 -39.83 69.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -78.28 -45.5 22.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -58.07 -37.59 74.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.84 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 81.8 p -101.23 -11.45 19.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 59.89 48.31 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 62.7 p -127.36 162.95 25.09 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -96.79 94.78 7.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.936 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.619 HG21 HD11 ' A' ' 130' ' ' ILE . 79.2 mt -90.43 122.3 41.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.106 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 68.9 t -113.81 129.46 69.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.119 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.6 p -77.47 147.75 75.92 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.576 0.703 . . . . 0.0 111.183 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 177.81 5.22 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.43 165.22 51.49 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -68.2 -45.95 71.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 0.0 110.879 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -101.7 42.75 1.11 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -136.07 173.43 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -67.2 143.94 97.92 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 89.12 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.368 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 112' ' ' VAL . 77.9 t -134.7 134.49 54.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.089 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -104.05 122.72 45.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -92.82 123.95 36.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.122 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.421 HG22 HG12 ' A' ' 141' ' ' ILE . 46.5 t -118.71 119.09 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.086 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.3 m -107.35 138.1 44.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.144 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.448 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.88 -169.96 31.28 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.436 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.768 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.0 mmt -52.53 159.47 1.66 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.561 0.696 . . . . 0.0 110.876 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 0.56 5.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.656 2.237 . . . . 0.0 112.35 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.38 -47.17 2.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.43 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 28.8 m-20 -65.42 -44.9 85.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 157' ' ' MET . 18.7 m -63.79 -37.87 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.154 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -73.53 -31.65 63.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 46.4 mtp180 -69.57 -36.9 76.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -64.32 -37.41 87.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.08 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -53.68 -58.66 6.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.812 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' GLU . . . . . 0.453 ' HG3' ' N ' ' A' ' 167' ' ' GLU . 1.0 OUTLIER -48.74 -35.44 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.926 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.453 ' N ' ' HG3' ' A' ' 166' ' ' GLU . 5.4 mm-40 -69.47 -46.76 65.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 93.9 mt -63.32 -49.36 83.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.165 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -60.61 -41.7 95.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.5 -53.07 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -40.17 -41.06 1.22 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 68.7 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.109 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.9 t -125.38 162.5 24.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.135 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.5 m -135.49 122.29 21.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.098 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.7 pt -111.81 156.12 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.17 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 47.7 mm-40 -111.74 98.83 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.9 t -66.04 141.42 18.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.137 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.4 ttp180 -112.33 113.24 25.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.464 HG13 HG12 ' A' ' 112' ' ' VAL . 3.8 m -132.8 151.07 77.41 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.459 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 126.72 13.64 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.352 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.411 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -36.44 -33.4 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 115' ' ' PRO . 84.8 mtt180 -62.22 -52.54 63.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.831 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.597 HG21 HG12 ' A' ' 172' ' ' ILE . 54.6 t -67.6 -34.15 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.098 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.1 t -40.17 -66.62 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.098 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.86 -36.5 26.7 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.475 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.5 mt -66.34 -41.84 89.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.883 0.373 . . . . 0.0 110.955 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.589 HG11 HG23 ' A' ' 168' ' ' ILE . 87.4 t -71.81 -54.6 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.107 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.424 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 92.5 t -50.95 -49.14 28.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.18 172.67 46.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.477 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -47.96 105.47 0.09 OUTLIER 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.712 2.274 . . . . 0.0 112.313 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 9.0 tppt? 45.5 44.5 9.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 64.11 76.07 0.32 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.484 ' O ' ' CZ ' ' A' ' 132' ' ' ARG . . . -124.21 -26.82 3.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 111.119 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 96.2 m -93.77 -35.91 12.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.145 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.795 HD11 HG21 ' A' ' 141' ' ' ILE . 5.1 tp -72.76 -29.94 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.155 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 132' ' ' ARG . 8.3 ptmt -58.94 -36.95 75.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.484 ' CZ ' ' O ' ' A' ' 128' ' ' ALA . 0.7 OUTLIER -67.04 -52.69 39.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.858 179.996 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.6 mt -46.4 -50.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.451 ' CG ' HD12 ' A' ' 141' ' ' ILE . 60.9 mt-30 -46.2 -35.39 5.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -81.31 -51.43 8.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -52.07 -35.3 47.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.875 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.4 p -104.1 -11.18 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.152 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 67.5 m80 55.99 54.66 7.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.872 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.478 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 82.5 p -137.38 147.37 45.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.169 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -80.5 97.38 7.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.795 HG21 HD11 ' A' ' 130' ' ' ILE . 85.5 mt -90.84 118.52 36.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.426 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 93.3 t -106.48 123.46 61.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.175 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.4 p -81.84 148.95 62.5 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.585 0.707 . . . . 0.0 111.124 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 172.57 12.39 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.06 157.93 34.19 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ARG . . . . . 0.446 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 6.0 ptp180 -55.09 -42.3 72.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.9 p-10 -102.02 43.81 1.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -135.7 168.11 19.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -69.56 149.45 96.99 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.688 0.756 . . . . 0.0 110.832 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.4 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.8 Cg_endo -69.8 91.38 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 112' ' ' VAL . 96.9 t -145.67 130.42 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.168 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.424 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 57.3 m-85 -99.46 136.45 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.911 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -107.55 106.47 16.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.08 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.5 t -100.44 117.77 46.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 85.1 m -106.55 136.18 46.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.16 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.445 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 152.79 175.88 24.76 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.45 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.596 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.4 mmt -41.68 159.56 0.18 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.52 0.676 . . . . 0.0 110.912 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 0.81 5.11 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.663 2.242 . . . . 0.0 112.374 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.11 -35.1 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.905 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.478 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.3 m-20 -72.03 -46.95 55.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 157' ' ' MET . 27.9 m -64.09 -37.59 80.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -55.44 -45.09 76.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.845 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -57.27 -54.57 45.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.74 -51.96 8.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.512 ' HG3' HG22 ' A' ' 112' ' ' VAL . 68.8 ttp85 -45.28 -45.17 11.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -61.49 -42.47 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -61.92 -57.32 12.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.589 HG23 HG11 ' A' ' 122' ' ' VAL . 78.3 mt -52.46 -49.56 42.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -63.54 -43.76 96.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.866 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.58 -57.5 2.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' A' ' 170' ' ' ALA . 77.4 m-70 -37.13 -38.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.597 HG12 HG21 ' A' ' 118' ' ' VAL . 51.1 mt . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.103 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.889 0.376 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.419 ' OG1' ' N ' ' A' ' 109' ' ' THR . 1.6 t -135.34 174.58 10.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.18 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.419 ' N ' ' OG1' ' A' ' 108' ' ' THR . 56.7 m -148.16 127.26 12.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.15 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.428 ' CD1' ' HE ' ' A' ' 165' ' ' ARG . 21.2 pt -118.35 155.12 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.494 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 1.7 mp0 -108.53 97.14 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.448 HG22 ' HG3' ' A' ' 165' ' ' ARG . 82.7 t -68.14 137.89 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.183 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 24.9 ttt180 -103.44 116.5 32.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.55 147.4 61.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.602 0.715 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.54 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.4 Cg_endo -69.7 126.94 13.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.663 2.242 . . . . 0.0 112.344 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.412 ' C ' ' O ' ' A' ' 115' ' ' PRO . 32.4 t80 -36.59 -31.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' PRO . 15.2 ttm180 -64.66 -51.6 61.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.54 HG23 ' HG2' ' A' ' 115' ' ' PRO . 42.3 t -64.89 -31.65 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.118 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.8 t -41.63 -70.68 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.11 -28.48 1.33 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.6 mt -75.11 -48.95 21.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 0.0 110.936 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.53 HG23 HG12 ' A' ' 118' ' ' VAL . 40.1 t -59.83 -60.13 2.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.104 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.1 t -46.06 -63.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.107 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 89.04 172.46 46.16 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_exo -48.04 99.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.7 2.267 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 30.5 tttm 49.75 49.69 19.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.06 73.66 0.46 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.18 -38.76 2.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 111.12 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 80.1 m -83.64 -44.98 13.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.164 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 133' ' ' ILE . 10.0 tp -57.84 -26.92 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.3 tttt -63.79 -45.78 88.13 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -36.19 56.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.928 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 130' ' ' ILE . 48.6 mt -66.57 -58.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.131 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.62 ' CG ' HD12 ' A' ' 141' ' ' ILE . 53.8 mt-30 -52.1 -36.05 49.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 56.3 mm-40 -78.74 -34.68 45.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -67.26 -38.5 85.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.835 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 53.1 p -107.18 -0.4 22.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.138 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 37.1 m170 52.71 52.59 13.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 16.5 p -123.08 179.98 4.48 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.115 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -117.11 98.18 6.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.636 HG21 HD11 ' A' ' 130' ' ' ILE . 79.5 mt -90.62 127.1 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 75.3 t -112.07 121.05 63.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.0 p -74.78 145.96 82.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.585 0.707 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 179.98 3.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.632 2.221 . . . . 0.0 112.297 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.42 165.04 51.37 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.5 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -70.04 -45.04 68.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 0.0 110.868 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 49.6 m-20 -103.22 41.74 1.23 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -133.01 174.45 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -68.28 144.3 96.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.598 0.713 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 100.97 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 112' ' ' VAL . 91.4 t -149.88 130.55 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -100.68 132.61 45.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.45 111.59 24.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.124 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 41.5 t -99.91 117.96 45.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.108 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 96.2 m -109.53 131.97 54.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 158.44 -177.81 34.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.473 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 20.4 mmt -49.59 158.31 0.84 Allowed Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.557 0.694 . . . . 0.0 110.901 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' PRO . . . . . 0.41 ' HA ' HG21 ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.75 -1.96 9.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -115.6 -23.36 8.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.412 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 16.6 m-20 -84.82 -54.76 4.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.5 m -58.26 -27.0 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.149 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -70.38 -39.13 74.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.875 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.45 -50.42 45.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -52.5 -42.99 64.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.448 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.5 ttm180 -47.14 -53.17 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -50.85 -43.88 59.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.72 -51.37 69.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 50.2 mt -55.26 -44.09 73.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.163 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -68.18 -44.46 75.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -42.68 -51.28 5.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.086 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -42.01 -38.66 1.69 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.516 HG12 HG21 ' A' ' 118' ' ' VAL . 57.1 mt . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.154 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 3.8 pp0? . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.88 0.372 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.6 t -134.72 164.47 27.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 89.8 m -131.25 122.46 26.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.179 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.4 pt -114.5 148.9 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.0 mm-40 -109.33 101.35 10.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 165' ' ' ARG . 88.2 t -70.2 143.27 14.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.138 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -114.04 120.93 42.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.851 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.669 HG11 HG22 ' A' ' 168' ' ' ILE . 11.1 m -139.68 150.92 64.84 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.653 0.739 . . . . 0.0 111.117 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.541 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.1 Cg_endo -69.74 125.49 12.22 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.655 2.236 . . . . 0.0 112.344 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.8 t80 -34.52 -35.53 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 115' ' ' PRO . 75.5 mtt-85 -59.56 -49.37 78.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.541 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.7 t -69.61 -35.28 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.107 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.9 t -39.51 -63.37 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.171 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.89 -42.23 37.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.0 mt -60.46 -43.46 96.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.816 0.341 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.418 ' HA ' ' CE1' ' A' ' 171' ' ' HIS . 58.3 t -69.98 -60.37 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.12 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.5 t -37.08 -51.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.42 166.79 42.44 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_exo -48.01 92.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.36 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 53.3 mmtt 58.51 41.63 22.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.918 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.54 66.29 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -111.76 -40.36 4.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.884 0.373 . . . . 0.0 111.115 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.3 m -84.82 -43.94 13.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.994 HD11 HG21 ' A' ' 141' ' ' ILE . 7.0 tp -58.52 -28.18 35.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -71.32 -43.42 67.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 35.0 ttm-85 -60.16 -39.95 88.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.506 HD12 ' HA ' ' A' ' 130' ' ' ILE . 58.0 mt -59.21 -50.1 81.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.128 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -48.77 -36.8 17.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.922 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -80.21 -51.08 9.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.913 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -54.2 -33.64 58.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.9 p -104.2 -14.83 15.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.141 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 9.8 m80 60.26 52.76 4.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.455 HG21 ' HA ' ' A' ' 161' ' ' VAL . 77.7 p -138.81 145.22 39.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -78.42 100.21 6.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.994 HG21 HD11 ' A' ' 130' ' ' ILE . 93.9 mt -96.23 122.08 47.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.083 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.4 t -112.96 132.28 62.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.6 p -85.17 152.53 58.59 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.626 0.727 . . . . 0.0 111.114 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.48 3.68 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.665 2.244 . . . . 0.0 112.364 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.88 169.76 53.41 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -70.1 -47.47 61.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.837 0.351 . . . . 0.0 110.872 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -103.79 40.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 18.3 mmmt -131.66 172.17 12.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -68.77 144.23 95.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.632 0.729 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 99.25 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.695 2.263 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 85.4 t -148.99 118.71 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.95 149.86 24.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.19 109.5 14.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.043 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.631 HG22 HG12 ' A' ' 141' ' ' ILE . 68.4 t -102.4 133.69 45.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.16 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 25.9 m -118.81 135.45 54.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.506 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 150.85 -179.33 27.65 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.433 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.685 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.5 mmt -43.49 159.44 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.534 0.683 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -0.17 6.56 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -119.29 -39.23 2.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -68.63 -40.42 80.33 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.685 HG22 ' O ' ' A' ' 157' ' ' MET . 20.2 m -72.42 -34.86 49.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -59.96 -39.93 87.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 43.6 ttt180 -61.27 -55.68 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.24 -43.08 3.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.092 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.436 ' HG3' HG22 ' A' ' 112' ' ' VAL . 72.1 ttt-85 -56.31 -40.65 74.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -54.57 -45.46 73.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -66.61 -57.16 7.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.917 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.669 HG22 HG11 ' A' ' 114' ' ' VAL . 71.7 mt -49.0 -45.82 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.165 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -71.13 -44.22 66.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.51 -57.97 1.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.129 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 122' ' ' VAL . 13.2 m170 -36.19 -40.18 0.21 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.857 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.414 ' HA ' HG21 ' A' ' 118' ' ' VAL . 50.2 mt . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -130.63 168.34 17.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.2 m -136.96 118.67 15.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.0 pt -107.3 150.62 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.112 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -109.61 94.16 4.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.466 HG12 HG13 ' A' ' 114' ' ' VAL . 79.4 t -67.16 139.74 20.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -109.25 111.89 23.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.477 HG11 HG22 ' A' ' 168' ' ' ILE . 7.2 m -128.39 150.89 75.56 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.589 0.709 . . . . 0.0 111.136 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.505 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.77 123.56 10.22 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.668 2.245 . . . . 0.0 112.373 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 22.8 t80 -34.84 -32.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.5 ' N ' ' O ' ' A' ' 115' ' ' PRO . 50.5 mtt85 -62.68 -49.13 76.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.542 HG12 HG23 ' A' ' 122' ' ' VAL . 56.0 t -70.35 -31.31 46.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.5 t -43.07 -64.46 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.1 -41.17 22.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.486 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 18.0 mt -63.19 -47.94 80.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.879 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.542 HG23 HG12 ' A' ' 118' ' ' VAL . 61.5 t -62.66 -61.71 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.131 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.6 t -43.16 -50.39 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 80.74 173.01 46.49 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.464 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' LYS . 64.6 Cg_exo -47.92 114.64 1.17 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.674 2.249 . . . . 0.0 112.372 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' PRO . 0.0 OUTLIER 34.13 43.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.886 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.38 84.45 0.12 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -133.52 -34.37 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 58.9 m -89.72 -43.7 10.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.089 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.799 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -68.21 -27.79 38.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.094 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttmt -68.29 -37.46 80.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.8 ttm180 -64.33 -46.82 81.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.854 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.819 HG23 ' OE1' ' A' ' 167' ' ' GLU . 36.6 mt -55.69 -42.8 71.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.13 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.428 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 29.9 mt-30 -57.23 -24.35 54.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.98 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 51.9 mm-40 -89.83 -47.03 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.401 ' NH1' ' OE2' ' A' ' 167' ' ' GLU . 6.3 ptm180 -64.16 -31.54 72.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.485 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 73.9 p -100.23 -12.83 19.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.158 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 27.2 m80 57.21 54.4 6.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 72.5 p -141.76 140.62 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -78.47 97.28 5.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.799 HG21 HD11 ' A' ' 130' ' ' ILE . 96.2 mt -88.78 108.71 19.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.138 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.3 t -91.95 133.65 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.116 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.0 p -91.81 146.13 32.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.558 0.694 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 177.17 5.82 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.733 2.289 . . . . 0.0 112.297 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.87 -178.02 50.11 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.514 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 50.3 ptt85 -83.08 -38.47 22.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.834 0.35 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -110.0 41.81 1.64 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -135.61 164.86 26.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -62.25 142.58 95.84 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.923 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 103.57 1.19 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.655 2.237 . . . . 0.0 112.348 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.3 t -148.28 115.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -86.96 128.44 35.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.915 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -103.36 104.28 14.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -95.9 122.2 47.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.6 m -108.65 137.15 47.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 151.95 -179.76 28.26 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.619 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.6 mmt -47.12 159.34 0.4 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 110.897 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 0.28 5.86 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.718 2.278 . . . . 0.0 112.351 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -118.4 -32.1 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.846 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.475 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.0 m-20 -73.58 -48.49 32.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 154' ' ' VAL . 32.9 m -65.62 -40.13 87.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 25.9 t0 -51.17 -41.88 60.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 15.3 ttm180 -65.24 -47.58 76.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.819 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.94 54.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.09 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.49 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 22.7 ttt85 -55.3 -45.26 76.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.854 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -60.98 -38.18 85.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.819 ' OE1' HG23 ' A' ' 133' ' ' ILE . 12.8 mt-10 -66.94 -50.52 62.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.886 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.477 HG22 HG11 ' A' ' 114' ' ' VAL . 66.6 mt -60.75 -43.41 95.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.49 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 60.3 mt-10 -66.15 -47.46 73.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.411 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -45.35 -55.36 6.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.411 ' C ' ' O ' ' A' ' 170' ' ' ALA . 30.0 m170 -37.23 -41.01 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 56.4 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.414 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 4.8 pp0? . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.92 0.391 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.7 t -133.1 165.35 24.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.134 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.1 m -133.54 122.47 23.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -116.11 147.73 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -105.97 106.77 17.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.428 HG12 HG13 ' A' ' 114' ' ' VAL . 97.6 t -71.83 141.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.107 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -111.7 115.91 29.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.882 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.428 HG13 HG12 ' A' ' 112' ' ' VAL . 4.1 m -136.57 150.27 69.82 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.564 0.697 . . . . 0.0 111.158 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.492 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.71 130.22 19.01 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.344 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -40.6 -33.76 0.3 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.423 ' HB3' ' NH1' ' A' ' 117' ' ' ARG . 5.6 mmm180 -61.76 -48.24 81.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.499 HG12 HG23 ' A' ' 122' ' ' VAL . 54.5 t -71.7 -32.67 46.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.401 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.9 t -40.73 -65.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.81 -40.42 26.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.89 -40.65 98.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 0.0 110.926 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.575 HG11 HG23 ' A' ' 168' ' ' ILE . 59.1 t -69.01 -63.5 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 95.5 t -38.43 -50.85 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.15 169.19 42.95 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -47.98 105.74 0.09 OUTLIER 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.697 2.265 . . . . 0.0 112.32 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt 45.22 39.29 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.921 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.76 86.51 0.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.479 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -134.87 -39.07 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.808 0.337 . . . . 0.0 111.047 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.0 m -86.65 -43.8 12.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.175 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.597 HG23 ' HD2' ' A' ' 131' ' ' LYS . 4.9 tp -60.95 -41.27 88.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.597 ' HD2' HG23 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -55.56 -38.39 69.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.835 179.855 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -58.62 -45.91 88.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.405 HD12 HD12 ' A' ' 130' ' ' ILE . 64.2 mt -55.26 -43.41 70.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.132 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.462 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 68.1 mt-30 -56.51 -37.18 70.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 7.3 mm100 -78.67 -54.24 6.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 23.0 mmm-85 -51.17 -34.83 33.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 70.0 p -102.52 -12.76 17.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 36.0 m80 57.22 52.94 8.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.435 HG21 ' HA ' ' A' ' 161' ' ' VAL . 63.8 p -136.11 159.19 42.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -89.34 98.88 12.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.556 HG12 HG22 ' A' ' 154' ' ' VAL . 71.1 mt -97.31 112.93 30.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.185 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 70.7 t -102.6 135.57 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.8 p -85.03 149.62 53.48 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.564 0.697 . . . . 0.0 111.146 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 177.58 5.44 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.2 161.84 49.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptp85 -66.48 -44.06 83.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -103.57 39.67 1.56 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.864 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -133.92 166.57 22.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -61.49 145.76 90.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.669 0.747 . . . . 0.0 110.904 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HB3' HG21 ' A' ' 119' ' ' VAL . 54.7 Cg_endo -69.7 98.16 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.653 2.235 . . . . 0.0 112.39 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 87.0 t -149.53 125.33 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.59 150.1 20.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.14 113.19 21.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.556 HG22 HG12 ' A' ' 141' ' ' ILE . 96.9 t -104.93 123.12 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.4 m -112.23 139.24 47.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.115 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.425 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 147.49 -173.79 27.48 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.73 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.2 mmt -48.56 159.32 0.54 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.502 0.668 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -1.06 7.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.657 2.238 . . . . 0.0 112.337 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -115.67 -49.79 2.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -59.47 -41.64 90.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -72.3 -34.33 48.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -58.34 -42.32 86.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -65.99 -36.78 84.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.892 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ALA . . . . . 0.433 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -60.02 -31.52 70.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 48.3 ttt180 -71.64 -52.4 18.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.85 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -62.54 -30.57 71.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -70.98 -54.34 11.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.575 HG23 HG11 ' A' ' 122' ' ' VAL . 72.1 mt -58.61 -46.69 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -65.0 -37.52 87.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.61 -53.79 6.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -41.8 -32.99 0.45 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.425 HG12 HG21 ' A' ' 118' ' ' VAL . 83.5 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.111 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.888 0.375 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.8 t -133.42 170.44 15.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.19 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.4 m -141.98 129.01 20.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.43 ' CD1' ' HE ' ' A' ' 165' ' ' ARG . 20.4 pt -122.04 158.91 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.454 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 2.0 mp0 -113.81 106.37 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.96 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.801 ' O ' HG13 ' A' ' 151' ' ' VAL . 93.9 t -75.61 142.28 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -110.37 120.31 42.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -142.49 150.71 55.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.615 0.721 . . . . 0.0 111.154 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.539 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.77 125.26 11.93 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.323 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.473 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 27.1 t80 -35.85 -34.65 0.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.959 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.428 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.0 ttp180 -59.74 -49.91 75.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.539 HG23 ' HG2' ' A' ' 115' ' ' PRO . 56.1 t -69.56 -34.27 60.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 98.9 t -40.15 -66.97 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.147 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.64 -41.14 18.47 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.513 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.505 HD12 ' HA ' ' A' ' 118' ' ' VAL . 19.2 mt -62.22 -43.32 99.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.491 HG23 HG12 ' A' ' 118' ' ' VAL . 97.5 t -68.03 -62.12 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.075 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.521 ' O ' HG22 ' A' ' 130' ' ' ILE . 97.5 t -40.04 -54.03 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.177 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 87.64 167.57 43.67 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_exo -47.93 94.8 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.717 2.278 . . . . 0.0 112.338 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 29.6 mtpt 55.07 42.17 31.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.905 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.32 79.01 0.31 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.478 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -128.47 -38.78 1.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.867 0.365 . . . . 0.0 111.104 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.2 m -87.08 -40.26 14.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.087 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.521 HG22 ' O ' ' A' ' 123' ' ' VAL . 5.0 tp -64.7 -33.33 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.141 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 18.2 tttp -59.49 -42.34 91.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -54.96 -47.79 74.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.812 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.541 HG23 ' OE1' ' A' ' 167' ' ' GLU . 54.3 mt -54.8 -48.81 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.418 ' CG ' HD12 ' A' ' 141' ' ' ILE . 61.1 mt-30 -48.25 -38.59 18.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 86.7 mm-40 -81.12 -52.56 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -51.37 -32.64 26.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.4 p -106.53 -13.56 15.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.141 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 41.2 m80 60.0 53.43 4.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.481 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 55.2 p -135.49 139.79 44.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.121 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -77.75 90.47 4.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.979 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -83.29 142.14 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.163 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 86.6 t -131.01 121.23 49.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.119 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 78.6 p -73.0 150.01 90.05 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.562 0.696 . . . . 0.0 111.152 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 176.91 6.17 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.252 . . . . 0.0 112.363 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -77.08 150.46 37.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -57.17 -36.42 70.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -110.34 40.35 1.98 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 49.2 mmtt -134.72 165.77 24.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.42 144.54 62.35 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 94.01 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.658 2.239 . . . . 0.0 112.396 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.801 HG13 ' O ' ' A' ' 112' ' ' VAL . 89.3 t -145.72 135.55 18.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.089 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -102.51 128.43 49.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -100.21 109.86 22.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 161' ' ' VAL . 67.3 t -100.77 130.17 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 21.7 m -117.91 135.1 54.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.135 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 153.87 179.72 29.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.504 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.471 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.9 mmt -46.57 159.28 0.36 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.53 0.681 . . . . 0.0 110.905 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 0.85 5.06 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.673 2.249 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -118.47 -29.13 5.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.914 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.481 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 8.4 m-20 -78.22 -46.47 20.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.838 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.471 HG22 ' O ' ' A' ' 157' ' ' MET . 16.0 m -68.32 -23.56 28.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -66.72 -39.12 87.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 24.2 ttm-85 -70.15 -46.87 63.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.37 -34.62 58.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.118 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.43 ' HE ' ' CD1' ' A' ' 110' ' ' ILE . 13.6 ttm180 -64.48 -50.87 65.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -62.9 -24.68 67.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.541 ' OE1' HG23 ' A' ' 133' ' ' ILE . 22.3 mt-10 -77.08 -56.5 4.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 76.2 mt -52.73 -53.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -56.28 -43.37 78.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -41.78 -58.3 2.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.444 ' C ' ' O ' ' A' ' 170' ' ' ALA . 9.8 m80 -34.45 -36.07 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.527 HG12 HG21 ' A' ' 118' ' ' VAL . 64.9 mt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.869 0.366 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -125.61 159.48 32.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.2 m -128.51 116.42 19.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -104.77 155.32 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -114.42 101.0 8.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 91.3 t -69.64 141.97 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 23.6 ttp180 -111.67 112.05 23.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.49 HG11 HG22 ' A' ' 168' ' ' ILE . 2.4 m -134.11 151.4 76.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.614 0.721 . . . . 0.0 111.108 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.542 ' CB ' ' NH1' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.74 138.37 37.72 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.682 2.255 . . . . 0.0 112.322 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.0 t80 -46.96 -37.91 9.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.542 ' NH1' ' CB ' ' A' ' 115' ' ' PRO . 8.6 ptp85 -59.01 -38.62 79.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.491 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 19.8 t -78.0 -36.42 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.171 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 97.1 t -41.37 -63.7 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.07 -39.21 18.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.3 mt -65.15 -43.9 90.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 0.0 110.921 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 73.4 t -71.57 -60.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.7 t -42.28 -45.54 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 73.92 173.34 27.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.482 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.4 Cg_exo -48.03 114.74 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.7 pttm 36.1 39.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.895 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.44 73.77 0.78 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.61 -38.49 3.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 m -85.5 -44.25 12.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.82 HD11 HG21 ' A' ' 141' ' ' ILE . 6.1 tp -60.82 -31.16 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -68.03 -40.18 82.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -60.85 -44.23 97.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.833 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 73.0 mt -54.58 -54.58 21.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.126 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.539 ' HG3' HD12 ' A' ' 141' ' ' ILE . 76.1 mt-30 -42.81 -30.9 0.43 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -78.27 -53.72 7.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.4 -32.17 56.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 74.1 p -102.22 -17.5 15.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.178 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 134' ' ' GLN . 16.9 m170 59.27 54.94 4.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.821 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.468 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.3 p -135.28 174.51 10.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -106.21 89.94 3.21 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.82 HG21 HD11 ' A' ' 130' ' ' ILE . 84.8 mt -82.89 137.14 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.1 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 91.7 t -124.63 132.14 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.166 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.7 p -90.26 147.86 37.82 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.582 0.706 . . . . 0.0 111.166 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -179.11 2.67 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.315 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.44 176.92 51.5 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.52 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ARG . . . . . 0.419 ' HD3' ' C ' ' A' ' 146' ' ' ARG . 0.2 OUTLIER -80.23 -35.29 36.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -106.87 39.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 38.7 mmtt -138.01 175.43 9.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -71.98 143.41 86.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.592 0.71 . . . . 0.0 110.935 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 89.66 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.644 2.229 . . . . 0.0 112.394 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 75.4 t -138.17 119.64 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.71 148.88 25.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.86 105.62 10.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.08 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 161' ' ' VAL . 96.0 t -100.89 127.03 54.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.128 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -112.79 138.68 49.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 150.4 176.04 23.03 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.618 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -41.03 159.4 0.16 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.582 0.706 . . . . 0.0 110.87 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 0.58 5.4 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.706 2.271 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -118.35 -35.46 3.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.468 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.1 m-20 -69.25 -46.31 67.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.904 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 154' ' ' VAL . 33.7 m -68.88 -38.61 78.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.134 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -52.37 -42.04 63.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 42.0 ttt85 -63.82 -52.56 59.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -45.58 -49.28 14.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.079 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 44.4 ttt180 -51.6 -40.5 59.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -57.61 -47.98 80.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -65.04 -56.69 11.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.937 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.49 HG22 HG11 ' A' ' 114' ' ' VAL . 65.4 mt -47.84 -50.69 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.132 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -65.89 -47.03 76.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.433 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.83 -55.75 1.46 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 170' ' ' ALA . 74.1 m80 -36.02 -43.11 0.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.833 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.419 HG12 HG21 ' A' ' 118' ' ' VAL . 73.6 mt . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.092 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.853 0.358 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -147.71 156.97 43.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.162 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 97.8 m -127.9 122.49 32.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.675 HD12 ' HE ' ' A' ' 165' ' ' ARG . 22.6 pt -111.27 154.84 12.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 20.5 mm100 -109.9 101.76 10.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.735 HG22 ' HG3' ' A' ' 165' ' ' ARG . 54.0 t -69.67 132.98 32.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 14.9 ttp180 -100.39 118.95 37.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.549 HG13 HG12 ' A' ' 112' ' ' VAL . 3.3 m -141.14 150.45 58.85 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.624 0.726 . . . . 0.0 111.085 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 133.18 24.98 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -42.42 -26.89 0.13 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 60.2 ttp85 -69.35 -54.06 16.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.766 HG21 HG12 ' A' ' 172' ' ' ILE . 35.8 t -63.65 -27.29 42.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.1 t -46.5 -71.09 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -43.68 -34.67 2.79 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 8.7 mt -67.39 -44.19 79.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 83.9 t -69.42 -65.58 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.9 t -37.63 -61.5 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.78 166.15 38.64 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.514 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_exo -47.97 93.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt 56.98 54.03 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.939 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 54.93 70.95 0.8 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.71 -41.14 2.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 111.084 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 73.7 m -78.59 -44.5 23.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.155 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 133' ' ' ILE . 7.5 tp -54.4 -29.59 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.7 tptp -54.57 -44.64 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -61.27 -22.12 64.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 130' ' ' ILE . 70.5 mt -83.1 -31.56 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.136 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.708 ' HG3' HD12 ' A' ' 141' ' ' ILE . 44.8 mt-30 -83.34 -24.45 32.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLN . . . . . 0.472 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.82 -41.01 19.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.472 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 14.9 mmm180 -64.62 -35.68 81.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -100.56 -18.12 16.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.16 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.4 m80 62.28 46.18 6.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.822 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.454 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.6 p -120.67 164.55 16.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 t80 -95.66 88.25 4.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 134' ' ' GLN . 79.9 mt -88.69 132.81 32.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.103 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.4 t -117.96 132.09 68.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.167 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 64.4 p -85.55 148.07 48.25 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.596 0.713 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 176.49 6.73 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.647 2.231 . . . . 0.0 112.356 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.56 179.22 53.24 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.48 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -79.16 -43.25 24.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.884 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.7 p-10 -104.79 43.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 52.9 mmtt -134.08 169.04 17.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.407 ' H ' ' CD ' ' A' ' 149' ' ' GLU . 2.0 pm0 -66.57 143.99 98.43 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.669 0.747 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 95.7 0.56 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 2.267 . . . . 0.0 112.313 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.2 t -147.7 119.59 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.172 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -88.27 140.27 29.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.02 110.17 20.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.081 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.489 HG12 HG12 ' A' ' 161' ' ' VAL . 23.8 t -103.98 122.51 56.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 93.6 m -111.03 130.59 55.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.153 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.491 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 158.31 178.16 32.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.475 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.703 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.5 mmt -45.37 158.94 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -0.69 7.2 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.737 2.291 . . . . 0.0 112.32 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.78 -25.38 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.908 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.454 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 5.5 m-20 -83.07 -48.52 10.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.703 HG22 ' O ' ' A' ' 157' ' ' MET . 34.1 m -64.78 -36.96 78.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -58.36 -45.28 88.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.855 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -61.46 -43.91 98.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.873 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.92 -44.01 70.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.735 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.6 ttm180 -59.42 -42.85 92.8 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.872 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' GLU . . . . . 0.425 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 18.2 mt-10 -53.37 -42.88 67.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.935 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -71.3 -51.61 23.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.877 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 61.6 mt -49.34 -53.99 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -67.38 -41.45 85.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.59 -61.44 0.71 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 170' ' ' ALA . 59.1 m-70 -34.46 -41.29 0.12 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.842 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.766 HG12 HG21 ' A' ' 118' ' ' VAL . 93.4 mt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.903 0.382 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.4 t -129.47 159.66 35.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -131.24 120.64 23.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.187 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 25.0 pt -111.15 152.89 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 38.2 mm-40 -108.02 100.66 9.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.896 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 168' ' ' ILE . 88.4 t -73.09 141.97 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.147 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 37.5 ttt-85 -104.98 120.88 42.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.429 HG21 ' CE1' ' A' ' 152' ' ' PHE . 4.8 m -140.49 151.07 62.84 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.688 0.756 . . . . 0.0 111.074 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.546 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.2 Cg_endo -69.79 138.4 37.64 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.685 2.256 . . . . 0.0 112.314 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -47.52 -26.21 1.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.927 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 ttm180 -69.6 -46.99 65.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.835 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 122' ' ' VAL . 41.2 t -68.39 -29.37 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.108 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.4 t -42.27 -65.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.66 -34.08 9.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.4 -46.11 61.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.85 0.357 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.598 HG23 HG12 ' A' ' 118' ' ' VAL . 91.9 t -64.89 -57.92 9.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.459 HG22 ' CG2' ' A' ' 143' ' ' THR . 90.2 t -55.28 -49.24 74.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.095 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.94 172.69 48.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.44 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.95 99.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.652 2.235 . . . . 0.0 112.382 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? 54.01 42.71 31.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.46 68.38 1.67 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.52 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.28 -35.18 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.893 0.378 . . . . 0.0 111.109 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 33.1 m -75.94 -39.41 56.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.751 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -67.21 -23.08 29.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -62.58 -38.5 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -66.44 -37.8 85.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.844 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 66.7 mt -70.48 -49.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.116 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -52.32 -37.49 55.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -81.82 -52.41 7.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 -52.89 -33.87 52.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.7 p -103.54 -15.15 15.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.165 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 17.8 m170 60.95 53.79 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.47 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.5 p -138.01 138.27 38.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 51.9 t80 -76.74 91.92 3.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.751 HG21 HD11 ' A' ' 130' ' ' ILE . 77.7 mt -83.64 134.41 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.1 t -120.28 129.32 75.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.137 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.459 ' CG2' HG22 ' A' ' 123' ' ' VAL . 41.6 p -83.8 153.12 63.94 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.54 0.686 . . . . 0.0 111.191 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 177.06 5.97 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.684 2.256 . . . . 0.0 112.366 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -75.06 155.67 48.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.45 -28.49 70.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.86 0.362 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -119.91 38.01 4.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -135.91 162.13 33.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -53.99 143.86 40.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.638 0.732 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.73 97.68 0.65 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.695 2.263 . . . . 0.0 112.331 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.3 t -145.32 117.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.429 ' CE1' HG21 ' A' ' 114' ' ' VAL . 35.4 m-85 -86.73 146.31 26.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.86 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -121.74 99.13 6.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.43 HG12 HG12 ' A' ' 161' ' ' VAL . 46.6 t -87.63 131.1 36.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -117.09 131.07 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.177 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 156.43 175.13 27.04 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.456 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.577 ' O ' HG22 ' A' ' 161' ' ' VAL . 21.6 mmt -39.2 159.49 0.1 Allowed Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.576 0.703 . . . . 0.0 110.902 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.723 2.282 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -119.7 -38.38 2.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.4 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.2 m-20 -66.77 -46.42 75.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 157' ' ' MET . 20.5 m -67.72 -38.1 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -52.89 -43.1 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 11.9 ttt180 -61.89 -57.92 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.06 -48.54 4.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 16.9 ttp85 -48.34 -40.24 24.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -55.48 -64.82 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 58.1 mm-40 -54.22 -46.35 72.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 112' ' ' VAL . 47.7 mt -44.63 -65.91 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.082 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.446 ' HB2' HD12 ' A' ' 172' ' ' ILE . 0.7 OUTLIER -69.36 -29.52 67.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.861 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -48.74 -48.99 40.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -46.89 -26.32 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 69.6 mt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--O 1.233 0.189 0 CA-C-O 120.889 0.376 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.9 t -124.5 168.4 13.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.123 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 25.6 m -137.34 124.63 21.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 23.0 pt -122.46 155.24 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.091 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -105.2 111.66 24.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.548 HG12 HG13 ' A' ' 114' ' ' VAL . 70.4 t -76.77 135.04 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -106.65 117.65 34.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.584 HG11 HG22 ' A' ' 168' ' ' ILE . 8.7 m -137.96 151.05 69.42 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.669 0.747 . . . . 0.0 111.121 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.418 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.68 134.37 27.98 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -47.09 -21.98 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 91.7 mtt-85 -72.59 -44.02 62.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.605 HG21 HG12 ' A' ' 172' ' ' ILE . 39.6 t -74.31 -34.41 36.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.15 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.8 t -38.23 -69.92 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.155 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.31 -36.21 4.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.472 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 118' ' ' VAL . 15.1 mt -68.01 -44.16 77.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.882 0.373 . . . . 0.0 110.958 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.561 HG23 HG12 ' A' ' 118' ' ' VAL . 57.5 t -65.53 -63.28 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.3 t -40.88 -50.43 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.142 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 79.97 169.08 38.51 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.05 101.23 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.353 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.4 tptm 50.26 44.39 26.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.71 72.9 0.7 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.63 -39.81 2.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 111.12 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -84.49 -43.57 14.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -58.53 -37.88 67.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 27.4 tttm -57.09 -43.2 81.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 74.3 mtt-85 -57.27 -44.35 83.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.876 HG23 ' OE1' ' A' ' 167' ' ' GLU . 58.7 mt -57.93 -46.43 87.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.164 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.511 ' HG3' HD12 ' A' ' 141' ' ' ILE . 53.6 mt-30 -60.8 -20.32 61.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 -90.28 -45.6 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -66.97 -32.7 74.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.45 ' CG2' ' OE2' ' A' ' 167' ' ' GLU . 66.7 p -101.48 -15.63 17.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 11.6 m170 56.79 49.91 13.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.571 HG21 ' HA ' ' A' ' 161' ' ' VAL . 57.9 p -131.8 146.8 52.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.173 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 26.1 t80 -78.85 96.64 5.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 130' ' ' ILE . 91.4 mt -90.97 115.63 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.456 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 97.2 t -105.73 124.99 61.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.568 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.0 p -76.65 152.62 83.2 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.604 0.716 . . . . 0.0 111.177 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 175.79 7.67 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.692 2.261 . . . . 0.0 112.337 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.51 158.98 46.0 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.467 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 12.6 ptp180 -62.27 -44.01 97.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.867 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.43 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 30.8 t0 -103.95 42.35 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.901 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 8.0 mmmm -138.34 163.93 30.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.96 148.73 83.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 101.44 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.709 2.273 . . . . 0.0 112.344 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.2 t -153.82 119.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.094 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.568 ' CE2' HG22 ' A' ' 143' ' ' THR . 52.1 m-85 -89.79 156.93 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.456 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.87 104.76 9.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.138 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 34.1 t -95.81 124.0 48.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.7 m -115.53 134.06 55.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.145 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 154.09 -172.37 32.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.5 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.552 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.0 mmt -50.45 159.4 0.87 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.581 0.705 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.678 2.252 . . . . 0.0 112.362 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -120.03 -33.38 3.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 57.3 m-20 -73.62 -48.73 30.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.571 ' HA ' HG21 ' A' ' 139' ' ' THR . 17.3 m -63.67 -36.1 75.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -61.15 -38.91 88.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -63.17 -40.74 98.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -61.78 -33.39 74.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 47.0 ttp85 -67.16 -50.48 61.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.42 -26.04 66.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.876 ' OE1' HG23 ' A' ' 133' ' ' ILE . 67.5 mt-10 -77.83 -52.91 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.584 HG22 HG11 ' A' ' 114' ' ' VAL . 72.6 mt -58.81 -40.15 79.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -71.87 -38.59 70.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.916 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.2 -54.85 5.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 43.8 m170 -41.65 -32.07 0.34 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.605 HG12 HG21 ' A' ' 118' ' ' VAL . 76.9 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.2 t -127.55 161.3 29.12 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.082 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.7 m -132.31 122.4 25.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.26 156.11 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 49.3 mm-40 -109.88 100.55 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.943 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 94.4 t -67.85 141.01 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 34.6 ttp180 -109.3 124.77 51.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.86 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -146.52 149.57 37.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.56 0.695 . . . . 0.0 111.142 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 139.03 39.31 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.326 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 t80 -49.17 -20.91 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 ttm-85 -74.35 -46.24 41.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.741 HG21 HG12 ' A' ' 172' ' ' ILE . 16.7 t -68.6 -37.28 77.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 87.3 t -39.75 -64.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.098 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.72 -36.6 13.26 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 12.8 mt -70.04 -43.08 71.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.775 0.321 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.461 HG23 HG12 ' A' ' 118' ' ' VAL . 48.8 t -67.31 -63.1 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 96.4 t -38.97 -49.77 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.87 172.61 33.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -47.95 102.81 0.05 OUTLIER 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 91.0 mttt 46.16 44.41 12.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.58 70.67 1.08 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.11 -37.06 3.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 111.088 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 35.4 m -87.96 -44.39 11.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.158 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.696 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -60.79 -28.06 42.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.153 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.9 ttpp -64.67 -46.97 80.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.938 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.2 mtt180 -51.74 -50.55 60.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 56.8 mt -50.14 -54.95 6.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.135 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.674 ' HG3' HD12 ' A' ' 141' ' ' ILE . 46.6 mt-30 -45.89 -37.07 5.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.901 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -79.79 -59.15 2.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -43.51 -37.64 2.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.861 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.6 p -101.03 -22.81 14.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.086 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.7 m80 69.85 52.62 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.466 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.0 p -133.46 155.19 49.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 35.4 t80 -90.07 95.47 10.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.964 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.696 HG21 HD11 ' A' ' 130' ' ' ILE . 90.3 mt -86.77 138.49 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.5 t -129.28 124.08 59.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.187 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.709 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.3 p -80.18 152.68 74.0 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.562 0.696 . . . . 0.0 111.121 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -175.59 1.2 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.6 169.48 45.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.31 -22.87 59.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 20.3 p-10 -123.0 40.77 3.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -138.94 174.19 10.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -68.02 143.94 96.62 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.611 0.72 . . . . 0.0 110.915 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 91.15 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.646 2.231 . . . . 0.0 112.32 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.7 t -138.74 120.04 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.139 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.709 ' CE2' HG22 ' A' ' 143' ' ' THR . 36.2 m-85 -89.1 147.94 23.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -117.92 113.56 21.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.115 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.526 HG12 HG12 ' A' ' 161' ' ' VAL . 53.8 t -106.68 124.4 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 60.2 m -111.54 137.38 49.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.61 -177.27 29.61 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.441 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.804 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.7 mmt -47.28 159.1 0.43 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.545 0.688 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.29 8.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -115.71 -37.01 4.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.839 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 -71.13 -50.62 31.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.903 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.804 HG22 ' O ' ' A' ' 157' ' ' MET . 32.0 m -59.4 -29.51 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.091 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.02 -42.06 94.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -65.83 -32.21 73.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ALA . . . . . 0.491 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -66.82 -36.3 82.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.42 ' CG ' ' OE1' ' A' ' 169' ' ' GLU . 41.5 ttt180 -65.31 -59.57 3.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' GLU . . . . . 0.475 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 1.7 pp20? -51.92 -31.46 28.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -67.56 -55.39 13.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.4 mt -58.27 -53.66 43.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.42 ' OE1' ' CG ' ' A' ' 165' ' ' ARG . 29.0 mt-10 -58.77 -41.52 86.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -41.38 -59.23 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.106 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 50.1 m170 -37.75 -37.91 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.741 HG12 HG21 ' A' ' 118' ' ' VAL . 84.1 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.898 0.38 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.1 t -133.97 163.96 28.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.11 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 56.8 m -131.87 126.16 33.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.152 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.4 pt -111.84 155.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.133 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -112.59 101.01 9.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.451 HG22 ' HG3' ' A' ' 165' ' ' ARG . 90.5 t -72.75 141.28 16.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.139 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.8 ttm180 -111.6 115.37 29.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.409 HG11 HG22 ' A' ' 168' ' ' ILE . 3.5 m -133.37 150.69 75.85 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.658 0.742 . . . . 0.0 111.103 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.49 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.5 Cg_endo -69.84 123.84 10.47 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.636 2.224 . . . . 0.0 112.31 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -35.2 -32.82 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 115' ' ' PRO . 10.9 mmm180 -63.12 -51.96 64.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.49 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 40.1 t -65.36 -32.19 57.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.159 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 122' ' ' VAL . 75.8 t -42.66 -72.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 119' ' ' VAL . . . -37.64 -36.79 0.31 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.5 mt -69.99 -39.59 75.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.898 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.483 ' N ' ' O ' ' A' ' 119' ' ' VAL . 38.4 t -68.92 -63.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.3 t -43.97 -55.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.079 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.84 172.83 49.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -48.03 107.09 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.638 2.225 . . . . 0.0 112.369 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 43.9 39.16 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.73 75.47 0.52 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -120.34 -41.51 2.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.086 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 83.4 m -81.49 -44.77 16.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.151 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 133' ' ' ILE . 9.7 tp -54.67 -40.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.149 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 130' ' ' ILE . 10.4 ttpp -51.72 -44.55 63.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.427 ' HA ' ' CG ' ' A' ' 135' ' ' GLN . 21.8 mtp180 -63.63 -20.58 65.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 130' ' ' ILE . 71.4 mt -79.81 -37.44 18.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.726 ' CG ' HD12 ' A' ' 141' ' ' ILE . 69.1 mt-30 -78.12 -26.96 48.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLN . . . . . 0.479 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.85 -41.38 19.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.479 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 13.9 mmt180 -62.4 -39.26 92.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 38.8 p -101.3 -6.53 24.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.155 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 74.1 m80 55.2 52.8 11.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.467 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 13.1 p -129.02 150.15 50.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.18 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -90.66 92.6 8.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.732 HG12 HG22 ' A' ' 154' ' ' VAL . 69.7 mt -84.67 124.08 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.773 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 79.7 t -100.41 109.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.6 p -79.04 148.84 72.45 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.707 . . . . 0.0 111.125 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.86 23.17 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.27 -164.33 27.75 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.482 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -71.67 -54.2 11.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.783 0.325 . . . . 0.0 110.849 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -103.88 41.29 1.31 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.66 140.05 50.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.943 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.52 143.31 2.95 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 82.14 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.653 2.236 . . . . 0.0 112.347 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 112' ' ' VAL . 46.3 t -139.63 119.93 14.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.128 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.654 ' CE2' HG22 ' A' ' 143' ' ' THR . 23.9 m-85 -90.58 147.43 23.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.856 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.773 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -119.53 98.57 6.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.07 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.732 HG22 HG12 ' A' ' 141' ' ' ILE . 58.0 t -86.12 119.27 34.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.187 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.1 m -107.71 132.34 53.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.115 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.432 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 155.64 -173.0 33.76 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.539 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.9 mmt -50.58 158.7 1.02 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.589 0.709 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -2.49 10.24 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.695 2.263 . . . . 0.0 112.353 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -113.25 -32.67 6.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.467 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 21.4 m-20 -77.16 -53.57 7.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 157' ' ' MET . 17.8 m -54.29 -34.55 27.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.151 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.436 ' C ' ' OE2' ' A' ' 166' ' ' GLU . 23.2 t0 -59.38 -67.86 0.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.858 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 21.3 ttm-85 -43.76 -51.27 7.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.75 -36.5 3.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.451 ' HG3' HG22 ' A' ' 112' ' ' VAL . 37.6 ttp180 -72.57 -34.61 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 166' ' ' GLU . 0.1 OUTLIER -57.77 -39.68 78.01 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.888 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -71.56 -53.72 12.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.409 HG22 HG11 ' A' ' 114' ' ' VAL . 70.3 mt -49.96 -48.98 22.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -65.26 -43.38 91.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.438 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -44.39 -57.66 3.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.08 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.438 ' C ' ' O ' ' A' ' 170' ' ' ALA . 11.4 m80 -35.45 -37.91 0.09 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.45 HG12 HG21 ' A' ' 118' ' ' VAL . 66.7 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.473 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 1.7 pp0? . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.861 0.362 . . . . 0.0 110.943 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.8 t -134.31 157.33 46.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 91.5 m -128.4 118.29 22.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.9 pt -106.91 154.34 7.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLN . . . . . 0.45 ' NE2' ' HB2' ' A' ' 153' ' ' ALA . 43.4 mm-40 -112.27 105.74 14.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.503 HG22 ' CD ' ' A' ' 165' ' ' ARG . 93.4 t -82.12 144.77 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.16 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.44 ' O ' ' CG1' ' A' ' 114' ' ' VAL . 7.9 mpt_? -109.54 147.37 33.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.44 ' CG1' ' O ' ' A' ' 113' ' ' ARG . 7.6 m -158.45 151.11 18.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.627 0.727 . . . . 0.0 111.151 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.498 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.7 Cg_endo -69.72 127.03 14.03 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.713 2.275 . . . . 0.0 112.361 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -41.42 -24.42 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.918 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 115' ' ' PRO . 46.9 mtt85 -71.28 -43.81 66.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.559 HG21 HG12 ' A' ' 172' ' ' ILE . 41.2 t -74.56 -34.96 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.093 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.1 t -39.71 -63.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.36 -39.2 9.66 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.495 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -67.56 -46.62 72.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.881 0.372 . . . . 0.0 110.937 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.546 HG23 HG12 ' A' ' 118' ' ' VAL . 59.0 t -63.79 -63.88 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 87.1 t -40.4 -49.59 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 72.7 172.87 22.04 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.477 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.7 Cg_exo -47.99 118.21 2.98 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.718 2.279 . . . . 0.0 112.352 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.434 ' C ' ' O ' ' A' ' 125' ' ' PRO . 8.0 ptpp? 35.25 43.63 0.13 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 62.46 65.66 3.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.447 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.33 -39.27 6.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.838 0.351 . . . . 0.0 111.048 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.1 m -83.91 -50.34 8.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.158 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.489 HD11 HG21 ' A' ' 141' ' ' ILE . 7.3 tp -49.94 -40.8 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.435 ' N ' HG23 ' A' ' 130' ' ' ILE . 25.0 tttp -60.92 -43.88 97.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 49.4 mtt180 -54.33 -41.14 68.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.467 HD11 ' CE1' ' A' ' 171' ' ' HIS . 54.8 mt -59.28 -49.93 81.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.461 ' HG3' HD12 ' A' ' 141' ' ' ILE . 42.1 mt-30 -47.77 -34.67 8.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -80.59 -54.44 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 53.7 mtt-85 -51.96 -33.42 37.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.865 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.478 HG21 ' HA ' ' A' ' 164' ' ' ALA . 37.4 p -103.59 -16.62 15.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 72.8 m80 61.23 51.15 4.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.565 HG21 ' HA ' ' A' ' 161' ' ' VAL . 38.0 p -136.52 141.51 43.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.129 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -77.15 97.42 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.489 HG21 HD11 ' A' ' 130' ' ' ILE . 79.8 mt -89.93 141.48 14.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.137 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.5 t -125.91 129.09 72.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.072 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 35.3 p -86.12 149.14 49.4 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.583 0.706 . . . . 0.0 111.135 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 177.83 5.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.663 2.242 . . . . 0.0 112.364 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.35 170.91 52.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 18.8 ptt180 -71.34 -42.24 68.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.33 . . . . 0.0 110.861 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 2.5 p30 -104.61 42.09 1.25 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.82 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -139.18 159.3 42.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.894 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -58.03 142.59 79.63 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.623 0.725 . . . . 0.0 110.895 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 101.77 0.96 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.319 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -147.83 115.16 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.099 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -82.89 143.5 30.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.45 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . . . -118.97 106.71 12.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.099 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.413 HG22 HG12 ' A' ' 141' ' ' ILE . 47.4 t -95.51 123.15 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 72.8 m -110.58 129.93 55.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLY . . . . . 0.497 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.78 178.8 32.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.478 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.56 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -44.56 159.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.561 0.696 . . . . 0.0 110.877 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 0.75 5.19 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.643 2.229 . . . . 0.0 112.32 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -117.99 -37.53 3.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.878 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.465 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.4 m-20 -71.14 -45.71 62.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.565 ' HA ' HG21 ' A' ' 139' ' ' THR . 13.8 m -66.8 -38.16 80.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -55.9 -39.63 71.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -62.78 -47.21 84.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ALA . . . . . 0.478 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -49.32 -42.83 42.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.068 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.503 ' CD ' HG22 ' A' ' 112' ' ' VAL . 11.7 tpt180 -48.9 -46.63 43.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 49.0 mm-40 -63.74 -37.46 87.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -63.3 -59.65 4.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 58.8 mt -53.03 -50.44 44.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.138 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -59.97 -43.25 95.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.415 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -47.0 -56.03 7.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.099 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.467 ' CE1' HD11 ' A' ' 133' ' ' ILE . 27.3 m170 -37.17 -41.34 0.38 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.559 HG12 HG21 ' A' ' 118' ' ' VAL . 57.3 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.434 ' HB3' ' HE2' ' A' ' 157' ' ' MET . 11.5 pt20 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.887 0.375 . . . . 0.0 110.911 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.5 t -133.78 164.2 27.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 93.1 m -132.69 124.55 28.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.135 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.9 pt -110.47 152.02 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -108.17 96.77 6.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 114' ' ' VAL . 76.9 t -68.02 137.05 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -108.58 115.71 30.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.916 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 112' ' ' VAL . 11.4 m -137.29 151.11 70.92 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.589 0.709 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.543 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.3 Cg_endo -69.72 127.77 15.1 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.355 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -39.56 -27.34 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 115' ' ' PRO . 22.0 ttm180 -67.12 -44.94 78.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.899 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.545 HG12 HG23 ' A' ' 122' ' ' VAL . 55.2 t -74.51 -29.15 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 74.1 t -45.12 -63.07 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.104 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.91 -38.26 30.52 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.49 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.5 mt -66.78 -45.5 78.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.903 0.382 . . . . 0.0 110.971 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.545 HG23 HG12 ' A' ' 118' ' ' VAL . 89.9 t -66.28 -58.23 7.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.13 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.3 t -44.16 -54.85 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.411 ' O ' ' N ' ' A' ' 126' ' ' LYS . . . 85.12 172.77 49.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.494 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.0 88.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.411 ' N ' ' O ' ' A' ' 124' ' ' GLY . 34.4 tttp 58.01 48.64 12.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.891 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.69 60.03 7.01 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.502 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.93 -40.21 6.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.845 0.355 . . . . 0.0 111.069 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 94.2 m -85.77 -50.79 6.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.701 HD11 HG21 ' A' ' 141' ' ' ILE . 8.4 tp -52.53 -28.98 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.12 -49.14 71.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -51.04 -40.14 57.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.882 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.4 mt -63.46 -47.16 92.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.496 ' CG ' HD12 ' A' ' 141' ' ' ILE . 70.4 mt-30 -48.1 -36.85 14.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 67.3 mm-40 -82.24 -50.12 9.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.7 mtt85 -52.78 -33.91 50.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.882 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.3 p -105.68 -12.08 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.144 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 15.5 m170 58.26 54.12 5.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.466 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 70.5 p -139.46 139.11 36.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.423 ' HE2' HG22 ' A' ' 142' ' ' VAL . 38.2 t80 -75.25 97.94 3.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.701 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -87.71 122.99 40.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.147 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.423 HG22 ' HE2' ' A' ' 140' ' ' TYR . 94.0 t -107.02 128.27 62.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.781 HG22 ' HE1' ' A' ' 152' ' ' PHE . 34.1 p -87.38 144.32 35.62 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.583 0.706 . . . . 0.0 111.128 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -177.28 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.705 2.27 . . . . 0.0 112.304 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -90.7 -175.16 44.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 6.1 ptp85 -84.9 -41.16 16.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -100.77 40.08 1.31 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -138.42 169.44 17.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.91 144.18 95.47 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.713 0.768 . . . . 0.0 110.89 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 87.5 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.727 2.285 . . . . 0.0 112.316 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.4 t -137.86 121.17 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.781 ' HE1' HG22 ' A' ' 143' ' ' THR . 69.9 m-85 -91.12 143.98 26.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.41 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -114.87 104.57 12.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 161' ' ' VAL . 46.7 t -95.05 124.41 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 27.0 m -110.83 132.8 53.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 155.13 177.56 28.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.639 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.8 mmt -43.03 159.55 0.21 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.56 0.695 . . . . 0.0 110.865 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.69 5.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.736 2.291 . . . . 0.0 112.339 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -118.71 -35.66 3.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.907 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.466 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 71.0 m-20 -69.33 -45.75 68.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.882 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 154' ' ' VAL . 35.2 m -67.01 -39.38 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.143 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 11.5 t70 -54.5 -42.3 70.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.865 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -53.89 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.92 -52.25 25.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.412 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 50.0 ttt85 -42.51 -39.38 2.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.866 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -68.49 -45.53 72.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -58.57 -54.55 45.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.405 HG23 HG11 ' A' ' 122' ' ' VAL . 84.4 mt -55.12 -51.12 57.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.412 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 66.0 mt-10 -59.13 -46.0 89.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.901 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.445 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.13 -57.55 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.06 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 170' ' ' ALA . 14.7 m170 -34.9 -42.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.514 HG12 HG21 ' A' ' 118' ' ' VAL . 74.9 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.127 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.0 t -123.53 159.67 28.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.174 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.621 ' OG1' HG23 ' A' ' 155' ' ' THR . 84.2 m -130.26 120.69 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.097 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.716 HD12 ' HE ' ' A' ' 165' ' ' ARG . 36.3 pt -108.38 154.97 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.109 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.9 mm-40 -113.82 96.14 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.596 ' O ' HG13 ' A' ' 151' ' ' VAL . 96.0 t -66.68 140.73 18.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.127 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -106.14 110.96 23.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.467 HG13 HG12 ' A' ' 112' ' ' VAL . 3.2 m -133.32 151.27 77.25 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 0.0 111.11 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.479 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 149.79 67.37 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.703 2.269 . . . . 0.0 112.334 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -55.24 -39.34 69.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.923 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.45 ' HG3' ' N ' ' A' ' 118' ' ' VAL . 4.6 ptp180 -57.78 -41.85 82.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.479 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 16.5 t -71.53 -37.29 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 150' ' ' PRO . 77.5 t -43.06 -69.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -41.21 -34.46 0.94 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.7 mt -71.22 -56.92 5.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.447 HG12 HD13 ' A' ' 130' ' ' ILE . 86.7 t -52.83 -57.58 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.145 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 74.5 t -49.77 -54.74 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.11 169.84 42.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -47.93 97.37 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.718 2.278 . . . . 0.0 112.347 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.0 mttt 54.52 47.65 22.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.888 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.84 68.18 1.79 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -112.2 -38.38 4.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 0.0 111.1 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 72.6 m -86.46 -42.71 13.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.152 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 141' ' ' ILE . 5.2 tp -62.87 -36.48 75.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.2 ttpt -55.89 -46.18 78.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -53.83 -41.86 67.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 65.8 mt -61.38 -59.21 4.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.621 ' HG3' HD12 ' A' ' 141' ' ' ILE . 72.4 mt-30 -41.54 -36.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.899 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -80.83 -53.37 6.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -51.19 -34.53 32.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.1 p -105.93 -8.47 17.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 13.5 m170 53.58 54.55 9.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.866 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.1 p -135.39 147.75 49.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -82.66 96.85 8.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.777 HG21 HD11 ' A' ' 130' ' ' ILE . 75.1 mt -89.94 116.16 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.145 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.0 t -102.76 113.99 41.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.156 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.456 HG22 ' CE2' ' A' ' 152' ' ' PHE . 37.9 p -72.57 153.42 91.69 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.521 0.677 . . . . 0.0 111.154 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 177.66 5.31 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.678 2.252 . . . . 0.0 112.375 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -85.01 170.69 45.66 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.502 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ARG . . . . . 0.474 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 4.2 ptm85 -69.53 -48.49 60.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 110.922 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASP . . . . . 0.474 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.7 p30 -99.92 43.42 1.06 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -138.54 168.79 19.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -66.82 144.25 98.47 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.632 0.729 . . . . 0.0 110.926 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.52 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.1 Cg_endo -69.85 100.16 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.311 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.596 HG13 ' O ' ' A' ' 112' ' ' VAL . 90.5 t -147.06 127.92 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' PHE . . . . . 0.456 ' CE2' HG22 ' A' ' 143' ' ' THR . 48.3 m-85 -96.62 125.89 41.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.96 99.58 9.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.074 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.553 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -88.77 133.69 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.621 HG23 ' OG1' ' A' ' 109' ' ' THR . 32.2 m -120.04 128.79 53.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 157.74 178.25 31.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.681 ' O ' HG22 ' A' ' 161' ' ' VAL . 9.0 mmt -41.04 159.2 0.17 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.559 0.695 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.7 8.91 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.678 2.252 . . . . 0.0 112.333 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' GLU . . . . . 0.448 ' C ' ' OE1' ' A' ' 159' ' ' GLU . 0.5 OUTLIER -116.97 -38.06 3.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.965 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ASN . . . . . 0.436 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.9 m-20 -67.35 -45.55 76.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.681 HG22 ' O ' ' A' ' 157' ' ' MET . 30.0 m -68.51 -40.04 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 29.8 t0 -53.19 -40.26 64.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 33.1 ttt-85 -64.68 -59.17 4.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.33 -45.82 6.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.716 ' HE ' HD12 ' A' ' 110' ' ' ILE . 21.1 ttm180 -47.71 -45.15 28.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -53.96 -61.19 2.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 13.4 mm-40 -53.6 -39.12 64.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ILE . . . . . 0.535 HD12 ' HA ' ' A' ' 165' ' ' ARG . 61.2 mt -55.84 -70.55 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.444 ' HB2' HD12 ' A' ' 172' ' ' ILE . 2.3 pt-20 -59.69 -33.21 71.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.899 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -37.25 -57.1 0.91 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.083 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 170' ' ' ALA . 17.6 m80 -37.63 -41.84 0.51 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.837 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.444 HD12 ' HB2' ' A' ' 169' ' ' GLU . 74.2 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.849 0.356 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.3 t -135.43 161.97 33.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.113 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.7 m -136.2 124.97 23.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.098 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.7 pt -114.28 154.3 15.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.3 mm-40 -109.58 106.55 16.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 94.4 t -73.85 137.99 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 16.0 ttm180 -109.54 115.68 30.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.87 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.448 HG13 HG12 ' A' ' 112' ' ' VAL . 4.5 m -135.51 150.8 73.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.653 0.739 . . . . 0.0 111.109 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.4 Cg_endo -69.77 129.14 17.07 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.345 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -39.47 -28.59 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.894 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.6 mmt180 -65.86 -51.43 58.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.848 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.797 HG21 HG12 ' A' ' 172' ' ' ILE . 28.9 t -66.59 -36.7 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.16 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 118' ' ' VAL . 77.4 t -37.32 -69.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.114 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.93 -39.49 8.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 118' ' ' VAL . 14.2 mt -64.67 -41.14 96.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.902 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.532 HG23 HG12 ' A' ' 118' ' ' VAL . 22.0 t -68.89 -64.99 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.098 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 122' ' ' VAL . 89.4 t -37.35 -46.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.41 173.13 32.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.417 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.1 Cg_exo -47.99 112.55 0.6 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.658 2.239 . . . . 0.0 112.341 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.2 ptmt 36.64 41.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.905 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.55 83.29 0.2 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.471 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.38 -41.34 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.864 0.364 . . . . 0.0 111.083 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 39.5 m -84.16 -44.18 14.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.121 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.71 HD11 HG21 ' A' ' 141' ' ' ILE . 5.8 tp -60.02 -40.47 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.424 ' N ' HG23 ' A' ' 130' ' ' ILE . 37.0 tttp -58.28 -41.93 85.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.898 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -56.45 -42.68 78.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.88 -48.23 88.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLN . . . . . 0.561 ' HG3' HD12 ' A' ' 141' ' ' ILE . 78.9 mt-30 -48.56 -36.72 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.929 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 4.3 mm100 -82.48 -54.84 4.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.93 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -49.95 -32.53 15.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -105.6 -13.6 15.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.105 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 28.0 m80 58.84 54.41 5.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' THR . . . . . 0.41 HG21 ' HA ' ' A' ' 161' ' ' VAL . 68.5 p -139.88 143.3 36.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -77.49 100.55 6.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.922 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.71 HG21 HD11 ' A' ' 130' ' ' ILE . 75.9 mt -92.79 119.1 39.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.3 t -109.6 127.52 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.104 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.6 p -85.26 151.61 56.91 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.562 0.696 . . . . 0.0 111.197 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 177.67 5.33 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.689 2.26 . . . . 0.0 112.354 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.7 168.15 49.18 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.44 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.19 -43.91 93.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.814 0.34 . . . . 0.0 110.836 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -103.18 43.6 1.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -132.45 171.61 13.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.21 148.85 91.54 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 110.871 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 87.64 0.56 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.349 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.4 t -143.78 121.13 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.087 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -90.31 153.64 20.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.832 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.7 106.96 11.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.094 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.602 HG12 HG12 ' A' ' 161' ' ' VAL . 50.7 t -97.74 125.28 50.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 75.1 m -112.3 137.38 50.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.49 -173.13 31.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.495 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' MET . . . . . 0.742 ' O ' HG22 ' A' ' 161' ' ' VAL . 8.2 mmt -53.89 159.86 2.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 0.0 110.877 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' PRO . . . . . 0.428 ' HD2' ' SD ' ' A' ' 157' ' ' MET . 54.2 Cg_endo -69.7 -0.55 7.02 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.672 2.248 . . . . 0.0 112.391 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' GLU . . . . . 0.431 ' CD ' ' HB3' ' A' ' 157' ' ' MET . 23.5 pm0 -118.01 -26.25 6.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -82.63 -43.51 16.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 157' ' ' MET . 35.7 m -69.5 -35.14 65.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -56.76 -47.81 79.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.9 ttt-85 -57.31 -55.24 37.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.21 -45.38 5.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -52.43 -45.5 66.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -64.39 -42.53 96.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -58.39 -53.84 53.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 91.0 mt -55.59 -54.79 21.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -56.63 -46.23 81.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' ALA . . . . . 0.441 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.36 -60.29 0.8 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.132 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 170' ' ' ALA . 40.7 m170 -34.95 -38.77 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.872 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.797 HG12 HG21 ' A' ' 118' ' ' VAL . 74.7 mt . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.093 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 13.3 t -117.49 -56.88 2.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.865 0.364 . . . . 0.0 110.845 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.0 m -138.32 151.82 47.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.87 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.53 53.69 0.23 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 10.9 t -154.73 135.74 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.888 0.375 . . . . 0.0 110.901 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.1 t -92.87 105.54 17.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 145.67 116.26 1.01 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -111.33 -75.31 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -57.51 -178.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.889 0.376 . . . . 0.0 110.944 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.5 t -141.73 161.25 38.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 90.4 m -131.28 124.18 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.165 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.5 pt -114.29 153.14 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.125 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 52.6 mm-40 -109.87 106.26 15.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.553 HG22 ' HG3' ' A' ' 165' ' ' ARG . 74.7 t -77.59 135.61 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.114 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 8.9 ttp-105 -104.8 120.89 42.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.862 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.6 m -136.46 150.72 71.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.609 0.718 . . . . 0.0 111.124 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.534 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.7 130.63 19.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.682 2.255 . . . . 0.0 112.363 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -45.04 -22.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.939 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.425 ' HB2' ' NH1' ' A' ' 117' ' ' ARG . 14.7 ttm105 -72.08 -44.23 63.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.918 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.637 HG12 HG23 ' A' ' 122' ' ' VAL . 74.9 t -76.03 -31.68 22.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 122' ' ' VAL . 42.6 t -39.3 -74.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -38.74 -34.33 0.26 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.547 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.421 HD12 ' HA ' ' A' ' 118' ' ' VAL . 13.2 mt -71.67 -44.21 64.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.637 HG23 HG12 ' A' ' 118' ' ' VAL . 86.9 t -66.04 -62.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.119 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.412 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 84.7 t -46.8 -48.27 7.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.85 172.71 49.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.97 91.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 12.2 mmtp 53.13 38.59 27.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 78.32 72.89 1.13 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.535 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.39 -27.25 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.102 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 65.7 m -98.68 -44.77 6.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.606 HD11 HG21 ' A' ' 141' ' ' ILE . 9.3 tp -60.64 -25.19 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.9 tttp -66.51 -32.0 73.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -67.26 -43.58 81.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.582 HD12 HD12 ' A' ' 130' ' ' ILE . 77.3 mt -57.89 -56.88 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.159 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.592 ' HG3' HD12 ' A' ' 141' ' ' ILE . 29.4 mt-30 -45.24 -31.97 1.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -82.07 -55.69 4.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 mmm180 -56.28 -24.42 42.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.422 HG21 ' HA ' ' A' ' 164' ' ' ALA . 80.6 p -109.75 -13.03 14.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 54.3 52.79 11.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.479 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 26.8 p -129.99 170.04 14.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.155 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -102.28 94.91 5.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.606 HG21 HD11 ' A' ' 130' ' ' ILE . 82.3 mt -93.9 125.83 46.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.76 130.12 68.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.6 p -84.11 145.29 45.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.611 0.719 . . . . 0.0 111.094 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -179.78 3.17 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -80.56 -172.11 44.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -92.55 -31.62 15.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.828 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 9.6 t0 -112.1 35.97 3.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -131.3 169.93 15.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -67.82 144.28 97.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.615 0.721 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.25 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.705 2.27 . . . . 0.0 112.319 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.2 t -148.26 113.83 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.412 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 55.9 m-85 -84.06 141.46 31.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.93 121.53 45.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.6 122.47 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 43.0 m -112.9 122.93 49.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.563 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 169.54 -173.09 43.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.623 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.1 mmt -52.39 159.24 1.66 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.602 0.715 . . . . 0.0 110.857 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -0.86 7.54 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.658 2.239 . . . . 0.0 112.302 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -115.7 -26.03 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.479 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.3 m-20 -85.11 -54.63 4.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 157' ' ' MET . 24.9 m -53.68 -32.54 21.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -79.14 -23.5 43.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -76.27 -37.51 57.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ALA . . . . . 0.422 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -70.76 -38.5 73.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.092 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.553 ' HG3' HG22 ' A' ' 112' ' ' VAL . 57.5 ttt180 -54.43 -44.21 72.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.93 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -55.58 -49.28 73.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 17.8 mm-40 -59.93 -45.98 90.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.929 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 94.9 mt -53.18 -58.96 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.126 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -62.4 -32.69 73.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -51.45 -42.31 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -56.28 -33.5 65.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.566 HG12 HG21 ' A' ' 118' ' ' VAL . 81.6 mt -47.97 -38.16 7.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 26.1 m -88.76 -39.39 13.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.784 HD13 ' N ' ' A' ' 175' ' ' ARG . 0.9 OUTLIER -55.35 130.63 43.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.896 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.784 ' N ' HD13 ' A' ' 174' ' ' LEU . 4.3 ptp180 -77.36 118.0 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.2 t -132.42 85.22 2.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 135.87 172.27 12.6 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.501 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 161.64 45.13 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.705 2.27 . . . . 0.0 112.355 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 65.8 p -108.69 -43.45 4.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.1 t -51.36 117.38 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.854 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.452 -179.94 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 22.8 t 65.76 41.7 3.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.791 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.3 t -86.61 -43.58 12.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.867 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 75.36 167.02 20.6 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.522 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 84.1 p -102.18 45.04 0.98 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.876 0.37 . . . . 0.0 110.877 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 67.0 p -82.03 167.91 18.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.88 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -71.54 -42.06 56.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.508 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 148.73 -89.75 0.14 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.459 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.418 ' OE1' HG22 ' A' ' 155' ' ' THR . 25.2 pt20 -62.62 177.44 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.922 0.392 . . . . 0.0 110.924 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.7 t -137.56 164.68 28.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.512 ' OG1' HG23 ' A' ' 155' ' ' THR . 99.2 m -138.14 115.29 10.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.075 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 42.4 pt -107.89 151.88 9.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.434 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 2.1 mp0 -110.98 106.72 15.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 151' ' ' VAL . 86.9 t -73.7 141.39 16.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 42.5 ttp85 -108.67 110.13 21.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.469 HG13 HG12 ' A' ' 112' ' ' VAL . 2.5 m -132.59 148.85 71.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.675 0.75 . . . . 0.0 111.112 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.481 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.74 145.84 58.49 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.532 ' HA ' HG23 ' A' ' 119' ' ' VAL . 19.3 t80 -53.93 -41.54 67.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -54.85 -29.46 55.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.481 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 15.8 t -85.6 -34.82 8.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HA ' ' A' ' 116' ' ' TYR . 77.8 t -37.32 -66.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.52 -33.28 4.41 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.1 mt -70.61 -57.02 5.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.844 0.354 . . . . 0.0 110.889 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.43 HG23 HG12 ' A' ' 118' ' ' VAL . 62.9 t -56.37 -55.98 16.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.12 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.4 t -47.14 -55.57 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.36 167.85 43.91 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_exo -47.96 93.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.648 2.232 . . . . 0.0 112.356 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.3 tmtt? 60.89 46.43 8.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 59.59 61.59 7.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.493 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.47 -41.56 5.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.843 0.354 . . . . 0.0 111.122 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.2 m -78.91 -46.42 18.5 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.618 HD11 HG21 ' A' ' 141' ' ' ILE . 10.7 tp -51.57 -34.39 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.088 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.7 tttt -66.55 -40.58 89.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 25.9 ttp180 -62.3 -22.24 65.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.96 -41.43 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.488 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.4 mt-30 -67.95 -30.64 69.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' A' ' 136' ' ' ARG . 10.1 pt20 -80.7 -48.63 12.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.938 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.502 ' N ' ' CG ' ' A' ' 135' ' ' GLN . 60.0 mtt180 -59.03 -35.25 72.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 49.9 p -100.11 -13.28 19.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.136 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 19.8 m80 58.93 54.22 5.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.47 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 34.2 p -132.19 -176.79 4.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.091 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -116.74 97.4 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.953 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.707 HG12 HG22 ' A' ' 154' ' ' VAL . 74.4 mt -94.61 133.12 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -115.11 134.94 56.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.6 p -88.1 146.98 39.5 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.591 0.71 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -178.27 2.28 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -87.38 169.55 39.7 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 8.6 ptt85 -70.63 -40.54 73.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.837 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -105.54 42.24 1.26 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.846 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 26.5 mmtp -136.08 168.22 19.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.37 144.06 98.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.659 0.742 . . . . 0.0 110.901 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 82.78 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.693 2.262 . . . . 0.0 112.359 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 112' ' ' VAL . 76.2 t -133.29 129.62 56.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -96.53 139.95 31.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -112.78 110.01 19.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.116 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.707 HG22 HG12 ' A' ' 141' ' ' ILE . 96.3 t -101.33 133.22 45.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.512 HG23 ' OG1' ' A' ' 109' ' ' THR . 19.9 m -119.46 135.42 54.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.422 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 153.64 -177.1 31.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.529 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.542 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.1 mmt -49.27 158.36 0.75 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.549 0.69 . . . . 0.0 110.918 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 0.49 5.55 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -117.76 -29.79 5.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.47 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.1 m-20 -79.18 -47.93 15.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.542 HG22 ' O ' ' A' ' 157' ' ' MET . 15.7 m -66.15 -26.64 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -66.99 -40.39 87.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 7.5 ttt85 -66.88 -56.51 9.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -46.7 -46.27 20.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.055 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.3 ttt180 -49.7 -39.96 38.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 36.6 mt-10 -60.67 -52.1 66.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -58.56 -33.55 70.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 67.7 mt -63.24 -66.43 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.4 -32.54 74.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -39.72 -54.98 2.0 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.115 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -39.89 -40.56 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.444 HG12 HG21 ' A' ' 118' ' ' VAL . 71.1 mt -43.59 -50.63 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 62.4 p -61.53 -50.98 70.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 3.7 mp -52.07 175.33 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -164.88 120.87 1.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 4.6 t -123.15 166.97 14.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.857 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -51.99 146.06 14.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.508 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 154.66 67.7 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.664 2.243 . . . . 0.0 112.396 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 4.9 m -167.24 137.2 2.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.871 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.3 m -144.07 120.35 10.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.461 -179.916 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.9 m -90.39 97.5 11.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.907 0.385 . . . . 0.0 110.837 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.3 m -116.0 155.06 28.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.44 116.38 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.463 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 17.9 p -126.76 -36.0 2.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.833 0.349 . . . . 0.0 110.812 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' GLY . 17.7 t -78.27 155.2 30.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.816 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 104' ' ' SER . . . -34.6 -47.62 0.63 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 178.27 -58.15 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -97.59 160.84 14.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.939 0.399 . . . . 0.0 110.869 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.0 t -128.66 158.61 38.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.5 m -130.12 113.69 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.177 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.3 pt -103.48 154.85 5.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.106 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.462 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 2.3 mp0 -112.54 107.98 16.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.818 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.7 t -77.79 141.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -110.2 117.39 33.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.842 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 168' ' ' ILE . 12.2 m -137.6 151.11 70.25 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.629 0.728 . . . . 0.0 111.112 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.503 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.78 126.7 13.6 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.659 2.24 . . . . 0.0 112.351 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -36.4 -35.53 0.08 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.942 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.8 tpp85 -59.74 -46.88 87.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.503 HG23 ' HG2' ' A' ' 115' ' ' PRO . 48.8 t -72.41 -31.14 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.57 ' O ' HG23 ' A' ' 123' ' ' VAL . 53.1 t -45.59 -59.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -52.73 -41.54 57.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.479 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -61.89 -48.89 78.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.83 0.348 . . . . 0.0 110.882 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 84.1 t -64.04 -52.65 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 119' ' ' VAL . 93.8 t -49.15 -56.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.166 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 88.49 172.73 46.89 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.93 100.66 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.722 2.281 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? 50.89 43.25 28.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.901 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.35 80.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.526 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.69 -31.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 40.5 m -89.91 -39.47 13.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.965 HD11 HG21 ' A' ' 141' ' ' ILE . 5.0 tp -65.07 -29.34 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.179 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.521 ' HD2' HG23 ' A' ' 130' ' ' ILE . 2.0 mptm? -67.76 -42.21 82.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.937 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 70.3 mtp180 -56.16 -43.79 78.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.841 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 57.2 mt -57.44 -44.84 85.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.447 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.8 mt-30 -51.71 -38.18 54.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.935 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -79.2 -51.11 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -55.68 -30.72 61.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.9 p -106.63 -10.88 16.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 56.13 51.51 11.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.2 p -137.34 143.08 41.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -78.33 95.54 5.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.965 HG21 HD11 ' A' ' 130' ' ' ILE . 78.8 mt -88.34 110.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 98.4 t -95.85 120.84 45.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.094 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 82.4 p -77.79 147.3 74.07 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.569 0.699 . . . . 0.0 111.134 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 171.95 13.5 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.685 2.256 . . . . 0.0 112.386 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.67 177.87 54.05 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 7.5 ptp85 -77.69 -33.59 53.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.788 0.327 . . . . 0.0 110.864 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -110.5 41.58 1.74 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.825 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.7 mmmt -137.84 159.33 42.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -57.21 145.25 67.22 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.657 0.742 . . . . 0.0 110.87 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.409 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.5 Cg_endo -69.8 96.78 0.61 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.67 2.247 . . . . 0.0 112.319 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 112' ' ' VAL . 94.8 t -145.52 132.65 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.0 m-85 -102.36 117.13 34.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.99 109.4 20.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.429 HG22 HG12 ' A' ' 141' ' ' ILE . 56.8 t -100.14 122.61 52.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 49.9 m -108.19 131.71 54.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.146 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.415 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.18 177.63 30.48 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.498 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.501 ' O ' HG22 ' A' ' 161' ' ' VAL . 10.5 mmt -42.51 159.41 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.553 0.692 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 0.83 5.06 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.702 2.268 . . . . 0.0 112.37 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -118.42 -37.33 3.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.425 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.4 m-20 -69.3 -45.67 69.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -67.83 -37.12 77.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.82 -42.44 84.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -64.16 -48.37 76.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.97 -47.93 43.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.531 ' HG3' HG22 ' A' ' 112' ' ' VAL . 33.2 ttt180 -51.05 -43.76 60.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -53.28 -44.74 68.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -68.15 -56.3 9.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.461 HG22 HG11 ' A' ' 114' ' ' VAL . 73.2 mt -47.7 -45.68 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -70.29 -45.04 67.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.44 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.32 -57.24 2.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.113 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.44 ' C ' ' O ' ' A' ' 170' ' ' ALA . 47.5 m80 -35.38 -34.62 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.478 HG12 HG21 ' A' ' 118' ' ' VAL . 58.5 mt -54.84 -49.06 72.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.522 ' O ' HG23 ' A' ' 173' ' ' THR . 14.5 t -94.83 44.18 1.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.12 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 64.2 tp -110.17 148.27 32.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 176' ' ' SER . 6.2 ptm180 -108.0 54.42 0.66 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 175' ' ' ARG . 6.2 t 34.41 42.66 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -77.65 178.21 52.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.499 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 123.34 10.0 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 43.8 t -69.62 131.48 44.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 5.6 t -44.4 155.46 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.467 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.7 p -71.79 81.04 0.87 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.873 0.368 . . . . 0.0 110.82 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.9 t -148.84 155.8 41.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.889 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -175.8 60.14 0.11 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.479 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 58.6 m -45.35 100.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.941 0.401 . . . . 0.0 110.876 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 21.0 m -39.13 -47.95 1.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.871 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -114.62 91.15 0.56 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.464 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -136.14 31.83 2.57 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.549 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 -116.74 176.99 4.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.857 0.361 . . . . 0.0 110.918 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.4 t -139.92 163.53 32.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.14 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -129.28 125.69 37.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.161 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.5 pt -112.18 164.51 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 50.3 mm-40 -121.71 97.93 5.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG13 ' A' ' 151' ' ' VAL . 95.3 t -68.78 142.74 15.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.125 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.3 ttt85 -112.55 121.56 45.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.2 m -141.98 151.07 58.27 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.616 0.722 . . . . 0.0 111.147 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.3 Cg_endo -69.8 125.54 12.24 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.671 2.247 . . . . 0.0 112.344 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.437 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.7 t80 -35.26 -33.21 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.876 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 115' ' ' PRO . 87.3 mtt-85 -61.68 -49.94 74.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.867 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.3 t -68.72 -35.03 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 56.1 t -39.06 -62.76 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -54.43 -38.92 63.83 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.467 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.7 mt -63.34 -43.54 97.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.558 HG23 HG12 ' A' ' 118' ' ' VAL . 89.4 t -68.48 -61.95 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 88.8 t -40.78 -49.04 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.119 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 78.45 172.86 41.37 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -47.95 97.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.653 2.235 . . . . 0.0 112.409 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 47.83 50.47 15.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.913 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.79 74.33 0.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -121.78 -45.15 2.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 67.2 m -82.21 -44.73 15.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.619 HD11 HG21 ' A' ' 141' ' ' ILE . 6.4 tp -57.43 -38.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.5 mttp -53.58 -39.87 65.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.416 ' HD2' ' N ' ' A' ' 132' ' ' ARG . 1.0 OUTLIER -57.75 -36.07 71.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.58 HD12 HD12 ' A' ' 130' ' ' ILE . 46.8 mt -69.94 -46.9 71.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.61 ' HG3' HD12 ' A' ' 141' ' ' ILE . 42.4 mt-30 -55.15 -39.83 69.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -78.28 -45.5 22.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -58.07 -37.59 74.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.84 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 81.8 p -101.23 -11.45 19.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 59.89 48.31 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 62.7 p -127.36 162.95 25.09 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -96.79 94.78 7.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.936 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.619 HG21 HD11 ' A' ' 130' ' ' ILE . 79.2 mt -90.43 122.3 41.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.106 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 68.9 t -113.81 129.46 69.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.119 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.6 p -77.47 147.75 75.92 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.576 0.703 . . . . 0.0 111.183 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 177.81 5.22 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.43 165.22 51.49 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -68.2 -45.95 71.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 0.0 110.879 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -101.7 42.75 1.11 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -136.07 173.43 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -67.2 143.94 97.92 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 89.12 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.368 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 112' ' ' VAL . 77.9 t -134.7 134.49 54.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.089 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -104.05 122.72 45.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -92.82 123.95 36.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.122 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.421 HG22 HG12 ' A' ' 141' ' ' ILE . 46.5 t -118.71 119.09 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.086 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.3 m -107.35 138.1 44.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.144 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.448 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.88 -169.96 31.28 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.436 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.768 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.0 mmt -52.53 159.47 1.66 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.561 0.696 . . . . 0.0 110.876 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 0.56 5.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.656 2.237 . . . . 0.0 112.35 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.38 -47.17 2.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.43 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 28.8 m-20 -65.42 -44.9 85.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 157' ' ' MET . 18.7 m -63.79 -37.87 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.154 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -73.53 -31.65 63.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 46.4 mtp180 -69.57 -36.9 76.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -64.32 -37.41 87.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.08 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -53.68 -58.66 6.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.812 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' GLU . . . . . 0.453 ' HG3' ' N ' ' A' ' 167' ' ' GLU . 1.0 OUTLIER -48.74 -35.44 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.926 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.453 ' N ' ' HG3' ' A' ' 166' ' ' GLU . 5.4 mm-40 -69.47 -46.76 65.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 93.9 mt -63.32 -49.36 83.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.165 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -60.61 -41.7 95.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.5 -53.07 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 80.0 m80 -40.17 -41.06 1.22 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 68.7 mt -44.2 -50.42 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.109 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 78.3 p -93.95 42.1 1.09 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.569 ' C ' HD23 ' A' ' 174' ' ' LEU . 7.0 tt -95.03 -54.13 3.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 10.4 ptm180 -113.82 164.29 13.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.852 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 48.3 t -71.72 -62.52 1.39 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -174.57 -157.39 15.92 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.517 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 179' ' ' SER . 54.0 Cg_endo -69.76 2.7 3.29 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.353 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 178' ' ' PRO . 34.6 t -34.58 119.34 0.44 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.846 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.4 p -69.55 -21.8 63.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 179.977 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.532 -0.227 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 68.5 m -134.01 113.23 11.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.854 -179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 30.8 p -56.17 -25.72 47.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -120.41 167.41 13.75 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.496 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 26.7 m -59.63 133.33 55.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.89 0.376 . . . . 0.0 110.888 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.6 t -68.35 176.94 2.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.889 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -86.59 -179.15 49.3 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.453 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -94.06 -97.66 1.58 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.418 ' HB3' ' HE2' ' A' ' 157' ' ' MET . 7.3 pt20 -110.83 168.81 9.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.9 t -125.38 162.5 24.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.135 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.5 m -135.49 122.29 21.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.098 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.7 pt -111.81 156.12 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.17 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 47.7 mm-40 -111.74 98.83 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.9 t -66.04 141.42 18.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.137 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.4 ttp180 -112.33 113.24 25.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.464 HG13 HG12 ' A' ' 112' ' ' VAL . 3.8 m -132.8 151.07 77.41 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.459 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 126.72 13.64 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.352 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.411 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -36.44 -33.4 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 115' ' ' PRO . 84.8 mtt180 -62.22 -52.54 63.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.831 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.597 HG21 HG12 ' A' ' 172' ' ' ILE . 54.6 t -67.6 -34.15 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.098 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.1 t -40.17 -66.62 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.098 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.86 -36.5 26.7 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.475 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.5 mt -66.34 -41.84 89.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.883 0.373 . . . . 0.0 110.955 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.589 HG11 HG23 ' A' ' 168' ' ' ILE . 87.4 t -71.81 -54.6 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.107 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.424 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 92.5 t -50.95 -49.14 28.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.18 172.67 46.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.477 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -47.96 105.47 0.09 OUTLIER 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.712 2.274 . . . . 0.0 112.313 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 9.0 tppt? 45.5 44.5 9.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 64.11 76.07 0.32 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.484 ' O ' ' CZ ' ' A' ' 132' ' ' ARG . . . -124.21 -26.82 3.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 111.119 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 96.2 m -93.77 -35.91 12.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.145 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.795 HD11 HG21 ' A' ' 141' ' ' ILE . 5.1 tp -72.76 -29.94 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.155 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 132' ' ' ARG . 8.3 ptmt -58.94 -36.95 75.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.484 ' CZ ' ' O ' ' A' ' 128' ' ' ALA . 0.7 OUTLIER -67.04 -52.69 39.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.858 179.996 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.6 mt -46.4 -50.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.451 ' CG ' HD12 ' A' ' 141' ' ' ILE . 60.9 mt-30 -46.2 -35.39 5.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -81.31 -51.43 8.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -52.07 -35.3 47.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.875 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.4 p -104.1 -11.18 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.152 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 67.5 m80 55.99 54.66 7.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.872 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.478 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 82.5 p -137.38 147.37 45.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.169 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -80.5 97.38 7.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.795 HG21 HD11 ' A' ' 130' ' ' ILE . 85.5 mt -90.84 118.52 36.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.426 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 93.3 t -106.48 123.46 61.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.175 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.4 p -81.84 148.95 62.5 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.585 0.707 . . . . 0.0 111.124 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 172.57 12.39 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.06 157.93 34.19 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ARG . . . . . 0.446 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 6.0 ptp180 -55.09 -42.3 72.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.9 p-10 -102.02 43.81 1.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -135.7 168.11 19.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -69.56 149.45 96.99 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.688 0.756 . . . . 0.0 110.832 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.4 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.8 Cg_endo -69.8 91.38 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 112' ' ' VAL . 96.9 t -145.67 130.42 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.168 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.424 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 57.3 m-85 -99.46 136.45 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.911 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -107.55 106.47 16.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.08 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.5 t -100.44 117.77 46.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 85.1 m -106.55 136.18 46.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.16 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.445 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 152.79 175.88 24.76 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.45 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.596 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.4 mmt -41.68 159.56 0.18 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.52 0.676 . . . . 0.0 110.912 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 0.81 5.11 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.663 2.242 . . . . 0.0 112.374 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.11 -35.1 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.905 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.478 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.3 m-20 -72.03 -46.95 55.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 157' ' ' MET . 27.9 m -64.09 -37.59 80.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -55.44 -45.09 76.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.845 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -57.27 -54.57 45.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.74 -51.96 8.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.512 ' HG3' HG22 ' A' ' 112' ' ' VAL . 68.8 ttp85 -45.28 -45.17 11.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -61.49 -42.47 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -61.92 -57.32 12.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.589 HG23 HG11 ' A' ' 122' ' ' VAL . 78.3 mt -52.46 -49.56 42.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -63.54 -43.76 96.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.866 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.58 -57.5 2.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' A' ' 170' ' ' ALA . 77.4 m-70 -37.13 -38.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.597 HG12 HG21 ' A' ' 118' ' ' VAL . 51.1 mt -49.31 -53.33 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.103 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 174' ' ' LEU . 91.8 m -81.92 -43.13 18.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.185 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.657 HD23 ' HB2' ' A' ' 175' ' ' ARG . 8.6 tt -35.92 -48.61 0.58 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.657 ' HB2' HD23 ' A' ' 174' ' ' LEU . 13.3 ttt85 -151.82 108.1 3.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 24.3 m -65.95 176.65 1.57 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -65.84 -97.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.502 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 111.28 2.77 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 64.2 m -54.48 -60.34 3.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 2.6 m -117.94 121.56 41.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.478 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 87.0 p -165.87 125.94 1.74 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 110.83 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.3 t -164.98 136.86 4.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.861 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -122.36 62.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.493 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 50.8 m -39.14 -58.12 1.2 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.963 0.411 . . . . 0.0 110.866 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.8 t -74.16 133.64 42.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.843 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -112.59 -128.84 5.07 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.53 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.72 109.24 0.84 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.508 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -69.81 172.51 7.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.889 0.376 . . . . 0.0 110.91 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.419 ' OG1' ' N ' ' A' ' 109' ' ' THR . 1.6 t -135.34 174.58 10.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.18 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.419 ' N ' ' OG1' ' A' ' 108' ' ' THR . 56.7 m -148.16 127.26 12.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.15 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.428 ' CD1' ' HE ' ' A' ' 165' ' ' ARG . 21.2 pt -118.35 155.12 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.494 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 1.7 mp0 -108.53 97.14 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.448 HG22 ' HG3' ' A' ' 165' ' ' ARG . 82.7 t -68.14 137.89 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.183 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 24.9 ttt180 -103.44 116.5 32.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.55 147.4 61.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.602 0.715 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.54 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.4 Cg_endo -69.7 126.94 13.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.663 2.242 . . . . 0.0 112.344 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.412 ' C ' ' O ' ' A' ' 115' ' ' PRO . 32.4 t80 -36.59 -31.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' PRO . 15.2 ttm180 -64.66 -51.6 61.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.54 HG23 ' HG2' ' A' ' 115' ' ' PRO . 42.3 t -64.89 -31.65 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.118 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.8 t -41.63 -70.68 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.11 -28.48 1.33 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.6 mt -75.11 -48.95 21.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 0.0 110.936 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.53 HG23 HG12 ' A' ' 118' ' ' VAL . 40.1 t -59.83 -60.13 2.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.104 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.1 t -46.06 -63.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.107 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 89.04 172.46 46.16 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_exo -48.04 99.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.7 2.267 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 30.5 tttm 49.75 49.69 19.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.06 73.66 0.46 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.18 -38.76 2.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 111.12 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 80.1 m -83.64 -44.98 13.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.164 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 133' ' ' ILE . 10.0 tp -57.84 -26.92 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.3 tttt -63.79 -45.78 88.13 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -36.19 56.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.928 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 130' ' ' ILE . 48.6 mt -66.57 -58.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.131 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.62 ' CG ' HD12 ' A' ' 141' ' ' ILE . 53.8 mt-30 -52.1 -36.05 49.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 56.3 mm-40 -78.74 -34.68 45.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -67.26 -38.5 85.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.835 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 53.1 p -107.18 -0.4 22.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.138 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 37.1 m170 52.71 52.59 13.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 16.5 p -123.08 179.98 4.48 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.115 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -117.11 98.18 6.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.636 HG21 HD11 ' A' ' 130' ' ' ILE . 79.5 mt -90.62 127.1 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 75.3 t -112.07 121.05 63.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.0 p -74.78 145.96 82.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.585 0.707 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 179.98 3.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.632 2.221 . . . . 0.0 112.297 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.42 165.04 51.37 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.5 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -70.04 -45.04 68.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 0.0 110.868 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 49.6 m-20 -103.22 41.74 1.23 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -133.01 174.45 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -68.28 144.3 96.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.598 0.713 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 100.97 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 112' ' ' VAL . 91.4 t -149.88 130.55 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -100.68 132.61 45.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.45 111.59 24.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.124 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 41.5 t -99.91 117.96 45.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.108 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 96.2 m -109.53 131.97 54.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 158.44 -177.81 34.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.473 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 20.4 mmt -49.59 158.31 0.84 Allowed Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.557 0.694 . . . . 0.0 110.901 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.41 ' HA ' HG21 ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.75 -1.96 9.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -115.6 -23.36 8.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.412 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 16.6 m-20 -84.82 -54.76 4.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.5 m -58.26 -27.0 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.149 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -70.38 -39.13 74.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.875 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.45 -50.42 45.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -52.5 -42.99 64.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.448 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.5 ttm180 -47.14 -53.17 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -50.85 -43.88 59.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.72 -51.37 69.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 50.2 mt -55.26 -44.09 73.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.163 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -68.18 -44.46 75.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.719 ' C ' HD12 ' A' ' 174' ' ' LEU . . . -42.68 -51.28 5.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.086 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -42.01 -38.66 1.69 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.516 HG12 HG21 ' A' ' 118' ' ' VAL . 57.1 mt -52.5 -61.61 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.154 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.9 t -87.34 37.05 0.76 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.719 HD12 ' C ' ' A' ' 170' ' ' ALA . 11.4 mt -131.75 150.99 51.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -67.19 141.51 57.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.8 p -142.35 124.06 15.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.86 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -133.86 86.11 0.27 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.5 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 123.2 9.86 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.716 2.277 . . . . 0.0 112.329 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.9 t -64.13 152.02 41.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 66.7 m -58.56 133.33 55.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.507 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 63.2 p -79.52 158.76 27.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.87 0.367 . . . . 0.0 110.847 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.6 m -80.18 103.37 10.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.846 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -97.21 -97.61 1.93 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 54.9 m -118.58 131.57 56.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.874 0.368 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 87.8 p -84.26 -47.99 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.828 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -99.84 175.6 27.74 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.463 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -134.11 -54.17 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.483 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 3.8 pp0? -70.61 175.36 4.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.88 0.372 . . . . 0.0 110.935 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.6 t -134.72 164.47 27.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 89.8 m -131.25 122.46 26.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.179 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.4 pt -114.5 148.9 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.0 mm-40 -109.33 101.35 10.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 165' ' ' ARG . 88.2 t -70.2 143.27 14.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.138 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -114.04 120.93 42.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.851 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.669 HG11 HG22 ' A' ' 168' ' ' ILE . 11.1 m -139.68 150.92 64.84 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.653 0.739 . . . . 0.0 111.117 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.541 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.1 Cg_endo -69.74 125.49 12.22 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.655 2.236 . . . . 0.0 112.344 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.8 t80 -34.52 -35.53 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 115' ' ' PRO . 75.5 mtt-85 -59.56 -49.37 78.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.541 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.7 t -69.61 -35.28 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.107 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.9 t -39.51 -63.37 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.171 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.89 -42.23 37.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.0 mt -60.46 -43.46 96.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.816 0.341 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.418 ' HA ' ' CE1' ' A' ' 171' ' ' HIS . 58.3 t -69.98 -60.37 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.12 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.5 t -37.08 -51.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.42 166.79 42.44 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_exo -48.01 92.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.36 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 53.3 mmtt 58.51 41.63 22.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.918 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.54 66.29 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -111.76 -40.36 4.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.884 0.373 . . . . 0.0 111.115 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.3 m -84.82 -43.94 13.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.994 HD11 HG21 ' A' ' 141' ' ' ILE . 7.0 tp -58.52 -28.18 35.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -71.32 -43.42 67.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 35.0 ttm-85 -60.16 -39.95 88.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.506 HD12 ' HA ' ' A' ' 130' ' ' ILE . 58.0 mt -59.21 -50.1 81.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.128 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -48.77 -36.8 17.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.922 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -80.21 -51.08 9.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.913 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -54.2 -33.64 58.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.9 p -104.2 -14.83 15.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.141 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 9.8 m80 60.26 52.76 4.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.455 HG21 ' HA ' ' A' ' 161' ' ' VAL . 77.7 p -138.81 145.22 39.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -78.42 100.21 6.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.994 HG21 HD11 ' A' ' 130' ' ' ILE . 93.9 mt -96.23 122.08 47.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.083 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.4 t -112.96 132.28 62.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.6 p -85.17 152.53 58.59 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.626 0.727 . . . . 0.0 111.114 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.48 3.68 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.665 2.244 . . . . 0.0 112.364 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.88 169.76 53.41 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -70.1 -47.47 61.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.837 0.351 . . . . 0.0 110.872 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -103.79 40.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 18.3 mmmt -131.66 172.17 12.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -68.77 144.23 95.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.632 0.729 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 99.25 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.695 2.263 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 85.4 t -148.99 118.71 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.95 149.86 24.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.19 109.5 14.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.043 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.631 HG22 HG12 ' A' ' 141' ' ' ILE . 68.4 t -102.4 133.69 45.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.16 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 25.9 m -118.81 135.45 54.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.506 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 150.85 -179.33 27.65 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.433 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.685 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.5 mmt -43.49 159.44 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.534 0.683 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -0.17 6.56 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -119.29 -39.23 2.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -68.63 -40.42 80.33 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.685 HG22 ' O ' ' A' ' 157' ' ' MET . 20.2 m -72.42 -34.86 49.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -59.96 -39.93 87.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 43.6 ttt180 -61.27 -55.68 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.24 -43.08 3.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.092 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.436 ' HG3' HG22 ' A' ' 112' ' ' VAL . 72.1 ttt-85 -56.31 -40.65 74.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -54.57 -45.46 73.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -66.61 -57.16 7.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.917 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.669 HG22 HG11 ' A' ' 114' ' ' VAL . 71.7 mt -49.0 -45.82 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.165 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -71.13 -44.22 66.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.51 -57.97 1.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.129 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 122' ' ' VAL . 13.2 m170 -36.19 -40.18 0.21 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.857 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.414 ' HA ' HG21 ' A' ' 118' ' ' VAL . 50.2 mt -49.28 -58.79 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 27.6 m -66.82 -48.3 69.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.151 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 5.2 mp -66.76 172.81 3.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.93 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HD3' ' C ' ' A' ' 175' ' ' ARG . 0.2 OUTLIER -153.7 135.93 14.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.873 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.6 t 64.79 42.24 4.64 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.852 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 82.52 -170.13 50.0 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 154.13 68.2 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.712 2.274 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 67.3 m -59.22 123.89 18.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.874 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -132.2 128.2 37.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.894 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.474 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.509 -0.237 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 29.4 m -96.7 103.0 14.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.839 0.352 . . . . 0.0 110.842 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.0 p -150.52 126.33 10.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.11 112.9 2.01 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.479 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.2 t -59.34 146.45 39.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 55.0 p -153.49 110.24 3.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.851 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -173.4 -179.05 43.81 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.508 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.91 103.59 1.87 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.442 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -80.73 172.77 13.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -130.63 168.34 17.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.2 m -136.96 118.67 15.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.0 pt -107.3 150.62 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.112 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -109.61 94.16 4.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.466 HG12 HG13 ' A' ' 114' ' ' VAL . 79.4 t -67.16 139.74 20.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -109.25 111.89 23.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.477 HG11 HG22 ' A' ' 168' ' ' ILE . 7.2 m -128.39 150.89 75.56 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.589 0.709 . . . . 0.0 111.136 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.505 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.77 123.56 10.22 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.668 2.245 . . . . 0.0 112.373 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 22.8 t80 -34.84 -32.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.5 ' N ' ' O ' ' A' ' 115' ' ' PRO . 50.5 mtt85 -62.68 -49.13 76.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.542 HG12 HG23 ' A' ' 122' ' ' VAL . 56.0 t -70.35 -31.31 46.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.5 t -43.07 -64.46 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.1 -41.17 22.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.486 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 18.0 mt -63.19 -47.94 80.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.879 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.542 HG23 HG12 ' A' ' 118' ' ' VAL . 61.5 t -62.66 -61.71 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.131 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.6 t -43.16 -50.39 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 80.74 173.01 46.49 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.464 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' LYS . 64.6 Cg_exo -47.92 114.64 1.17 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.674 2.249 . . . . 0.0 112.372 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' PRO . 0.0 OUTLIER 34.13 43.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.886 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.38 84.45 0.12 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -133.52 -34.37 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 58.9 m -89.72 -43.7 10.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.089 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.799 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -68.21 -27.79 38.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.094 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttmt -68.29 -37.46 80.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.8 ttm180 -64.33 -46.82 81.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.854 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.819 HG23 ' OE1' ' A' ' 167' ' ' GLU . 36.6 mt -55.69 -42.8 71.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.13 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.428 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 29.9 mt-30 -57.23 -24.35 54.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.98 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 51.9 mm-40 -89.83 -47.03 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.401 ' NH1' ' OE2' ' A' ' 167' ' ' GLU . 6.3 ptm180 -64.16 -31.54 72.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.485 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 73.9 p -100.23 -12.83 19.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.158 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 27.2 m80 57.21 54.4 6.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 72.5 p -141.76 140.62 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -78.47 97.28 5.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.799 HG21 HD11 ' A' ' 130' ' ' ILE . 96.2 mt -88.78 108.71 19.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.138 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.3 t -91.95 133.65 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.116 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.0 p -91.81 146.13 32.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.558 0.694 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 177.17 5.82 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.733 2.289 . . . . 0.0 112.297 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.87 -178.02 50.11 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.514 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 50.3 ptt85 -83.08 -38.47 22.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.834 0.35 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -110.0 41.81 1.64 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -135.61 164.86 26.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -62.25 142.58 95.84 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.923 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 103.57 1.19 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.655 2.237 . . . . 0.0 112.348 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.3 t -148.28 115.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -86.96 128.44 35.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.915 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -103.36 104.28 14.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -95.9 122.2 47.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.6 m -108.65 137.15 47.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 151.95 -179.76 28.26 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.619 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.6 mmt -47.12 159.34 0.4 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 110.897 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 0.28 5.86 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.718 2.278 . . . . 0.0 112.351 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -118.4 -32.1 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.846 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.475 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.0 m-20 -73.58 -48.49 32.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 154' ' ' VAL . 32.9 m -65.62 -40.13 87.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 25.9 t0 -51.17 -41.88 60.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 15.3 ttm180 -65.24 -47.58 76.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.819 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.94 54.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.09 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.49 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 22.7 ttt85 -55.3 -45.26 76.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.854 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -60.98 -38.18 85.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.819 ' OE1' HG23 ' A' ' 133' ' ' ILE . 12.8 mt-10 -66.94 -50.52 62.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.886 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.477 HG22 HG11 ' A' ' 114' ' ' VAL . 66.6 mt -60.75 -43.41 95.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.49 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 60.3 mt-10 -66.15 -47.46 73.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.411 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -45.35 -55.36 6.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.411 ' C ' ' O ' ' A' ' 170' ' ' ALA . 30.0 m170 -37.23 -41.01 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 56.4 mt -43.72 -52.39 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 98.3 m -99.22 92.18 5.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.169 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 23.5 tp -172.06 134.33 0.74 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.971 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 38.2 ptt85 -97.82 79.2 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 26.1 t -159.47 130.44 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 152.03 146.2 4.3 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.51 5.53 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.689 2.26 . . . . 0.0 112.371 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' SER . . . . . 0.407 ' O ' ' C ' ' A' ' 180' ' ' SER . 18.5 m -45.25 118.34 1.67 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 180' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 179' ' ' SER . 79.7 p -37.77 110.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.482 179.979 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 64.1 m -130.16 151.6 50.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.872 0.368 . . . . 0.0 110.86 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 35.9 m -128.42 151.98 48.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -132.97 135.15 7.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 94.4 p -156.52 127.56 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.853 0.358 . . . . 0.0 110.841 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 92.7 p -106.56 112.92 26.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.838 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 114.78 175.19 18.57 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.525 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.453 ' O ' ' CE ' ' A' ' 157' ' ' MET . . . 117.07 41.64 0.69 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.443 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.414 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 4.8 pp0? -120.15 173.07 7.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.92 0.391 . . . . 0.0 110.904 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.7 t -133.1 165.35 24.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.134 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.1 m -133.54 122.47 23.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -116.11 147.73 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -105.97 106.77 17.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.428 HG12 HG13 ' A' ' 114' ' ' VAL . 97.6 t -71.83 141.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.107 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -111.7 115.91 29.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.882 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.428 HG13 HG12 ' A' ' 112' ' ' VAL . 4.1 m -136.57 150.27 69.82 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.564 0.697 . . . . 0.0 111.158 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.492 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.71 130.22 19.01 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.344 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -40.6 -33.76 0.3 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.423 ' HB3' ' NH1' ' A' ' 117' ' ' ARG . 5.6 mmm180 -61.76 -48.24 81.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.499 HG12 HG23 ' A' ' 122' ' ' VAL . 54.5 t -71.7 -32.67 46.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.401 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.9 t -40.73 -65.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.81 -40.42 26.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.89 -40.65 98.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 0.0 110.926 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.575 HG11 HG23 ' A' ' 168' ' ' ILE . 59.1 t -69.01 -63.5 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 95.5 t -38.43 -50.85 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.15 169.19 42.95 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -47.98 105.74 0.09 OUTLIER 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.697 2.265 . . . . 0.0 112.32 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt 45.22 39.29 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.921 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.76 86.51 0.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.479 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -134.87 -39.07 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.808 0.337 . . . . 0.0 111.047 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.0 m -86.65 -43.8 12.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.175 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.597 HG23 ' HD2' ' A' ' 131' ' ' LYS . 4.9 tp -60.95 -41.27 88.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.597 ' HD2' HG23 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -55.56 -38.39 69.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.835 179.855 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -58.62 -45.91 88.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.405 HD12 HD12 ' A' ' 130' ' ' ILE . 64.2 mt -55.26 -43.41 70.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.132 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.462 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 68.1 mt-30 -56.51 -37.18 70.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 7.3 mm100 -78.67 -54.24 6.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 23.0 mmm-85 -51.17 -34.83 33.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 70.0 p -102.52 -12.76 17.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 36.0 m80 57.22 52.94 8.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.435 HG21 ' HA ' ' A' ' 161' ' ' VAL . 63.8 p -136.11 159.19 42.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -89.34 98.88 12.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.556 HG12 HG22 ' A' ' 154' ' ' VAL . 71.1 mt -97.31 112.93 30.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.185 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 70.7 t -102.6 135.57 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.8 p -85.03 149.62 53.48 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.564 0.697 . . . . 0.0 111.146 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 177.58 5.44 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.2 161.84 49.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptp85 -66.48 -44.06 83.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -103.57 39.67 1.56 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.864 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -133.92 166.57 22.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -61.49 145.76 90.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.669 0.747 . . . . 0.0 110.904 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HB3' HG21 ' A' ' 119' ' ' VAL . 54.7 Cg_endo -69.7 98.16 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.653 2.235 . . . . 0.0 112.39 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 87.0 t -149.53 125.33 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.59 150.1 20.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.14 113.19 21.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.556 HG22 HG12 ' A' ' 141' ' ' ILE . 96.9 t -104.93 123.12 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.4 m -112.23 139.24 47.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.115 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.425 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 147.49 -173.79 27.48 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.73 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.2 mmt -48.56 159.32 0.54 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.502 0.668 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -1.06 7.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.657 2.238 . . . . 0.0 112.337 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -115.67 -49.79 2.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -59.47 -41.64 90.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -72.3 -34.33 48.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -58.34 -42.32 86.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -65.99 -36.78 84.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.892 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ALA . . . . . 0.433 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -60.02 -31.52 70.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 48.3 ttt180 -71.64 -52.4 18.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.85 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -62.54 -30.57 71.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -70.98 -54.34 11.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.575 HG23 HG11 ' A' ' 122' ' ' VAL . 72.1 mt -58.61 -46.69 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -65.0 -37.52 87.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.582 ' O ' HG22 ' A' ' 173' ' ' THR . . . -44.61 -53.79 6.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -41.8 -32.99 0.45 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.425 HG12 HG21 ' A' ' 118' ' ' VAL . 83.5 mt -50.81 -51.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.111 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.582 HG22 ' O ' ' A' ' 170' ' ' ALA . 6.1 t -77.61 -21.86 51.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.438 ' C ' HD23 ' A' ' 174' ' ' LEU . 6.8 tt -62.19 144.45 55.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 9.4 mtp-105 -138.24 114.24 10.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 6.4 t -101.54 -60.29 1.55 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -161.72 151.9 22.18 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 161.03 47.5 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.647 2.231 . . . . 0.0 112.353 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.7 t -132.48 -61.4 0.86 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 54.1 m -56.67 129.87 42.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.5 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 36.4 t -103.8 158.71 16.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.938 0.399 . . . . 0.0 110.809 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.6 p -111.7 174.24 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.847 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -139.61 -103.94 0.58 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.524 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.7 t -104.9 100.26 9.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.856 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 76.8 p -89.36 -44.89 9.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.813 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 144.63 178.02 19.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.469 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -84.96 -113.2 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.508 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? -77.54 175.59 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.888 0.375 . . . . 0.0 110.934 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.8 t -133.42 170.44 15.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.19 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.4 m -141.98 129.01 20.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.43 ' CD1' ' HE ' ' A' ' 165' ' ' ARG . 20.4 pt -122.04 158.91 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.454 ' N ' ' CD ' ' A' ' 111' ' ' GLN . 2.0 mp0 -113.81 106.37 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.96 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.801 ' O ' HG13 ' A' ' 151' ' ' VAL . 93.9 t -75.61 142.28 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -110.37 120.31 42.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -142.49 150.71 55.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.615 0.721 . . . . 0.0 111.154 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.539 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.77 125.26 11.93 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.323 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.473 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 27.1 t80 -35.85 -34.65 0.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.959 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.428 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.0 ttp180 -59.74 -49.91 75.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.539 HG23 ' HG2' ' A' ' 115' ' ' PRO . 56.1 t -69.56 -34.27 60.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 98.9 t -40.15 -66.97 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.147 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.64 -41.14 18.47 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.513 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.505 HD12 ' HA ' ' A' ' 118' ' ' VAL . 19.2 mt -62.22 -43.32 99.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.491 HG23 HG12 ' A' ' 118' ' ' VAL . 97.5 t -68.03 -62.12 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.075 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.521 ' O ' HG22 ' A' ' 130' ' ' ILE . 97.5 t -40.04 -54.03 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.177 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 87.64 167.57 43.67 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_exo -47.93 94.8 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.717 2.278 . . . . 0.0 112.338 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 29.6 mtpt 55.07 42.17 31.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.905 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.32 79.01 0.31 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.478 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -128.47 -38.78 1.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.867 0.365 . . . . 0.0 111.104 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.2 m -87.08 -40.26 14.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.087 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.521 HG22 ' O ' ' A' ' 123' ' ' VAL . 5.0 tp -64.7 -33.33 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.141 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 18.2 tttp -59.49 -42.34 91.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -54.96 -47.79 74.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.812 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.541 HG23 ' OE1' ' A' ' 167' ' ' GLU . 54.3 mt -54.8 -48.81 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.418 ' CG ' HD12 ' A' ' 141' ' ' ILE . 61.1 mt-30 -48.25 -38.59 18.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 86.7 mm-40 -81.12 -52.56 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -51.37 -32.64 26.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.4 p -106.53 -13.56 15.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.141 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 41.2 m80 60.0 53.43 4.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.481 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 55.2 p -135.49 139.79 44.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.121 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -77.75 90.47 4.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.979 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -83.29 142.14 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.163 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 86.6 t -131.01 121.23 49.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.119 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 78.6 p -73.0 150.01 90.05 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.562 0.696 . . . . 0.0 111.152 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 176.91 6.17 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.252 . . . . 0.0 112.363 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -77.08 150.46 37.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -57.17 -36.42 70.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -110.34 40.35 1.98 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 49.2 mmtt -134.72 165.77 24.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.42 144.54 62.35 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 94.01 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.658 2.239 . . . . 0.0 112.396 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.801 HG13 ' O ' ' A' ' 112' ' ' VAL . 89.3 t -145.72 135.55 18.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.089 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -102.51 128.43 49.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -100.21 109.86 22.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 161' ' ' VAL . 67.3 t -100.77 130.17 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 21.7 m -117.91 135.1 54.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.135 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 153.87 179.72 29.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.504 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.471 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.9 mmt -46.57 159.28 0.36 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.53 0.681 . . . . 0.0 110.905 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 0.85 5.06 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.673 2.249 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -118.47 -29.13 5.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.914 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.481 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 8.4 m-20 -78.22 -46.47 20.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.838 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.471 HG22 ' O ' ' A' ' 157' ' ' MET . 16.0 m -68.32 -23.56 28.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -66.72 -39.12 87.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 24.2 ttm-85 -70.15 -46.87 63.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.37 -34.62 58.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.118 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.43 ' HE ' ' CD1' ' A' ' 110' ' ' ILE . 13.6 ttm180 -64.48 -50.87 65.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -62.9 -24.68 67.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.541 ' OE1' HG23 ' A' ' 133' ' ' ILE . 22.3 mt-10 -77.08 -56.5 4.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 76.2 mt -52.73 -53.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -56.28 -43.37 78.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -41.78 -58.3 2.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.444 ' C ' ' O ' ' A' ' 170' ' ' ALA . 9.8 m80 -34.45 -36.07 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.527 HG12 HG21 ' A' ' 118' ' ' VAL . 64.9 mt -54.1 -61.21 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.147 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.9 t -67.85 -25.11 65.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.123 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 9.7 tp -60.34 147.58 40.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -92.14 156.86 17.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 24.7 p -108.95 -44.99 3.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -79.31 142.71 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -2.26 9.87 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.66 2.24 . . . . 0.0 112.36 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 44.3 m -156.94 163.24 39.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.0 m -153.6 138.99 17.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.479 -179.944 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.4 p -146.35 137.61 24.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.911 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.1 m -100.53 86.51 3.16 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.847 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 60.99 -136.97 48.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.534 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.9 p -111.95 126.91 55.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.832 0.349 . . . . 0.0 110.821 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 57.7 m -119.7 149.62 41.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.841 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -81.24 77.52 2.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.46 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -160.94 80.03 0.15 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -87.25 161.95 17.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.869 0.366 . . . . 0.0 110.913 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -125.61 159.48 32.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.2 m -128.51 116.42 19.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -104.77 155.32 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -114.42 101.0 8.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 91.3 t -69.64 141.97 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 23.6 ttp180 -111.67 112.05 23.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.49 HG11 HG22 ' A' ' 168' ' ' ILE . 2.4 m -134.11 151.4 76.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.614 0.721 . . . . 0.0 111.108 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.542 ' CB ' ' NH1' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.74 138.37 37.72 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.682 2.255 . . . . 0.0 112.322 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.0 t80 -46.96 -37.91 9.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.542 ' NH1' ' CB ' ' A' ' 115' ' ' PRO . 8.6 ptp85 -59.01 -38.62 79.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.491 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 19.8 t -78.0 -36.42 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.171 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 97.1 t -41.37 -63.7 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.07 -39.21 18.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.3 mt -65.15 -43.9 90.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 0.0 110.921 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 73.4 t -71.57 -60.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.7 t -42.28 -45.54 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 73.92 173.34 27.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.482 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.4 Cg_exo -48.03 114.74 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.7 pttm 36.1 39.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.895 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.44 73.77 0.78 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.61 -38.49 3.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 m -85.5 -44.25 12.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.82 HD11 HG21 ' A' ' 141' ' ' ILE . 6.1 tp -60.82 -31.16 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -68.03 -40.18 82.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -60.85 -44.23 97.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.833 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 73.0 mt -54.58 -54.58 21.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.126 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.539 ' HG3' HD12 ' A' ' 141' ' ' ILE . 76.1 mt-30 -42.81 -30.9 0.43 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -78.27 -53.72 7.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.4 -32.17 56.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 74.1 p -102.22 -17.5 15.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.178 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 134' ' ' GLN . 16.9 m170 59.27 54.94 4.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.821 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.468 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.3 p -135.28 174.51 10.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -106.21 89.94 3.21 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.82 HG21 HD11 ' A' ' 130' ' ' ILE . 84.8 mt -82.89 137.14 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.1 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 91.7 t -124.63 132.14 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.166 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.7 p -90.26 147.86 37.82 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.582 0.706 . . . . 0.0 111.166 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -179.11 2.67 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.315 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.44 176.92 51.5 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.52 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ARG . . . . . 0.419 ' HD3' ' C ' ' A' ' 146' ' ' ARG . 0.2 OUTLIER -80.23 -35.29 36.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -106.87 39.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 38.7 mmtt -138.01 175.43 9.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -71.98 143.41 86.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.592 0.71 . . . . 0.0 110.935 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 89.66 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.644 2.229 . . . . 0.0 112.394 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 75.4 t -138.17 119.64 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.71 148.88 25.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.86 105.62 10.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.08 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 161' ' ' VAL . 96.0 t -100.89 127.03 54.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.128 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -112.79 138.68 49.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 150.4 176.04 23.03 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.618 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -41.03 159.4 0.16 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.582 0.706 . . . . 0.0 110.87 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 0.58 5.4 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.706 2.271 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -118.35 -35.46 3.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.468 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.1 m-20 -69.25 -46.31 67.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.904 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 154' ' ' VAL . 33.7 m -68.88 -38.61 78.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.134 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -52.37 -42.04 63.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 42.0 ttt85 -63.82 -52.56 59.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -45.58 -49.28 14.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.079 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 44.4 ttt180 -51.6 -40.5 59.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -57.61 -47.98 80.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -65.04 -56.69 11.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.937 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.49 HG22 HG11 ' A' ' 114' ' ' VAL . 65.4 mt -47.84 -50.69 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.132 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -65.89 -47.03 76.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.433 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.83 -55.75 1.46 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 170' ' ' ALA . 74.1 m80 -36.02 -43.11 0.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.833 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.419 HG12 HG21 ' A' ' 118' ' ' VAL . 73.6 mt -44.49 -58.24 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.092 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 174' ' ' LEU . 95.5 m -58.82 -52.12 67.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 173' ' ' THR . 9.3 tp -35.78 135.35 0.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.939 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -66.29 151.44 47.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 40.1 m -78.63 147.49 33.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -103.17 -80.98 1.49 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -32.62 18.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 2.244 . . . . 0.0 112.373 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 3.7 t 66.99 51.42 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 9.8 m 56.13 43.77 26.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.826 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.491 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 29.9 p 40.85 42.29 1.42 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.859 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.9 m -56.39 172.76 0.21 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.851 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 164.01 46.31 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 53.4 m -83.2 140.46 32.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.892 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 57.2 p -137.63 128.76 27.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.861 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.83 124.06 5.37 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.495 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.94 -108.89 0.57 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.497 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 -71.54 -176.92 1.69 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.853 0.358 . . . . 0.0 110.914 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -147.71 156.97 43.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.162 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 97.8 m -127.9 122.49 32.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.675 HD12 ' HE ' ' A' ' 165' ' ' ARG . 22.6 pt -111.27 154.84 12.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 20.5 mm100 -109.9 101.76 10.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.735 HG22 ' HG3' ' A' ' 165' ' ' ARG . 54.0 t -69.67 132.98 32.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 14.9 ttp180 -100.39 118.95 37.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.549 HG13 HG12 ' A' ' 112' ' ' VAL . 3.3 m -141.14 150.45 58.85 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.624 0.726 . . . . 0.0 111.085 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 133.18 24.98 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -42.42 -26.89 0.13 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 60.2 ttp85 -69.35 -54.06 16.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.766 HG21 HG12 ' A' ' 172' ' ' ILE . 35.8 t -63.65 -27.29 42.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.1 t -46.5 -71.09 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -43.68 -34.67 2.79 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 8.7 mt -67.39 -44.19 79.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 83.9 t -69.42 -65.58 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.9 t -37.63 -61.5 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.78 166.15 38.64 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.514 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_exo -47.97 93.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt 56.98 54.03 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.939 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 54.93 70.95 0.8 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.71 -41.14 2.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 111.084 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 73.7 m -78.59 -44.5 23.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.155 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 133' ' ' ILE . 7.5 tp -54.4 -29.59 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.7 tptp -54.57 -44.64 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -61.27 -22.12 64.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 130' ' ' ILE . 70.5 mt -83.1 -31.56 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.136 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.708 ' HG3' HD12 ' A' ' 141' ' ' ILE . 44.8 mt-30 -83.34 -24.45 32.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLN . . . . . 0.472 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.82 -41.01 19.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.935 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.472 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 14.9 mmm180 -64.62 -35.68 81.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -100.56 -18.12 16.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.16 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.4 m80 62.28 46.18 6.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.822 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.454 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.6 p -120.67 164.55 16.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 t80 -95.66 88.25 4.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 134' ' ' GLN . 79.9 mt -88.69 132.81 32.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.103 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.4 t -117.96 132.09 68.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.167 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 64.4 p -85.55 148.07 48.25 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.596 0.713 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 176.49 6.73 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.647 2.231 . . . . 0.0 112.356 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.56 179.22 53.24 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.48 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -79.16 -43.25 24.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.884 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.7 p-10 -104.79 43.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 52.9 mmtt -134.08 169.04 17.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.407 ' H ' ' CD ' ' A' ' 149' ' ' GLU . 2.0 pm0 -66.57 143.99 98.43 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.669 0.747 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 95.7 0.56 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 2.267 . . . . 0.0 112.313 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.2 t -147.7 119.59 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.172 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -88.27 140.27 29.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.02 110.17 20.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.081 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.489 HG12 HG12 ' A' ' 161' ' ' VAL . 23.8 t -103.98 122.51 56.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 93.6 m -111.03 130.59 55.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.153 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.491 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 158.31 178.16 32.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.475 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.703 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.5 mmt -45.37 158.94 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -0.69 7.2 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.737 2.291 . . . . 0.0 112.32 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.78 -25.38 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.908 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.454 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 5.5 m-20 -83.07 -48.52 10.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.703 HG22 ' O ' ' A' ' 157' ' ' MET . 34.1 m -64.78 -36.96 78.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -58.36 -45.28 88.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.855 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -61.46 -43.91 98.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.873 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.92 -44.01 70.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.735 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.6 ttm180 -59.42 -42.85 92.8 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.872 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' GLU . . . . . 0.425 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 18.2 mt-10 -53.37 -42.88 67.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.935 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -71.3 -51.61 23.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.877 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 61.6 mt -49.34 -53.99 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -67.38 -41.45 85.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.59 -61.44 0.71 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 170' ' ' ALA . 59.1 m-70 -34.46 -41.29 0.12 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.842 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.766 HG12 HG21 ' A' ' 118' ' ' VAL . 93.4 mt -47.78 -55.34 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 49.6 p -99.93 88.26 3.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.3 tp -150.43 157.25 42.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 18.9 ttt180 -160.15 142.47 13.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 39.5 m -61.33 126.23 26.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 133.32 -95.03 0.28 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.495 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 101.55 0.93 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.692 2.261 . . . . 0.0 112.315 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 t -165.81 174.34 9.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 87.1 p -84.55 -43.78 14.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.452 179.963 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.3 t -156.54 112.84 3.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.864 0.364 . . . . 0.0 110.851 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.9 m -102.46 170.03 8.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 103' ' ' SER . . . 156.89 -79.46 0.18 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.526 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 102' ' ' GLY . 8.3 t -36.54 110.15 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.858 0.361 . . . . 0.0 110.867 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.9 t -74.89 168.65 19.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.855 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -153.96 -48.08 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.504 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.71 111.65 1.66 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -55.92 169.83 0.34 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.4 t -129.47 159.66 35.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -131.24 120.64 23.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.187 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 25.0 pt -111.15 152.89 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 38.2 mm-40 -108.02 100.66 9.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.896 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 168' ' ' ILE . 88.4 t -73.09 141.97 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.147 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 37.5 ttt-85 -104.98 120.88 42.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.429 HG21 ' CE1' ' A' ' 152' ' ' PHE . 4.8 m -140.49 151.07 62.84 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.688 0.756 . . . . 0.0 111.074 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.546 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.2 Cg_endo -69.79 138.4 37.64 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.685 2.256 . . . . 0.0 112.314 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -47.52 -26.21 1.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.927 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 ttm180 -69.6 -46.99 65.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.835 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 122' ' ' VAL . 41.2 t -68.39 -29.37 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.108 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.4 t -42.27 -65.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.66 -34.08 9.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.4 -46.11 61.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.85 0.357 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.598 HG23 HG12 ' A' ' 118' ' ' VAL . 91.9 t -64.89 -57.92 9.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.459 HG22 ' CG2' ' A' ' 143' ' ' THR . 90.2 t -55.28 -49.24 74.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.095 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.94 172.69 48.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.44 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.95 99.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.652 2.235 . . . . 0.0 112.382 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? 54.01 42.71 31.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.46 68.38 1.67 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.52 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.28 -35.18 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.893 0.378 . . . . 0.0 111.109 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 33.1 m -75.94 -39.41 56.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.751 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -67.21 -23.08 29.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -62.58 -38.5 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -66.44 -37.8 85.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.844 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 66.7 mt -70.48 -49.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.116 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -52.32 -37.49 55.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -81.82 -52.41 7.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 -52.89 -33.87 52.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.7 p -103.54 -15.15 15.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.165 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 17.8 m170 60.95 53.79 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.47 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.5 p -138.01 138.27 38.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 51.9 t80 -76.74 91.92 3.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.751 HG21 HD11 ' A' ' 130' ' ' ILE . 77.7 mt -83.64 134.41 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.1 t -120.28 129.32 75.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.137 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.459 ' CG2' HG22 ' A' ' 123' ' ' VAL . 41.6 p -83.8 153.12 63.94 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.54 0.686 . . . . 0.0 111.191 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 177.06 5.97 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.684 2.256 . . . . 0.0 112.366 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -75.06 155.67 48.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.45 -28.49 70.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.86 0.362 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -119.91 38.01 4.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -135.91 162.13 33.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -53.99 143.86 40.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.638 0.732 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.73 97.68 0.65 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.695 2.263 . . . . 0.0 112.331 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.3 t -145.32 117.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.429 ' CE1' HG21 ' A' ' 114' ' ' VAL . 35.4 m-85 -86.73 146.31 26.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.86 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -121.74 99.13 6.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.43 HG12 HG12 ' A' ' 161' ' ' VAL . 46.6 t -87.63 131.1 36.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -117.09 131.07 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.177 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 156.43 175.13 27.04 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.456 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.577 ' O ' HG22 ' A' ' 161' ' ' VAL . 21.6 mmt -39.2 159.49 0.1 Allowed Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.576 0.703 . . . . 0.0 110.902 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.723 2.282 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -119.7 -38.38 2.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.4 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.2 m-20 -66.77 -46.42 75.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 157' ' ' MET . 20.5 m -67.72 -38.1 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -52.89 -43.1 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 11.9 ttt180 -61.89 -57.92 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.06 -48.54 4.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 16.9 ttp85 -48.34 -40.24 24.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -55.48 -64.82 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 58.1 mm-40 -54.22 -46.35 72.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 112' ' ' VAL . 47.7 mt -44.63 -65.91 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.082 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.446 ' HB2' HD12 ' A' ' 172' ' ' ILE . 0.7 OUTLIER -69.36 -29.52 67.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.861 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.555 ' O ' HD23 ' A' ' 174' ' ' LEU . . . -48.74 -48.99 40.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.41 ' HA ' HD23 ' A' ' 174' ' ' LEU . 9.1 m170 -46.89 -26.32 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 69.6 mt -51.71 -39.08 23.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.73 ' C ' HD22 ' A' ' 174' ' ' LEU . 9.8 t -99.62 45.44 0.99 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.73 HD22 ' C ' ' A' ' 173' ' ' THR . 4.3 mm? -131.35 162.79 29.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -106.46 111.09 23.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 2.1 m -141.24 168.14 20.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.828 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 154.85 66.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -48.08 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.629 2.219 . . . . 0.0 112.309 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 22.9 t -153.94 152.23 30.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.843 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.4 t -133.86 82.58 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.885 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.0 t -100.53 -53.91 2.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.896 0.379 . . . . 0.0 110.826 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.1 m -123.34 98.4 5.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.897 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 52.42 -158.93 3.21 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 8.8 t -120.48 94.93 4.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.867 0.365 . . . . 0.0 110.875 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 36.7 m -151.42 172.67 15.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.88 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -112.85 -59.89 0.42 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.473 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -149.97 -83.01 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.489 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -91.23 159.31 16.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.885 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.9 t -124.5 168.4 13.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.123 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 25.6 m -137.34 124.63 21.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 23.0 pt -122.46 155.24 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.091 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -105.2 111.66 24.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.548 HG12 HG13 ' A' ' 114' ' ' VAL . 70.4 t -76.77 135.04 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -106.65 117.65 34.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.584 HG11 HG22 ' A' ' 168' ' ' ILE . 8.7 m -137.96 151.05 69.42 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.669 0.747 . . . . 0.0 111.121 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.418 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.68 134.37 27.98 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -47.09 -21.98 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 91.7 mtt-85 -72.59 -44.02 62.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.605 HG21 HG12 ' A' ' 172' ' ' ILE . 39.6 t -74.31 -34.41 36.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.15 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.8 t -38.23 -69.92 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.155 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.31 -36.21 4.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.472 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 118' ' ' VAL . 15.1 mt -68.01 -44.16 77.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.882 0.373 . . . . 0.0 110.958 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.561 HG23 HG12 ' A' ' 118' ' ' VAL . 57.5 t -65.53 -63.28 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.3 t -40.88 -50.43 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.142 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 79.97 169.08 38.51 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.05 101.23 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.353 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.4 tptm 50.26 44.39 26.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.71 72.9 0.7 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.63 -39.81 2.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 111.12 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -84.49 -43.57 14.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -58.53 -37.88 67.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 27.4 tttm -57.09 -43.2 81.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 74.3 mtt-85 -57.27 -44.35 83.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.876 HG23 ' OE1' ' A' ' 167' ' ' GLU . 58.7 mt -57.93 -46.43 87.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.164 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.511 ' HG3' HD12 ' A' ' 141' ' ' ILE . 53.6 mt-30 -60.8 -20.32 61.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 -90.28 -45.6 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -66.97 -32.7 74.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.45 ' CG2' ' OE2' ' A' ' 167' ' ' GLU . 66.7 p -101.48 -15.63 17.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 11.6 m170 56.79 49.91 13.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.571 HG21 ' HA ' ' A' ' 161' ' ' VAL . 57.9 p -131.8 146.8 52.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.173 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 26.1 t80 -78.85 96.64 5.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 130' ' ' ILE . 91.4 mt -90.97 115.63 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.456 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 97.2 t -105.73 124.99 61.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.568 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.0 p -76.65 152.62 83.2 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.604 0.716 . . . . 0.0 111.177 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 175.79 7.67 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.692 2.261 . . . . 0.0 112.337 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.51 158.98 46.0 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.467 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 12.6 ptp180 -62.27 -44.01 97.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.867 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.43 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 30.8 t0 -103.95 42.35 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.901 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 8.0 mmmm -138.34 163.93 30.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.96 148.73 83.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 101.44 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.709 2.273 . . . . 0.0 112.344 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.2 t -153.82 119.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.094 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.568 ' CE2' HG22 ' A' ' 143' ' ' THR . 52.1 m-85 -89.79 156.93 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.456 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.87 104.76 9.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.138 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 34.1 t -95.81 124.0 48.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.7 m -115.53 134.06 55.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.145 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 154.09 -172.37 32.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.5 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.552 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.0 mmt -50.45 159.4 0.87 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.581 0.705 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.678 2.252 . . . . 0.0 112.362 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -120.03 -33.38 3.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 57.3 m-20 -73.62 -48.73 30.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.571 ' HA ' HG21 ' A' ' 139' ' ' THR . 17.3 m -63.67 -36.1 75.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -61.15 -38.91 88.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -63.17 -40.74 98.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -61.78 -33.39 74.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 47.0 ttp85 -67.16 -50.48 61.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.42 -26.04 66.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.876 ' OE1' HG23 ' A' ' 133' ' ' ILE . 67.5 mt-10 -77.83 -52.91 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.584 HG22 HG11 ' A' ' 114' ' ' VAL . 72.6 mt -58.81 -40.15 79.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -71.87 -38.59 70.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.916 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.2 -54.85 5.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 43.8 m170 -41.65 -32.07 0.34 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.605 HG12 HG21 ' A' ' 118' ' ' VAL . 76.9 mt -55.79 -44.81 78.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.443 ' O ' ' C ' ' A' ' 174' ' ' LEU . 88.4 m -63.85 -50.35 69.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 173' ' ' THR . 33.2 mt -34.41 -55.74 0.52 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 48.53 45.27 21.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 2.6 m -38.82 -48.49 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.836 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 147.7 -96.1 0.17 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.483 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 161.83 44.41 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.67 2.247 . . . . 0.0 112.349 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 31.8 p -126.4 104.03 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.902 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 2.8 m -66.21 113.52 4.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.881 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.479 179.977 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 47.7 m 46.78 42.18 11.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 110.864 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 t -101.5 123.1 45.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.889 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 51.69 -160.55 2.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.541 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 35.3 t -126.59 103.18 7.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.371 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.5 m -148.64 121.98 9.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.816 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 63.86 161.59 0.42 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -168.33 -106.49 0.19 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.51 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -95.05 167.48 11.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.2 t -127.55 161.3 29.12 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.082 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.7 m -132.31 122.4 25.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.26 156.11 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 49.3 mm-40 -109.88 100.55 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.943 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 94.4 t -67.85 141.01 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 34.6 ttp180 -109.3 124.77 51.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.86 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -146.52 149.57 37.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.56 0.695 . . . . 0.0 111.142 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 139.03 39.31 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.326 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 t80 -49.17 -20.91 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 ttm-85 -74.35 -46.24 41.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.741 HG21 HG12 ' A' ' 172' ' ' ILE . 16.7 t -68.6 -37.28 77.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 87.3 t -39.75 -64.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.098 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.72 -36.6 13.26 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 12.8 mt -70.04 -43.08 71.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.775 0.321 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.461 HG23 HG12 ' A' ' 118' ' ' VAL . 48.8 t -67.31 -63.1 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 96.4 t -38.97 -49.77 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.87 172.61 33.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -47.95 102.81 0.05 OUTLIER 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 91.0 mttt 46.16 44.41 12.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.58 70.67 1.08 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.11 -37.06 3.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 111.088 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 35.4 m -87.96 -44.39 11.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.158 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.696 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -60.79 -28.06 42.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.153 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.9 ttpp -64.67 -46.97 80.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.938 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.2 mtt180 -51.74 -50.55 60.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 56.8 mt -50.14 -54.95 6.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.135 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.674 ' HG3' HD12 ' A' ' 141' ' ' ILE . 46.6 mt-30 -45.89 -37.07 5.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.901 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -79.79 -59.15 2.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -43.51 -37.64 2.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.861 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.6 p -101.03 -22.81 14.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.086 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.7 m80 69.85 52.62 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.466 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.0 p -133.46 155.19 49.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 35.4 t80 -90.07 95.47 10.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.964 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.696 HG21 HD11 ' A' ' 130' ' ' ILE . 90.3 mt -86.77 138.49 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.5 t -129.28 124.08 59.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.187 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.709 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.3 p -80.18 152.68 74.0 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.562 0.696 . . . . 0.0 111.121 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -175.59 1.2 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.6 169.48 45.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.31 -22.87 59.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 20.3 p-10 -123.0 40.77 3.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -138.94 174.19 10.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -68.02 143.94 96.62 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.611 0.72 . . . . 0.0 110.915 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 91.15 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.646 2.231 . . . . 0.0 112.32 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.7 t -138.74 120.04 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.139 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.709 ' CE2' HG22 ' A' ' 143' ' ' THR . 36.2 m-85 -89.1 147.94 23.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -117.92 113.56 21.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.115 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.526 HG12 HG12 ' A' ' 161' ' ' VAL . 53.8 t -106.68 124.4 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 60.2 m -111.54 137.38 49.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.61 -177.27 29.61 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.441 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.804 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.7 mmt -47.28 159.1 0.43 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.545 0.688 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.29 8.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -115.71 -37.01 4.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.839 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 -71.13 -50.62 31.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.903 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.804 HG22 ' O ' ' A' ' 157' ' ' MET . 32.0 m -59.4 -29.51 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.091 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.02 -42.06 94.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -65.83 -32.21 73.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ALA . . . . . 0.491 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -66.82 -36.3 82.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.42 ' CG ' ' OE1' ' A' ' 169' ' ' GLU . 41.5 ttt180 -65.31 -59.57 3.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' GLU . . . . . 0.475 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 1.7 pp20? -51.92 -31.46 28.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -67.56 -55.39 13.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.4 mt -58.27 -53.66 43.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.42 ' OE1' ' CG ' ' A' ' 165' ' ' ARG . 29.0 mt-10 -58.77 -41.52 86.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -41.38 -59.23 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.106 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 50.1 m170 -37.75 -37.91 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.741 HG12 HG21 ' A' ' 118' ' ' VAL . 84.1 mt -45.95 -65.29 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 170' ' ' ALA . 10.0 t -65.59 -32.21 73.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.201 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 5.2 tt -52.29 113.42 1.03 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.908 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 69.38 44.74 0.9 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.869 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 93.7 p -98.96 145.76 26.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.848 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 112.5 -176.31 17.66 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 91.95 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.713 2.275 . . . . 0.0 112.32 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 71.7 m -93.53 134.83 35.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 1.5 t 70.66 41.95 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.872 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.486 -179.963 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 92.5 p -90.63 -49.01 6.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.856 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.3 t 65.31 42.06 4.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -109.55 140.47 15.75 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.434 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.9 t -104.42 -47.93 3.97 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.899 0.381 . . . . 0.0 110.898 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.0 t -60.63 170.52 1.41 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -139.15 -92.62 0.25 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.453 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.15 98.32 0.88 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.536 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -98.94 169.38 9.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.901 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.1 t -133.97 163.96 28.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.11 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 56.8 m -131.87 126.16 33.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.152 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.4 pt -111.84 155.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.133 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -112.59 101.01 9.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.451 HG22 ' HG3' ' A' ' 165' ' ' ARG . 90.5 t -72.75 141.28 16.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.139 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.8 ttm180 -111.6 115.37 29.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.409 HG11 HG22 ' A' ' 168' ' ' ILE . 3.5 m -133.37 150.69 75.85 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.658 0.742 . . . . 0.0 111.103 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.49 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.5 Cg_endo -69.84 123.84 10.47 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.636 2.224 . . . . 0.0 112.31 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -35.2 -32.82 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 115' ' ' PRO . 10.9 mmm180 -63.12 -51.96 64.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.49 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 40.1 t -65.36 -32.19 57.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.159 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 122' ' ' VAL . 75.8 t -42.66 -72.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 119' ' ' VAL . . . -37.64 -36.79 0.31 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.5 mt -69.99 -39.59 75.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.898 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.483 ' N ' ' O ' ' A' ' 119' ' ' VAL . 38.4 t -68.92 -63.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.3 t -43.97 -55.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.079 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.84 172.83 49.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -48.03 107.09 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.638 2.225 . . . . 0.0 112.369 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 43.9 39.16 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.73 75.47 0.52 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -120.34 -41.51 2.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.086 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 83.4 m -81.49 -44.77 16.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.151 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 133' ' ' ILE . 9.7 tp -54.67 -40.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.149 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 130' ' ' ILE . 10.4 ttpp -51.72 -44.55 63.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.427 ' HA ' ' CG ' ' A' ' 135' ' ' GLN . 21.8 mtp180 -63.63 -20.58 65.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 130' ' ' ILE . 71.4 mt -79.81 -37.44 18.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.726 ' CG ' HD12 ' A' ' 141' ' ' ILE . 69.1 mt-30 -78.12 -26.96 48.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLN . . . . . 0.479 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.85 -41.38 19.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.479 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 13.9 mmt180 -62.4 -39.26 92.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 38.8 p -101.3 -6.53 24.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.155 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 74.1 m80 55.2 52.8 11.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.467 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 13.1 p -129.02 150.15 50.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.18 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -90.66 92.6 8.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.732 HG12 HG22 ' A' ' 154' ' ' VAL . 69.7 mt -84.67 124.08 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.773 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 79.7 t -100.41 109.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.6 p -79.04 148.84 72.45 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.707 . . . . 0.0 111.125 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.86 23.17 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.27 -164.33 27.75 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.482 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -71.67 -54.2 11.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.783 0.325 . . . . 0.0 110.849 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -103.88 41.29 1.31 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.66 140.05 50.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.943 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.52 143.31 2.95 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 82.14 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.653 2.236 . . . . 0.0 112.347 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 112' ' ' VAL . 46.3 t -139.63 119.93 14.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.128 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.654 ' CE2' HG22 ' A' ' 143' ' ' THR . 23.9 m-85 -90.58 147.43 23.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.856 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.773 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -119.53 98.57 6.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.07 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.732 HG22 HG12 ' A' ' 141' ' ' ILE . 58.0 t -86.12 119.27 34.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.187 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.1 m -107.71 132.34 53.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.115 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.432 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 155.64 -173.0 33.76 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.539 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.9 mmt -50.58 158.7 1.02 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.589 0.709 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -2.49 10.24 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.695 2.263 . . . . 0.0 112.353 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -113.25 -32.67 6.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.467 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 21.4 m-20 -77.16 -53.57 7.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 157' ' ' MET . 17.8 m -54.29 -34.55 27.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.151 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.436 ' C ' ' OE2' ' A' ' 166' ' ' GLU . 23.2 t0 -59.38 -67.86 0.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.858 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 21.3 ttm-85 -43.76 -51.27 7.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.75 -36.5 3.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.451 ' HG3' HG22 ' A' ' 112' ' ' VAL . 37.6 ttp180 -72.57 -34.61 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 166' ' ' GLU . 0.1 OUTLIER -57.77 -39.68 78.01 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.888 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -71.56 -53.72 12.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.409 HG22 HG11 ' A' ' 114' ' ' VAL . 70.3 mt -49.96 -48.98 22.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -65.26 -43.38 91.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.438 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -44.39 -57.66 3.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.08 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.438 ' C ' ' O ' ' A' ' 170' ' ' ALA . 11.4 m80 -35.45 -37.91 0.09 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.45 HG12 HG21 ' A' ' 118' ' ' VAL . 66.7 mt -51.99 -55.47 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 30.2 m -68.12 -47.35 68.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 4.7 tp -48.65 113.55 0.79 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.24 116.13 28.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 36.8 m -80.07 -52.79 7.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 79.73 175.09 47.48 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.47 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.82 0.28 5.92 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.682 2.255 . . . . 0.0 112.338 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 3.8 m -47.58 150.71 0.94 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 4.5 m -84.62 124.2 31.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.851 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.475 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.5 m -102.84 120.35 40.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.889 0.376 . . . . 0.0 110.865 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 t -113.05 99.99 8.27 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 178.41 144.47 5.62 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 68.7 m -109.05 143.62 38.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.886 0.374 . . . . 0.0 110.855 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.3 p -49.53 -55.44 13.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.32 42.27 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.45 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -114.34 -46.69 0.62 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.47 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.473 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 1.7 pp0? -92.69 178.59 5.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.861 0.362 . . . . 0.0 110.943 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.8 t -134.31 157.33 46.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 91.5 m -128.4 118.29 22.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.9 pt -106.91 154.34 7.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.45 ' NE2' ' HB2' ' A' ' 153' ' ' ALA . 43.4 mm-40 -112.27 105.74 14.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.503 HG22 ' CD ' ' A' ' 165' ' ' ARG . 93.4 t -82.12 144.77 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.16 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.44 ' O ' ' CG1' ' A' ' 114' ' ' VAL . 7.9 mpt_? -109.54 147.37 33.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.44 ' CG1' ' O ' ' A' ' 113' ' ' ARG . 7.6 m -158.45 151.11 18.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.627 0.727 . . . . 0.0 111.151 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.498 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.7 Cg_endo -69.72 127.03 14.03 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.713 2.275 . . . . 0.0 112.361 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -41.42 -24.42 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.918 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 115' ' ' PRO . 46.9 mtt85 -71.28 -43.81 66.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.559 HG21 HG12 ' A' ' 172' ' ' ILE . 41.2 t -74.56 -34.96 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.093 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.1 t -39.71 -63.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.36 -39.2 9.66 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.495 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -67.56 -46.62 72.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.881 0.372 . . . . 0.0 110.937 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.546 HG23 HG12 ' A' ' 118' ' ' VAL . 59.0 t -63.79 -63.88 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 87.1 t -40.4 -49.59 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 72.7 172.87 22.04 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.477 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.7 Cg_exo -47.99 118.21 2.98 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.718 2.279 . . . . 0.0 112.352 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.434 ' C ' ' O ' ' A' ' 125' ' ' PRO . 8.0 ptpp? 35.25 43.63 0.13 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 62.46 65.66 3.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.447 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.33 -39.27 6.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.838 0.351 . . . . 0.0 111.048 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.1 m -83.91 -50.34 8.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.158 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.489 HD11 HG21 ' A' ' 141' ' ' ILE . 7.3 tp -49.94 -40.8 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.435 ' N ' HG23 ' A' ' 130' ' ' ILE . 25.0 tttp -60.92 -43.88 97.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 49.4 mtt180 -54.33 -41.14 68.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.467 HD11 ' CE1' ' A' ' 171' ' ' HIS . 54.8 mt -59.28 -49.93 81.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.461 ' HG3' HD12 ' A' ' 141' ' ' ILE . 42.1 mt-30 -47.77 -34.67 8.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -80.59 -54.44 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 53.7 mtt-85 -51.96 -33.42 37.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.865 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.478 HG21 ' HA ' ' A' ' 164' ' ' ALA . 37.4 p -103.59 -16.62 15.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 72.8 m80 61.23 51.15 4.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.565 HG21 ' HA ' ' A' ' 161' ' ' VAL . 38.0 p -136.52 141.51 43.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.129 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -77.15 97.42 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.489 HG21 HD11 ' A' ' 130' ' ' ILE . 79.8 mt -89.93 141.48 14.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.137 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.5 t -125.91 129.09 72.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.072 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 35.3 p -86.12 149.14 49.4 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.583 0.706 . . . . 0.0 111.135 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 177.83 5.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.663 2.242 . . . . 0.0 112.364 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.35 170.91 52.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 18.8 ptt180 -71.34 -42.24 68.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.33 . . . . 0.0 110.861 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 2.5 p30 -104.61 42.09 1.25 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.82 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -139.18 159.3 42.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.894 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -58.03 142.59 79.63 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.623 0.725 . . . . 0.0 110.895 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 101.77 0.96 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.319 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -147.83 115.16 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.099 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -82.89 143.5 30.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.45 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . . . -118.97 106.71 12.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.099 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.413 HG22 HG12 ' A' ' 141' ' ' ILE . 47.4 t -95.51 123.15 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 72.8 m -110.58 129.93 55.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.497 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.78 178.8 32.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.478 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.56 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -44.56 159.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.561 0.696 . . . . 0.0 110.877 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 0.75 5.19 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.643 2.229 . . . . 0.0 112.32 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -117.99 -37.53 3.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.878 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.465 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.4 m-20 -71.14 -45.71 62.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.565 ' HA ' HG21 ' A' ' 139' ' ' THR . 13.8 m -66.8 -38.16 80.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -55.9 -39.63 71.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -62.78 -47.21 84.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ALA . . . . . 0.478 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -49.32 -42.83 42.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.068 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.503 ' CD ' HG22 ' A' ' 112' ' ' VAL . 11.7 tpt180 -48.9 -46.63 43.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 49.0 mm-40 -63.74 -37.46 87.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -63.3 -59.65 4.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 58.8 mt -53.03 -50.44 44.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.138 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -59.97 -43.25 95.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.415 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -47.0 -56.03 7.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.099 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.467 ' CE1' HD11 ' A' ' 133' ' ' ILE . 27.3 m170 -37.17 -41.34 0.38 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.559 HG12 HG21 ' A' ' 118' ' ' VAL . 57.3 mt -46.57 -57.82 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.436 ' O ' HG23 ' A' ' 173' ' ' THR . 13.9 t -89.66 42.46 1.09 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.172 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 55.8 tp -78.0 90.89 4.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.904 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? 59.24 46.76 12.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.902 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 71.8 m -67.9 160.1 29.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.913 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.77 -95.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -2.9 10.91 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.714 2.276 . . . . 0.0 112.358 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 16.5 t -93.22 114.94 27.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 93.9 p -75.87 -45.86 33.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.388 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.3 t -121.82 165.29 16.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.871 0.367 . . . . 0.0 110.871 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.9 m -48.51 152.84 0.86 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.85 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -135.13 -99.63 0.61 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.482 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.8 t -173.7 145.39 1.17 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.842 0.353 . . . . 0.0 110.869 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 92.0 p -82.49 96.4 8.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.839 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -122.18 166.24 14.85 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.437 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.13 104.59 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.447 ' HB3' ' HE2' ' A' ' 157' ' ' MET . 11.5 pt20 -83.01 174.9 10.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.887 0.375 . . . . 0.0 110.911 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.5 t -133.78 164.2 27.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 93.1 m -132.69 124.55 28.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.135 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.9 pt -110.47 152.02 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -108.17 96.77 6.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 114' ' ' VAL . 76.9 t -68.02 137.05 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -108.58 115.71 30.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.916 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 112' ' ' VAL . 11.4 m -137.29 151.11 70.92 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.589 0.709 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.543 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.3 Cg_endo -69.72 127.77 15.1 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.355 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -39.56 -27.34 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 115' ' ' PRO . 22.0 ttm180 -67.12 -44.94 78.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.899 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.545 HG12 HG23 ' A' ' 122' ' ' VAL . 55.2 t -74.51 -29.15 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 74.1 t -45.12 -63.07 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.104 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.91 -38.26 30.52 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.49 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.5 mt -66.78 -45.5 78.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.903 0.382 . . . . 0.0 110.971 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.545 HG23 HG12 ' A' ' 118' ' ' VAL . 89.9 t -66.28 -58.23 7.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.13 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.3 t -44.16 -54.85 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.411 ' O ' ' N ' ' A' ' 126' ' ' LYS . . . 85.12 172.77 49.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.494 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.0 88.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.411 ' N ' ' O ' ' A' ' 124' ' ' GLY . 34.4 tttp 58.01 48.64 12.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.891 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.69 60.03 7.01 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.502 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.93 -40.21 6.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.845 0.355 . . . . 0.0 111.069 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 94.2 m -85.77 -50.79 6.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.701 HD11 HG21 ' A' ' 141' ' ' ILE . 8.4 tp -52.53 -28.98 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.12 -49.14 71.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -51.04 -40.14 57.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.882 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.4 mt -63.46 -47.16 92.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.496 ' CG ' HD12 ' A' ' 141' ' ' ILE . 70.4 mt-30 -48.1 -36.85 14.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 67.3 mm-40 -82.24 -50.12 9.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.7 mtt85 -52.78 -33.91 50.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.882 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.3 p -105.68 -12.08 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.144 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 15.5 m170 58.26 54.12 5.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.466 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 70.5 p -139.46 139.11 36.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.423 ' HE2' HG22 ' A' ' 142' ' ' VAL . 38.2 t80 -75.25 97.94 3.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.701 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -87.71 122.99 40.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.147 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.423 HG22 ' HE2' ' A' ' 140' ' ' TYR . 94.0 t -107.02 128.27 62.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.781 HG22 ' HE1' ' A' ' 152' ' ' PHE . 34.1 p -87.38 144.32 35.62 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.583 0.706 . . . . 0.0 111.128 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -177.28 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.705 2.27 . . . . 0.0 112.304 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -90.7 -175.16 44.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 6.1 ptp85 -84.9 -41.16 16.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -100.77 40.08 1.31 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -138.42 169.44 17.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.91 144.18 95.47 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.713 0.768 . . . . 0.0 110.89 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 87.5 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.727 2.285 . . . . 0.0 112.316 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.4 t -137.86 121.17 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.781 ' HE1' HG22 ' A' ' 143' ' ' THR . 69.9 m-85 -91.12 143.98 26.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.41 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -114.87 104.57 12.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 161' ' ' VAL . 46.7 t -95.05 124.41 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 27.0 m -110.83 132.8 53.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 155.13 177.56 28.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.639 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.8 mmt -43.03 159.55 0.21 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.56 0.695 . . . . 0.0 110.865 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.69 5.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.736 2.291 . . . . 0.0 112.339 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -118.71 -35.66 3.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.907 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.466 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 71.0 m-20 -69.33 -45.75 68.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.882 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 154' ' ' VAL . 35.2 m -67.01 -39.38 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.143 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 11.5 t70 -54.5 -42.3 70.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.865 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -53.89 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.92 -52.25 25.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.412 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 50.0 ttt85 -42.51 -39.38 2.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.866 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -68.49 -45.53 72.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -58.57 -54.55 45.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.405 HG23 HG11 ' A' ' 122' ' ' VAL . 84.4 mt -55.12 -51.12 57.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.412 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 66.0 mt-10 -59.13 -46.0 89.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.901 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.445 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.13 -57.55 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.06 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 170' ' ' ALA . 14.7 m170 -34.9 -42.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.514 HG12 HG21 ' A' ' 118' ' ' VAL . 74.9 mt -47.85 -53.46 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.127 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 38.5 m -73.03 -44.68 60.52 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.618 HD13 ' N ' ' A' ' 175' ' ' ARG . 0.5 OUTLIER -43.38 130.4 4.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.959 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.618 ' N ' HD13 ' A' ' 174' ' ' LEU . 23.3 ptt180 -86.93 129.54 34.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.468 ' O ' ' C ' ' A' ' 177' ' ' GLY . 3.3 m -122.64 -46.06 2.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' GLY . . . . . 0.468 ' C ' ' O ' ' A' ' 176' ' ' SER . . . -32.73 96.21 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.486 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 178' ' ' PRO . . . . . 0.431 ' N ' ' O ' ' A' ' 176' ' ' SER . 53.7 Cg_endo -69.71 168.75 20.6 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.667 2.244 . . . . 0.0 112.392 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 180' ' ' SER . 30.6 t -93.74 153.92 18.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.857 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 179' ' ' SER . 83.0 p 37.46 42.21 0.32 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.863 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.458 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 t -152.5 174.06 14.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.883 0.373 . . . . 0.0 110.844 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.4 p -165.97 174.59 9.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.832 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -108.65 90.99 0.64 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.465 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.7 t -50.25 145.55 6.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.362 . . . . 0.0 110.86 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.3 t -83.64 41.79 0.81 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.866 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 149.37 154.72 6.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.49 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -101.96 -102.21 2.61 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.509 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -52.63 157.78 1.47 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.867 0.365 . . . . 0.0 110.961 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.0 t -123.53 159.67 28.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.174 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.621 ' OG1' HG23 ' A' ' 155' ' ' THR . 84.2 m -130.26 120.69 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.097 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.716 HD12 ' HE ' ' A' ' 165' ' ' ARG . 36.3 pt -108.38 154.97 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.109 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.9 mm-40 -113.82 96.14 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.596 ' O ' HG13 ' A' ' 151' ' ' VAL . 96.0 t -66.68 140.73 18.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.127 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -106.14 110.96 23.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.467 HG13 HG12 ' A' ' 112' ' ' VAL . 3.2 m -133.32 151.27 77.25 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 0.0 111.11 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.479 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 149.79 67.37 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.703 2.269 . . . . 0.0 112.334 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -55.24 -39.34 69.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.923 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.45 ' HG3' ' N ' ' A' ' 118' ' ' VAL . 4.6 ptp180 -57.78 -41.85 82.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.479 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 16.5 t -71.53 -37.29 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 150' ' ' PRO . 77.5 t -43.06 -69.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -41.21 -34.46 0.94 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.7 mt -71.22 -56.92 5.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.447 HG12 HD13 ' A' ' 130' ' ' ILE . 86.7 t -52.83 -57.58 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.145 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 74.5 t -49.77 -54.74 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.11 169.84 42.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -47.93 97.37 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.718 2.278 . . . . 0.0 112.347 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.0 mttt 54.52 47.65 22.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.888 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.84 68.18 1.79 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -112.2 -38.38 4.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 0.0 111.1 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 72.6 m -86.46 -42.71 13.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.152 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 141' ' ' ILE . 5.2 tp -62.87 -36.48 75.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.2 ttpt -55.89 -46.18 78.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -53.83 -41.86 67.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 65.8 mt -61.38 -59.21 4.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.621 ' HG3' HD12 ' A' ' 141' ' ' ILE . 72.4 mt-30 -41.54 -36.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.899 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -80.83 -53.37 6.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -51.19 -34.53 32.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.1 p -105.93 -8.47 17.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 13.5 m170 53.58 54.55 9.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.866 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.1 p -135.39 147.75 49.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -82.66 96.85 8.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.777 HG21 HD11 ' A' ' 130' ' ' ILE . 75.1 mt -89.94 116.16 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.145 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.0 t -102.76 113.99 41.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.156 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.456 HG22 ' CE2' ' A' ' 152' ' ' PHE . 37.9 p -72.57 153.42 91.69 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.521 0.677 . . . . 0.0 111.154 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 177.66 5.31 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.678 2.252 . . . . 0.0 112.375 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -85.01 170.69 45.66 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.502 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ARG . . . . . 0.474 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 4.2 ptm85 -69.53 -48.49 60.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 110.922 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASP . . . . . 0.474 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.7 p30 -99.92 43.42 1.06 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -138.54 168.79 19.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -66.82 144.25 98.47 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.632 0.729 . . . . 0.0 110.926 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.52 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.1 Cg_endo -69.85 100.16 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.311 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.596 HG13 ' O ' ' A' ' 112' ' ' VAL . 90.5 t -147.06 127.92 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.456 ' CE2' HG22 ' A' ' 143' ' ' THR . 48.3 m-85 -96.62 125.89 41.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.96 99.58 9.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.074 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.553 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -88.77 133.69 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.621 HG23 ' OG1' ' A' ' 109' ' ' THR . 32.2 m -120.04 128.79 53.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 157.74 178.25 31.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.681 ' O ' HG22 ' A' ' 161' ' ' VAL . 9.0 mmt -41.04 159.2 0.17 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.559 0.695 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.7 8.91 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.678 2.252 . . . . 0.0 112.333 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.448 ' C ' ' OE1' ' A' ' 159' ' ' GLU . 0.5 OUTLIER -116.97 -38.06 3.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.965 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ASN . . . . . 0.436 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.9 m-20 -67.35 -45.55 76.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.681 HG22 ' O ' ' A' ' 157' ' ' MET . 30.0 m -68.51 -40.04 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 29.8 t0 -53.19 -40.26 64.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 33.1 ttt-85 -64.68 -59.17 4.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.33 -45.82 6.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.716 ' HE ' HD12 ' A' ' 110' ' ' ILE . 21.1 ttm180 -47.71 -45.15 28.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -53.96 -61.19 2.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 13.4 mm-40 -53.6 -39.12 64.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ILE . . . . . 0.535 HD12 ' HA ' ' A' ' 165' ' ' ARG . 61.2 mt -55.84 -70.55 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.444 ' HB2' HD12 ' A' ' 172' ' ' ILE . 2.3 pt-20 -59.69 -33.21 71.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.899 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -37.25 -57.1 0.91 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.083 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 170' ' ' ALA . 17.6 m80 -37.63 -41.84 0.51 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.837 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.444 HD12 ' HB2' ' A' ' 169' ' ' GLU . 74.2 mt -41.5 -54.32 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 174' ' ' LEU . 66.9 p -61.67 -46.0 91.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.166 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 173' ' ' THR . 20.7 tp -34.56 151.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 39.4 mtt-85 -144.46 136.76 26.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 40.1 p -102.02 43.43 1.07 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.826 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 147.98 94.74 0.14 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' PRO . . . . . 0.4 ' O ' ' C ' ' A' ' 179' ' ' SER . 53.9 Cg_endo -69.8 -14.1 35.49 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.632 2.221 . . . . 0.0 112.385 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' SER . . . . . 0.4 ' C ' ' O ' ' A' ' 178' ' ' PRO . 17.4 m -38.29 141.98 0.2 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.82 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 34.6 p -121.03 135.82 55.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.83 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.502 -179.993 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.434 -0.267 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 83.8 p -81.29 168.37 18.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.898 0.38 . . . . 0.0 110.827 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 33.4 t -119.52 115.46 24.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -177.27 -79.19 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 66.5 p -127.56 42.85 3.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.874 0.369 . . . . 0.0 110.897 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 29.2 p -75.77 111.28 10.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.867 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -117.78 -160.76 11.77 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.462 ' O ' ' CE ' ' A' ' 157' ' ' MET . . . 153.32 118.9 0.73 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -175.42 177.54 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.849 0.356 . . . . 0.0 110.938 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.3 t -135.43 161.97 33.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.113 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.7 m -136.2 124.97 23.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.098 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.7 pt -114.28 154.3 15.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.3 mm-40 -109.58 106.55 16.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 94.4 t -73.85 137.99 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 16.0 ttm180 -109.54 115.68 30.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.87 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.448 HG13 HG12 ' A' ' 112' ' ' VAL . 4.5 m -135.51 150.8 73.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.653 0.739 . . . . 0.0 111.109 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.4 Cg_endo -69.77 129.14 17.07 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.345 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -39.47 -28.59 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.894 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.6 mmt180 -65.86 -51.43 58.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.848 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.797 HG21 HG12 ' A' ' 172' ' ' ILE . 28.9 t -66.59 -36.7 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.16 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 118' ' ' VAL . 77.4 t -37.32 -69.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.114 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.93 -39.49 8.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 118' ' ' VAL . 14.2 mt -64.67 -41.14 96.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.902 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.532 HG23 HG12 ' A' ' 118' ' ' VAL . 22.0 t -68.89 -64.99 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.098 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 122' ' ' VAL . 89.4 t -37.35 -46.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.41 173.13 32.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.417 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.1 Cg_exo -47.99 112.55 0.6 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.658 2.239 . . . . 0.0 112.341 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.2 ptmt 36.64 41.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.905 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.55 83.29 0.2 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.471 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.38 -41.34 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.864 0.364 . . . . 0.0 111.083 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 39.5 m -84.16 -44.18 14.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.121 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.71 HD11 HG21 ' A' ' 141' ' ' ILE . 5.8 tp -60.02 -40.47 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.424 ' N ' HG23 ' A' ' 130' ' ' ILE . 37.0 tttp -58.28 -41.93 85.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.898 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -56.45 -42.68 78.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.88 -48.23 88.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLN . . . . . 0.561 ' HG3' HD12 ' A' ' 141' ' ' ILE . 78.9 mt-30 -48.56 -36.72 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.929 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 4.3 mm100 -82.48 -54.84 4.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.93 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -49.95 -32.53 15.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -105.6 -13.6 15.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.105 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 28.0 m80 58.84 54.41 5.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' THR . . . . . 0.41 HG21 ' HA ' ' A' ' 161' ' ' VAL . 68.5 p -139.88 143.3 36.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -77.49 100.55 6.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.922 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.71 HG21 HD11 ' A' ' 130' ' ' ILE . 75.9 mt -92.79 119.1 39.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.3 t -109.6 127.52 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.104 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.6 p -85.26 151.61 56.91 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.562 0.696 . . . . 0.0 111.197 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 177.67 5.33 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.689 2.26 . . . . 0.0 112.354 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.7 168.15 49.18 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.44 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.19 -43.91 93.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.814 0.34 . . . . 0.0 110.836 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -103.18 43.6 1.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -132.45 171.61 13.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.21 148.85 91.54 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 110.871 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 87.64 0.56 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.349 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.4 t -143.78 121.13 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.087 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -90.31 153.64 20.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.832 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.7 106.96 11.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.094 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.602 HG12 HG12 ' A' ' 161' ' ' VAL . 50.7 t -97.74 125.28 50.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 75.1 m -112.3 137.38 50.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.49 -173.13 31.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.495 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' MET . . . . . 0.742 ' O ' HG22 ' A' ' 161' ' ' VAL . 8.2 mmt -53.89 159.86 2.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 0.0 110.877 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.428 ' HD2' ' SD ' ' A' ' 157' ' ' MET . 54.2 Cg_endo -69.7 -0.55 7.02 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.672 2.248 . . . . 0.0 112.391 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.431 ' CD ' ' HB3' ' A' ' 157' ' ' MET . 23.5 pm0 -118.01 -26.25 6.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -82.63 -43.51 16.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 157' ' ' MET . 35.7 m -69.5 -35.14 65.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -56.76 -47.81 79.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.9 ttt-85 -57.31 -55.24 37.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.21 -45.38 5.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -52.43 -45.5 66.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -64.39 -42.53 96.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -58.39 -53.84 53.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 91.0 mt -55.59 -54.79 21.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -56.63 -46.23 81.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' ALA . . . . . 0.441 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.36 -60.29 0.8 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.132 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 170' ' ' ALA . 40.7 m170 -34.95 -38.77 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.872 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.797 HG12 HG21 ' A' ' 118' ' ' VAL . 74.7 mt -50.71 -59.4 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.093 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.32 46.32 0.93 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.2 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 9.5 tt -145.21 124.16 12.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -106.69 142.79 35.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.823 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 22.7 m -99.51 167.52 10.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.847 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 115.28 -178.54 17.82 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 163.2 39.18 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 73.1 m -120.36 -44.48 2.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.9 t -56.29 -58.22 8.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.962 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.889 0.376 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.5 t -141.73 161.25 38.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 90.4 m -131.28 124.18 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.165 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.5 pt -114.29 153.14 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.125 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 52.6 mm-40 -109.87 106.26 15.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.553 HG22 ' HG3' ' A' ' 165' ' ' ARG . 74.7 t -77.59 135.61 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.114 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 8.9 ttp-105 -104.8 120.89 42.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.862 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.6 m -136.46 150.72 71.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.609 0.718 . . . . 0.0 111.124 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.534 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.7 130.63 19.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.682 2.255 . . . . 0.0 112.363 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -45.04 -22.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.939 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.425 ' NH1' ' HB2' ' A' ' 117' ' ' ARG . 14.7 ttm105 -72.08 -44.23 63.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.918 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.637 HG12 HG23 ' A' ' 122' ' ' VAL . 74.9 t -76.03 -31.68 22.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 122' ' ' VAL . 42.6 t -39.3 -74.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -38.74 -34.33 0.26 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.547 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.421 HD12 ' HA ' ' A' ' 118' ' ' VAL . 13.2 mt -71.67 -44.21 64.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.637 HG23 HG12 ' A' ' 118' ' ' VAL . 86.9 t -66.04 -62.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.119 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.412 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 84.7 t -46.8 -48.27 7.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.85 172.71 49.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.97 91.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 12.2 mmtp 53.13 38.59 27.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 78.32 72.89 1.13 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.535 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.39 -27.25 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.102 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 65.7 m -98.68 -44.77 6.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.606 HD11 HG21 ' A' ' 141' ' ' ILE . 9.3 tp -60.64 -25.19 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.9 tttp -66.51 -32.0 73.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -67.26 -43.58 81.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.582 HD12 HD12 ' A' ' 130' ' ' ILE . 77.3 mt -57.89 -56.88 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.159 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.592 ' HG3' HD12 ' A' ' 141' ' ' ILE . 29.4 mt-30 -45.24 -31.97 1.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -82.07 -55.69 4.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 mmm180 -56.28 -24.42 42.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.422 HG21 ' HA ' ' A' ' 164' ' ' ALA . 80.6 p -109.75 -13.03 14.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 54.3 52.79 11.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.479 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 26.8 p -129.99 170.04 14.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.155 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -102.28 94.91 5.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.606 HG21 HD11 ' A' ' 130' ' ' ILE . 82.3 mt -93.9 125.83 46.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.76 130.12 68.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.6 p -84.11 145.29 45.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.611 0.719 . . . . 0.0 111.094 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -179.78 3.17 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -80.56 -172.11 44.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -92.55 -31.62 15.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.828 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 9.6 t0 -112.1 35.97 3.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -131.3 169.93 15.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -67.82 144.28 97.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.615 0.721 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.25 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.705 2.27 . . . . 0.0 112.319 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.2 t -148.26 113.83 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.412 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 55.9 m-85 -84.06 141.46 31.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.93 121.53 45.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.6 122.47 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 43.0 m -112.9 122.93 49.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.563 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 169.54 -173.09 43.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.623 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.1 mmt -52.39 159.24 1.66 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.602 0.715 . . . . 0.0 110.857 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -0.86 7.54 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.658 2.239 . . . . 0.0 112.302 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -115.7 -26.03 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.479 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.3 m-20 -85.11 -54.63 4.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 157' ' ' MET . 24.9 m -53.68 -32.54 21.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -79.14 -23.5 43.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -76.27 -37.51 57.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . 0.422 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -70.76 -38.5 73.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.092 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.553 ' HG3' HG22 ' A' ' 112' ' ' VAL . 57.5 ttt180 -54.43 -44.21 72.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.93 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -55.58 -49.28 73.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 17.8 mm-40 -59.93 -45.98 90.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.929 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 94.9 mt -53.18 -58.96 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.126 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -62.4 -32.69 73.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -51.45 -42.31 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -56.28 -33.5 65.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.566 HG12 HG21 ' A' ' 118' ' ' VAL . 81.6 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.418 ' OE1' HG22 ' A' ' 155' ' ' THR . 25.2 pt20 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.922 0.392 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.7 t -137.56 164.68 28.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.784 HG22 HE22 ' A' ' 111' ' ' GLN . 99.2 m -138.14 115.29 10.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.075 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.44 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 42.4 pt -107.89 151.88 9.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.784 HE22 HG22 ' A' ' 109' ' ' THR . 1.1 mp0 -110.98 106.72 15.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 151' ' ' VAL . 86.9 t -73.7 141.39 16.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 42.5 ttp85 -108.67 110.13 21.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.469 HG13 HG12 ' A' ' 112' ' ' VAL . 2.5 m -132.59 148.85 71.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.675 0.75 . . . . 0.0 111.112 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.481 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.74 145.84 58.49 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.532 ' HA ' HG23 ' A' ' 119' ' ' VAL . 19.3 t80 -53.93 -41.54 67.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -54.85 -29.46 55.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.481 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 15.8 t -85.6 -34.82 8.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HA ' ' A' ' 116' ' ' TYR . 77.8 t -37.32 -66.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.52 -33.28 4.41 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.1 mt -70.61 -57.02 5.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.844 0.354 . . . . 0.0 110.889 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.43 HG23 HG12 ' A' ' 118' ' ' VAL . 62.9 t -56.37 -55.98 16.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.12 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.4 t -47.14 -55.57 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.36 167.85 43.91 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_exo -47.96 93.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.648 2.232 . . . . 0.0 112.356 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.3 tmtt? 60.89 46.43 8.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 59.59 61.59 7.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.493 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.47 -41.56 5.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.843 0.354 . . . . 0.0 111.122 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.2 m -78.91 -46.42 18.5 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.618 HD11 HG21 ' A' ' 141' ' ' ILE . 10.7 tp -51.57 -34.39 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.088 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.7 tttt -66.55 -40.58 89.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 25.9 ttp180 -62.3 -22.24 65.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.96 -41.43 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.488 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.4 mt-30 -67.95 -30.64 69.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' A' ' 136' ' ' ARG . 10.1 pt20 -80.7 -48.63 12.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.938 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.502 ' N ' ' CG ' ' A' ' 135' ' ' GLN . 60.0 mtt180 -59.03 -35.25 72.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 49.9 p -100.11 -13.28 19.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.136 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 19.8 m80 58.93 54.22 5.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.47 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 34.2 p -132.19 -176.79 4.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.091 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -116.74 97.4 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.953 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.707 HG12 HG22 ' A' ' 154' ' ' VAL . 74.4 mt -94.61 133.12 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -115.11 134.94 56.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.6 p -88.1 146.98 39.5 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.591 0.71 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -178.27 2.28 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -87.38 169.55 39.7 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 8.6 ptt85 -70.63 -40.54 73.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.837 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -105.54 42.24 1.26 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.846 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 26.5 mmtp -136.08 168.22 19.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.37 144.06 98.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.659 0.742 . . . . 0.0 110.901 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 82.78 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.693 2.262 . . . . 0.0 112.359 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 112' ' ' VAL . 76.2 t -133.29 129.62 56.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -96.53 139.95 31.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -112.78 110.01 19.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.116 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.707 HG22 HG12 ' A' ' 141' ' ' ILE . 96.3 t -101.33 133.22 45.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.512 HG23 ' OG1' ' A' ' 109' ' ' THR . 19.9 m -119.46 135.42 54.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.422 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 153.64 -177.1 31.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.529 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.542 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.1 mmt -49.27 158.36 0.75 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.549 0.69 . . . . 0.0 110.918 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 0.49 5.55 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -117.76 -29.79 5.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.47 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.1 m-20 -79.18 -47.93 15.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.542 HG22 ' O ' ' A' ' 157' ' ' MET . 15.7 m -66.15 -26.64 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -66.99 -40.39 87.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 7.5 ttt85 -66.88 -56.51 9.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -46.7 -46.27 20.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.055 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.3 ttt180 -49.7 -39.96 38.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 36.6 mt-10 -60.67 -52.1 66.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -58.56 -33.55 70.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 67.7 mt -63.24 -66.43 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.4 -32.54 74.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -39.72 -54.98 2.0 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.115 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -39.89 -40.56 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.444 HG12 HG21 ' A' ' 118' ' ' VAL . 71.1 mt . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.939 0.399 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.0 t -128.66 158.61 38.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.617 HG22 HE22 ' A' ' 111' ' ' GLN . 23.5 m -130.12 113.69 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.177 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.524 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 43.3 pt -103.48 154.85 5.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.617 HE22 HG22 ' A' ' 109' ' ' THR . 1.6 mp0 -112.54 107.98 16.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.818 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.7 t -77.79 141.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -110.2 117.39 33.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.842 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 168' ' ' ILE . 12.2 m -137.6 151.11 70.25 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.629 0.728 . . . . 0.0 111.112 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.503 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.78 126.7 13.6 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.659 2.24 . . . . 0.0 112.351 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -36.4 -35.53 0.08 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.942 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.8 tpp85 -59.74 -46.88 87.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.503 HG23 ' HG2' ' A' ' 115' ' ' PRO . 48.8 t -72.41 -31.14 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.57 ' O ' HG23 ' A' ' 123' ' ' VAL . 53.1 t -45.59 -59.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -52.73 -41.54 57.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.479 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -61.89 -48.89 78.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.83 0.348 . . . . 0.0 110.882 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 84.1 t -64.04 -52.65 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 119' ' ' VAL . 93.8 t -49.15 -56.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.166 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 88.49 172.73 46.89 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.93 100.66 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.722 2.281 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? 50.89 43.25 28.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.901 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.35 80.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.526 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.69 -31.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 40.5 m -89.91 -39.47 13.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.965 HD11 HG21 ' A' ' 141' ' ' ILE . 5.0 tp -65.07 -29.34 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.179 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.521 ' HD2' HG23 ' A' ' 130' ' ' ILE . 2.0 mptm? -67.76 -42.21 82.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.937 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 70.3 mtp180 -56.16 -43.79 78.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.841 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 57.2 mt -57.44 -44.84 85.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.447 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.8 mt-30 -51.71 -38.18 54.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.935 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -79.2 -51.11 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -55.68 -30.72 61.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.9 p -106.63 -10.88 16.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 56.13 51.51 11.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.2 p -137.34 143.08 41.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -78.33 95.54 5.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.965 HG21 HD11 ' A' ' 130' ' ' ILE . 78.8 mt -88.34 110.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 98.4 t -95.85 120.84 45.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.094 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 82.4 p -77.79 147.3 74.07 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.569 0.699 . . . . 0.0 111.134 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 171.95 13.5 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.685 2.256 . . . . 0.0 112.386 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.67 177.87 54.05 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 7.5 ptp85 -77.69 -33.59 53.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.788 0.327 . . . . 0.0 110.864 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -110.5 41.58 1.74 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.825 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.7 mmmt -137.84 159.33 42.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -57.21 145.25 67.22 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.657 0.742 . . . . 0.0 110.87 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.409 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.5 Cg_endo -69.8 96.78 0.61 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.67 2.247 . . . . 0.0 112.319 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 112' ' ' VAL . 94.8 t -145.52 132.65 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.0 m-85 -102.36 117.13 34.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.99 109.4 20.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.429 HG22 HG12 ' A' ' 141' ' ' ILE . 56.8 t -100.14 122.61 52.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 49.9 m -108.19 131.71 54.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.146 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.415 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.18 177.63 30.48 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.498 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.501 ' O ' HG22 ' A' ' 161' ' ' VAL . 10.5 mmt -42.51 159.41 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.553 0.692 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 0.83 5.06 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.702 2.268 . . . . 0.0 112.37 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -118.42 -37.33 3.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.425 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.4 m-20 -69.3 -45.67 69.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -67.83 -37.12 77.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.82 -42.44 84.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -64.16 -48.37 76.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.97 -47.93 43.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.531 ' HG3' HG22 ' A' ' 112' ' ' VAL . 33.2 ttt180 -51.05 -43.76 60.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -53.28 -44.74 68.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -68.15 -56.3 9.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.461 HG22 HG11 ' A' ' 114' ' ' VAL . 73.2 mt -47.7 -45.68 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -70.29 -45.04 67.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.44 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.32 -57.24 2.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.113 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.44 ' C ' ' O ' ' A' ' 170' ' ' ALA . 47.5 m80 -35.38 -34.62 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.478 HG12 HG21 ' A' ' 118' ' ' VAL . 58.5 mt . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.129 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.857 0.361 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.4 t -139.92 163.53 32.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.14 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -129.28 125.69 37.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.161 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.5 pt -112.18 164.51 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 50.3 mm-40 -121.71 97.93 5.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG13 ' A' ' 151' ' ' VAL . 95.3 t -68.78 142.74 15.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.125 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.3 ttt85 -112.55 121.56 45.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.2 m -141.98 151.07 58.27 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.616 0.722 . . . . 0.0 111.147 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.3 Cg_endo -69.8 125.54 12.24 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.671 2.247 . . . . 0.0 112.344 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.437 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.7 t80 -35.26 -33.21 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.876 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 115' ' ' PRO . 87.3 mtt-85 -61.68 -49.94 74.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.867 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.3 t -68.72 -35.03 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 56.1 t -39.06 -62.76 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -54.43 -38.92 63.83 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.467 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.7 mt -63.34 -43.54 97.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.558 HG23 HG12 ' A' ' 118' ' ' VAL . 89.4 t -68.48 -61.95 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 88.8 t -40.78 -49.04 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.119 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 78.45 172.86 41.37 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -47.95 97.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.653 2.235 . . . . 0.0 112.409 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 47.83 50.47 15.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.913 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.79 74.33 0.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -121.78 -45.15 2.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 67.2 m -82.21 -44.73 15.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.619 HD11 HG21 ' A' ' 141' ' ' ILE . 6.4 tp -57.43 -38.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.5 mttp -53.58 -39.87 65.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.416 ' N ' ' HD2' ' A' ' 132' ' ' ARG . 1.0 OUTLIER -57.75 -36.07 71.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.58 HD12 HD12 ' A' ' 130' ' ' ILE . 46.8 mt -69.94 -46.9 71.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.61 ' HG3' HD12 ' A' ' 141' ' ' ILE . 42.4 mt-30 -55.15 -39.83 69.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -78.28 -45.5 22.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -58.07 -37.59 74.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.84 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 81.8 p -101.23 -11.45 19.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 59.89 48.31 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 62.7 p -127.36 162.95 25.09 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -96.79 94.78 7.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.936 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.619 HG21 HD11 ' A' ' 130' ' ' ILE . 79.2 mt -90.43 122.3 41.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.106 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 68.9 t -113.81 129.46 69.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.119 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.6 p -77.47 147.75 75.92 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.576 0.703 . . . . 0.0 111.183 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 177.81 5.22 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.43 165.22 51.49 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -68.2 -45.95 71.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 0.0 110.879 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -101.7 42.75 1.11 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -136.07 173.43 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -67.2 143.94 97.92 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 89.12 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.368 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 112' ' ' VAL . 77.9 t -134.7 134.49 54.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.089 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -104.05 122.72 45.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -92.82 123.95 36.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.122 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.421 HG22 HG12 ' A' ' 141' ' ' ILE . 46.5 t -118.71 119.09 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.086 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.3 m -107.35 138.1 44.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.144 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.448 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.88 -169.96 31.28 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.436 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.768 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.0 mmt -52.53 159.47 1.66 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.561 0.696 . . . . 0.0 110.876 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 0.56 5.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.656 2.237 . . . . 0.0 112.35 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.38 -47.17 2.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.43 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 28.8 m-20 -65.42 -44.9 85.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 157' ' ' MET . 18.7 m -63.79 -37.87 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.154 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -73.53 -31.65 63.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 46.4 mtp180 -69.57 -36.9 76.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -64.32 -37.41 87.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.08 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -53.68 -58.66 6.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.812 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . 0.453 ' HG3' ' N ' ' A' ' 167' ' ' GLU . 1.0 OUTLIER -48.74 -35.44 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.926 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.453 ' N ' ' HG3' ' A' ' 166' ' ' GLU . 5.4 mm-40 -69.47 -46.76 65.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 93.9 mt -63.32 -49.36 83.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.165 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -60.61 -41.7 95.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.5 -53.07 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -40.17 -41.06 1.22 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 68.7 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.109 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.9 t -125.38 162.5 24.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.135 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.5 m -135.49 122.29 21.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.098 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.7 pt -111.81 156.12 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.17 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 47.7 mm-40 -111.74 98.83 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.9 t -66.04 141.42 18.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.137 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.4 ttp180 -112.33 113.24 25.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.464 HG13 HG12 ' A' ' 112' ' ' VAL . 3.8 m -132.8 151.07 77.41 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.459 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 126.72 13.64 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.352 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.411 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -36.44 -33.4 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 115' ' ' PRO . 84.8 mtt180 -62.22 -52.54 63.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.831 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.597 HG21 HG12 ' A' ' 172' ' ' ILE . 54.6 t -67.6 -34.15 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.098 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.1 t -40.17 -66.62 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.098 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.86 -36.5 26.7 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.475 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.5 mt -66.34 -41.84 89.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.883 0.373 . . . . 0.0 110.955 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.589 HG11 HG23 ' A' ' 168' ' ' ILE . 87.4 t -71.81 -54.6 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.107 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.424 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 92.5 t -50.95 -49.14 28.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.18 172.67 46.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.477 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -47.96 105.47 0.09 OUTLIER 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.712 2.274 . . . . 0.0 112.313 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 9.0 tppt? 45.5 44.5 9.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 64.11 76.07 0.32 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.484 ' O ' ' CZ ' ' A' ' 132' ' ' ARG . . . -124.21 -26.82 3.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 111.119 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 96.2 m -93.77 -35.91 12.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.145 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.795 HD11 HG21 ' A' ' 141' ' ' ILE . 5.1 tp -72.76 -29.94 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.155 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 132' ' ' ARG . 8.3 ptmt -58.94 -36.95 75.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.484 ' CZ ' ' O ' ' A' ' 128' ' ' ALA . 0.7 OUTLIER -67.04 -52.69 39.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.858 179.996 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.416 HD11 ' HE1' ' A' ' 171' ' ' HIS . 72.6 mt -46.4 -50.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.451 ' CG ' HD12 ' A' ' 141' ' ' ILE . 60.9 mt-30 -46.2 -35.39 5.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -81.31 -51.43 8.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -52.07 -35.3 47.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.875 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.4 p -104.1 -11.18 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.152 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 67.5 m80 55.99 54.66 7.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.872 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.478 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 82.5 p -137.38 147.37 45.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.169 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -80.5 97.38 7.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.795 HG21 HD11 ' A' ' 130' ' ' ILE . 85.5 mt -90.84 118.52 36.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.426 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 93.3 t -106.48 123.46 61.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.175 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.4 p -81.84 148.95 62.5 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.585 0.707 . . . . 0.0 111.124 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 172.57 12.39 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.06 157.93 34.19 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . 0.446 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 6.0 ptp180 -55.09 -42.3 72.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.9 p-10 -102.02 43.81 1.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -135.7 168.11 19.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -69.56 149.45 96.99 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.688 0.756 . . . . 0.0 110.832 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.4 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.8 Cg_endo -69.8 91.38 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 112' ' ' VAL . 96.9 t -145.67 130.42 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.168 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.424 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 57.3 m-85 -99.46 136.45 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.911 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -107.55 106.47 16.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.08 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.5 t -100.44 117.77 46.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 85.1 m -106.55 136.18 46.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.16 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.445 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 152.79 175.88 24.76 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.45 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.596 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.4 mmt -41.68 159.56 0.18 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.52 0.676 . . . . 0.0 110.912 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 0.81 5.11 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.663 2.242 . . . . 0.0 112.374 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.11 -35.1 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.905 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.478 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.3 m-20 -72.03 -46.95 55.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 157' ' ' MET . 27.9 m -64.09 -37.59 80.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -55.44 -45.09 76.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.845 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -57.27 -54.57 45.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.74 -51.96 8.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.512 ' HG3' HG22 ' A' ' 112' ' ' VAL . 68.8 ttp85 -45.28 -45.17 11.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -61.49 -42.47 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -61.92 -57.32 12.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.589 HG23 HG11 ' A' ' 122' ' ' VAL . 78.3 mt -52.46 -49.56 42.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -63.54 -43.76 96.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.866 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.58 -57.5 2.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' A' ' 170' ' ' ALA . 37.9 m80 -37.13 -38.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.597 HG12 HG21 ' A' ' 118' ' ' VAL . 51.1 mt . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.103 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.889 0.376 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.419 ' OG1' ' N ' ' A' ' 109' ' ' THR . 1.6 t -135.34 174.58 10.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.18 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.705 HG22 HE22 ' A' ' 111' ' ' GLN . 56.7 m -148.16 127.26 12.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.15 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.428 ' CD1' ' HE ' ' A' ' 165' ' ' ARG . 21.2 pt -118.35 155.12 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.705 HE22 HG22 ' A' ' 109' ' ' THR . 1.0 OUTLIER -108.53 97.14 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.448 HG22 ' HG3' ' A' ' 165' ' ' ARG . 82.7 t -68.14 137.89 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.183 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 24.9 ttt180 -103.44 116.5 32.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.55 147.4 61.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.602 0.715 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.54 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.4 Cg_endo -69.7 126.94 13.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.663 2.242 . . . . 0.0 112.344 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.412 ' C ' ' O ' ' A' ' 115' ' ' PRO . 32.4 t80 -36.59 -31.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' PRO . 15.2 ttm180 -64.66 -51.6 61.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.54 HG23 ' HG2' ' A' ' 115' ' ' PRO . 42.3 t -64.89 -31.65 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.118 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.8 t -41.63 -70.68 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.11 -28.48 1.33 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.6 mt -75.11 -48.95 21.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 0.0 110.936 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.53 HG23 HG12 ' A' ' 118' ' ' VAL . 40.1 t -59.83 -60.13 2.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.104 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.1 t -46.06 -63.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.107 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 89.04 172.46 46.16 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_exo -48.04 99.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.7 2.267 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 30.5 tttm 49.75 49.69 19.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.06 73.66 0.46 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.18 -38.76 2.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 111.12 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 80.1 m -83.64 -44.98 13.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.164 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 133' ' ' ILE . 10.0 tp -57.84 -26.92 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.3 tttt -63.79 -45.78 88.13 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -36.19 56.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.928 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 130' ' ' ILE . 48.6 mt -66.57 -58.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.131 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.62 ' CG ' HD12 ' A' ' 141' ' ' ILE . 53.8 mt-30 -52.1 -36.05 49.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 56.3 mm-40 -78.74 -34.68 45.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -67.26 -38.5 85.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.835 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 53.1 p -107.18 -0.4 22.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.138 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 37.1 m170 52.71 52.59 13.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 16.5 p -123.08 179.98 4.48 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.115 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -117.11 98.18 6.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.636 HG21 HD11 ' A' ' 130' ' ' ILE . 79.5 mt -90.62 127.1 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 75.3 t -112.07 121.05 63.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.0 p -74.78 145.96 82.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.585 0.707 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 179.98 3.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.632 2.221 . . . . 0.0 112.297 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.42 165.04 51.37 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.5 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -70.04 -45.04 68.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 0.0 110.868 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 49.6 m-20 -103.22 41.74 1.23 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -133.01 174.45 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -68.28 144.3 96.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.598 0.713 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 100.97 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 112' ' ' VAL . 91.4 t -149.88 130.55 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -100.68 132.61 45.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.45 111.59 24.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.124 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 41.5 t -99.91 117.96 45.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.108 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 96.2 m -109.53 131.97 54.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 158.44 -177.81 34.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.473 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 20.4 mmt -49.59 158.31 0.84 Allowed Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.557 0.694 . . . . 0.0 110.901 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . 0.41 ' HA ' HG21 ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.75 -1.96 9.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -115.6 -23.36 8.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.412 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 16.6 m-20 -84.82 -54.76 4.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.5 m -58.26 -27.0 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.149 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -70.38 -39.13 74.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.875 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.45 -50.42 45.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -52.5 -42.99 64.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.448 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.5 ttm180 -47.14 -53.17 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -50.85 -43.88 59.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.72 -51.37 69.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 50.2 mt -55.26 -44.09 73.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.163 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -68.18 -44.46 75.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -42.68 -51.28 5.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.086 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -42.01 -38.66 1.69 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.516 HG12 HG21 ' A' ' 118' ' ' VAL . 57.1 mt . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.154 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.88 0.372 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.6 t -134.72 164.47 27.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 89.8 m -131.25 122.46 26.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.179 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.4 pt -114.5 148.9 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.0 mm-40 -109.33 101.35 10.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 165' ' ' ARG . 88.2 t -70.2 143.27 14.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.138 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -114.04 120.93 42.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.851 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.669 HG11 HG22 ' A' ' 168' ' ' ILE . 11.1 m -139.68 150.92 64.84 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.653 0.739 . . . . 0.0 111.117 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.541 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.1 Cg_endo -69.74 125.49 12.22 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.655 2.236 . . . . 0.0 112.344 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.8 t80 -34.52 -35.53 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 115' ' ' PRO . 75.5 mtt-85 -59.56 -49.37 78.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.541 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.7 t -69.61 -35.28 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.107 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.9 t -39.51 -63.37 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.171 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.89 -42.23 37.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.0 mt -60.46 -43.46 96.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.816 0.341 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.418 ' HA ' ' CE1' ' A' ' 171' ' ' HIS . 58.3 t -69.98 -60.37 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.12 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.5 t -37.08 -51.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.42 166.79 42.44 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_exo -48.01 92.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.36 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 53.3 mmtt 58.51 41.63 22.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.918 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.54 66.29 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -111.76 -40.36 4.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.884 0.373 . . . . 0.0 111.115 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.3 m -84.82 -43.94 13.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.994 HD11 HG21 ' A' ' 141' ' ' ILE . 7.0 tp -58.52 -28.18 35.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -71.32 -43.42 67.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 35.0 ttm-85 -60.16 -39.95 88.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.506 HD12 ' HA ' ' A' ' 130' ' ' ILE . 58.0 mt -59.21 -50.1 81.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.128 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -48.77 -36.8 17.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.922 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -80.21 -51.08 9.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.913 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -54.2 -33.64 58.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.9 p -104.2 -14.83 15.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.141 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 9.8 m80 60.26 52.76 4.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.455 HG21 ' HA ' ' A' ' 161' ' ' VAL . 77.7 p -138.81 145.22 39.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -78.42 100.21 6.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.994 HG21 HD11 ' A' ' 130' ' ' ILE . 93.9 mt -96.23 122.08 47.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.083 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.4 t -112.96 132.28 62.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.6 p -85.17 152.53 58.59 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.626 0.727 . . . . 0.0 111.114 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.48 3.68 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.665 2.244 . . . . 0.0 112.364 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.88 169.76 53.41 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -70.1 -47.47 61.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.837 0.351 . . . . 0.0 110.872 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -103.79 40.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 18.3 mmmt -131.66 172.17 12.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -68.77 144.23 95.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.632 0.729 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 99.25 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.695 2.263 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 85.4 t -148.99 118.71 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.95 149.86 24.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.19 109.5 14.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.043 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.631 HG22 HG12 ' A' ' 141' ' ' ILE . 68.4 t -102.4 133.69 45.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.16 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 25.9 m -118.81 135.45 54.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.506 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 150.85 -179.33 27.65 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.433 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.685 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.5 mmt -43.49 159.44 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.534 0.683 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -0.17 6.56 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -119.29 -39.23 2.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -68.63 -40.42 80.33 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.685 HG22 ' O ' ' A' ' 157' ' ' MET . 20.2 m -72.42 -34.86 49.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -59.96 -39.93 87.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 43.6 ttt180 -61.27 -55.68 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.24 -43.08 3.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.092 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.436 ' HG3' HG22 ' A' ' 112' ' ' VAL . 72.1 ttt-85 -56.31 -40.65 74.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -54.57 -45.46 73.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -66.61 -57.16 7.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.917 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.669 HG22 HG11 ' A' ' 114' ' ' VAL . 71.7 mt -49.0 -45.82 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.165 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -71.13 -44.22 66.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.51 -57.97 1.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.129 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 122' ' ' VAL . 13.2 m170 -36.19 -40.18 0.21 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.857 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.414 ' HA ' HG21 ' A' ' 118' ' ' VAL . 50.2 mt . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -130.63 168.34 17.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.2 m -136.96 118.67 15.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.0 pt -107.3 150.62 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.112 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -109.61 94.16 4.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.466 HG12 HG13 ' A' ' 114' ' ' VAL . 79.4 t -67.16 139.74 20.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -109.25 111.89 23.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.477 HG11 HG22 ' A' ' 168' ' ' ILE . 7.2 m -128.39 150.89 75.56 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.589 0.709 . . . . 0.0 111.136 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.505 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.77 123.56 10.22 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.668 2.245 . . . . 0.0 112.373 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 22.8 t80 -34.84 -32.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.5 ' N ' ' O ' ' A' ' 115' ' ' PRO . 50.5 mtt85 -62.68 -49.13 76.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.542 HG12 HG23 ' A' ' 122' ' ' VAL . 56.0 t -70.35 -31.31 46.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.5 t -43.07 -64.46 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.1 -41.17 22.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.486 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 18.0 mt -63.19 -47.94 80.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.879 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.542 HG23 HG12 ' A' ' 118' ' ' VAL . 61.5 t -62.66 -61.71 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.131 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.6 t -43.16 -50.39 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 80.74 173.01 46.49 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.464 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' LYS . 64.6 Cg_exo -47.92 114.64 1.17 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.674 2.249 . . . . 0.0 112.372 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' PRO . 0.0 OUTLIER 34.13 43.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.886 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.38 84.45 0.12 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -133.52 -34.37 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 58.9 m -89.72 -43.7 10.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.089 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.799 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -68.21 -27.79 38.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.094 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttmt -68.29 -37.46 80.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.8 ttm180 -64.33 -46.82 81.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.854 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.819 HG23 ' OE1' ' A' ' 167' ' ' GLU . 36.6 mt -55.69 -42.8 71.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.13 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.428 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 79.0 mt-30 -57.23 -24.35 54.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.98 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 51.9 mm-40 -89.83 -47.03 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.401 ' NH1' ' OE2' ' A' ' 167' ' ' GLU . 6.3 ptm180 -64.16 -31.54 72.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.485 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 73.9 p -100.23 -12.83 19.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.158 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 27.2 m80 57.21 54.4 6.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 72.5 p -141.76 140.62 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -78.47 97.28 5.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.799 HG21 HD11 ' A' ' 130' ' ' ILE . 96.2 mt -88.78 108.71 19.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.138 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.3 t -91.95 133.65 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.116 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.0 p -91.81 146.13 32.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.558 0.694 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 177.17 5.82 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.733 2.289 . . . . 0.0 112.297 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.87 -178.02 50.11 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.514 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 50.3 ptt85 -83.08 -38.47 22.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.834 0.35 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -110.0 41.81 1.64 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -135.61 164.86 26.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -62.25 142.58 95.84 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.923 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 103.57 1.19 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.655 2.237 . . . . 0.0 112.348 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.3 t -148.28 115.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -86.96 128.44 35.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.915 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -103.36 104.28 14.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -95.9 122.2 47.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.6 m -108.65 137.15 47.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 151.95 -179.76 28.26 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.619 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.6 mmt -47.12 159.34 0.4 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 110.897 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 0.28 5.86 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.718 2.278 . . . . 0.0 112.351 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -118.4 -32.1 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.846 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.475 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.0 m-20 -73.58 -48.49 32.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 154' ' ' VAL . 32.9 m -65.62 -40.13 87.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 25.9 t0 -51.17 -41.88 60.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 15.3 ttm180 -65.24 -47.58 76.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.819 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.94 54.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.09 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.49 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 22.7 ttt85 -55.3 -45.26 76.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.854 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -60.98 -38.18 85.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.819 ' OE1' HG23 ' A' ' 133' ' ' ILE . 12.8 mt-10 -66.94 -50.52 62.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.886 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.477 HG22 HG11 ' A' ' 114' ' ' VAL . 66.6 mt -60.75 -43.41 95.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.49 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 60.3 mt-10 -66.15 -47.46 73.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.411 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -45.35 -55.36 6.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.411 ' C ' ' O ' ' A' ' 170' ' ' ALA . 30.0 m170 -37.23 -41.01 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 56.4 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.414 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 4.8 pp0? . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.92 0.391 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.7 t -133.1 165.35 24.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.134 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.1 m -133.54 122.47 23.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -116.11 147.73 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -105.97 106.77 17.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.428 HG12 HG13 ' A' ' 114' ' ' VAL . 97.6 t -71.83 141.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.107 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -111.7 115.91 29.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.882 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.428 HG13 HG12 ' A' ' 112' ' ' VAL . 4.1 m -136.57 150.27 69.82 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.564 0.697 . . . . 0.0 111.158 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.492 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.71 130.22 19.01 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.344 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -40.6 -33.76 0.3 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.423 ' HB3' ' NH1' ' A' ' 117' ' ' ARG . 5.6 mmm180 -61.76 -48.24 81.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.499 HG12 HG23 ' A' ' 122' ' ' VAL . 54.5 t -71.7 -32.67 46.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.401 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.9 t -40.73 -65.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.81 -40.42 26.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.89 -40.65 98.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 0.0 110.926 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.575 HG11 HG23 ' A' ' 168' ' ' ILE . 59.1 t -69.01 -63.5 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 95.5 t -38.43 -50.85 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.15 169.19 42.95 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -47.98 105.74 0.09 OUTLIER 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.697 2.265 . . . . 0.0 112.32 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt 45.22 39.29 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.921 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.76 86.51 0.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.479 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -134.87 -39.07 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.808 0.337 . . . . 0.0 111.047 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.0 m -86.65 -43.8 12.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.175 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.597 HG23 ' HD2' ' A' ' 131' ' ' LYS . 4.9 tp -60.95 -41.27 88.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.597 ' HD2' HG23 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -55.56 -38.39 69.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.835 179.855 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -58.62 -45.91 88.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.405 HD12 HD12 ' A' ' 130' ' ' ILE . 64.2 mt -55.26 -43.41 70.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.132 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.462 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 68.1 mt-30 -56.51 -37.18 70.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . 0.456 ' NE2' ' HA ' ' A' ' 135' ' ' GLN . 7.4 mm-40 -78.67 -54.24 6.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.922 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 23.0 mmm-85 -51.17 -34.83 33.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 70.0 p -102.52 -12.76 17.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 36.0 m80 57.22 52.94 8.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.435 HG21 ' HA ' ' A' ' 161' ' ' VAL . 63.8 p -136.11 159.19 42.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -89.34 98.88 12.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.556 HG12 HG22 ' A' ' 154' ' ' VAL . 71.1 mt -97.31 112.93 30.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.185 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 70.7 t -102.6 135.57 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.8 p -85.03 149.62 53.48 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.564 0.697 . . . . 0.0 111.146 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 177.58 5.44 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.2 161.84 49.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptp85 -66.48 -44.06 83.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -103.57 39.67 1.56 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.864 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -133.92 166.57 22.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -61.49 145.76 90.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.669 0.747 . . . . 0.0 110.904 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HB3' HG21 ' A' ' 119' ' ' VAL . 54.7 Cg_endo -69.7 98.16 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.653 2.235 . . . . 0.0 112.39 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 87.0 t -149.53 125.33 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.59 150.1 20.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.14 113.19 21.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.556 HG22 HG12 ' A' ' 141' ' ' ILE . 96.9 t -104.93 123.12 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.4 m -112.23 139.24 47.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.115 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.425 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 147.49 -173.79 27.48 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.73 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.2 mmt -48.56 159.32 0.54 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.502 0.668 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -1.06 7.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.657 2.238 . . . . 0.0 112.337 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -115.67 -49.79 2.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -59.47 -41.64 90.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -72.3 -34.33 48.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -58.34 -42.32 86.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -65.99 -36.78 84.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.892 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . 0.433 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -60.02 -31.52 70.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 48.3 ttt180 -71.64 -52.4 18.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.85 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -62.54 -30.57 71.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -70.98 -54.34 11.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.575 HG23 HG11 ' A' ' 122' ' ' VAL . 72.1 mt -58.61 -46.69 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -65.0 -37.52 87.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.61 -53.79 6.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -41.8 -32.99 0.45 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.425 HG12 HG21 ' A' ' 118' ' ' VAL . 83.5 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.111 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.888 0.375 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.8 t -133.42 170.44 15.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.19 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.701 HG22 HE22 ' A' ' 111' ' ' GLN . 94.4 m -141.98 129.01 20.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.453 ' O ' ' NE2' ' A' ' 111' ' ' GLN . 20.4 pt -122.04 158.91 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.701 HE22 HG22 ' A' ' 109' ' ' THR . 1.2 mp0 -113.81 106.37 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.96 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.801 ' O ' HG13 ' A' ' 151' ' ' VAL . 93.9 t -75.61 142.28 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -110.37 120.31 42.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -142.49 150.71 55.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.615 0.721 . . . . 0.0 111.154 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.539 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.77 125.26 11.93 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.323 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.473 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 27.1 t80 -35.85 -34.65 0.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.959 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.428 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.0 ttp180 -59.74 -49.91 75.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.539 HG23 ' HG2' ' A' ' 115' ' ' PRO . 56.1 t -69.56 -34.27 60.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 98.9 t -40.15 -66.97 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.147 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.64 -41.14 18.47 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.513 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.505 HD12 ' HA ' ' A' ' 118' ' ' VAL . 19.2 mt -62.22 -43.32 99.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.491 HG23 HG12 ' A' ' 118' ' ' VAL . 97.5 t -68.03 -62.12 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.075 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.521 ' O ' HG22 ' A' ' 130' ' ' ILE . 97.5 t -40.04 -54.03 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.177 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 87.64 167.57 43.67 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_exo -47.93 94.8 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.717 2.278 . . . . 0.0 112.338 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 29.6 mtpt 55.07 42.17 31.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.905 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.32 79.01 0.31 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.478 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -128.47 -38.78 1.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.867 0.365 . . . . 0.0 111.104 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.2 m -87.08 -40.26 14.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.087 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.521 HG22 ' O ' ' A' ' 123' ' ' VAL . 5.0 tp -64.7 -33.33 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.141 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 18.2 tttp -59.49 -42.34 91.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -54.96 -47.79 74.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.812 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.541 HG23 ' OE1' ' A' ' 167' ' ' GLU . 54.3 mt -54.8 -48.81 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.418 ' CG ' HD12 ' A' ' 141' ' ' ILE . 61.1 mt-30 -48.25 -38.59 18.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 86.7 mm-40 -81.12 -52.56 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -51.37 -32.64 26.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.4 p -106.53 -13.56 15.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.141 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 41.2 m80 60.0 53.43 4.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.481 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 55.2 p -135.49 139.79 44.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.121 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -77.75 90.47 4.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.979 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -83.29 142.14 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.163 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 86.6 t -131.01 121.23 49.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.119 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 78.6 p -73.0 150.01 90.05 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.562 0.696 . . . . 0.0 111.152 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 176.91 6.17 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.252 . . . . 0.0 112.363 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -77.08 150.46 37.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -57.17 -36.42 70.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -110.34 40.35 1.98 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 49.2 mmtt -134.72 165.77 24.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.42 144.54 62.35 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 94.01 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.658 2.239 . . . . 0.0 112.396 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.801 HG13 ' O ' ' A' ' 112' ' ' VAL . 89.3 t -145.72 135.55 18.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.089 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -102.51 128.43 49.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -100.21 109.86 22.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 161' ' ' VAL . 67.3 t -100.77 130.17 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 21.7 m -117.91 135.1 54.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.135 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 153.87 179.72 29.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.504 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.471 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.9 mmt -46.57 159.28 0.36 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.53 0.681 . . . . 0.0 110.905 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 0.85 5.06 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.673 2.249 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -118.47 -29.13 5.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.914 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.481 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 8.4 m-20 -78.22 -46.47 20.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.838 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.471 HG22 ' O ' ' A' ' 157' ' ' MET . 16.0 m -68.32 -23.56 28.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -66.72 -39.12 87.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 24.2 ttm-85 -70.15 -46.87 63.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.37 -34.62 58.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.118 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.43 ' HE ' ' CD1' ' A' ' 110' ' ' ILE . 13.6 ttm180 -64.48 -50.87 65.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -62.9 -24.68 67.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.541 ' OE1' HG23 ' A' ' 133' ' ' ILE . 22.3 mt-10 -77.08 -56.5 4.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 76.2 mt -52.73 -53.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -56.28 -43.37 78.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -41.78 -58.3 2.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.444 ' C ' ' O ' ' A' ' 170' ' ' ALA . 9.8 m80 -34.45 -36.07 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.527 HG12 HG21 ' A' ' 118' ' ' VAL . 64.9 mt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.147 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.869 0.366 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -125.61 159.48 32.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.2 m -128.51 116.42 19.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -104.77 155.32 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -114.42 101.0 8.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 91.3 t -69.64 141.97 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 23.6 ttp180 -111.67 112.05 23.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.49 HG11 HG22 ' A' ' 168' ' ' ILE . 2.4 m -134.11 151.4 76.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.614 0.721 . . . . 0.0 111.108 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.542 ' CB ' ' NH1' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.74 138.37 37.72 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.682 2.255 . . . . 0.0 112.322 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.0 t80 -46.96 -37.91 9.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.542 ' NH1' ' CB ' ' A' ' 115' ' ' PRO . 8.6 ptp85 -59.01 -38.62 79.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.491 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 19.8 t -78.0 -36.42 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.171 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 97.1 t -41.37 -63.7 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.07 -39.21 18.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.3 mt -65.15 -43.9 90.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 0.0 110.921 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 73.4 t -71.57 -60.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.7 t -42.28 -45.54 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 73.92 173.34 27.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.482 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.4 Cg_exo -48.03 114.74 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.7 pttm 36.1 39.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.895 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.44 73.77 0.78 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.61 -38.49 3.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 m -85.5 -44.25 12.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.82 HD11 HG21 ' A' ' 141' ' ' ILE . 6.1 tp -60.82 -31.16 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -68.03 -40.18 82.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -60.85 -44.23 97.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.833 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 73.0 mt -54.58 -54.58 21.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.126 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.539 ' HG3' HD12 ' A' ' 141' ' ' ILE . 76.1 mt-30 -42.81 -30.9 0.43 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -78.27 -53.72 7.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.4 -32.17 56.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 74.1 p -102.22 -17.5 15.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.178 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 134' ' ' GLN . 16.9 m170 59.27 54.94 4.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.821 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.468 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.3 p -135.28 174.51 10.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -106.21 89.94 3.21 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.82 HG21 HD11 ' A' ' 130' ' ' ILE . 84.8 mt -82.89 137.14 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.1 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 91.7 t -124.63 132.14 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.166 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.7 p -90.26 147.86 37.82 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.582 0.706 . . . . 0.0 111.166 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -179.11 2.67 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.315 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.44 176.92 51.5 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.52 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . 0.419 ' C ' ' HD3' ' A' ' 146' ' ' ARG . 0.2 OUTLIER -80.23 -35.29 36.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -106.87 39.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 38.7 mmtt -138.01 175.43 9.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -71.98 143.41 86.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.592 0.71 . . . . 0.0 110.935 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 89.66 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.644 2.229 . . . . 0.0 112.394 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 75.4 t -138.17 119.64 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.71 148.88 25.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.86 105.62 10.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.08 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 161' ' ' VAL . 96.0 t -100.89 127.03 54.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.128 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -112.79 138.68 49.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 150.4 176.04 23.03 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.618 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -41.03 159.4 0.16 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.582 0.706 . . . . 0.0 110.87 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 0.58 5.4 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.706 2.271 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -118.35 -35.46 3.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.468 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.1 m-20 -69.25 -46.31 67.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.904 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 154' ' ' VAL . 33.7 m -68.88 -38.61 78.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.134 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -52.37 -42.04 63.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 42.0 ttt85 -63.82 -52.56 59.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -45.58 -49.28 14.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.079 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 44.4 ttt180 -51.6 -40.5 59.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -57.61 -47.98 80.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -65.04 -56.69 11.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.937 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.49 HG22 HG11 ' A' ' 114' ' ' VAL . 65.4 mt -47.84 -50.69 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.132 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -65.89 -47.03 76.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.433 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.83 -55.75 1.46 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 170' ' ' ALA . 95.2 m-70 -36.02 -43.11 0.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.833 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.419 HG12 HG21 ' A' ' 118' ' ' VAL . 73.6 mt . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.092 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.853 0.358 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -147.71 156.97 43.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.162 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 97.8 m -127.9 122.49 32.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.675 HD12 ' HE ' ' A' ' 165' ' ' ARG . 22.6 pt -111.27 154.84 12.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -109.9 101.76 10.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.735 HG22 ' HG3' ' A' ' 165' ' ' ARG . 54.0 t -69.67 132.98 32.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 14.9 ttp180 -100.39 118.95 37.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.549 HG13 HG12 ' A' ' 112' ' ' VAL . 3.3 m -141.14 150.45 58.85 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.624 0.726 . . . . 0.0 111.085 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 133.18 24.98 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -42.42 -26.89 0.13 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 60.2 ttp85 -69.35 -54.06 16.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.766 HG21 HG12 ' A' ' 172' ' ' ILE . 35.8 t -63.65 -27.29 42.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.1 t -46.5 -71.09 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -43.68 -34.67 2.79 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 8.7 mt -67.39 -44.19 79.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 83.9 t -69.42 -65.58 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.9 t -37.63 -61.5 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.78 166.15 38.64 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.514 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_exo -47.97 93.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt 56.98 54.03 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.939 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 54.93 70.95 0.8 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.71 -41.14 2.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 111.084 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 73.7 m -78.59 -44.5 23.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.155 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 133' ' ' ILE . 7.5 tp -54.4 -29.59 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.7 tptp -54.57 -44.64 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -61.27 -22.12 64.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 130' ' ' ILE . 70.5 mt -83.1 -31.56 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.136 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.708 ' HG3' HD12 ' A' ' 141' ' ' ILE . 44.8 mt-30 -83.34 -24.45 32.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . 0.472 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.82 -41.01 19.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.472 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 14.9 mmm180 -64.62 -35.68 81.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -100.56 -18.12 16.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.16 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.4 m80 62.28 46.18 6.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.822 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.454 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.6 p -120.67 164.55 16.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 t80 -95.66 88.25 4.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 134' ' ' GLN . 79.9 mt -88.69 132.81 32.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.103 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.4 t -117.96 132.09 68.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.167 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 64.4 p -85.55 148.07 48.25 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.596 0.713 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 176.49 6.73 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.647 2.231 . . . . 0.0 112.356 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.56 179.22 53.24 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.48 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -79.16 -43.25 24.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.884 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.7 p-10 -104.79 43.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 52.9 mmtt -134.08 169.04 17.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.407 ' H ' ' CD ' ' A' ' 149' ' ' GLU . 2.0 pm0 -66.57 143.99 98.43 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.669 0.747 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 95.7 0.56 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 2.267 . . . . 0.0 112.313 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.2 t -147.7 119.59 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.172 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -88.27 140.27 29.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.02 110.17 20.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.081 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.489 HG12 HG12 ' A' ' 161' ' ' VAL . 23.8 t -103.98 122.51 56.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 93.6 m -111.03 130.59 55.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.153 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.491 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 158.31 178.16 32.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.475 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.703 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.5 mmt -45.37 158.94 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -0.69 7.2 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.737 2.291 . . . . 0.0 112.32 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.78 -25.38 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.908 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.454 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 5.5 m-20 -83.07 -48.52 10.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.703 HG22 ' O ' ' A' ' 157' ' ' MET . 34.1 m -64.78 -36.96 78.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -58.36 -45.28 88.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.855 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -61.46 -43.91 98.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.873 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.92 -44.01 70.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.735 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.6 ttm180 -59.42 -42.85 92.8 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.872 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . 0.425 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 18.2 mt-10 -53.37 -42.88 67.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.935 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -71.3 -51.61 23.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.877 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 61.6 mt -49.34 -53.99 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -67.38 -41.45 85.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.59 -61.44 0.71 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 170' ' ' ALA . 32.7 m170 -34.46 -41.29 0.12 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.842 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.766 HG12 HG21 ' A' ' 118' ' ' VAL . 93.4 mt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.903 0.382 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.4 t -129.47 159.66 35.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -131.24 120.64 23.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.187 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 25.0 pt -111.15 152.89 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 38.2 mm-40 -108.02 100.66 9.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.896 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 168' ' ' ILE . 88.4 t -73.09 141.97 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.147 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 37.5 ttt-85 -104.98 120.88 42.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.429 HG21 ' CE1' ' A' ' 152' ' ' PHE . 4.8 m -140.49 151.07 62.84 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.688 0.756 . . . . 0.0 111.074 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.546 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.2 Cg_endo -69.79 138.4 37.64 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.685 2.256 . . . . 0.0 112.314 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -47.52 -26.21 1.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.927 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 ttm180 -69.6 -46.99 65.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.835 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 122' ' ' VAL . 41.2 t -68.39 -29.37 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.108 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.4 t -42.27 -65.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.66 -34.08 9.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.4 -46.11 61.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.85 0.357 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.598 HG23 HG12 ' A' ' 118' ' ' VAL . 91.9 t -64.89 -57.92 9.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.459 HG22 ' CG2' ' A' ' 143' ' ' THR . 90.2 t -55.28 -49.24 74.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.095 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.94 172.69 48.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.44 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.95 99.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.652 2.235 . . . . 0.0 112.382 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? 54.01 42.71 31.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.46 68.38 1.67 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.52 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.28 -35.18 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.893 0.378 . . . . 0.0 111.109 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 33.1 m -75.94 -39.41 56.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.751 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -67.21 -23.08 29.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -62.58 -38.5 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -66.44 -37.8 85.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.844 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 66.7 mt -70.48 -49.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.116 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -52.32 -37.49 55.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -81.82 -52.41 7.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 -52.89 -33.87 52.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.7 p -103.54 -15.15 15.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.165 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 17.8 m170 60.95 53.79 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.47 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.5 p -138.01 138.27 38.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 51.9 t80 -76.74 91.92 3.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.751 HG21 HD11 ' A' ' 130' ' ' ILE . 77.7 mt -83.64 134.41 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.1 t -120.28 129.32 75.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.137 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.459 ' CG2' HG22 ' A' ' 123' ' ' VAL . 41.6 p -83.8 153.12 63.94 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.54 0.686 . . . . 0.0 111.191 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 177.06 5.97 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.684 2.256 . . . . 0.0 112.366 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -75.06 155.67 48.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.45 -28.49 70.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.86 0.362 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -119.91 38.01 4.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -135.91 162.13 33.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -53.99 143.86 40.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.638 0.732 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.73 97.68 0.65 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.695 2.263 . . . . 0.0 112.331 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.3 t -145.32 117.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.429 ' CE1' HG21 ' A' ' 114' ' ' VAL . 35.4 m-85 -86.73 146.31 26.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.86 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -121.74 99.13 6.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.43 HG12 HG12 ' A' ' 161' ' ' VAL . 46.6 t -87.63 131.1 36.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -117.09 131.07 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.177 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 156.43 175.13 27.04 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.456 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.577 ' O ' HG22 ' A' ' 161' ' ' VAL . 21.6 mmt -39.2 159.49 0.1 Allowed Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.576 0.703 . . . . 0.0 110.902 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.723 2.282 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -119.7 -38.38 2.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.4 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.2 m-20 -66.77 -46.42 75.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 157' ' ' MET . 20.5 m -67.72 -38.1 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -52.89 -43.1 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 11.9 ttt180 -61.89 -57.92 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.06 -48.54 4.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 16.9 ttp85 -48.34 -40.24 24.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -55.48 -64.82 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 58.1 mm-40 -54.22 -46.35 72.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 112' ' ' VAL . 47.7 mt -44.63 -65.91 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.082 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.446 ' HB2' HD12 ' A' ' 172' ' ' ILE . 0.7 OUTLIER -69.36 -29.52 67.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.861 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -48.74 -48.99 40.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -46.89 -26.32 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 69.6 mt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--O 1.233 0.189 0 CA-C-O 120.889 0.376 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.9 t -124.5 168.4 13.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.123 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 25.6 m -137.34 124.63 21.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 23.0 pt -122.46 155.24 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.091 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -105.2 111.66 24.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.548 HG12 HG13 ' A' ' 114' ' ' VAL . 70.4 t -76.77 135.04 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -106.65 117.65 34.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.584 HG11 HG22 ' A' ' 168' ' ' ILE . 8.7 m -137.96 151.05 69.42 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.669 0.747 . . . . 0.0 111.121 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.418 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.68 134.37 27.98 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -47.09 -21.98 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 91.7 mtt-85 -72.59 -44.02 62.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.605 HG21 HG12 ' A' ' 172' ' ' ILE . 39.6 t -74.31 -34.41 36.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.15 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.8 t -38.23 -69.92 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.155 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.31 -36.21 4.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.472 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 118' ' ' VAL . 15.1 mt -68.01 -44.16 77.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.882 0.373 . . . . 0.0 110.958 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.561 HG23 HG12 ' A' ' 118' ' ' VAL . 57.5 t -65.53 -63.28 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.3 t -40.88 -50.43 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.142 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 79.97 169.08 38.51 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.05 101.23 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.353 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.4 tptm 50.26 44.39 26.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.71 72.9 0.7 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.63 -39.81 2.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 111.12 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -84.49 -43.57 14.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -58.53 -37.88 67.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 27.4 tttm -57.09 -43.2 81.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 74.3 mtt-85 -57.27 -44.35 83.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.876 HG23 ' OE1' ' A' ' 167' ' ' GLU . 58.7 mt -57.93 -46.43 87.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.164 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.511 ' HG3' HD12 ' A' ' 141' ' ' ILE . 53.6 mt-30 -60.8 -20.32 61.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 -90.28 -45.6 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -66.97 -32.7 74.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.45 ' CG2' ' OE2' ' A' ' 167' ' ' GLU . 66.7 p -101.48 -15.63 17.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 11.6 m170 56.79 49.91 13.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.571 HG21 ' HA ' ' A' ' 161' ' ' VAL . 57.9 p -131.8 146.8 52.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.173 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 26.1 t80 -78.85 96.64 5.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 130' ' ' ILE . 91.4 mt -90.97 115.63 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.456 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 97.2 t -105.73 124.99 61.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.568 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.0 p -76.65 152.62 83.2 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.604 0.716 . . . . 0.0 111.177 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 175.79 7.67 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.692 2.261 . . . . 0.0 112.337 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.51 158.98 46.0 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.467 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 12.6 ptp180 -62.27 -44.01 97.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.867 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.43 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 30.8 t0 -103.95 42.35 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.901 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 8.0 mmmm -138.34 163.93 30.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.96 148.73 83.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 101.44 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.709 2.273 . . . . 0.0 112.344 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.2 t -153.82 119.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.094 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.568 ' CE2' HG22 ' A' ' 143' ' ' THR . 52.1 m-85 -89.79 156.93 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.456 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.87 104.76 9.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.138 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 34.1 t -95.81 124.0 48.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.7 m -115.53 134.06 55.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.145 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 154.09 -172.37 32.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.5 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.552 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.0 mmt -50.45 159.4 0.87 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.581 0.705 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.678 2.252 . . . . 0.0 112.362 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -120.03 -33.38 3.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 57.3 m-20 -73.62 -48.73 30.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.571 ' HA ' HG21 ' A' ' 139' ' ' THR . 17.3 m -63.67 -36.1 75.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -61.15 -38.91 88.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -63.17 -40.74 98.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -61.78 -33.39 74.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 47.0 ttp85 -67.16 -50.48 61.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.42 -26.04 66.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.876 ' OE1' HG23 ' A' ' 133' ' ' ILE . 67.5 mt-10 -77.83 -52.91 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.584 HG22 HG11 ' A' ' 114' ' ' VAL . 72.6 mt -58.81 -40.15 79.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -71.87 -38.59 70.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.916 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.2 -54.85 5.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 43.8 m170 -41.65 -32.07 0.34 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.605 HG12 HG21 ' A' ' 118' ' ' VAL . 76.9 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.2 t -127.55 161.3 29.12 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.082 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.7 m -132.31 122.4 25.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.26 156.11 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 49.3 mm-40 -109.88 100.55 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.943 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 94.4 t -67.85 141.01 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 34.6 ttp180 -109.3 124.77 51.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.86 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -146.52 149.57 37.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.56 0.695 . . . . 0.0 111.142 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 139.03 39.31 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.326 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 t80 -49.17 -20.91 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 ttm-85 -74.35 -46.24 41.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.741 HG21 HG12 ' A' ' 172' ' ' ILE . 16.7 t -68.6 -37.28 77.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 87.3 t -39.75 -64.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.098 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.72 -36.6 13.26 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 12.8 mt -70.04 -43.08 71.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.775 0.321 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.461 HG23 HG12 ' A' ' 118' ' ' VAL . 48.8 t -67.31 -63.1 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 96.4 t -38.97 -49.77 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.87 172.61 33.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -47.95 102.81 0.05 OUTLIER 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 91.0 mttt 46.16 44.41 12.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.58 70.67 1.08 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.11 -37.06 3.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 111.088 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 35.4 m -87.96 -44.39 11.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.158 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.696 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -60.79 -28.06 42.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.153 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.9 ttpp -64.67 -46.97 80.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.938 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.2 mtt180 -51.74 -50.55 60.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 56.8 mt -50.14 -54.95 6.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.135 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.674 ' HG3' HD12 ' A' ' 141' ' ' ILE . 46.6 mt-30 -45.89 -37.07 5.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.901 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -79.79 -59.15 2.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -43.51 -37.64 2.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.861 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.6 p -101.03 -22.81 14.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.086 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.7 m80 69.85 52.62 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.466 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.0 p -133.46 155.19 49.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 35.4 t80 -90.07 95.47 10.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.964 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.696 HG21 HD11 ' A' ' 130' ' ' ILE . 90.3 mt -86.77 138.49 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.5 t -129.28 124.08 59.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.187 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.709 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.3 p -80.18 152.68 74.0 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.562 0.696 . . . . 0.0 111.121 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -175.59 1.2 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.6 169.48 45.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.31 -22.87 59.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 20.3 p-10 -123.0 40.77 3.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -138.94 174.19 10.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -68.02 143.94 96.62 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.611 0.72 . . . . 0.0 110.915 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 91.15 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.646 2.231 . . . . 0.0 112.32 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.7 t -138.74 120.04 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.139 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.709 ' CE2' HG22 ' A' ' 143' ' ' THR . 36.2 m-85 -89.1 147.94 23.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -117.92 113.56 21.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.115 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.526 HG12 HG12 ' A' ' 161' ' ' VAL . 53.8 t -106.68 124.4 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 60.2 m -111.54 137.38 49.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.61 -177.27 29.61 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.441 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.804 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.7 mmt -47.28 159.1 0.43 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.545 0.688 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.29 8.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -115.71 -37.01 4.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.839 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 -71.13 -50.62 31.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.903 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.804 HG22 ' O ' ' A' ' 157' ' ' MET . 32.0 m -59.4 -29.51 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.091 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.02 -42.06 94.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -65.83 -32.21 73.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . 0.491 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -66.82 -36.3 82.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.42 ' CG ' ' OE1' ' A' ' 169' ' ' GLU . 41.5 ttt180 -65.31 -59.57 3.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . 0.475 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 1.7 pp20? -51.92 -31.46 28.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -67.56 -55.39 13.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.4 mt -58.27 -53.66 43.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.42 ' OE1' ' CG ' ' A' ' 165' ' ' ARG . 29.0 mt-10 -58.77 -41.52 86.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -41.38 -59.23 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.106 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 50.1 m170 -37.75 -37.91 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.741 HG12 HG21 ' A' ' 118' ' ' VAL . 84.1 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.898 0.38 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.1 t -133.97 163.96 28.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.11 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 56.8 m -131.87 126.16 33.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.152 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.4 pt -111.84 155.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.133 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -112.59 101.01 9.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.451 HG22 ' HG3' ' A' ' 165' ' ' ARG . 90.5 t -72.75 141.28 16.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.139 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.8 ttm180 -111.6 115.37 29.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.409 HG11 HG22 ' A' ' 168' ' ' ILE . 3.5 m -133.37 150.69 75.85 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.658 0.742 . . . . 0.0 111.103 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.49 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.5 Cg_endo -69.84 123.84 10.47 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.636 2.224 . . . . 0.0 112.31 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -35.2 -32.82 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 115' ' ' PRO . 10.9 mmm180 -63.12 -51.96 64.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.49 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 40.1 t -65.36 -32.19 57.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.159 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 122' ' ' VAL . 75.8 t -42.66 -72.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 119' ' ' VAL . . . -37.64 -36.79 0.31 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.5 mt -69.99 -39.59 75.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.898 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.483 ' N ' ' O ' ' A' ' 119' ' ' VAL . 38.4 t -68.92 -63.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.3 t -43.97 -55.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.079 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.84 172.83 49.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -48.03 107.09 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.638 2.225 . . . . 0.0 112.369 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 43.9 39.16 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.73 75.47 0.52 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -120.34 -41.51 2.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.086 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 83.4 m -81.49 -44.77 16.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.151 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 133' ' ' ILE . 9.7 tp -54.67 -40.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.149 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 130' ' ' ILE . 10.4 ttpp -51.72 -44.55 63.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.427 ' HA ' ' CG ' ' A' ' 135' ' ' GLN . 21.8 mtp180 -63.63 -20.58 65.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 130' ' ' ILE . 71.4 mt -79.81 -37.44 18.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.726 ' CG ' HD12 ' A' ' 141' ' ' ILE . 69.1 mt-30 -78.12 -26.96 48.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . 0.479 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.85 -41.38 19.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.479 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 13.9 mmt180 -62.4 -39.26 92.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 38.8 p -101.3 -6.53 24.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.155 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 74.1 m80 55.2 52.8 11.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.467 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 13.1 p -129.02 150.15 50.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.18 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -90.66 92.6 8.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.732 HG12 HG22 ' A' ' 154' ' ' VAL . 69.7 mt -84.67 124.08 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.773 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 79.7 t -100.41 109.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.6 p -79.04 148.84 72.45 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.707 . . . . 0.0 111.125 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.86 23.17 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.27 -164.33 27.75 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.482 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -71.67 -54.2 11.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.783 0.325 . . . . 0.0 110.849 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -103.88 41.29 1.31 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.66 140.05 50.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.943 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.52 143.31 2.95 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 82.14 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.653 2.236 . . . . 0.0 112.347 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 112' ' ' VAL . 46.3 t -139.63 119.93 14.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.128 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.654 ' CE2' HG22 ' A' ' 143' ' ' THR . 23.9 m-85 -90.58 147.43 23.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.856 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.773 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -119.53 98.57 6.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.07 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.732 HG22 HG12 ' A' ' 141' ' ' ILE . 58.0 t -86.12 119.27 34.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.187 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.1 m -107.71 132.34 53.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.115 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.432 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 155.64 -173.0 33.76 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.539 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.9 mmt -50.58 158.7 1.02 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.589 0.709 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -2.49 10.24 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.695 2.263 . . . . 0.0 112.353 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -113.25 -32.67 6.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.467 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 21.4 m-20 -77.16 -53.57 7.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 157' ' ' MET . 17.8 m -54.29 -34.55 27.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.151 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.436 ' C ' ' OE2' ' A' ' 166' ' ' GLU . 23.2 t0 -59.38 -67.86 0.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.858 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 21.3 ttm-85 -43.76 -51.27 7.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.75 -36.5 3.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.451 ' HG3' HG22 ' A' ' 112' ' ' VAL . 37.6 ttp180 -72.57 -34.61 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 166' ' ' GLU . 0.1 OUTLIER -57.77 -39.68 78.01 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.888 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -71.56 -53.72 12.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.409 HG22 HG11 ' A' ' 114' ' ' VAL . 70.3 mt -49.96 -48.98 22.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -65.26 -43.38 91.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.438 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -44.39 -57.66 3.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.08 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.438 ' C ' ' O ' ' A' ' 170' ' ' ALA . 11.4 m80 -35.45 -37.91 0.09 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.45 HG12 HG21 ' A' ' 118' ' ' VAL . 66.7 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.473 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.861 0.362 . . . . 0.0 110.943 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.8 t -134.31 157.33 46.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 91.5 m -128.4 118.29 22.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.9 pt -106.91 154.34 7.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.45 ' NE2' ' HB2' ' A' ' 153' ' ' ALA . 43.4 mm-40 -112.27 105.74 14.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.503 HG22 ' CD ' ' A' ' 165' ' ' ARG . 93.4 t -82.12 144.77 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.16 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.44 ' O ' ' CG1' ' A' ' 114' ' ' VAL . 7.9 mpt_? -109.54 147.37 33.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.44 ' CG1' ' O ' ' A' ' 113' ' ' ARG . 7.6 m -158.45 151.11 18.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.627 0.727 . . . . 0.0 111.151 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.498 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.7 Cg_endo -69.72 127.03 14.03 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.713 2.275 . . . . 0.0 112.361 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -41.42 -24.42 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.918 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 115' ' ' PRO . 46.9 mtt85 -71.28 -43.81 66.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.559 HG21 HG12 ' A' ' 172' ' ' ILE . 41.2 t -74.56 -34.96 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.093 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.1 t -39.71 -63.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.36 -39.2 9.66 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.495 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -67.56 -46.62 72.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.881 0.372 . . . . 0.0 110.937 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.546 HG23 HG12 ' A' ' 118' ' ' VAL . 59.0 t -63.79 -63.88 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 87.1 t -40.4 -49.59 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 72.7 172.87 22.04 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.477 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.7 Cg_exo -47.99 118.21 2.98 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.718 2.279 . . . . 0.0 112.352 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.434 ' C ' ' O ' ' A' ' 125' ' ' PRO . 8.0 ptpp? 35.25 43.63 0.13 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 62.46 65.66 3.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.447 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.33 -39.27 6.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.838 0.351 . . . . 0.0 111.048 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.1 m -83.91 -50.34 8.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.158 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.489 HD11 HG21 ' A' ' 141' ' ' ILE . 7.3 tp -49.94 -40.8 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.435 ' N ' HG23 ' A' ' 130' ' ' ILE . 25.0 tttp -60.92 -43.88 97.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 49.4 mtt180 -54.33 -41.14 68.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.467 HD11 ' CE1' ' A' ' 171' ' ' HIS . 54.8 mt -59.28 -49.93 81.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.461 ' HG3' HD12 ' A' ' 141' ' ' ILE . 62.1 mt-30 -47.77 -34.67 8.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -80.59 -54.44 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 53.7 mtt-85 -51.96 -33.42 37.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.865 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.478 HG21 ' HA ' ' A' ' 164' ' ' ALA . 37.4 p -103.59 -16.62 15.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 72.8 m80 61.23 51.15 4.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.565 HG21 ' HA ' ' A' ' 161' ' ' VAL . 38.0 p -136.52 141.51 43.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.129 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -77.15 97.42 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.489 HG21 HD11 ' A' ' 130' ' ' ILE . 79.8 mt -89.93 141.48 14.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.137 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.5 t -125.91 129.09 72.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.072 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 35.3 p -86.12 149.14 49.4 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.583 0.706 . . . . 0.0 111.135 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 177.83 5.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.663 2.242 . . . . 0.0 112.364 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.35 170.91 52.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 18.8 ptt180 -71.34 -42.24 68.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.33 . . . . 0.0 110.861 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 2.5 p30 -104.61 42.09 1.25 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.82 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -139.18 159.3 42.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.894 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -58.03 142.59 79.63 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.623 0.725 . . . . 0.0 110.895 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 101.77 0.96 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.319 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -147.83 115.16 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.099 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -82.89 143.5 30.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.45 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . . . -118.97 106.71 12.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.099 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.413 HG22 HG12 ' A' ' 141' ' ' ILE . 47.4 t -95.51 123.15 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 72.8 m -110.58 129.93 55.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . 0.497 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.78 178.8 32.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.478 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.56 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -44.56 159.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.561 0.696 . . . . 0.0 110.877 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 0.75 5.19 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.643 2.229 . . . . 0.0 112.32 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -117.99 -37.53 3.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.878 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.465 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.4 m-20 -71.14 -45.71 62.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.565 ' HA ' HG21 ' A' ' 139' ' ' THR . 13.8 m -66.8 -38.16 80.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -55.9 -39.63 71.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -62.78 -47.21 84.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . 0.478 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -49.32 -42.83 42.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.068 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.503 ' CD ' HG22 ' A' ' 112' ' ' VAL . 11.7 tpt180 -48.9 -46.63 43.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 49.0 mm-40 -63.74 -37.46 87.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -63.3 -59.65 4.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 58.8 mt -53.03 -50.44 44.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.138 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -59.97 -43.25 95.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.415 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -47.0 -56.03 7.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.099 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.467 ' CE1' HD11 ' A' ' 133' ' ' ILE . 27.3 m170 -37.17 -41.34 0.38 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.559 HG12 HG21 ' A' ' 118' ' ' VAL . 57.3 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.434 ' HB3' ' HE2' ' A' ' 157' ' ' MET . 11.5 pt20 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.887 0.375 . . . . 0.0 110.911 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.5 t -133.78 164.2 27.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 93.1 m -132.69 124.55 28.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.135 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.9 pt -110.47 152.02 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . 0.679 HE22 ' HB2' ' A' ' 153' ' ' ALA . 4.6 mm-40 -108.17 96.77 6.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.908 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 114' ' ' VAL . 76.9 t -68.02 137.05 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -108.58 115.71 30.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.916 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 112' ' ' VAL . 11.4 m -137.29 151.11 70.92 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.589 0.709 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.543 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.3 Cg_endo -69.72 127.77 15.1 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.355 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -39.56 -27.34 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 115' ' ' PRO . 22.0 ttm180 -67.12 -44.94 78.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.899 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.545 HG12 HG23 ' A' ' 122' ' ' VAL . 55.2 t -74.51 -29.15 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 74.1 t -45.12 -63.07 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.104 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.91 -38.26 30.52 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.49 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.5 mt -66.78 -45.5 78.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.903 0.382 . . . . 0.0 110.971 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.545 HG23 HG12 ' A' ' 118' ' ' VAL . 89.9 t -66.28 -58.23 7.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.13 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.3 t -44.16 -54.85 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.411 ' O ' ' N ' ' A' ' 126' ' ' LYS . . . 85.12 172.77 49.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.494 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.0 88.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.411 ' N ' ' O ' ' A' ' 124' ' ' GLY . 34.4 tttp 58.01 48.64 12.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.891 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.69 60.03 7.01 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.502 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.93 -40.21 6.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.845 0.355 . . . . 0.0 111.069 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 94.2 m -85.77 -50.79 6.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.701 HD11 HG21 ' A' ' 141' ' ' ILE . 8.4 tp -52.53 -28.98 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.12 -49.14 71.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -51.04 -40.14 57.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.882 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.4 mt -63.46 -47.16 92.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.496 ' CG ' HD12 ' A' ' 141' ' ' ILE . 70.4 mt-30 -48.1 -36.85 14.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 67.3 mm-40 -82.24 -50.12 9.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.7 mtt85 -52.78 -33.91 50.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.882 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.3 p -105.68 -12.08 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.144 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 15.5 m170 58.26 54.12 5.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.466 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 70.5 p -139.46 139.11 36.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.423 ' HE2' HG22 ' A' ' 142' ' ' VAL . 38.2 t80 -75.25 97.94 3.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.701 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -87.71 122.99 40.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.147 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.423 HG22 ' HE2' ' A' ' 140' ' ' TYR . 94.0 t -107.02 128.27 62.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.781 HG22 ' HE1' ' A' ' 152' ' ' PHE . 34.1 p -87.38 144.32 35.62 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.583 0.706 . . . . 0.0 111.128 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -177.28 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.705 2.27 . . . . 0.0 112.304 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -90.7 -175.16 44.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 6.1 ptp85 -84.9 -41.16 16.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -100.77 40.08 1.31 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -138.42 169.44 17.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.91 144.18 95.47 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.713 0.768 . . . . 0.0 110.89 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 87.5 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.727 2.285 . . . . 0.0 112.316 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.4 t -137.86 121.17 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.781 ' HE1' HG22 ' A' ' 143' ' ' THR . 69.9 m-85 -91.12 143.98 26.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.679 ' HB2' HE22 ' A' ' 111' ' ' GLN . . . -114.87 104.57 12.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 161' ' ' VAL . 46.7 t -95.05 124.41 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 27.0 m -110.83 132.8 53.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 155.13 177.56 28.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.639 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.8 mmt -43.03 159.55 0.21 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.56 0.695 . . . . 0.0 110.865 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.69 5.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.736 2.291 . . . . 0.0 112.339 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -118.71 -35.66 3.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.907 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.466 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 71.0 m-20 -69.33 -45.75 68.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.882 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 154' ' ' VAL . 35.2 m -67.01 -39.38 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.143 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 11.5 t70 -54.5 -42.3 70.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.865 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -53.89 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.92 -52.25 25.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.412 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 50.0 ttt85 -42.51 -39.38 2.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.866 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -68.49 -45.53 72.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -58.57 -54.55 45.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.405 HG23 HG11 ' A' ' 122' ' ' VAL . 84.4 mt -55.12 -51.12 57.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.412 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 66.0 mt-10 -59.13 -46.0 89.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.901 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.445 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.13 -57.55 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.06 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 170' ' ' ALA . 14.7 m170 -34.9 -42.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.514 HG12 HG21 ' A' ' 118' ' ' VAL . 74.9 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.127 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--O 1.232 0.161 0 CA-C-O 120.867 0.365 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.0 t -123.53 159.67 28.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.174 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.621 ' OG1' HG23 ' A' ' 155' ' ' THR . 84.2 m -130.26 120.69 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.097 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.716 HD12 ' HE ' ' A' ' 165' ' ' ARG . 36.3 pt -108.38 154.97 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.109 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.9 mm-40 -113.82 96.14 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.596 ' O ' HG13 ' A' ' 151' ' ' VAL . 96.0 t -66.68 140.73 18.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.127 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -106.14 110.96 23.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.467 HG13 HG12 ' A' ' 112' ' ' VAL . 3.2 m -133.32 151.27 77.25 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 0.0 111.11 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.479 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 149.79 67.37 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.703 2.269 . . . . 0.0 112.334 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -55.24 -39.34 69.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.923 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.45 ' HG3' ' N ' ' A' ' 118' ' ' VAL . 4.6 ptp180 -57.78 -41.85 82.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.479 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 16.5 t -71.53 -37.29 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 150' ' ' PRO . 77.5 t -43.06 -69.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -41.21 -34.46 0.94 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.7 mt -71.22 -56.92 5.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.447 HG12 HD13 ' A' ' 130' ' ' ILE . 86.7 t -52.83 -57.58 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.145 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 74.5 t -49.77 -54.74 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.11 169.84 42.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -47.93 97.37 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.718 2.278 . . . . 0.0 112.347 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.0 mttt 54.52 47.65 22.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.888 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.84 68.18 1.79 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -112.2 -38.38 4.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 0.0 111.1 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 72.6 m -86.46 -42.71 13.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.152 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 141' ' ' ILE . 5.2 tp -62.87 -36.48 75.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.2 ttpt -55.89 -46.18 78.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -53.83 -41.86 67.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 65.8 mt -61.38 -59.21 4.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.621 ' HG3' HD12 ' A' ' 141' ' ' ILE . 72.4 mt-30 -41.54 -36.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.899 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -80.83 -53.37 6.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -51.19 -34.53 32.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.1 p -105.93 -8.47 17.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 13.5 m170 53.58 54.55 9.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.866 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.1 p -135.39 147.75 49.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -82.66 96.85 8.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.777 HG21 HD11 ' A' ' 130' ' ' ILE . 75.1 mt -89.94 116.16 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.145 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.0 t -102.76 113.99 41.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.156 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.456 HG22 ' CE2' ' A' ' 152' ' ' PHE . 37.9 p -72.57 153.42 91.69 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.521 0.677 . . . . 0.0 111.154 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 177.66 5.31 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.678 2.252 . . . . 0.0 112.375 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -85.01 170.69 45.66 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.502 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . 0.474 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 4.2 ptm85 -69.53 -48.49 60.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 110.922 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . 0.474 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.7 p30 -99.92 43.42 1.06 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -138.54 168.79 19.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -66.82 144.25 98.47 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.632 0.729 . . . . 0.0 110.926 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.52 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.1 Cg_endo -69.85 100.16 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.311 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.596 HG13 ' O ' ' A' ' 112' ' ' VAL . 90.5 t -147.06 127.92 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . 0.456 ' CE2' HG22 ' A' ' 143' ' ' THR . 48.3 m-85 -96.62 125.89 41.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.96 99.58 9.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.074 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.553 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -88.77 133.69 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.621 HG23 ' OG1' ' A' ' 109' ' ' THR . 32.2 m -120.04 128.79 53.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 157.74 178.25 31.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.681 ' O ' HG22 ' A' ' 161' ' ' VAL . 9.0 mmt -41.04 159.2 0.17 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.559 0.695 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.7 8.91 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.678 2.252 . . . . 0.0 112.333 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . 0.448 ' C ' ' OE1' ' A' ' 159' ' ' GLU . 0.5 OUTLIER -116.97 -38.06 3.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.965 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . 0.436 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.9 m-20 -67.35 -45.55 76.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.681 HG22 ' O ' ' A' ' 157' ' ' MET . 30.0 m -68.51 -40.04 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 29.8 t0 -53.19 -40.26 64.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 33.1 ttt-85 -64.68 -59.17 4.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.33 -45.82 6.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.716 ' HE ' HD12 ' A' ' 110' ' ' ILE . 21.1 ttm180 -47.71 -45.15 28.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -53.96 -61.19 2.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 13.4 mm-40 -53.6 -39.12 64.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . 0.535 HD12 ' HA ' ' A' ' 165' ' ' ARG . 61.2 mt -55.84 -70.55 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.444 ' HB2' HD12 ' A' ' 172' ' ' ILE . 2.3 pt-20 -59.69 -33.21 71.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.899 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -37.25 -57.1 0.91 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.083 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 170' ' ' ALA . 17.6 m80 -37.63 -41.84 0.51 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.837 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.444 HD12 ' HB2' ' A' ' 169' ' ' GLU . 74.2 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.849 0.356 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.3 t -135.43 161.97 33.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.113 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.7 m -136.2 124.97 23.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.098 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.7 pt -114.28 154.3 15.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.3 mm-40 -109.58 106.55 16.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 94.4 t -73.85 137.99 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 16.0 ttm180 -109.54 115.68 30.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.87 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.448 HG13 HG12 ' A' ' 112' ' ' VAL . 4.5 m -135.51 150.8 73.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.653 0.739 . . . . 0.0 111.109 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.4 Cg_endo -69.77 129.14 17.07 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.345 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -39.47 -28.59 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.894 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.6 mmt180 -65.86 -51.43 58.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.848 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.797 HG21 HG12 ' A' ' 172' ' ' ILE . 28.9 t -66.59 -36.7 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.16 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 118' ' ' VAL . 77.4 t -37.32 -69.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.114 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.93 -39.49 8.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 118' ' ' VAL . 14.2 mt -64.67 -41.14 96.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.902 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.532 HG23 HG12 ' A' ' 118' ' ' VAL . 22.0 t -68.89 -64.99 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.098 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 122' ' ' VAL . 89.4 t -37.35 -46.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.41 173.13 32.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.417 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.1 Cg_exo -47.99 112.55 0.6 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.658 2.239 . . . . 0.0 112.341 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.2 ptmt 36.64 41.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.905 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.55 83.29 0.2 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.471 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.38 -41.34 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.864 0.364 . . . . 0.0 111.083 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 39.5 m -84.16 -44.18 14.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.121 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.71 HD11 HG21 ' A' ' 141' ' ' ILE . 5.8 tp -60.02 -40.47 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.424 ' N ' HG23 ' A' ' 130' ' ' ILE . 37.0 tttp -58.28 -41.93 85.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.898 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -56.45 -42.68 78.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.88 -48.23 88.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . 0.561 ' HG3' HD12 ' A' ' 141' ' ' ILE . 78.9 mt-30 -48.56 -36.72 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.929 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 4.3 mm100 -82.48 -54.84 4.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.93 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -49.95 -32.53 15.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -105.6 -13.6 15.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.105 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 28.0 m80 58.84 54.41 5.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . 0.41 HG21 ' HA ' ' A' ' 161' ' ' VAL . 68.5 p -139.88 143.3 36.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -77.49 100.55 6.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.922 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.71 HG21 HD11 ' A' ' 130' ' ' ILE . 75.9 mt -92.79 119.1 39.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.3 t -109.6 127.52 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.104 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.6 p -85.26 151.61 56.91 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.562 0.696 . . . . 0.0 111.197 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 177.67 5.33 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.689 2.26 . . . . 0.0 112.354 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.7 168.15 49.18 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.44 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.19 -43.91 93.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.814 0.34 . . . . 0.0 110.836 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -103.18 43.6 1.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -132.45 171.61 13.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.21 148.85 91.54 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 110.871 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 87.64 0.56 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.349 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.4 t -143.78 121.13 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.087 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -90.31 153.64 20.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.832 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.7 106.96 11.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.094 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.602 HG12 HG12 ' A' ' 161' ' ' VAL . 50.7 t -97.74 125.28 50.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 75.1 m -112.3 137.38 50.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.49 -173.13 31.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.495 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' MET . . . . . 0.742 ' O ' HG22 ' A' ' 161' ' ' VAL . 8.2 mmt -53.89 159.86 2.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 0.0 110.877 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' PRO . . . . . 0.428 ' HD2' ' SD ' ' A' ' 157' ' ' MET . 54.2 Cg_endo -69.7 -0.55 7.02 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.672 2.248 . . . . 0.0 112.391 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' GLU . . . . . 0.431 ' CD ' ' HB3' ' A' ' 157' ' ' MET . 23.5 pm0 -118.01 -26.25 6.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -82.63 -43.51 16.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 157' ' ' MET . 35.7 m -69.5 -35.14 65.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -56.76 -47.81 79.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.9 ttt-85 -57.31 -55.24 37.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.21 -45.38 5.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -52.43 -45.5 66.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -64.39 -42.53 96.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -58.39 -53.84 53.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 91.0 mt -55.59 -54.79 21.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -56.63 -46.23 81.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' ALA . . . . . 0.441 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.36 -60.29 0.8 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.132 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 170' ' ' ALA . 40.7 m170 -34.95 -38.77 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.872 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.797 HG12 HG21 ' A' ' 118' ' ' VAL . 74.7 mt . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.093 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 13.3 t -117.49 -56.88 2.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.865 0.364 . . . . 0.0 110.845 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.0 m -138.32 151.82 47.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.87 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 121.53 53.69 0.23 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 10.9 t -154.73 135.74 13.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.888 0.375 . . . . 0.0 110.901 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.1 t -92.87 105.54 17.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.841 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 145.67 116.26 1.01 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -111.33 -75.31 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -57.51 -178.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.889 0.376 . . . . 0.0 110.944 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.5 t -141.73 161.25 38.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 90.4 m -131.28 124.18 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.165 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.5 pt -114.29 153.14 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.125 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 52.6 mm-40 -109.87 106.26 15.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.553 HG22 ' HG3' ' A' ' 165' ' ' ARG . 74.7 t -77.59 135.61 26.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.114 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 8.9 ttp-105 -104.8 120.89 42.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.862 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.6 m -136.46 150.72 71.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.609 0.718 . . . . 0.0 111.124 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.534 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.7 130.63 19.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.682 2.255 . . . . 0.0 112.363 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -45.04 -22.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.939 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.425 ' NH1' ' HB2' ' A' ' 117' ' ' ARG . 14.7 ttm105 -72.08 -44.23 63.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.918 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.637 HG12 HG23 ' A' ' 122' ' ' VAL . 74.9 t -76.03 -31.68 22.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 122' ' ' VAL . 42.6 t -39.3 -74.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.107 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -38.74 -34.33 0.26 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.547 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.421 HD12 ' HA ' ' A' ' 118' ' ' VAL . 13.2 mt -71.67 -44.21 64.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.864 0.364 . . . . 0.0 110.876 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.637 HG23 HG12 ' A' ' 118' ' ' VAL . 86.9 t -66.04 -62.04 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.119 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.412 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 84.7 t -46.8 -48.27 7.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.85 172.71 49.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.97 91.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 12.2 mmtp 53.13 38.59 27.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 78.32 72.89 1.13 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.535 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -124.39 -27.25 3.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.821 0.343 . . . . 0.0 111.102 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 65.7 m -98.68 -44.77 6.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.606 HD11 HG21 ' A' ' 141' ' ' ILE . 9.3 tp -60.64 -25.19 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.9 tttp -66.51 -32.0 73.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -67.26 -43.58 81.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.582 HD12 HD12 ' A' ' 130' ' ' ILE . 77.3 mt -57.89 -56.88 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.159 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.592 ' HG3' HD12 ' A' ' 141' ' ' ILE . 29.4 mt-30 -45.24 -31.97 1.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -82.07 -55.69 4.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 6.5 mmm180 -56.28 -24.42 42.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.422 HG21 ' HA ' ' A' ' 164' ' ' ALA . 80.6 p -109.75 -13.03 14.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 54.3 52.79 11.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.479 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 26.8 p -129.99 170.04 14.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.155 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -102.28 94.91 5.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.898 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.606 HG21 HD11 ' A' ' 130' ' ' ILE . 82.3 mt -93.9 125.83 46.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.146 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.76 130.12 68.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.6 p -84.11 145.29 45.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.611 0.719 . . . . 0.0 111.094 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -179.78 3.17 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -80.56 -172.11 44.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.492 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -92.55 -31.62 15.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.828 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 9.6 t0 -112.1 35.97 3.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -131.3 169.93 15.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.914 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 18.4 pt-20 -67.82 144.28 97.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.615 0.721 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.25 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.705 2.27 . . . . 0.0 112.319 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.2 t -148.26 113.83 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.412 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 55.9 m-85 -84.06 141.46 31.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.93 121.53 45.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 22.6 t -115.6 122.47 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 43.0 m -112.9 122.93 49.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.563 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 169.54 -173.09 43.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.474 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.623 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.1 mmt -52.39 159.24 1.66 Allowed Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.602 0.715 . . . . 0.0 110.857 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -0.86 7.54 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.658 2.239 . . . . 0.0 112.302 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -115.7 -26.03 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.479 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.3 m-20 -85.11 -54.63 4.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 157' ' ' MET . 24.9 m -53.68 -32.54 21.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -79.14 -23.5 43.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -76.27 -37.51 57.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . 0.422 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -70.76 -38.5 73.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.092 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.553 ' HG3' HG22 ' A' ' 112' ' ' VAL . 57.5 ttt180 -54.43 -44.21 72.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.93 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 -55.58 -49.28 73.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 17.8 mm-40 -59.93 -45.98 90.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.929 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 94.9 mt -53.18 -58.96 2.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.126 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -62.4 -32.69 73.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -51.45 -42.31 61.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 23.4 m170 -56.28 -33.5 65.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.566 HG12 HG21 ' A' ' 118' ' ' VAL . 81.6 mt -47.97 -38.16 7.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 26.1 m -88.76 -39.39 13.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.15 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.784 HD13 ' N ' ' A' ' 175' ' ' ARG . 0.9 OUTLIER -55.35 130.63 43.19 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.896 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.784 ' N ' HD13 ' A' ' 174' ' ' LEU . 4.3 ptp180 -77.36 118.0 19.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.2 t -132.42 85.22 2.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 135.87 172.27 12.6 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.501 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 161.64 45.13 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.705 2.27 . . . . 0.0 112.355 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 65.8 p -108.69 -43.45 4.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.1 t -51.36 117.38 2.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.854 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.452 -179.94 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 22.8 t 65.76 41.7 3.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.791 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.3 t -86.61 -43.58 12.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.867 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 75.36 167.02 20.6 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.522 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 84.1 p -102.18 45.04 0.98 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.876 0.37 . . . . 0.0 110.877 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 67.0 p -82.03 167.91 18.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.88 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -71.54 -42.06 56.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.508 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 148.73 -89.75 0.14 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.459 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.418 ' OE1' HG22 ' A' ' 155' ' ' THR . 25.2 pt20 -62.62 177.44 0.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.922 0.392 . . . . 0.0 110.924 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.7 t -137.56 164.68 28.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.16 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.784 HG22 HE22 ' A' ' 111' ' ' GLN . 99.2 m -138.14 115.29 10.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.075 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.44 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 42.4 pt -107.89 151.88 9.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.784 HE22 HG22 ' A' ' 109' ' ' THR . 1.1 mp0 -110.98 106.72 15.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.893 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 151' ' ' VAL . 86.9 t -73.7 141.39 16.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 42.5 ttp85 -108.67 110.13 21.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.469 HG13 HG12 ' A' ' 112' ' ' VAL . 2.5 m -132.59 148.85 71.22 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.675 0.75 . . . . 0.0 111.112 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.481 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.74 145.84 58.49 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.726 2.284 . . . . 0.0 112.33 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.532 ' HA ' HG23 ' A' ' 119' ' ' VAL . 19.3 t80 -53.93 -41.54 67.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.87 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -54.85 -29.46 55.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.871 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.481 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 15.8 t -85.6 -34.82 8.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.123 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG23 ' HA ' ' A' ' 116' ' ' TYR . 77.8 t -37.32 -66.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.52 -33.28 4.41 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.1 mt -70.61 -57.02 5.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.844 0.354 . . . . 0.0 110.889 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.43 HG23 HG12 ' A' ' 118' ' ' VAL . 62.9 t -56.37 -55.98 16.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.12 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 97.4 t -47.14 -55.57 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.36 167.85 43.91 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_exo -47.96 93.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.648 2.232 . . . . 0.0 112.356 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.3 tmtt? 60.89 46.43 8.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 59.59 61.59 7.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.493 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.47 -41.56 5.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.843 0.354 . . . . 0.0 111.122 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.2 m -78.91 -46.42 18.5 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.13 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.618 HD11 HG21 ' A' ' 141' ' ' ILE . 10.7 tp -51.57 -34.39 15.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.088 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.7 tttt -66.55 -40.58 89.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 25.9 ttp180 -62.3 -22.24 65.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -78.96 -41.43 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.116 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.488 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.4 mt-30 -67.95 -30.64 69.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' A' ' 136' ' ' ARG . 10.1 pt20 -80.7 -48.63 12.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.938 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.502 ' N ' ' CG ' ' A' ' 135' ' ' GLN . 60.0 mtt180 -59.03 -35.25 72.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 49.9 p -100.11 -13.28 19.05 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.136 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 19.8 m80 58.93 54.22 5.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.47 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 34.2 p -132.19 -176.79 4.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.091 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -116.74 97.4 5.96 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.953 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.707 HG12 HG22 ' A' ' 154' ' ' VAL . 74.4 mt -94.61 133.12 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.152 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 90.3 t -115.11 134.94 56.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.143 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 69.6 p -88.1 146.98 39.5 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.591 0.71 . . . . 0.0 111.106 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -178.27 2.28 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -87.38 169.55 39.7 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 8.6 ptt85 -70.63 -40.54 73.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.833 0.349 . . . . 0.0 110.837 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -105.54 42.24 1.26 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.846 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 26.5 mmtp -136.08 168.22 19.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.37 144.06 98.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.659 0.742 . . . . 0.0 110.901 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 82.78 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.693 2.262 . . . . 0.0 112.359 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 112' ' ' VAL . 76.2 t -133.29 129.62 56.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -96.53 139.95 31.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -112.78 110.01 19.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.116 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.707 HG22 HG12 ' A' ' 141' ' ' ILE . 96.3 t -101.33 133.22 45.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.512 HG23 ' OG1' ' A' ' 109' ' ' THR . 19.9 m -119.46 135.42 54.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.422 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 153.64 -177.1 31.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.529 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.542 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.1 mmt -49.27 158.36 0.75 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.549 0.69 . . . . 0.0 110.918 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 0.49 5.55 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.684 2.256 . . . . 0.0 112.313 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -117.76 -29.79 5.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.47 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 7.1 m-20 -79.18 -47.93 15.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.542 HG22 ' O ' ' A' ' 157' ' ' MET . 15.7 m -66.15 -26.64 38.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -66.99 -40.39 87.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.888 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 7.5 ttt85 -66.88 -56.51 9.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.847 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -46.7 -46.27 20.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.055 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 37.3 ttt180 -49.7 -39.96 38.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.906 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 36.6 mt-10 -60.67 -52.1 66.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.888 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -58.56 -33.55 70.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 67.7 mt -63.24 -66.43 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.4 -32.54 74.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.444 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -39.72 -54.98 2.0 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.115 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -39.89 -40.56 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.444 HG12 HG21 ' A' ' 118' ' ' VAL . 71.1 mt -43.59 -50.63 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 62.4 p -61.53 -50.98 70.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 3.7 mp -52.07 175.33 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -164.88 120.87 1.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 4.6 t -123.15 166.97 14.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.857 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -51.99 146.06 14.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.508 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 154.66 67.7 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.664 2.243 . . . . 0.0 112.396 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 4.9 m -167.24 137.2 2.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.871 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.3 m -144.07 120.35 10.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.461 -179.916 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.9 m -90.39 97.5 11.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.907 0.385 . . . . 0.0 110.837 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.3 m -116.0 155.06 28.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.879 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 123.44 116.38 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.463 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 17.9 p -126.76 -36.0 2.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.833 0.349 . . . . 0.0 110.812 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 105' ' ' GLY . 17.7 t -78.27 155.2 30.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.816 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 104' ' ' SER . . . -34.6 -47.62 0.63 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.454 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 178.27 -58.15 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -97.59 160.84 14.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.939 0.399 . . . . 0.0 110.869 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.0 t -128.66 158.61 38.08 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.617 HG22 HE22 ' A' ' 111' ' ' GLN . 23.5 m -130.12 113.69 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.177 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.524 ' C ' ' NE2' ' A' ' 111' ' ' GLN . 43.3 pt -103.48 154.85 5.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.106 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.617 HE22 HG22 ' A' ' 109' ' ' THR . 1.6 mp0 -112.54 107.98 16.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.818 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.7 t -77.79 141.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -110.2 117.39 33.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.842 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 168' ' ' ILE . 12.2 m -137.6 151.11 70.25 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.629 0.728 . . . . 0.0 111.112 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.503 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.78 126.7 13.6 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.659 2.24 . . . . 0.0 112.351 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -36.4 -35.53 0.08 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.942 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.8 tpp85 -59.74 -46.88 87.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.503 HG23 ' HG2' ' A' ' 115' ' ' PRO . 48.8 t -72.41 -31.14 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.111 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.57 ' O ' HG23 ' A' ' 123' ' ' VAL . 53.1 t -45.59 -59.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -52.73 -41.54 57.83 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.479 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.1 mt -61.89 -48.89 78.47 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.83 0.348 . . . . 0.0 110.882 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 84.1 t -64.04 -52.65 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 119' ' ' VAL . 93.8 t -49.15 -56.17 2.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.166 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 88.49 172.73 46.89 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.489 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.93 100.66 0.04 OUTLIER 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.722 2.281 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 4.4 mtpm? 50.89 43.25 28.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.901 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.35 80.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.526 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.69 -31.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.83 0.348 . . . . 0.0 111.05 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 40.5 m -89.91 -39.47 13.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.097 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.965 HD11 HG21 ' A' ' 141' ' ' ILE . 5.0 tp -65.07 -29.34 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.179 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.521 ' HD2' HG23 ' A' ' 130' ' ' ILE . 2.0 mptm? -67.76 -42.21 82.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.937 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 70.3 mtp180 -56.16 -43.79 78.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.841 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 57.2 mt -57.44 -44.84 85.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.447 ' HG3' HD12 ' A' ' 141' ' ' ILE . 73.8 mt-30 -51.71 -38.18 54.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.935 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -79.2 -51.11 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.888 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 31.5 mmm-85 -55.68 -30.72 61.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.9 p -106.63 -10.88 16.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 56.13 51.51 11.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.2 p -137.34 143.08 41.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -78.33 95.54 5.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.965 HG21 HD11 ' A' ' 130' ' ' ILE . 78.8 mt -88.34 110.41 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 98.4 t -95.85 120.84 45.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.094 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 82.4 p -77.79 147.3 74.07 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.569 0.699 . . . . 0.0 111.134 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 171.95 13.5 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.685 2.256 . . . . 0.0 112.386 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.67 177.87 54.05 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 7.5 ptp85 -77.69 -33.59 53.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.788 0.327 . . . . 0.0 110.864 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -110.5 41.58 1.74 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.825 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.7 mmmt -137.84 159.33 42.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -57.21 145.25 67.22 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.657 0.742 . . . . 0.0 110.87 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.409 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.5 Cg_endo -69.8 96.78 0.61 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.67 2.247 . . . . 0.0 112.319 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 112' ' ' VAL . 94.8 t -145.52 132.65 15.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.0 m-85 -102.36 117.13 34.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.99 109.4 20.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.108 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.429 HG22 HG12 ' A' ' 141' ' ' ILE . 56.8 t -100.14 122.61 52.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 49.9 m -108.19 131.71 54.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.146 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.415 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.18 177.63 30.48 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.498 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.501 ' O ' HG22 ' A' ' 161' ' ' VAL . 10.5 mmt -42.51 159.41 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.553 0.692 . . . . 0.0 110.867 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 0.83 5.06 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.702 2.268 . . . . 0.0 112.37 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -118.42 -37.33 3.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.425 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.4 m-20 -69.3 -45.67 69.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -67.83 -37.12 77.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.13 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -57.82 -42.44 84.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.839 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -64.16 -48.37 76.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.97 -47.93 43.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.531 ' HG3' HG22 ' A' ' 112' ' ' VAL . 33.2 ttt180 -51.05 -43.76 60.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -53.28 -44.74 68.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.937 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -68.15 -56.3 9.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.461 HG22 HG11 ' A' ' 114' ' ' VAL . 73.2 mt -47.7 -45.68 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -70.29 -45.04 67.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.44 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.32 -57.24 2.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.113 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.44 ' C ' ' O ' ' A' ' 170' ' ' ALA . 47.5 m80 -35.38 -34.62 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.863 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.478 HG12 HG21 ' A' ' 118' ' ' VAL . 58.5 mt -54.84 -49.06 72.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.522 HG23 ' O ' ' A' ' 173' ' ' THR . 14.5 t -94.83 44.18 1.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.12 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 64.2 tp -110.17 148.27 32.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 176' ' ' SER . 6.2 ptm180 -108.0 54.42 0.66 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.45 ' C ' ' O ' ' A' ' 175' ' ' ARG . 6.2 t 34.41 42.66 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -77.65 178.21 52.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.499 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 123.34 10.0 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 2.247 . . . . 0.0 112.339 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 43.8 t -69.62 131.48 44.7 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.872 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 5.6 t -44.4 155.46 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.467 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.7 p -71.79 81.04 0.87 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.873 0.368 . . . . 0.0 110.82 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.9 t -148.84 155.8 41.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.889 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -175.8 60.14 0.11 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.479 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 58.6 m -45.35 100.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.941 0.401 . . . . 0.0 110.876 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 21.0 m -39.13 -47.95 1.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.871 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -114.62 91.15 0.56 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.464 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -136.14 31.83 2.57 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.549 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 -116.74 176.99 4.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.857 0.361 . . . . 0.0 110.918 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.4 t -139.92 163.53 32.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.14 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -129.28 125.69 37.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.161 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 29.5 pt -112.18 164.51 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 50.3 mm-40 -121.71 97.93 5.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG13 ' A' ' 151' ' ' VAL . 95.3 t -68.78 142.74 15.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.125 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.3 ttt85 -112.55 121.56 45.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.2 m -141.98 151.07 58.27 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.616 0.722 . . . . 0.0 111.147 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.3 Cg_endo -69.8 125.54 12.24 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.671 2.247 . . . . 0.0 112.344 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.437 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.7 t80 -35.26 -33.21 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.876 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.474 ' N ' ' O ' ' A' ' 115' ' ' PRO . 87.3 mtt-85 -61.68 -49.94 74.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.867 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.56 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.3 t -68.72 -35.03 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.153 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 56.1 t -39.06 -62.76 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.155 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -54.43 -38.92 63.83 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.467 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.7 mt -63.34 -43.54 97.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.894 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.558 HG23 HG12 ' A' ' 118' ' ' VAL . 89.4 t -68.48 -61.95 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 88.8 t -40.78 -49.04 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.119 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 78.45 172.86 41.37 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.487 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -47.95 97.49 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.653 2.235 . . . . 0.0 112.409 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 47.83 50.47 15.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.913 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.79 74.33 0.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -121.78 -45.15 2.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 67.2 m -82.21 -44.73 15.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.619 HD11 HG21 ' A' ' 141' ' ' ILE . 6.4 tp -57.43 -38.64 64.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.5 mttp -53.58 -39.87 65.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.945 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.416 ' N ' ' HD2' ' A' ' 132' ' ' ARG . 1.0 OUTLIER -57.75 -36.07 71.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.864 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.58 HD12 HD12 ' A' ' 130' ' ' ILE . 46.8 mt -69.94 -46.9 71.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.101 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.61 ' HG3' HD12 ' A' ' 141' ' ' ILE . 42.4 mt-30 -55.15 -39.83 69.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -78.28 -45.5 22.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 3.1 mmp_? -58.07 -37.59 74.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.84 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 81.8 p -101.23 -11.45 19.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 59.89 48.31 9.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.916 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 62.7 p -127.36 162.95 25.09 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -96.79 94.78 7.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.936 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.619 HG21 HD11 ' A' ' 130' ' ' ILE . 79.2 mt -90.43 122.3 41.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.106 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 68.9 t -113.81 129.46 69.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.119 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.6 p -77.47 147.75 75.92 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.576 0.703 . . . . 0.0 111.183 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 177.81 5.22 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.43 165.22 51.49 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -68.2 -45.95 71.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 0.0 110.879 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -101.7 42.75 1.11 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.851 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.7 mmtp -136.07 173.43 11.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -67.2 143.94 97.92 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 89.12 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.368 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 112' ' ' VAL . 77.9 t -134.7 134.49 54.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.089 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -104.05 122.72 45.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -92.82 123.95 36.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.122 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.421 HG22 HG12 ' A' ' 141' ' ' ILE . 46.5 t -118.71 119.09 60.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.086 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.3 m -107.35 138.1 44.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.144 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.448 ' CA ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.88 -169.96 31.28 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.436 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.768 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.0 mmt -52.53 159.47 1.66 Allowed Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.561 0.696 . . . . 0.0 110.876 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 0.56 5.51 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.656 2.237 . . . . 0.0 112.35 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.38 -47.17 2.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.866 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.43 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 28.8 m-20 -65.42 -44.9 85.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 157' ' ' MET . 18.7 m -63.79 -37.87 80.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.154 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 16.1 t0 -73.53 -31.65 63.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 46.4 mtp180 -69.57 -36.9 76.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -64.32 -37.41 87.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.08 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -53.68 -58.66 6.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.812 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . 0.453 ' HG3' ' N ' ' A' ' 167' ' ' GLU . 1.0 OUTLIER -48.74 -35.44 14.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.926 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.453 ' N ' ' HG3' ' A' ' 166' ' ' GLU . 5.4 mm-40 -69.47 -46.76 65.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.878 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 93.9 mt -63.32 -49.36 83.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.165 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -60.61 -41.7 95.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -39.5 -53.07 2.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -40.17 -41.06 1.22 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 68.7 mt -44.2 -50.42 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.109 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 78.3 p -93.95 42.1 1.09 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.118 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.569 HD23 ' C ' ' A' ' 174' ' ' LEU . 7.0 tt -95.03 -54.13 3.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.914 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 10.4 ptm180 -113.82 164.29 13.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.852 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 48.3 t -71.72 -62.52 1.39 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -174.57 -157.39 15.92 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.517 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 179' ' ' SER . 54.0 Cg_endo -69.76 2.7 3.29 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.699 2.266 . . . . 0.0 112.353 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . 0.423 ' C ' ' O ' ' A' ' 178' ' ' PRO . 34.6 t -34.58 119.34 0.44 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.846 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.4 p -69.55 -21.8 63.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.877 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 179.977 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.532 -0.227 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 68.5 m -134.01 113.23 11.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.854 -179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 30.8 p -56.17 -25.72 47.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -120.41 167.41 13.75 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.496 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 26.7 m -59.63 133.33 55.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.89 0.376 . . . . 0.0 110.888 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.6 t -68.35 176.94 2.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.889 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -86.59 -179.15 49.3 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.453 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -94.06 -97.66 1.58 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.418 ' HB3' ' HE2' ' A' ' 157' ' ' MET . 7.3 pt20 -110.83 168.81 9.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 6.9 t -125.38 162.5 24.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.135 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.5 m -135.49 122.29 21.07 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.098 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.7 pt -111.81 156.12 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.17 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 47.7 mm-40 -111.74 98.83 7.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 151' ' ' VAL . 88.9 t -66.04 141.42 18.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.137 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 25.4 ttp180 -112.33 113.24 25.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.869 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.464 HG13 HG12 ' A' ' 112' ' ' VAL . 3.8 m -132.8 151.07 77.41 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 111.13 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.459 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 126.72 13.64 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.69 2.26 . . . . 0.0 112.352 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.411 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -36.44 -33.4 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 115' ' ' PRO . 84.8 mtt180 -62.22 -52.54 63.36 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.831 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.597 HG21 HG12 ' A' ' 172' ' ' ILE . 54.6 t -67.6 -34.15 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.098 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.1 t -40.17 -66.62 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.098 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.86 -36.5 26.7 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.475 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.5 mt -66.34 -41.84 89.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.883 0.373 . . . . 0.0 110.955 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.589 HG11 HG23 ' A' ' 168' ' ' ILE . 87.4 t -71.81 -54.6 16.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.107 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.424 HG23 ' HZ ' ' A' ' 152' ' ' PHE . 92.5 t -50.95 -49.14 28.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.18 172.67 46.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.477 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -47.96 105.47 0.09 OUTLIER 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.712 2.274 . . . . 0.0 112.313 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 9.0 tppt? 45.5 44.5 9.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 64.11 76.07 0.32 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.484 ' O ' ' CZ ' ' A' ' 132' ' ' ARG . . . -124.21 -26.82 3.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 111.119 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 96.2 m -93.77 -35.91 12.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.145 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.795 HD11 HG21 ' A' ' 141' ' ' ILE . 5.1 tp -72.76 -29.94 31.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.155 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.464 ' HG3' ' N ' ' A' ' 132' ' ' ARG . 8.3 ptmt -58.94 -36.95 75.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.484 ' CZ ' ' O ' ' A' ' 128' ' ' ALA . 0.7 OUTLIER -67.04 -52.69 39.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.858 179.996 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.416 HD11 ' HE1' ' A' ' 171' ' ' HIS . 72.6 mt -46.4 -50.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.451 ' CG ' HD12 ' A' ' 141' ' ' ILE . 60.9 mt-30 -46.2 -35.39 5.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -81.31 -51.43 8.38 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -52.07 -35.3 47.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.875 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 59.4 p -104.1 -11.18 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.152 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 67.5 m80 55.99 54.66 7.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.872 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.478 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 82.5 p -137.38 147.37 45.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.169 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -80.5 97.38 7.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.795 HG21 HD11 ' A' ' 130' ' ' ILE . 85.5 mt -90.84 118.52 36.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.426 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 93.3 t -106.48 123.46 61.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.175 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.4 p -81.84 148.95 62.5 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.585 0.707 . . . . 0.0 111.124 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 172.57 12.39 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.246 . . . . 0.0 112.365 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.06 157.93 34.19 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . 0.446 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 6.0 ptp180 -55.09 -42.3 72.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.446 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.9 p-10 -102.02 43.81 1.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.899 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -135.7 168.11 19.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -69.56 149.45 96.99 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.688 0.756 . . . . 0.0 110.832 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.4 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.8 Cg_endo -69.8 91.38 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.706 2.271 . . . . 0.0 112.35 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 112' ' ' VAL . 96.9 t -145.67 130.42 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.168 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.424 ' HZ ' HG23 ' A' ' 123' ' ' VAL . 57.3 m-85 -99.46 136.45 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.911 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.426 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -107.55 106.47 16.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.08 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.5 t -100.44 117.77 46.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 85.1 m -106.55 136.18 46.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.16 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.445 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 152.79 175.88 24.76 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.45 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.596 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.4 mmt -41.68 159.56 0.18 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.52 0.676 . . . . 0.0 110.912 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 0.81 5.11 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.663 2.242 . . . . 0.0 112.374 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.11 -35.1 3.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.905 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.478 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.3 m-20 -72.03 -46.95 55.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.881 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 157' ' ' MET . 27.9 m -64.09 -37.59 80.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -55.44 -45.09 76.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.845 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 12.8 ttp180 -57.27 -54.57 45.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.74 -51.96 8.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.091 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.512 ' HG3' HG22 ' A' ' 112' ' ' VAL . 68.8 ttp85 -45.28 -45.17 11.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -61.49 -42.47 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -61.92 -57.32 12.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.589 HG23 HG11 ' A' ' 122' ' ' VAL . 78.3 mt -52.46 -49.56 42.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.108 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -63.54 -43.76 96.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.866 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.417 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -42.58 -57.5 2.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.112 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' A' ' 170' ' ' ALA . 37.9 m80 -37.13 -38.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.863 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.597 HG12 HG21 ' A' ' 118' ' ' VAL . 51.1 mt -49.31 -53.33 8.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.103 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 174' ' ' LEU . 91.8 m -81.92 -43.13 18.53 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.185 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.657 HD23 ' HB2' ' A' ' 175' ' ' ARG . 8.6 tt -35.92 -48.61 0.58 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.91 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.657 ' HB2' HD23 ' A' ' 174' ' ' LEU . 13.3 ttt85 -151.82 108.1 3.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.903 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 24.3 m -65.95 176.65 1.57 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -65.84 -97.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.502 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 111.28 2.77 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 64.2 m -54.48 -60.34 3.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 2.6 m -117.94 121.56 41.0 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.866 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.478 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 87.0 p -165.87 125.94 1.74 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 110.83 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 5.3 t -164.98 136.86 4.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.861 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -122.36 62.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.493 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 50.8 m -39.14 -58.12 1.2 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.963 0.411 . . . . 0.0 110.866 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.8 t -74.16 133.64 42.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.843 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -112.59 -128.84 5.07 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.53 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.72 109.24 0.84 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.508 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -69.81 172.51 7.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.889 0.376 . . . . 0.0 110.91 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.419 ' OG1' ' N ' ' A' ' 109' ' ' THR . 1.6 t -135.34 174.58 10.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.18 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.705 HG22 HE22 ' A' ' 111' ' ' GLN . 56.7 m -148.16 127.26 12.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.15 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.428 ' CD1' ' HE ' ' A' ' 165' ' ' ARG . 21.2 pt -118.35 155.12 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.705 HE22 HG22 ' A' ' 109' ' ' THR . 1.0 OUTLIER -108.53 97.14 6.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.89 179.926 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.448 HG22 ' HG3' ' A' ' 165' ' ' ARG . 82.7 t -68.14 137.89 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.183 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 24.9 ttt180 -103.44 116.5 32.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 m -135.55 147.4 61.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.602 0.715 . . . . 0.0 111.151 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.54 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.4 Cg_endo -69.7 126.94 13.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.663 2.242 . . . . 0.0 112.344 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.412 ' C ' ' O ' ' A' ' 115' ' ' PRO . 32.4 t80 -36.59 -31.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 115' ' ' PRO . 15.2 ttm180 -64.66 -51.6 61.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.54 HG23 ' HG2' ' A' ' 115' ' ' PRO . 42.3 t -64.89 -31.65 54.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.118 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.8 t -41.63 -70.68 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.11 -28.48 1.33 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.503 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.6 mt -75.11 -48.95 21.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.886 0.374 . . . . 0.0 110.936 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.53 HG23 HG12 ' A' ' 118' ' ' VAL . 40.1 t -59.83 -60.13 2.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.104 179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.1 t -46.06 -63.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.107 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 89.04 172.46 46.16 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_exo -48.04 99.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.7 2.267 . . . . 0.0 112.304 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 30.5 tttm 49.75 49.69 19.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.88 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.06 73.66 0.46 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.505 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.18 -38.76 2.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 111.12 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 80.1 m -83.64 -44.98 13.97 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.164 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 133' ' ' ILE . 10.0 tp -57.84 -26.92 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.3 tttt -63.79 -45.78 88.13 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.66 -36.19 56.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.928 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.783 HD12 HD12 ' A' ' 130' ' ' ILE . 48.6 mt -66.57 -58.41 6.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.131 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.62 ' CG ' HD12 ' A' ' 141' ' ' ILE . 53.8 mt-30 -52.1 -36.05 49.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 56.3 mm-40 -78.74 -34.68 45.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -67.26 -38.5 85.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.835 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 53.1 p -107.18 -0.4 22.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.138 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 37.1 m170 52.71 52.59 13.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 16.5 p -123.08 179.98 4.48 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.115 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -117.11 98.18 6.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.636 HG21 HD11 ' A' ' 130' ' ' ILE . 79.5 mt -90.62 127.1 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 75.3 t -112.07 121.05 63.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.0 p -74.78 145.96 82.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.585 0.707 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 179.98 3.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.632 2.221 . . . . 0.0 112.297 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.42 165.04 51.37 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.5 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 17.0 ptp180 -70.04 -45.04 68.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.844 0.354 . . . . 0.0 110.868 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 49.6 m-20 -103.22 41.74 1.23 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 4.4 mmmm -133.01 174.45 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.867 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -68.28 144.3 96.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.598 0.713 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 100.97 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.669 2.246 . . . . 0.0 112.384 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 112' ' ' VAL . 91.4 t -149.88 130.55 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -100.68 132.61 45.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.45 111.59 24.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.124 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 41.5 t -99.91 117.96 45.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.108 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 96.2 m -109.53 131.97 54.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.115 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 158.44 -177.81 34.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.473 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . . . . . . . . . 20.4 mmt -49.59 158.31 0.84 Allowed Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.557 0.694 . . . . 0.0 110.901 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.41 ' HA ' HG21 ' A' ' 108' ' ' THR . 53.6 Cg_endo -69.75 -1.96 9.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.692 2.261 . . . . 0.0 112.356 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -115.6 -23.36 8.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.412 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 16.6 m-20 -84.82 -54.76 4.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.5 m -58.26 -27.0 31.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.149 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -70.38 -39.13 74.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.875 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -69.45 -50.42 45.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.853 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -52.5 -42.99 64.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.448 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.5 ttm180 -47.14 -53.17 13.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.898 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -50.85 -43.88 59.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.72 -51.37 69.63 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 50.2 mt -55.26 -44.09 73.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.163 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -68.18 -44.46 75.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.881 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.719 ' C ' HD12 ' A' ' 174' ' ' LEU . . . -42.68 -51.28 5.32 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.086 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -42.01 -38.66 1.69 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.516 HG12 HG21 ' A' ' 118' ' ' VAL . 57.1 mt -52.5 -61.61 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.154 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 10.9 t -87.34 37.05 0.76 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.719 HD12 ' C ' ' A' ' 170' ' ' ALA . 11.4 mt -131.75 150.99 51.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.914 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -67.19 141.51 57.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.8 p -142.35 124.06 15.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.86 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -133.86 86.11 0.27 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.5 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 123.2 9.86 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.716 2.277 . . . . 0.0 112.329 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.9 t -64.13 152.02 41.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.816 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 66.7 m -58.56 133.33 55.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.507 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 63.2 p -79.52 158.76 27.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.87 0.367 . . . . 0.0 110.847 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.6 m -80.18 103.37 10.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.846 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -97.21 -97.61 1.93 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.513 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 54.9 m -118.58 131.57 56.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.874 0.368 . . . . 0.0 110.82 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 87.8 p -84.26 -47.99 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.828 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -99.84 175.6 27.74 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.463 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -134.11 -54.17 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.483 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.61 175.36 4.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.88 0.372 . . . . 0.0 110.935 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.6 t -134.72 164.47 27.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 89.8 m -131.25 122.46 26.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.179 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.4 pt -114.5 148.9 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.155 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.0 mm-40 -109.33 101.35 10.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 165' ' ' ARG . 88.2 t -70.2 143.27 14.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.138 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -114.04 120.93 42.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.851 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.669 HG11 HG22 ' A' ' 168' ' ' ILE . 11.1 m -139.68 150.92 64.84 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.653 0.739 . . . . 0.0 111.117 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.541 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.1 Cg_endo -69.74 125.49 12.22 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.655 2.236 . . . . 0.0 112.344 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 21.8 t80 -34.52 -35.53 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.45 ' N ' ' O ' ' A' ' 115' ' ' PRO . 75.5 mtt-85 -59.56 -49.37 78.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.877 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.541 HG23 ' HG2' ' A' ' 115' ' ' PRO . 55.7 t -69.61 -35.28 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.107 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 77.9 t -39.51 -63.37 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.171 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.89 -42.23 37.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 20.0 mt -60.46 -43.46 96.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.816 0.341 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.418 ' HA ' ' CE1' ' A' ' 171' ' ' HIS . 58.3 t -69.98 -60.37 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.12 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.5 t -37.08 -51.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 85.42 166.79 42.44 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_exo -48.01 92.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.703 2.269 . . . . 0.0 112.36 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 53.3 mmtt 58.51 41.63 22.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.918 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.54 66.29 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.461 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -111.76 -40.36 4.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.884 0.373 . . . . 0.0 111.115 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.3 m -84.82 -43.94 13.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.994 HD11 HG21 ' A' ' 141' ' ' ILE . 7.0 tp -58.52 -28.18 35.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.112 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -71.32 -43.42 67.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.888 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 35.0 ttm-85 -60.16 -39.95 88.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.506 HD12 ' HA ' ' A' ' 130' ' ' ILE . 58.0 mt -59.21 -50.1 81.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.128 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -48.77 -36.8 17.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.922 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -80.21 -51.08 9.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.913 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -54.2 -33.64 58.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.9 p -104.2 -14.83 15.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.141 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 9.8 m80 60.26 52.76 4.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.455 HG21 ' HA ' ' A' ' 161' ' ' VAL . 77.7 p -138.81 145.22 39.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -78.42 100.21 6.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.994 HG21 HD11 ' A' ' 130' ' ' ILE . 93.9 mt -96.23 122.08 47.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.083 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 87.4 t -112.96 132.28 62.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.134 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 66.6 p -85.17 152.53 58.59 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.626 0.727 . . . . 0.0 111.114 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 179.48 3.68 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.665 2.244 . . . . 0.0 112.364 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.88 169.76 53.41 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -70.1 -47.47 61.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.837 0.351 . . . . 0.0 110.872 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -103.79 40.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 18.3 mmmt -131.66 172.17 12.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.896 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -68.77 144.23 95.75 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.632 0.729 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 99.25 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.695 2.263 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 85.4 t -148.99 118.71 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.95 149.86 24.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.19 109.5 14.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.043 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.631 HG22 HG12 ' A' ' 141' ' ' ILE . 68.4 t -102.4 133.69 45.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.16 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 25.9 m -118.81 135.45 54.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.506 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 150.85 -179.33 27.65 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.433 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.685 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.5 mmt -43.49 159.44 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.534 0.683 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -0.17 6.56 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -119.29 -39.23 2.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 5.9 m-20 -68.63 -40.42 80.33 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.685 HG22 ' O ' ' A' ' 157' ' ' MET . 20.2 m -72.42 -34.86 49.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -59.96 -39.93 87.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 43.6 ttt180 -61.27 -55.68 29.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.24 -43.08 3.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.092 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.436 ' HG3' HG22 ' A' ' 112' ' ' VAL . 72.1 ttt-85 -56.31 -40.65 74.68 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -54.57 -45.46 73.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.874 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -66.61 -57.16 7.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.917 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.669 HG22 HG11 ' A' ' 114' ' ' VAL . 71.7 mt -49.0 -45.82 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.165 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -71.13 -44.22 66.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.87 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.51 -57.97 1.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.129 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 122' ' ' VAL . 13.2 m170 -36.19 -40.18 0.21 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.857 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.414 ' HA ' HG21 ' A' ' 118' ' ' VAL . 50.2 mt -49.28 -58.79 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 27.6 m -66.82 -48.3 69.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.151 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 5.2 mp -66.76 172.81 3.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.93 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HD3' ' C ' ' A' ' 175' ' ' ARG . 0.2 OUTLIER -153.7 135.93 14.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.873 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.6 t 64.79 42.24 4.64 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.852 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 82.52 -170.13 50.0 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 154.13 68.2 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.712 2.274 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 67.3 m -59.22 123.89 18.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.874 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 35.3 p -132.2 128.2 37.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.894 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.474 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.509 -0.237 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 29.4 m -96.7 103.0 14.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.839 0.352 . . . . 0.0 110.842 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.0 p -150.52 126.33 10.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 124.11 112.9 2.01 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.479 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.2 t -59.34 146.45 39.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.9 0.381 . . . . 0.0 110.849 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 55.0 p -153.49 110.24 3.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.851 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -173.4 -179.05 43.81 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.508 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.91 103.59 1.87 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.442 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -80.73 172.77 13.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.5 t -130.63 168.34 17.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.118 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 94.2 m -136.96 118.67 15.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.0 pt -107.3 150.62 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.112 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -109.61 94.16 4.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.466 HG12 HG13 ' A' ' 114' ' ' VAL . 79.4 t -67.16 139.74 20.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -109.25 111.89 23.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.907 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.477 HG11 HG22 ' A' ' 168' ' ' ILE . 7.2 m -128.39 150.89 75.56 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.589 0.709 . . . . 0.0 111.136 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.505 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.77 123.56 10.22 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.668 2.245 . . . . 0.0 112.373 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.443 ' C ' ' O ' ' A' ' 115' ' ' PRO . 22.8 t80 -34.84 -32.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.5 ' N ' ' O ' ' A' ' 115' ' ' PRO . 50.5 mtt85 -62.68 -49.13 76.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.542 HG12 HG23 ' A' ' 122' ' ' VAL . 56.0 t -70.35 -31.31 46.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 53.5 t -43.07 -64.46 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.1 -41.17 22.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.486 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 18.0 mt -63.19 -47.94 80.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.879 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.542 HG23 HG12 ' A' ' 118' ' ' VAL . 61.5 t -62.66 -61.71 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.131 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 93.6 t -43.16 -50.39 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.114 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 80.74 173.01 46.49 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.464 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 126' ' ' LYS . 64.6 Cg_exo -47.92 114.64 1.17 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.674 2.249 . . . . 0.0 112.372 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.445 ' C ' ' O ' ' A' ' 125' ' ' PRO . 0.0 OUTLIER 34.13 43.47 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.886 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.38 84.45 0.12 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.469 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -133.52 -34.37 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 111.058 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 58.9 m -89.72 -43.7 10.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.089 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.799 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -68.21 -27.79 38.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.094 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttmt -68.29 -37.46 80.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.8 ttm180 -64.33 -46.82 81.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.854 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.819 HG23 ' OE1' ' A' ' 167' ' ' GLU . 36.6 mt -55.69 -42.8 71.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.13 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.428 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 79.0 mt-30 -57.23 -24.35 54.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.98 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 51.9 mm-40 -89.83 -47.03 8.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.401 ' NH1' ' OE2' ' A' ' 167' ' ' GLU . 6.3 ptm180 -64.16 -31.54 72.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.485 ' CG2' ' OE1' ' A' ' 167' ' ' GLU . 73.9 p -100.23 -12.83 19.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.158 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 27.2 m80 57.21 54.4 6.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 72.5 p -141.76 140.62 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.133 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -78.47 97.28 5.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.926 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.799 HG21 HD11 ' A' ' 130' ' ' ILE . 96.2 mt -88.78 108.71 19.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.138 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.3 t -91.95 133.65 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.116 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.0 p -91.81 146.13 32.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.558 0.694 . . . . 0.0 111.131 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 177.17 5.82 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.733 2.289 . . . . 0.0 112.297 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.87 -178.02 50.11 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.514 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 50.3 ptt85 -83.08 -38.47 22.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.834 0.35 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -110.0 41.81 1.64 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -135.61 164.86 26.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.882 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -62.25 142.58 95.84 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.6 0.714 . . . . 0.0 110.923 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 103.57 1.19 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.655 2.237 . . . . 0.0 112.348 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.3 t -148.28 115.45 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -86.96 128.44 35.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.915 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -103.36 104.28 14.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -95.9 122.2 47.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.109 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.6 m -108.65 137.15 47.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 151.95 -179.76 28.26 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.494 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.619 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.6 mmt -47.12 159.34 0.4 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 110.897 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 0.28 5.86 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.718 2.278 . . . . 0.0 112.351 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -118.4 -32.1 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.846 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.475 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.0 m-20 -73.58 -48.49 32.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.649 HG12 HG12 ' A' ' 154' ' ' VAL . 32.9 m -65.62 -40.13 87.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 25.9 t0 -51.17 -41.88 60.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 15.3 ttm180 -65.24 -47.58 76.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.819 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -50.44 -42.94 54.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.09 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.49 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 22.7 ttt85 -55.3 -45.26 76.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.854 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -60.98 -38.18 85.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.819 ' OE1' HG23 ' A' ' 133' ' ' ILE . 12.8 mt-10 -66.94 -50.52 62.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.886 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.477 HG22 HG11 ' A' ' 114' ' ' VAL . 66.6 mt -60.75 -43.41 95.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.111 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.49 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 60.3 mt-10 -66.15 -47.46 73.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.411 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -45.35 -55.36 6.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.083 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.411 ' C ' ' O ' ' A' ' 170' ' ' ALA . 30.0 m170 -37.23 -41.01 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 56.4 mt -43.72 -52.39 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 98.3 m -99.22 92.18 5.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.169 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 23.5 tp -172.06 134.33 0.74 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.971 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 38.2 ptt85 -97.82 79.2 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.877 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 26.1 t -159.47 130.44 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.855 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 152.03 146.2 4.3 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.462 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.51 5.53 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.689 2.26 . . . . 0.0 112.371 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . 0.407 ' O ' ' C ' ' A' ' 180' ' ' SER . 18.5 m -45.25 118.34 1.67 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.869 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 179' ' ' SER . 79.7 p -37.77 110.81 0.14 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.849 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.482 179.979 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 64.1 m -130.16 151.6 50.51 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.872 0.368 . . . . 0.0 110.86 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 35.9 m -128.42 151.98 48.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -132.97 135.15 7.92 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 94.4 p -156.52 127.56 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.853 0.358 . . . . 0.0 110.841 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 92.7 p -106.56 112.92 26.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.838 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 114.78 175.19 18.57 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.525 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.453 ' O ' ' CE ' ' A' ' 157' ' ' MET . . . 117.07 41.64 0.69 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.443 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.414 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 4.8 pp0? -120.15 173.07 7.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.92 0.391 . . . . 0.0 110.904 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.7 t -133.1 165.35 24.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.134 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 52.1 m -133.54 122.47 23.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.11 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 22.6 pt -116.11 147.73 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -105.97 106.77 17.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.428 HG12 HG13 ' A' ' 114' ' ' VAL . 97.6 t -71.83 141.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.107 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 47.0 ttp180 -111.7 115.91 29.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.882 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.428 HG13 HG12 ' A' ' 112' ' ' VAL . 4.1 m -136.57 150.27 69.82 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.564 0.697 . . . . 0.0 111.158 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.492 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.9 Cg_endo -69.71 130.22 19.01 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.344 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.2 t80 -40.6 -33.76 0.3 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.423 ' HB3' ' NH1' ' A' ' 117' ' ' ARG . 5.6 mmm180 -61.76 -48.24 81.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.872 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.499 HG12 HG23 ' A' ' 122' ' ' VAL . 54.5 t -71.7 -32.67 46.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.401 HG21 ' HB3' ' A' ' 150' ' ' PRO . 48.9 t -40.73 -65.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.138 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.81 -40.42 26.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.89 -40.65 98.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.821 0.343 . . . . 0.0 110.926 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.575 HG11 HG23 ' A' ' 168' ' ' ILE . 59.1 t -69.01 -63.5 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 95.5 t -38.43 -50.85 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.15 169.19 42.95 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -47.98 105.74 0.09 OUTLIER 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.697 2.265 . . . . 0.0 112.32 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt 45.22 39.29 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.921 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.76 86.51 0.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.479 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -134.87 -39.07 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.808 0.337 . . . . 0.0 111.047 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.0 m -86.65 -43.8 12.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.175 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.597 HG23 ' HD2' ' A' ' 131' ' ' LYS . 4.9 tp -60.95 -41.27 88.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.123 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.597 ' HD2' HG23 ' A' ' 130' ' ' ILE . 0.0 OUTLIER -55.56 -38.39 69.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.835 179.855 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -58.62 -45.91 88.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.405 HD12 HD12 ' A' ' 130' ' ' ILE . 64.2 mt -55.26 -43.41 70.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.132 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.462 ' HG2' ' CG1' ' A' ' 141' ' ' ILE . 68.1 mt-30 -56.51 -37.18 70.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.886 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . 0.456 ' NE2' ' HA ' ' A' ' 135' ' ' GLN . 7.4 mm-40 -78.67 -54.24 6.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.922 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 23.0 mmm-85 -51.17 -34.83 33.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 70.0 p -102.52 -12.76 17.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.144 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 36.0 m80 57.22 52.94 8.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.435 HG21 ' HA ' ' A' ' 161' ' ' VAL . 63.8 p -136.11 159.19 42.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.129 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -89.34 98.88 12.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.939 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.556 HG12 HG22 ' A' ' 154' ' ' VAL . 71.1 mt -97.31 112.93 30.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.185 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 70.7 t -102.6 135.57 39.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.8 p -85.03 149.62 53.48 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.564 0.697 . . . . 0.0 111.146 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 177.58 5.44 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.714 2.276 . . . . 0.0 112.37 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.2 161.84 49.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.507 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptp85 -66.48 -44.06 83.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.864 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -103.57 39.67 1.56 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.864 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.5 mmtt -133.92 166.57 22.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -61.49 145.76 90.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.669 0.747 . . . . 0.0 110.904 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.401 ' HB3' HG21 ' A' ' 119' ' ' VAL . 54.7 Cg_endo -69.7 98.16 0.67 Allowed 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.653 2.235 . . . . 0.0 112.39 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 87.0 t -149.53 125.33 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -95.59 150.1 20.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -118.14 113.19 21.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.556 HG22 HG12 ' A' ' 141' ' ' ILE . 96.9 t -104.93 123.12 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.143 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 89.4 m -112.23 139.24 47.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.115 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.425 ' N ' HG11 ' A' ' 161' ' ' VAL . . . 147.49 -173.79 27.48 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.73 ' O ' HG22 ' A' ' 161' ' ' VAL . 16.2 mmt -48.56 159.32 0.54 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.502 0.668 . . . . 0.0 110.892 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -1.06 7.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.657 2.238 . . . . 0.0 112.337 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -115.67 -49.79 2.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 28.6 m-20 -59.47 -41.64 90.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 157' ' ' MET . 15.2 m -72.3 -34.33 48.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -58.34 -42.32 86.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 -65.99 -36.78 84.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.892 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . 0.433 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -60.02 -31.52 70.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 48.3 ttt180 -71.64 -52.4 18.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.85 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -62.54 -30.57 71.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -70.98 -54.34 11.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.865 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.575 HG23 HG11 ' A' ' 122' ' ' VAL . 72.1 mt -58.61 -46.69 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.116 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -65.0 -37.52 87.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.907 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.582 ' O ' HG22 ' A' ' 173' ' ' THR . . . -44.61 -53.79 6.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 51.2 m170 -41.8 -32.99 0.45 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.871 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.425 HG12 HG21 ' A' ' 118' ' ' VAL . 83.5 mt -50.81 -51.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.111 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.582 HG22 ' O ' ' A' ' 170' ' ' ALA . 6.1 t -77.61 -21.86 51.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.438 HD23 ' C ' ' A' ' 174' ' ' LEU . 6.8 tt -62.19 144.45 55.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 9.4 mtp-105 -138.24 114.24 10.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 6.4 t -101.54 -60.29 1.55 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.865 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -161.72 151.9 22.18 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 161.03 47.5 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.647 2.231 . . . . 0.0 112.353 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.7 t -132.48 -61.4 0.86 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 54.1 m -56.67 129.87 42.94 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.5 -179.997 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 36.4 t -103.8 158.71 16.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.938 0.399 . . . . 0.0 110.809 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.6 p -111.7 174.24 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.847 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -139.61 -103.94 0.58 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.524 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.7 t -104.9 100.26 9.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.856 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 76.8 p -89.36 -44.89 9.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.813 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 144.63 178.02 19.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.469 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -84.96 -113.2 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.508 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? -77.54 175.59 9.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.888 0.375 . . . . 0.0 110.934 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.8 t -133.42 170.44 15.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.19 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.701 HG22 HE22 ' A' ' 111' ' ' GLN . 94.4 m -141.98 129.01 20.8 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.129 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.453 ' O ' ' NE2' ' A' ' 111' ' ' GLN . 20.4 pt -122.04 158.91 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.701 HE22 HG22 ' A' ' 109' ' ' THR . 1.2 mp0 -113.81 106.37 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.96 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.801 ' O ' HG13 ' A' ' 151' ' ' VAL . 93.9 t -75.61 142.28 14.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.129 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 28.9 ttp180 -110.37 120.31 42.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.876 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -142.49 150.71 55.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.615 0.721 . . . . 0.0 111.154 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.539 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.8 Cg_endo -69.77 125.26 11.93 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.666 2.244 . . . . 0.0 112.323 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.473 ' HA ' ' CG2' ' A' ' 119' ' ' VAL . 27.1 t80 -35.85 -34.65 0.05 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.959 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.428 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.0 ttp180 -59.74 -49.91 75.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.831 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.539 HG23 ' HG2' ' A' ' 115' ' ' PRO . 56.1 t -69.56 -34.27 60.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.136 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.473 ' CG2' ' HA ' ' A' ' 116' ' ' TYR . 98.9 t -40.15 -66.97 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.147 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.64 -41.14 18.47 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.513 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.505 HD12 ' HA ' ' A' ' 118' ' ' VAL . 19.2 mt -62.22 -43.32 99.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.826 0.346 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.491 HG23 HG12 ' A' ' 118' ' ' VAL . 97.5 t -68.03 -62.12 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.075 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.521 ' O ' HG22 ' A' ' 130' ' ' ILE . 97.5 t -40.04 -54.03 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.177 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 87.64 167.57 43.67 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_exo -47.93 94.8 0.03 OUTLIER 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.717 2.278 . . . . 0.0 112.338 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 29.6 mtpt 55.07 42.17 31.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.905 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 69.32 79.01 0.31 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.478 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -128.47 -38.78 1.72 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.867 0.365 . . . . 0.0 111.104 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.2 m -87.08 -40.26 14.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.087 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.521 HG22 ' O ' ' A' ' 123' ' ' VAL . 5.0 tp -64.7 -33.33 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.141 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 18.2 tttp -59.49 -42.34 91.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -54.96 -47.79 74.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.812 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.541 HG23 ' OE1' ' A' ' 167' ' ' GLU . 54.3 mt -54.8 -48.81 73.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.418 ' CG ' HD12 ' A' ' 141' ' ' ILE . 61.1 mt-30 -48.25 -38.59 18.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 86.7 mm-40 -81.12 -52.56 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -51.37 -32.64 26.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 52.4 p -106.53 -13.56 15.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.141 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 41.2 m80 60.0 53.43 4.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.883 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.481 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 55.2 p -135.49 139.79 44.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.121 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -77.75 90.47 4.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.979 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.509 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -83.29 142.14 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.163 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 86.6 t -131.01 121.23 49.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.119 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 78.6 p -73.0 150.01 90.05 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.562 0.696 . . . . 0.0 111.152 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 176.91 6.17 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.252 . . . . 0.0 112.363 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -77.08 150.46 37.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.5 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -57.17 -36.42 70.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -110.34 40.35 1.98 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 49.2 mmtt -134.72 165.77 24.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -56.42 144.54 62.35 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 94.01 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.658 2.239 . . . . 0.0 112.396 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.801 HG13 ' O ' ' A' ' 112' ' ' VAL . 89.3 t -145.72 135.55 18.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.089 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -102.51 128.43 49.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.847 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -100.21 109.86 22.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.089 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 161' ' ' VAL . 67.3 t -100.77 130.17 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 21.7 m -117.91 135.1 54.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.135 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 153.87 179.72 29.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.504 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.471 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.9 mmt -46.57 159.28 0.36 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.53 0.681 . . . . 0.0 110.905 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 0.85 5.06 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.673 2.249 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -118.47 -29.13 5.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.914 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.481 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 8.4 m-20 -78.22 -46.47 20.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.838 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.471 HG22 ' O ' ' A' ' 157' ' ' MET . 16.0 m -68.32 -23.56 28.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.127 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -66.72 -39.12 87.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 24.2 ttm-85 -70.15 -46.87 63.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.37 -34.62 58.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.118 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.43 ' HE ' ' CD1' ' A' ' 110' ' ' ILE . 13.6 ttm180 -64.48 -50.87 65.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -62.9 -24.68 67.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.541 ' OE1' HG23 ' A' ' 133' ' ' ILE . 22.3 mt-10 -77.08 -56.5 4.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.957 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 76.2 mt -52.73 -53.45 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.112 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -56.28 -43.37 78.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -41.78 -58.3 2.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.076 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.444 ' C ' ' O ' ' A' ' 170' ' ' ALA . 9.8 m80 -34.45 -36.07 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.527 HG12 HG21 ' A' ' 118' ' ' VAL . 64.9 mt -54.1 -61.21 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.147 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.9 t -67.85 -25.11 65.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.123 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 9.7 tp -60.34 147.58 40.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.866 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -92.14 156.86 17.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 24.7 p -108.95 -44.99 3.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -79.31 142.71 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -2.26 9.87 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.66 2.24 . . . . 0.0 112.36 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 44.3 m -156.94 163.24 39.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.0 m -153.6 138.99 17.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.479 -179.944 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.4 p -146.35 137.61 24.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.911 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.1 m -100.53 86.51 3.16 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.847 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 60.99 -136.97 48.41 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.534 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.9 p -111.95 126.91 55.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.832 0.349 . . . . 0.0 110.821 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 57.7 m -119.7 149.62 41.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.841 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -81.24 77.52 2.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.46 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -160.94 80.03 0.15 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.51 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -87.25 161.95 17.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.869 0.366 . . . . 0.0 110.913 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -125.61 159.48 32.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.2 m -128.51 116.42 19.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.6 pt -104.77 155.32 6.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -114.42 101.0 8.74 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 91.3 t -69.64 141.97 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.093 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 23.6 ttp180 -111.67 112.05 23.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.887 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.49 HG11 HG22 ' A' ' 168' ' ' ILE . 2.4 m -134.11 151.4 76.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.614 0.721 . . . . 0.0 111.108 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.542 ' CB ' ' NH1' ' A' ' 117' ' ' ARG . 53.6 Cg_endo -69.74 138.37 37.72 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.682 2.255 . . . . 0.0 112.322 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.0 t80 -46.96 -37.91 9.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.542 ' NH1' ' CB ' ' A' ' 115' ' ' PRO . 8.6 ptp85 -59.01 -38.62 79.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.839 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.491 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 19.8 t -78.0 -36.42 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.171 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 97.1 t -41.37 -63.7 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.157 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.07 -39.21 18.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 14.3 mt -65.15 -43.9 90.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 0.0 110.921 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 73.4 t -71.57 -60.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.7 t -42.28 -45.54 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.132 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 73.92 173.34 27.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.482 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.427 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.4 Cg_exo -48.03 114.74 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.703 2.269 . . . . 0.0 112.333 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.7 pttm 36.1 39.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.895 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 71.44 73.77 0.78 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.61 -38.49 3.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 m -85.5 -44.25 12.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.143 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.82 HD11 HG21 ' A' ' 141' ' ' ILE . 6.1 tp -60.82 -31.16 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -68.03 -40.18 82.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -60.85 -44.23 97.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.833 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 73.0 mt -54.58 -54.58 21.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.126 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.539 ' HG3' HD12 ' A' ' 141' ' ' ILE . 76.1 mt-30 -42.81 -30.9 0.43 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.905 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -78.27 -53.72 7.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.1 mpp_? -54.4 -32.17 56.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 74.1 p -102.22 -17.5 15.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.178 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.4 ' N ' ' O ' ' A' ' 134' ' ' GLN . 16.9 m170 59.27 54.94 4.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.821 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.468 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.3 p -135.28 174.51 10.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.113 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -106.21 89.94 3.21 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.82 HG21 HD11 ' A' ' 130' ' ' ILE . 84.8 mt -82.89 137.14 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.1 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.439 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 91.7 t -124.63 132.14 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.166 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 80.7 p -90.26 147.86 37.82 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.582 0.706 . . . . 0.0 111.166 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -179.11 2.67 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.677 2.251 . . . . 0.0 112.315 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.44 176.92 51.5 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.52 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . 0.419 ' C ' ' HD3' ' A' ' 146' ' ' ARG . 0.2 OUTLIER -80.23 -35.29 36.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -106.87 39.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 38.7 mmtt -138.01 175.43 9.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -71.98 143.41 86.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.592 0.71 . . . . 0.0 110.935 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 89.66 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.644 2.229 . . . . 0.0 112.394 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 75.4 t -138.17 119.64 17.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.71 148.88 25.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.439 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.86 105.62 10.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.08 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 161' ' ' VAL . 96.0 t -100.89 127.03 54.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.128 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -112.79 138.68 49.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.157 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 150.4 176.04 23.03 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.618 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -41.03 159.4 0.16 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.582 0.706 . . . . 0.0 110.87 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 0.58 5.4 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.706 2.271 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -118.35 -35.46 3.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.468 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 6.1 m-20 -69.25 -46.31 67.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.904 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.695 HG12 HG12 ' A' ' 154' ' ' VAL . 33.7 m -68.88 -38.61 78.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.134 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -52.37 -42.04 63.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.856 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 42.0 ttt85 -63.82 -52.56 59.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.89 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -45.58 -49.28 14.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.079 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 44.4 ttt180 -51.6 -40.5 59.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 77.9 mt-10 -57.61 -47.98 80.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -65.04 -56.69 11.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.937 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.49 HG22 HG11 ' A' ' 114' ' ' VAL . 65.4 mt -47.84 -50.69 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.132 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -65.89 -47.03 76.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.849 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.433 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.83 -55.75 1.46 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 170' ' ' ALA . 95.2 m-70 -36.02 -43.11 0.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.833 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.419 HG12 HG21 ' A' ' 118' ' ' VAL . 73.6 mt -44.49 -58.24 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.092 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 174' ' ' LEU . 95.5 m -58.82 -52.12 67.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.189 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 173' ' ' THR . 9.3 tp -35.78 135.35 0.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.939 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 24.5 ttm180 -66.29 151.44 47.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 40.1 m -78.63 147.49 33.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . -103.17 -80.98 1.49 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.521 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -32.62 18.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.665 2.244 . . . . 0.0 112.373 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 3.7 t 66.99 51.42 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.863 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 9.8 m 56.13 43.77 26.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.826 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.491 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 29.9 p 40.85 42.29 1.42 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.859 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.9 m -56.39 172.76 0.21 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.851 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 164.01 46.31 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.492 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 53.4 m -83.2 140.46 32.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 110.892 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 57.2 p -137.63 128.76 27.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.861 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.83 124.06 5.37 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.495 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.94 -108.89 0.57 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.497 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 25.2 pt20 -71.54 -176.92 1.69 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.853 0.358 . . . . 0.0 110.914 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 8.8 t -147.71 156.97 43.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.162 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 97.8 m -127.9 122.49 32.62 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.675 HD12 ' HE ' ' A' ' 165' ' ' ARG . 22.6 pt -111.27 154.84 12.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -109.9 101.76 10.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.735 HG22 ' HG3' ' A' ' 165' ' ' ARG . 54.0 t -69.67 132.98 32.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 14.9 ttp180 -100.39 118.95 37.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.549 HG13 HG12 ' A' ' 112' ' ' VAL . 3.3 m -141.14 150.45 58.85 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.624 0.726 . . . . 0.0 111.085 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 133.18 24.98 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 28.0 t80 -42.42 -26.89 0.13 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 60.2 ttp85 -69.35 -54.06 16.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.766 HG21 HG12 ' A' ' 172' ' ' ILE . 35.8 t -63.65 -27.29 42.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.147 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.1 t -46.5 -71.09 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -43.68 -34.67 2.79 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 8.7 mt -67.39 -44.19 79.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.9 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 83.9 t -69.42 -65.58 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.9 t -37.63 -61.5 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.142 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.78 166.15 38.64 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.514 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_exo -47.97 93.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.697 2.265 . . . . 0.0 112.341 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt 56.98 54.03 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.939 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 54.93 70.95 0.8 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.52 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.71 -41.14 2.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 111.084 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 73.7 m -78.59 -44.5 23.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.155 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 133' ' ' ILE . 7.5 tp -54.4 -29.59 20.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.122 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.7 tptp -54.57 -44.64 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? -61.27 -22.12 64.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.824 HD12 HD12 ' A' ' 130' ' ' ILE . 70.5 mt -83.1 -31.56 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.136 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.708 ' HG3' HD12 ' A' ' 141' ' ' ILE . 44.8 mt-30 -83.34 -24.45 32.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . 0.472 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.82 -41.01 19.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.935 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.472 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 14.9 mmm180 -64.62 -35.68 81.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.6 p -100.56 -18.12 16.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.16 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.4 m80 62.28 46.18 6.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.822 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.454 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 73.6 p -120.67 164.55 16.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.133 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 52.4 t80 -95.66 88.25 4.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.708 HD12 ' HG3' ' A' ' 134' ' ' GLN . 79.9 mt -88.69 132.81 32.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.103 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 99.4 t -117.96 132.09 68.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.167 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 64.4 p -85.55 148.07 48.25 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.596 0.713 . . . . 0.0 111.126 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 176.49 6.73 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.647 2.231 . . . . 0.0 112.356 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.56 179.22 53.24 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.48 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -79.16 -43.25 24.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.884 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.7 p-10 -104.79 43.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.876 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 52.9 mmtt -134.08 169.04 17.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.9 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.407 ' H ' ' CD ' ' A' ' 149' ' ' GLU . 2.0 pm0 -66.57 143.99 98.43 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.669 0.747 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 95.7 0.56 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 2.267 . . . . 0.0 112.313 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.2 t -147.7 119.59 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.172 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -88.27 140.27 29.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -111.02 110.17 20.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.081 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.489 HG12 HG12 ' A' ' 161' ' ' VAL . 23.8 t -103.98 122.51 56.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.094 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 93.6 m -111.03 130.59 55.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.153 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.491 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 158.31 178.16 32.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.475 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.703 ' O ' HG22 ' A' ' 161' ' ' VAL . 12.5 mmt -45.37 158.94 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.577 0.703 . . . . 0.0 110.891 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -0.69 7.2 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.737 2.291 . . . . 0.0 112.32 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -117.78 -25.38 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.908 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.454 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 5.5 m-20 -83.07 -48.52 10.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.703 HG22 ' O ' ' A' ' 157' ' ' MET . 34.1 m -64.78 -36.96 78.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -58.36 -45.28 88.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.855 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -61.46 -43.91 98.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.873 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -53.92 -44.01 70.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.735 ' HG3' HG22 ' A' ' 112' ' ' VAL . 18.6 ttm180 -59.42 -42.85 92.8 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.872 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . 0.425 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 18.2 mt-10 -53.37 -42.88 67.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.935 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -71.3 -51.61 23.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.877 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 61.6 mt -49.34 -53.99 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.137 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -67.38 -41.45 85.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.897 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.439 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.59 -61.44 0.71 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.116 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 170' ' ' ALA . 32.7 m170 -34.46 -41.29 0.12 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.842 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.766 HG12 HG21 ' A' ' 118' ' ' VAL . 93.4 mt -47.78 -55.34 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 49.6 p -99.93 88.26 3.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.158 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.3 tp -150.43 157.25 42.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 18.9 ttt180 -160.15 142.47 13.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 39.5 m -61.33 126.23 26.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 133.32 -95.03 0.28 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.495 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 101.55 0.93 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.692 2.261 . . . . 0.0 112.315 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 t -165.81 174.34 9.73 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 87.1 p -84.55 -43.78 14.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.452 179.963 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.3 t -156.54 112.84 3.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.864 0.364 . . . . 0.0 110.851 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.9 m -102.46 170.03 8.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 103' ' ' SER . . . 156.89 -79.46 0.18 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.526 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 102' ' ' GLY . 8.3 t -36.54 110.15 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.858 0.361 . . . . 0.0 110.867 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.9 t -74.89 168.65 19.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.855 -179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -153.96 -48.08 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.504 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.71 111.65 1.66 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.498 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -55.92 169.83 0.34 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.4 t -129.47 159.66 35.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.135 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 41.5 m -131.24 120.64 23.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.187 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 25.0 pt -111.15 152.89 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.094 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 38.2 mm-40 -108.02 100.66 9.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.896 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 168' ' ' ILE . 88.4 t -73.09 141.97 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.147 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 37.5 ttt-85 -104.98 120.88 42.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.429 HG21 ' CE1' ' A' ' 152' ' ' PHE . 4.8 m -140.49 151.07 62.84 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.688 0.756 . . . . 0.0 111.074 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.546 ' HG2' HG23 ' A' ' 118' ' ' VAL . 53.2 Cg_endo -69.79 138.4 37.64 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.685 2.256 . . . . 0.0 112.314 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -47.52 -26.21 1.34 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.927 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 ttm180 -69.6 -46.99 65.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.835 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.598 HG12 HG23 ' A' ' 122' ' ' VAL . 41.2 t -68.39 -29.37 43.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.108 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.4 t -42.27 -65.77 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.111 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.66 -34.08 9.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.4 -46.11 61.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.85 0.357 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.598 HG23 HG12 ' A' ' 118' ' ' VAL . 91.9 t -64.89 -57.92 9.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.118 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.459 HG22 ' CG2' ' A' ' 143' ' ' THR . 90.2 t -55.28 -49.24 74.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.095 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.94 172.69 48.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.44 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_exo -47.95 99.15 0.04 OUTLIER 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.652 2.235 . . . . 0.0 112.382 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? 54.01 42.71 31.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.46 68.38 1.67 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.52 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -123.28 -35.18 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.893 0.378 . . . . 0.0 111.109 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 33.1 m -75.94 -39.41 56.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.751 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -67.21 -23.08 29.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -62.58 -38.5 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -66.44 -37.8 85.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.844 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 66.7 mt -70.48 -49.7 50.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.116 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 44.5 mt-30 -52.32 -37.49 55.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.931 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 65.0 mt-30 -81.82 -52.41 7.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 -52.89 -33.87 52.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.849 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.7 p -103.54 -15.15 15.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.165 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 17.8 m170 60.95 53.79 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.47 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.5 p -138.01 138.27 38.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 51.9 t80 -76.74 91.92 3.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.751 HG21 HD11 ' A' ' 130' ' ' ILE . 77.7 mt -83.64 134.41 27.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.125 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 76.1 t -120.28 129.32 75.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.137 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.459 ' CG2' HG22 ' A' ' 123' ' ' VAL . 41.6 p -83.8 153.12 63.94 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.54 0.686 . . . . 0.0 111.191 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 177.06 5.97 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.684 2.256 . . . . 0.0 112.366 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -75.06 155.67 48.07 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.45 -28.49 70.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.86 0.362 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -119.91 38.01 4.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -135.91 162.13 33.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.898 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -53.99 143.86 40.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.638 0.732 . . . . 0.0 110.893 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.73 97.68 0.65 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.695 2.263 . . . . 0.0 112.331 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.3 t -145.32 117.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.429 ' CE1' HG21 ' A' ' 114' ' ' VAL . 35.4 m-85 -86.73 146.31 26.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.86 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -121.74 99.13 6.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.43 HG12 HG12 ' A' ' 161' ' ' VAL . 46.6 t -87.63 131.1 36.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.134 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 97.9 m -117.09 131.07 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.177 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.437 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 156.43 175.13 27.04 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.456 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.577 ' O ' HG22 ' A' ' 161' ' ' VAL . 21.6 mmt -39.2 159.49 0.1 Allowed Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.576 0.703 . . . . 0.0 110.902 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.723 2.282 . . . . 0.0 112.36 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -119.7 -38.38 2.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.869 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.4 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 37.2 m-20 -66.77 -46.42 75.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 157' ' ' MET . 20.5 m -67.72 -38.1 79.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -52.89 -43.1 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 11.9 ttt180 -61.89 -57.92 9.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -42.06 -48.54 4.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 16.9 ttp85 -48.34 -40.24 24.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -55.48 -64.82 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 58.1 mm-40 -54.22 -46.35 72.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 112' ' ' VAL . 47.7 mt -44.63 -65.91 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.082 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.446 ' HB2' HD12 ' A' ' 172' ' ' ILE . 0.7 OUTLIER -69.36 -29.52 67.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.861 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.555 ' O ' HD23 ' A' ' 174' ' ' LEU . . . -48.74 -48.99 40.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.41 ' HA ' HD23 ' A' ' 174' ' ' LEU . 9.1 m170 -46.89 -26.32 0.96 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.882 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.453 HG12 HG21 ' A' ' 118' ' ' VAL . 69.6 mt -51.71 -39.08 23.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.127 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.73 ' C ' HD22 ' A' ' 174' ' ' LEU . 9.8 t -99.62 45.44 0.99 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.142 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.73 HD22 ' C ' ' A' ' 173' ' ' THR . 4.3 mm? -131.35 162.79 29.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 15.0 tpt180 -106.46 111.09 23.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 2.1 m -141.24 168.14 20.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.828 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 154.85 66.36 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -48.08 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.629 2.219 . . . . 0.0 112.309 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 22.9 t -153.94 152.23 30.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.843 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.4 t -133.86 82.58 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.885 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.356 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.529 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.0 t -100.53 -53.91 2.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.896 0.379 . . . . 0.0 110.826 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.1 m -123.34 98.4 5.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.897 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 52.42 -158.93 3.21 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 8.8 t -120.48 94.93 4.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.867 0.365 . . . . 0.0 110.875 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 36.7 m -151.42 172.67 15.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.88 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -112.85 -59.89 0.42 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.473 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -149.97 -83.01 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.489 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -91.23 159.31 16.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.885 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.9 t -124.5 168.4 13.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.123 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 25.6 m -137.34 124.63 21.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.093 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 23.0 pt -122.46 155.24 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.091 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -105.2 111.66 24.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.548 HG12 HG13 ' A' ' 114' ' ' VAL . 70.4 t -76.77 135.04 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -106.65 117.65 34.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.584 HG11 HG22 ' A' ' 168' ' ' ILE . 8.7 m -137.96 151.05 69.42 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.669 0.747 . . . . 0.0 111.121 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.418 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.2 Cg_endo -69.68 134.37 27.98 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -47.09 -21.98 0.3 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.902 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 91.7 mtt-85 -72.59 -44.02 62.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.865 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.605 HG21 HG12 ' A' ' 172' ' ' ILE . 39.6 t -74.31 -34.41 36.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.15 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.8 t -38.23 -69.92 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.155 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -44.31 -36.21 4.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.472 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 118' ' ' VAL . 15.1 mt -68.01 -44.16 77.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.882 0.373 . . . . 0.0 110.958 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.561 HG23 HG12 ' A' ' 118' ' ' VAL . 57.5 t -65.53 -63.28 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 82.3 t -40.88 -50.43 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.142 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 79.97 169.08 38.51 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.05 101.23 0.04 OUTLIER 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.353 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 8.4 tptm 50.26 44.39 26.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 66.71 72.9 0.7 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -119.63 -39.81 2.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 111.12 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -84.49 -43.57 14.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.946 HD11 HG21 ' A' ' 141' ' ' ILE . 7.4 tp -58.53 -37.88 67.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 27.4 tttm -57.09 -43.2 81.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.907 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 74.3 mtt-85 -57.27 -44.35 83.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.876 HG23 ' OE1' ' A' ' 167' ' ' GLU . 58.7 mt -57.93 -46.43 87.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.164 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.511 ' HG3' HD12 ' A' ' 141' ' ' ILE . 53.6 mt-30 -60.8 -20.32 61.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.934 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 5.4 mm100 -90.28 -45.6 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -66.97 -32.7 74.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.45 ' CG2' ' OE2' ' A' ' 167' ' ' GLU . 66.7 p -101.48 -15.63 17.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.173 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 11.6 m170 56.79 49.91 13.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.818 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.571 HG21 ' HA ' ' A' ' 161' ' ' VAL . 57.9 p -131.8 146.8 52.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.173 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 26.1 t80 -78.85 96.64 5.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.946 HG21 HD11 ' A' ' 130' ' ' ILE . 91.4 mt -90.97 115.63 30.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.16 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.456 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 97.2 t -105.73 124.99 61.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.12 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.568 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.0 p -76.65 152.62 83.2 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.604 0.716 . . . . 0.0 111.177 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 175.79 7.67 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.692 2.261 . . . . 0.0 112.337 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -78.51 158.98 46.0 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.467 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 12.6 ptp180 -62.27 -44.01 97.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.867 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.43 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 30.8 t0 -103.95 42.35 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.901 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 8.0 mmmm -138.34 163.93 30.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 14.9 pt-20 -60.96 148.73 83.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.895 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 101.44 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.709 2.273 . . . . 0.0 112.344 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 98.2 t -153.82 119.92 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.094 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.568 ' CE2' HG22 ' A' ' 143' ' ' THR . 52.1 m-85 -89.79 156.93 18.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.456 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -122.87 104.76 9.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.138 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 34.1 t -95.81 124.0 48.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.167 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.7 m -115.53 134.06 55.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.145 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 154.09 -172.37 32.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.5 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.552 ' O ' HG22 ' A' ' 161' ' ' VAL . 18.0 mmt -50.45 159.4 0.87 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.581 0.705 . . . . 0.0 110.868 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 0.87 5.01 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.678 2.252 . . . . 0.0 112.362 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -120.03 -33.38 3.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.909 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 57.3 m-20 -73.62 -48.73 30.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.571 ' HA ' HG21 ' A' ' 139' ' ' THR . 17.3 m -63.67 -36.1 75.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -61.15 -38.91 88.12 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.919 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -63.17 -40.74 98.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -61.78 -33.39 74.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.084 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 47.0 ttp85 -67.16 -50.48 61.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.42 -26.04 66.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.876 ' OE1' HG23 ' A' ' 133' ' ' ILE . 67.5 mt-10 -77.83 -52.91 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.584 HG22 HG11 ' A' ' 114' ' ' VAL . 72.6 mt -58.81 -40.15 79.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.133 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -71.87 -38.59 70.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.916 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . . . . . . . . . . . -44.2 -54.85 5.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 43.8 m170 -41.65 -32.07 0.34 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.605 HG12 HG21 ' A' ' 118' ' ' VAL . 76.9 mt -55.79 -44.81 78.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.136 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.443 ' O ' ' C ' ' A' ' 174' ' ' LEU . 88.4 m -63.85 -50.35 69.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 173' ' ' THR . 33.2 mt -34.41 -55.74 0.52 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.9 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 48.53 45.27 21.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 2.6 m -38.82 -48.49 1.54 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.836 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 147.7 -96.1 0.17 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.483 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 161.83 44.41 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.67 2.247 . . . . 0.0 112.349 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 31.8 p -126.4 104.03 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.902 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 2.8 m -66.21 113.52 4.62 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.881 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.479 179.977 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 47.7 m 46.78 42.18 11.44 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 110.864 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 t -101.5 123.1 45.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.889 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 51.69 -160.55 2.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.541 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 35.3 t -126.59 103.18 7.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.371 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.5 m -148.64 121.98 9.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.816 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 63.86 161.59 0.42 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -168.33 -106.49 0.19 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.51 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -95.05 167.48 11.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.2 t -127.55 161.3 29.12 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.082 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 87.7 m -132.31 122.4 25.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.143 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.26 156.11 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.131 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 49.3 mm-40 -109.88 100.55 9.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.943 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 94.4 t -67.85 141.01 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 34.6 ttp180 -109.3 124.77 51.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.86 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 5.1 m -146.52 149.57 37.63 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.56 0.695 . . . . 0.0 111.142 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 139.03 39.31 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.326 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 t80 -49.17 -20.91 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 ttm-85 -74.35 -46.24 41.94 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.741 HG21 HG12 ' A' ' 172' ' ' ILE . 16.7 t -68.6 -37.28 77.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 87.3 t -39.75 -64.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.098 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -47.72 -36.6 13.26 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 12.8 mt -70.04 -43.08 71.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.775 0.321 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.461 HG23 HG12 ' A' ' 118' ' ' VAL . 48.8 t -67.31 -63.1 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 96.4 t -38.97 -49.77 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.133 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.87 172.61 33.35 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.481 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -47.95 102.81 0.05 OUTLIER 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 91.0 mttt 46.16 44.41 12.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.901 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 67.58 70.67 1.08 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -117.11 -37.06 3.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 111.088 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 35.4 m -87.96 -44.39 11.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.158 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.696 HD11 HG21 ' A' ' 141' ' ' ILE . 6.6 tp -60.79 -28.06 42.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.153 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 12.9 ttpp -64.67 -46.97 80.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.938 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.2 mtt180 -51.74 -50.55 60.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.883 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 56.8 mt -50.14 -54.95 6.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.135 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.674 ' HG3' HD12 ' A' ' 141' ' ' ILE . 46.6 mt-30 -45.89 -37.07 5.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.901 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -79.79 -59.15 2.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.5 mmt180 -43.51 -37.64 2.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.861 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.6 p -101.03 -22.81 14.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.086 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 20.7 m80 69.85 52.62 0.4 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.831 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.466 HG21 ' HA ' ' A' ' 161' ' ' VAL . 81.0 p -133.46 155.19 49.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.142 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 35.4 t80 -90.07 95.47 10.23 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.964 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.696 HG21 HD11 ' A' ' 130' ' ' ILE . 90.3 mt -86.77 138.49 18.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.094 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 90.5 t -129.28 124.08 59.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.187 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.709 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.3 p -80.18 152.68 74.0 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.562 0.696 . . . . 0.0 111.121 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -175.59 1.2 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.396 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -84.6 169.48 45.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.31 -22.87 59.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 20.3 p-10 -123.0 40.77 3.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 27.6 mmmt -138.94 174.19 10.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -68.02 143.94 96.62 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.611 0.72 . . . . 0.0 110.915 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 91.15 0.52 Allowed 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.646 2.231 . . . . 0.0 112.32 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.7 t -138.74 120.04 16.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.139 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.709 ' CE2' HG22 ' A' ' 143' ' ' THR . 36.2 m-85 -89.1 147.94 23.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -117.92 113.56 21.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.115 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.526 HG12 HG12 ' A' ' 161' ' ' VAL . 53.8 t -106.68 124.4 62.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.133 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 60.2 m -111.54 137.38 49.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 161' ' ' VAL . . . 151.61 -177.27 29.61 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.441 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.804 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.7 mmt -47.28 159.1 0.43 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.545 0.688 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.29 8.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.717 2.278 . . . . 0.0 112.367 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -115.71 -37.01 4.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.839 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 -71.13 -50.62 31.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.903 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.804 HG22 ' O ' ' A' ' 157' ' ' MET . 32.0 m -59.4 -29.51 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.091 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.02 -42.06 94.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -65.83 -32.21 73.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . 0.491 ' HB3' HG11 ' A' ' 154' ' ' VAL . . . -66.82 -36.3 82.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.084 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.42 ' CG ' ' OE1' ' A' ' 169' ' ' GLU . 41.5 ttt180 -65.31 -59.57 3.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . 0.475 ' O ' ' HB2' ' A' ' 170' ' ' ALA . 1.7 pp20? -51.92 -31.46 28.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -67.56 -55.39 13.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 71.4 mt -58.27 -53.66 43.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.109 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.42 ' OE1' ' CG ' ' A' ' 165' ' ' ARG . 29.0 mt-10 -58.77 -41.52 86.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 166' ' ' GLU . . . -41.38 -59.23 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.106 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . . . . . . . . . 50.1 m170 -37.75 -37.91 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.741 HG12 HG21 ' A' ' 118' ' ' VAL . 84.1 mt -45.95 -65.29 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.132 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 170' ' ' ALA . 10.0 t -65.59 -32.21 73.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.201 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 5.2 tt -52.29 113.42 1.03 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.908 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 11.4 tpt180 69.38 44.74 0.9 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.869 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 93.7 p -98.96 145.76 26.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.848 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 112.5 -176.31 17.66 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.489 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 91.95 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.713 2.275 . . . . 0.0 112.32 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 71.7 m -93.53 134.83 35.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.882 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 1.5 t 70.66 41.95 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.872 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.486 -179.963 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 92.5 p -90.63 -49.01 6.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.9 0.381 . . . . 0.0 110.856 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.3 t 65.31 42.06 4.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -109.55 140.47 15.75 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.434 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.9 t -104.42 -47.93 3.97 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.899 0.381 . . . . 0.0 110.898 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.0 t -60.63 170.52 1.41 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -139.15 -92.62 0.25 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.453 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.15 98.32 0.88 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.536 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -98.94 169.38 9.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.898 0.38 . . . . 0.0 110.901 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 10.1 t -133.97 163.96 28.36 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.11 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 56.8 m -131.87 126.16 33.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.152 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 27.4 pt -111.84 155.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.133 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -112.59 101.01 9.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.451 HG22 ' HG3' ' A' ' 165' ' ' ARG . 90.5 t -72.75 141.28 16.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.139 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.8 ttm180 -111.6 115.37 29.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.409 HG11 HG22 ' A' ' 168' ' ' ILE . 3.5 m -133.37 150.69 75.85 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.658 0.742 . . . . 0.0 111.103 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.49 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.5 Cg_endo -69.84 123.84 10.47 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.636 2.224 . . . . 0.0 112.31 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.436 ' C ' ' O ' ' A' ' 115' ' ' PRO . 24.4 t80 -35.2 -32.82 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.899 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.481 ' N ' ' O ' ' A' ' 115' ' ' PRO . 10.9 mmm180 -63.12 -51.96 64.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.49 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 40.1 t -65.36 -32.19 57.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.159 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.483 ' O ' ' N ' ' A' ' 122' ' ' VAL . 75.8 t -42.66 -72.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 119' ' ' VAL . . . -37.64 -36.79 0.31 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.5 mt -69.99 -39.59 75.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.898 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.483 ' N ' ' O ' ' A' ' 119' ' ' VAL . 38.4 t -68.92 -63.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 94.3 t -43.97 -55.75 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.079 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 83.84 172.83 49.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.509 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -48.03 107.09 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.638 2.225 . . . . 0.0 112.369 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 43.9 39.16 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.915 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 68.73 75.47 0.52 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.493 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -120.34 -41.51 2.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.086 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 83.4 m -81.49 -44.77 16.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.151 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 133' ' ' ILE . 9.7 tp -54.67 -40.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.149 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.427 ' N ' HG23 ' A' ' 130' ' ' ILE . 10.4 ttpp -51.72 -44.55 63.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.904 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.427 ' HA ' ' CG ' ' A' ' 135' ' ' GLN . 21.8 mtp180 -63.63 -20.58 65.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.792 HD12 HD12 ' A' ' 130' ' ' ILE . 71.4 mt -79.81 -37.44 18.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.726 ' CG ' HD12 ' A' ' 141' ' ' ILE . 69.1 mt-30 -78.12 -26.96 48.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . 0.479 ' NE2' ' HG2' ' A' ' 136' ' ' ARG . 0.9 OUTLIER -82.85 -41.38 19.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.918 -179.927 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.479 ' HG2' ' NE2' ' A' ' 135' ' ' GLN . 13.9 mmt180 -62.4 -39.26 92.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.894 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 38.8 p -101.3 -6.53 24.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.155 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 74.1 m80 55.2 52.8 11.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.467 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 13.1 p -129.02 150.15 50.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.18 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -90.66 92.6 8.9 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.939 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.732 HG12 HG22 ' A' ' 154' ' ' VAL . 69.7 mt -84.67 124.08 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.773 ' HB ' ' HB3' ' A' ' 153' ' ' ALA . 79.7 t -100.41 109.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 152' ' ' PHE . 69.6 p -79.04 148.84 72.45 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.586 0.707 . . . . 0.0 111.125 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.86 23.17 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -79.27 -164.33 27.75 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.482 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -71.67 -54.2 11.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.783 0.325 . . . . 0.0 110.849 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -103.88 41.29 1.31 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.66 140.05 50.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.943 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -45.52 143.31 2.95 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.645 0.736 . . . . 0.0 110.897 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 82.14 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.653 2.236 . . . . 0.0 112.347 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 112' ' ' VAL . 46.3 t -139.63 119.93 14.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.128 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.654 ' CE2' HG22 ' A' ' 143' ' ' THR . 23.9 m-85 -90.58 147.43 23.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.856 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.773 ' HB3' ' HB ' ' A' ' 142' ' ' VAL . . . -119.53 98.57 6.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.07 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.732 HG22 HG12 ' A' ' 141' ' ' ILE . 58.0 t -86.12 119.27 34.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.187 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 87.1 m -107.71 132.34 53.46 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.115 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.432 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 155.64 -173.0 33.76 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.539 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.9 mmt -50.58 158.7 1.02 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.589 0.709 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -2.49 10.24 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.695 2.263 . . . . 0.0 112.353 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -113.25 -32.67 6.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.467 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 21.4 m-20 -77.16 -53.57 7.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.899 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 157' ' ' MET . 17.8 m -54.29 -34.55 27.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.151 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.436 ' C ' ' OE2' ' A' ' 166' ' ' GLU . 23.2 t0 -59.38 -67.86 0.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.858 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 21.3 ttm-85 -43.76 -51.27 7.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.859 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -44.75 -36.5 3.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.451 ' HG3' HG22 ' A' ' 112' ' ' VAL . 37.6 ttp180 -72.57 -34.61 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 166' ' ' GLU . 0.1 OUTLIER -57.77 -39.68 78.01 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.888 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -71.56 -53.72 12.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.409 HG22 HG11 ' A' ' 114' ' ' VAL . 70.3 mt -49.96 -48.98 22.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 -65.26 -43.38 91.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.438 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -44.39 -57.66 3.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.08 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.438 ' C ' ' O ' ' A' ' 170' ' ' ALA . 11.4 m80 -35.45 -37.91 0.09 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.45 HG12 HG21 ' A' ' 118' ' ' VAL . 66.7 mt -51.99 -55.47 9.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 30.2 m -68.12 -47.35 68.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 4.7 tp -48.65 113.55 0.79 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.24 116.13 28.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 36.8 m -80.07 -52.79 7.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.909 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 79.73 175.09 47.48 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.47 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.82 0.28 5.92 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.682 2.255 . . . . 0.0 112.338 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 3.8 m -47.58 150.71 0.94 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.833 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 4.5 m -84.62 124.2 31.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.851 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.475 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.5 m -102.84 120.35 40.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.889 0.376 . . . . 0.0 110.865 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 t -113.05 99.99 8.27 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.893 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 178.41 144.47 5.62 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 68.7 m -109.05 143.62 38.13 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.886 0.374 . . . . 0.0 110.855 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.3 p -49.53 -55.44 13.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.32 42.27 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.45 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -114.34 -46.69 0.62 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.47 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.473 ' C ' ' CD ' ' A' ' 107' ' ' GLN . 0.0 OUTLIER -92.69 178.59 5.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.861 0.362 . . . . 0.0 110.943 -179.872 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.8 t -134.31 157.33 46.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 91.5 m -128.4 118.29 22.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.17 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 20.9 pt -106.91 154.34 7.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.168 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.45 ' NE2' ' HB2' ' A' ' 153' ' ' ALA . 43.4 mm-40 -112.27 105.74 14.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.934 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.503 HG22 ' CD ' ' A' ' 165' ' ' ARG . 93.4 t -82.12 144.77 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.16 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.44 ' O ' ' CG1' ' A' ' 114' ' ' VAL . 7.9 mpt_? -109.54 147.37 33.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.859 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.44 ' CG1' ' O ' ' A' ' 113' ' ' ARG . 7.6 m -158.45 151.11 18.02 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.627 0.727 . . . . 0.0 111.151 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.498 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.7 Cg_endo -69.72 127.03 14.03 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.713 2.275 . . . . 0.0 112.361 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -41.42 -24.42 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.918 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 115' ' ' PRO . 46.9 mtt85 -71.28 -43.81 66.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.559 HG21 HG12 ' A' ' 172' ' ' ILE . 41.2 t -74.56 -34.96 36.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.093 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.1 t -39.71 -63.83 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -46.36 -39.2 9.66 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.495 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 13.2 mt -67.56 -46.62 72.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.881 0.372 . . . . 0.0 110.937 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.546 HG23 HG12 ' A' ' 118' ' ' VAL . 59.0 t -63.79 -63.88 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 87.1 t -40.4 -49.59 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 72.7 172.87 22.04 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.477 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.7 Cg_exo -47.99 118.21 2.98 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.718 2.279 . . . . 0.0 112.352 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.434 ' C ' ' O ' ' A' ' 125' ' ' PRO . 8.0 ptpp? 35.25 43.63 0.13 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 62.46 65.66 3.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.447 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.33 -39.27 6.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.838 0.351 . . . . 0.0 111.048 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 90.1 m -83.91 -50.34 8.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.158 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.489 HD11 HG21 ' A' ' 141' ' ' ILE . 7.3 tp -49.94 -40.8 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.435 ' N ' HG23 ' A' ' 130' ' ' ILE . 25.0 tttp -60.92 -43.88 97.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 49.4 mtt180 -54.33 -41.14 68.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.467 HD11 ' CE1' ' A' ' 171' ' ' HIS . 54.8 mt -59.28 -49.93 81.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.461 ' HG3' HD12 ' A' ' 141' ' ' ILE . 62.1 mt-30 -47.77 -34.67 8.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -80.59 -54.44 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.89 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 53.7 mtt-85 -51.96 -33.42 37.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.865 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.478 HG21 ' HA ' ' A' ' 164' ' ' ALA . 37.4 p -103.59 -16.62 15.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 72.8 m80 61.23 51.15 4.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.85 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.565 HG21 ' HA ' ' A' ' 161' ' ' VAL . 38.0 p -136.52 141.51 43.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.129 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -77.15 97.42 4.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.489 HG21 HD11 ' A' ' 130' ' ' ILE . 79.8 mt -89.93 141.48 14.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.137 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.5 t -125.91 129.09 72.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.072 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 35.3 p -86.12 149.14 49.4 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.583 0.706 . . . . 0.0 111.135 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 177.83 5.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.663 2.242 . . . . 0.0 112.364 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.35 170.91 52.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.483 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 18.8 ptt180 -71.34 -42.24 68.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.33 . . . . 0.0 110.861 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 2.5 p30 -104.61 42.09 1.25 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.82 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 22.2 mmtp -139.18 159.3 42.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.894 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -58.03 142.59 79.63 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.623 0.725 . . . . 0.0 110.895 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 101.77 0.96 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.319 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -147.83 115.16 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.099 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -82.89 143.5 30.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.45 ' HB2' ' NE2' ' A' ' 111' ' ' GLN . . . -118.97 106.71 12.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.099 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.413 HG22 HG12 ' A' ' 141' ' ' ILE . 47.4 t -95.51 123.15 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 72.8 m -110.58 129.93 55.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.497 ' C ' HG13 ' A' ' 161' ' ' VAL . . . 157.78 178.8 32.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.478 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.56 ' O ' HG22 ' A' ' 161' ' ' VAL . 14.0 mmt -44.56 159.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.561 0.696 . . . . 0.0 110.877 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 0.75 5.19 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.643 2.229 . . . . 0.0 112.32 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -117.99 -37.53 3.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.878 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.465 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.4 m-20 -71.14 -45.71 62.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.879 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.565 ' HA ' HG21 ' A' ' 139' ' ' THR . 13.8 m -66.8 -38.16 80.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.108 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -55.9 -39.63 71.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.897 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.0 ttt180 -62.78 -47.21 84.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.867 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . 0.478 ' HA ' HG21 ' A' ' 137' ' ' THR . . . -49.32 -42.83 42.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.068 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.503 ' CD ' HG22 ' A' ' 112' ' ' VAL . 11.7 tpt180 -48.9 -46.63 43.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.871 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 49.0 mm-40 -63.74 -37.46 87.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.866 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -63.3 -59.65 4.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 58.8 mt -53.03 -50.44 44.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.138 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 13.1 mt-10 -59.97 -43.25 95.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.88 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.415 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -47.0 -56.03 7.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.099 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.467 ' CE1' HD11 ' A' ' 133' ' ' ILE . 27.3 m170 -37.17 -41.34 0.38 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.559 HG12 HG21 ' A' ' 118' ' ' VAL . 57.3 mt -46.57 -57.82 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 173' ' ' THR . 13.9 t -89.66 42.46 1.09 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.172 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 55.8 tp -78.0 90.89 4.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.904 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? 59.24 46.76 12.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.902 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 71.8 m -67.9 160.1 29.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.913 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 138.77 -95.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.477 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -2.9 10.91 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.714 2.276 . . . . 0.0 112.358 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 16.5 t -93.22 114.94 27.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 93.9 p -75.87 -45.86 33.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.488 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.388 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.3 t -121.82 165.29 16.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.871 0.367 . . . . 0.0 110.871 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.9 m -48.51 152.84 0.86 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.85 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -135.13 -99.63 0.61 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.482 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.8 t -173.7 145.39 1.17 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.842 0.353 . . . . 0.0 110.869 -179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 92.0 p -82.49 96.4 8.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.839 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -122.18 166.24 14.85 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.437 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 79.13 104.59 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.462 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.447 ' HB3' ' HE2' ' A' ' 157' ' ' MET . 11.5 pt20 -83.01 174.9 10.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.887 0.375 . . . . 0.0 110.911 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.5 t -133.78 164.2 27.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 93.1 m -132.69 124.55 28.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.135 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.9 pt -110.47 152.02 12.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.679 HE22 ' HB2' ' A' ' 153' ' ' ALA . 4.6 mm-40 -108.17 96.77 6.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.908 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 114' ' ' VAL . 76.9 t -68.02 137.05 25.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.144 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -108.58 115.71 30.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.916 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 112' ' ' VAL . 11.4 m -137.29 151.11 70.92 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.589 0.709 . . . . 0.0 111.14 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.543 ' HG2' HG23 ' A' ' 118' ' ' VAL . 54.3 Cg_endo -69.72 127.77 15.1 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.355 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 24.4 t80 -39.56 -27.34 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 115' ' ' PRO . 22.0 ttm180 -67.12 -44.94 78.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.899 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.545 HG12 HG23 ' A' ' 122' ' ' VAL . 55.2 t -74.51 -29.15 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.18 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 74.1 t -45.12 -63.07 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.104 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.91 -38.26 30.52 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.49 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 15.5 mt -66.78 -45.5 78.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.903 0.382 . . . . 0.0 110.971 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.545 HG23 HG12 ' A' ' 118' ' ' VAL . 89.9 t -66.28 -58.23 7.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.13 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.3 t -44.16 -54.85 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.411 ' O ' ' N ' ' A' ' 126' ' ' LYS . . . 85.12 172.77 49.42 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.494 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -48.0 88.85 0.02 OUTLIER 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.411 ' N ' ' O ' ' A' ' 124' ' ' GLY . 34.4 tttp 58.01 48.64 12.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.891 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 65.69 60.03 7.01 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.502 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -104.93 -40.21 6.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.845 0.355 . . . . 0.0 111.069 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 94.2 m -85.77 -50.79 6.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.701 HD11 HG21 ' A' ' 141' ' ' ILE . 8.4 tp -52.53 -28.98 12.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.107 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.12 -49.14 71.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -51.04 -40.14 57.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.882 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 64.4 mt -63.46 -47.16 92.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.103 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.496 ' CG ' HD12 ' A' ' 141' ' ' ILE . 70.4 mt-30 -48.1 -36.85 14.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.939 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 67.3 mm-40 -82.24 -50.12 9.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.7 mtt85 -52.78 -33.91 50.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.882 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 64.3 p -105.68 -12.08 16.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.144 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 15.5 m170 58.26 54.12 5.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.466 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 70.5 p -139.46 139.11 36.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.423 ' HE2' HG22 ' A' ' 142' ' ' VAL . 38.2 t80 -75.25 97.94 3.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.701 HG21 HD11 ' A' ' 130' ' ' ILE . 78.9 mt -87.71 122.99 40.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.147 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.423 HG22 ' HE2' ' A' ' 140' ' ' TYR . 94.0 t -107.02 128.27 62.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.781 HG22 ' HE1' ' A' ' 152' ' ' PHE . 34.1 p -87.38 144.32 35.62 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 121.583 0.706 . . . . 0.0 111.128 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -177.28 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.705 2.27 . . . . 0.0 112.304 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -90.7 -175.16 44.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 6.1 ptp85 -84.9 -41.16 16.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.844 0.354 . . . . 0.0 110.898 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -100.77 40.08 1.31 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -138.42 169.44 17.78 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.91 144.18 95.47 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.713 0.768 . . . . 0.0 110.89 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 87.5 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.727 2.285 . . . . 0.0 112.316 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.4 t -137.86 121.17 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.09 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.781 ' HE1' HG22 ' A' ' 143' ' ' THR . 69.9 m-85 -91.12 143.98 26.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.863 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.679 ' HB2' HE22 ' A' ' 111' ' ' GLN . . . -114.87 104.57 12.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.093 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 161' ' ' VAL . 46.7 t -95.05 124.41 47.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 27.0 m -110.83 132.8 53.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.13 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 155.13 177.56 28.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.639 ' O ' HG22 ' A' ' 161' ' ' VAL . 22.8 mmt -43.03 159.55 0.21 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.56 0.695 . . . . 0.0 110.865 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 0.69 5.29 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.736 2.291 . . . . 0.0 112.339 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -118.71 -35.66 3.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.907 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.466 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 71.0 m-20 -69.33 -45.75 68.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.882 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.694 HG12 HG12 ' A' ' 154' ' ' VAL . 35.2 m -67.01 -39.38 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.143 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 11.5 t70 -54.5 -42.3 70.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.865 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.5 -53.89 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 -179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -48.92 -52.25 25.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.412 ' CZ ' ' OE2' ' A' ' 169' ' ' GLU . 50.0 ttt85 -42.51 -39.38 2.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.866 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -68.49 -45.53 72.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -58.57 -54.55 45.79 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.405 HG23 HG11 ' A' ' 122' ' ' VAL . 84.4 mt -55.12 -51.12 57.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.412 ' OE2' ' CZ ' ' A' ' 165' ' ' ARG . 66.0 mt-10 -59.13 -46.0 89.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.901 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.445 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.13 -57.55 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.06 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 170' ' ' ALA . 14.7 m170 -34.9 -42.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.514 HG12 HG21 ' A' ' 118' ' ' VAL . 74.9 mt -47.85 -53.46 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.127 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 38.5 m -73.03 -44.68 60.52 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.618 HD13 ' N ' ' A' ' 175' ' ' ARG . 0.5 OUTLIER -43.38 130.4 4.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.959 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.618 ' N ' HD13 ' A' ' 174' ' ' LEU . 23.3 ptt180 -86.93 129.54 34.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.468 ' O ' ' C ' ' A' ' 177' ' ' GLY . 3.3 m -122.64 -46.06 2.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.851 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . 0.468 ' C ' ' O ' ' A' ' 176' ' ' SER . . . -32.73 96.21 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.486 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . 0.431 ' N ' ' O ' ' A' ' 176' ' ' SER . 53.7 Cg_endo -69.71 168.75 20.6 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.667 2.244 . . . . 0.0 112.392 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . 0.405 ' O ' ' C ' ' A' ' 180' ' ' SER . 30.6 t -93.74 153.92 18.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.857 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 179' ' ' SER . 83.0 p 37.46 42.21 0.32 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.863 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.458 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 t -152.5 174.06 14.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.883 0.373 . . . . 0.0 110.844 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.4 p -165.97 174.59 9.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.832 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -108.65 90.99 0.64 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.465 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.7 t -50.25 145.55 6.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.362 . . . . 0.0 110.86 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.3 t -83.64 41.79 0.81 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.866 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 149.37 154.72 6.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.49 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -101.96 -102.21 2.61 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.509 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -52.63 157.78 1.47 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.867 0.365 . . . . 0.0 110.961 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.0 t -123.53 159.67 28.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.174 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.621 ' OG1' HG23 ' A' ' 155' ' ' THR . 84.2 m -130.26 120.69 24.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.097 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.716 HD12 ' HE ' ' A' ' 165' ' ' ARG . 36.3 pt -108.38 154.97 9.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.109 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 32.9 mm-40 -113.82 96.14 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.596 ' O ' HG13 ' A' ' 151' ' ' VAL . 96.0 t -66.68 140.73 18.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.127 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -106.14 110.96 23.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.857 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.467 HG13 HG12 ' A' ' 112' ' ' VAL . 3.2 m -133.32 151.27 77.25 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 0.0 111.11 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.479 ' HG2' ' CG2' ' A' ' 118' ' ' VAL . 53.6 Cg_endo -69.76 149.79 67.37 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.703 2.269 . . . . 0.0 112.334 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -55.24 -39.34 69.61 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.923 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.45 ' HG3' ' N ' ' A' ' 118' ' ' VAL . 4.6 ptp180 -57.78 -41.85 82.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.843 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.479 ' CG2' ' HG2' ' A' ' 115' ' ' PRO . 16.5 t -71.53 -37.29 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 150' ' ' PRO . 77.5 t -43.06 -69.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -41.21 -34.46 0.94 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.476 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.7 mt -71.22 -56.92 5.06 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.447 HG12 HD13 ' A' ' 130' ' ' ILE . 86.7 t -52.83 -57.58 4.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.145 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 74.5 t -49.77 -54.74 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 81.11 169.84 42.4 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -47.93 97.37 0.03 OUTLIER 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.718 2.278 . . . . 0.0 112.347 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . . . . . . . . . 62.0 mttt 54.52 47.65 22.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.888 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 60.84 68.18 1.79 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -112.2 -38.38 4.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 0.0 111.1 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 72.6 m -86.46 -42.71 13.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.152 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 141' ' ' ILE . 5.2 tp -62.87 -36.48 75.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.2 ttpt -55.89 -46.18 78.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.851 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -53.83 -41.86 67.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 65.8 mt -61.38 -59.21 4.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.621 ' HG3' HD12 ' A' ' 141' ' ' ILE . 72.4 mt-30 -41.54 -36.04 0.83 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.899 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -80.83 -53.37 6.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 9.4 mmm180 -51.19 -34.53 32.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.865 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 41.1 p -105.93 -8.47 17.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.138 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 13.5 m170 53.58 54.55 9.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.866 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 160' ' ' ASN . 68.1 p -135.39 147.75 49.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 31.7 t80 -82.66 96.85 8.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.968 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.777 HG21 HD11 ' A' ' 130' ' ' ILE . 75.1 mt -89.94 116.16 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.145 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 84.0 t -102.76 113.99 41.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.156 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.456 HG22 ' CE2' ' A' ' 152' ' ' PHE . 37.9 p -72.57 153.42 91.69 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.521 0.677 . . . . 0.0 111.154 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 177.66 5.31 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.678 2.252 . . . . 0.0 112.375 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -85.01 170.69 45.66 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.502 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . 0.474 ' HG3' ' N ' ' A' ' 147' ' ' ASP . 4.2 ptm85 -69.53 -48.49 60.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.825 0.345 . . . . 0.0 110.922 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . 0.474 ' N ' ' HG3' ' A' ' 146' ' ' ARG . 7.7 p30 -99.92 43.42 1.06 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.901 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 25.0 mmtp -138.54 168.79 19.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.864 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -66.82 144.25 98.47 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.632 0.729 . . . . 0.0 110.926 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.52 ' HB3' HG21 ' A' ' 119' ' ' VAL . 53.1 Cg_endo -69.85 100.16 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.311 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.596 HG13 ' O ' ' A' ' 112' ' ' VAL . 90.5 t -147.06 127.92 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.456 ' CE2' HG22 ' A' ' 143' ' ' THR . 48.3 m-85 -96.62 125.89 41.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.918 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -103.96 99.58 9.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.074 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.553 HG12 HG12 ' A' ' 161' ' ' VAL . 60.3 t -88.77 133.69 30.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.145 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.621 HG23 ' OG1' ' A' ' 109' ' ' THR . 32.2 m -120.04 128.79 53.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 157.74 178.25 31.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.46 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.681 ' O ' HG22 ' A' ' 161' ' ' VAL . 9.0 mmt -41.04 159.2 0.17 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.559 0.695 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.7 8.91 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.678 2.252 . . . . 0.0 112.333 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.448 ' C ' ' OE1' ' A' ' 159' ' ' GLU . 0.5 OUTLIER -116.97 -38.06 3.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.965 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . 0.436 ' HB3' ' CG2' ' A' ' 139' ' ' THR . 11.9 m-20 -67.35 -45.55 76.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.681 HG22 ' O ' ' A' ' 157' ' ' MET . 30.0 m -68.51 -40.04 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.112 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . 0.42 ' N ' HG23 ' A' ' 161' ' ' VAL . 29.8 t0 -53.19 -40.26 64.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 33.1 ttt-85 -64.68 -59.17 4.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.33 -45.82 6.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.716 ' HE ' HD12 ' A' ' 110' ' ' ILE . 21.1 ttm180 -47.71 -45.15 28.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -53.96 -61.19 2.46 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.419 ' O ' ' HB3' ' A' ' 170' ' ' ALA . 13.4 mm-40 -53.6 -39.12 64.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.917 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . 0.535 HD12 ' HA ' ' A' ' 165' ' ' ARG . 61.2 mt -55.84 -70.55 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.444 ' HB2' HD12 ' A' ' 172' ' ' ILE . 2.3 pt-20 -59.69 -33.21 71.29 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.899 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 167' ' ' GLU . . . -37.25 -57.1 0.91 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.083 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 170' ' ' ALA . 17.6 m80 -37.63 -41.84 0.51 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.837 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.444 HD12 ' HB2' ' A' ' 169' ' ' GLU . 74.2 mt -41.5 -54.32 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 174' ' ' LEU . 66.9 p -61.67 -46.0 91.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.166 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 173' ' ' THR . 20.7 tp -34.56 151.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 39.4 mtt-85 -144.46 136.76 26.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 40.1 p -102.02 43.43 1.07 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.826 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 147.98 94.74 0.14 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . 0.4 ' O ' ' C ' ' A' ' 179' ' ' SER . 53.9 Cg_endo -69.8 -14.1 35.49 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.632 2.221 . . . . 0.0 112.385 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . 0.4 ' C ' ' O ' ' A' ' 178' ' ' PRO . 17.4 m -38.29 141.98 0.2 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.82 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 34.6 p -121.03 135.82 55.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.83 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.502 -179.993 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.434 -0.267 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 83.8 p -81.29 168.37 18.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.898 0.38 . . . . 0.0 110.827 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 33.4 t -119.52 115.46 24.07 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.875 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . -177.27 -79.19 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.49 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 66.5 p -127.56 42.85 3.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.874 0.369 . . . . 0.0 110.897 -179.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 29.2 p -75.77 111.28 10.95 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.867 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -117.78 -160.76 11.77 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.462 ' O ' ' CE ' ' A' ' 157' ' ' MET . . . 153.32 118.9 0.73 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 14.0 pt20 -175.42 177.54 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.849 0.356 . . . . 0.0 110.938 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 9.3 t -135.43 161.97 33.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.113 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.7 m -136.2 124.97 23.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.098 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 34.7 pt -114.28 154.3 15.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . . . . . . . . . 43.3 mm-40 -109.58 106.55 16.3 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.448 HG12 HG13 ' A' ' 114' ' ' VAL . 94.4 t -73.85 137.99 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.13 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 16.0 ttm180 -109.54 115.68 30.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.87 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.448 HG13 HG12 ' A' ' 112' ' ' VAL . 4.5 m -135.51 150.8 73.26 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.653 0.739 . . . . 0.0 111.109 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 117' ' ' ARG . 53.4 Cg_endo -69.77 129.14 17.07 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.696 2.264 . . . . 0.0 112.345 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -39.47 -28.59 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.894 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 115' ' ' PRO . 34.6 mmt180 -65.86 -51.43 58.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.848 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.797 HG21 HG12 ' A' ' 172' ' ' ILE . 28.9 t -66.59 -36.7 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.16 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 118' ' ' VAL . 77.4 t -37.32 -69.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.114 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -45.93 -39.49 8.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.515 HD12 ' HA ' ' A' ' 118' ' ' VAL . 14.2 mt -64.67 -41.14 96.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.865 0.364 . . . . 0.0 110.902 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.532 HG23 HG12 ' A' ' 118' ' ' VAL . 22.0 t -68.89 -64.99 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.098 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' A' ' 122' ' ' VAL . 89.4 t -37.35 -46.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.144 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 75.41 173.13 32.83 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.483 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.417 ' O ' ' C ' ' A' ' 126' ' ' LYS . 65.1 Cg_exo -47.99 112.55 0.6 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.658 2.239 . . . . 0.0 112.341 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 125' ' ' PRO . 21.2 ptmt 36.64 41.1 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.905 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . 70.55 83.29 0.2 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.471 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -129.38 -41.34 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.864 0.364 . . . . 0.0 111.083 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 39.5 m -84.16 -44.18 14.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.121 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.71 HD11 HG21 ' A' ' 141' ' ' ILE . 5.8 tp -60.02 -40.47 83.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.149 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.424 ' N ' HG23 ' A' ' 130' ' ' ILE . 37.0 tttp -58.28 -41.93 85.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.898 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -56.45 -42.68 78.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 72.9 mt -59.88 -48.23 88.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . 0.561 ' HG3' HD12 ' A' ' 141' ' ' ILE . 78.9 mt-30 -48.56 -36.72 16.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.929 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLN . . . . . . . . . . . . . 4.3 mm100 -82.48 -54.84 4.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.93 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -49.95 -32.53 15.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 44.7 p -105.6 -13.6 15.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.105 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . . . . . . . . . 28.0 m80 58.84 54.41 5.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . 0.41 HG21 ' HA ' ' A' ' 161' ' ' VAL . 68.5 p -139.88 143.3 36.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -77.49 100.55 6.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.922 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.71 HG21 HD11 ' A' ' 130' ' ' ILE . 75.9 mt -92.79 119.1 39.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.135 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 89.3 t -109.6 127.52 66.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.104 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 74.6 p -85.26 151.61 56.91 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.562 0.696 . . . . 0.0 111.197 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 177.67 5.33 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.689 2.26 . . . . 0.0 112.354 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . -81.7 168.15 49.18 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.44 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.19 -43.91 93.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.814 0.34 . . . . 0.0 110.836 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -103.18 43.6 1.07 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 48.9 mttt -132.45 171.61 13.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.892 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.21 148.85 91.54 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.683 0.754 . . . . 0.0 110.871 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 87.64 0.56 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.349 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.4 t -143.78 121.13 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.087 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -90.31 153.64 20.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.832 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -122.7 106.96 11.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.094 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.602 HG12 HG12 ' A' ' 161' ' ' VAL . 50.7 t -97.74 125.28 50.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.144 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 75.1 m -112.3 137.38 50.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.164 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 152.49 -173.13 31.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.495 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' MET . . . . . 0.742 ' O ' HG22 ' A' ' 161' ' ' VAL . 8.2 mmt -53.89 159.86 2.5 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 0.0 110.877 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.428 ' HD2' ' SD ' ' A' ' 157' ' ' MET . 54.2 Cg_endo -69.7 -0.55 7.02 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.672 2.248 . . . . 0.0 112.391 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.431 ' CD ' ' HB3' ' A' ' 157' ' ' MET . 23.5 pm0 -118.01 -26.25 6.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 -82.63 -43.51 16.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 157' ' ' MET . 35.7 m -69.5 -35.14 65.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.183 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -56.76 -47.81 79.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' ARG . . . . . . . . . . . . . 27.9 ttt-85 -57.31 -55.24 37.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.834 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -43.21 -45.38 5.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 41.1 ttp180 -52.43 -45.5 66.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -64.39 -42.53 96.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.902 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -58.39 -53.84 53.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.879 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ILE . . . . . . . . . . . . . 91.0 mt -55.59 -54.79 21.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -56.63 -46.23 81.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' ALA . . . . . 0.441 ' O ' ' C ' ' A' ' 171' ' ' HIS . . . -38.36 -60.29 0.8 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.132 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 170' ' ' ALA . 40.7 m170 -34.95 -38.77 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.872 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.797 HG12 HG21 ' A' ' 118' ' ' VAL . 74.7 mt -50.71 -59.4 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.093 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.32 46.32 0.93 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.2 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 9.5 tt -145.21 124.16 12.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.942 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 46.8 mtp85 -106.69 142.79 35.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.823 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 22.7 m -99.51 167.52 10.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.847 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . 115.28 -178.54 17.82 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 163.2 39.18 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.683 2.255 . . . . 0.0 112.342 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 73.1 m -120.36 -44.48 2.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.84 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.9 t -56.29 -58.22 8.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.84 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 -179.962 . . . . . . . . 0 0 . 1 stop_ save_